0002017526 2025-01-01 2025-12-31 0002017526 2025-12-31 0002017526 2024-12-31 0002017526 us-gaap:CommonClassAMember 2025-12-31 0002017526 us-gaap:CommonClassAMember 2024-12-31 0002017526 us-gaap:CommonClassBMember 2025-12-31 0002017526 us-gaap:CommonClassBMember 2024-12-31 0002017526 srt:MaximumMember us-gaap:CommonClassBMember 2024-03-22 2024-12-31 0002017526 us-gaap:CommonClassBMember 2024-06-13 0002017526 2024-03-22 2024-12-31 0002017526 pcsc:ClassARedeemableOrdinarySharesMember 2025-01-01 2025-12-31 0002017526 pcsc:ClassARedeemableOrdinarySharesMember 2024-03-22 2024-12-31 0002017526 pcsc:ClassAAndBNonRedeemableOrdinarySharesMember 2025-01-01 2025-12-31 0002017526 pcsc:ClassAAndBNonRedeemableOrdinarySharesMember 2024-03-22 2024-12-31 0002017526 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-03-21 0002017526 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2024-03-21 0002017526 us-gaap:AdditionalPaidInCapitalMember 2024-03-21 0002017526 us-gaap:RetainedEarningsMember 2024-03-21 0002017526 2024-03-21 0002017526 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-03-22 2024-12-31 0002017526 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2024-03-22 2024-12-31 0002017526 us-gaap:AdditionalPaidInCapitalMember 2024-03-22 2024-12-31 0002017526 us-gaap:RetainedEarningsMember 2024-03-22 2024-12-31 0002017526 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-12-31 0002017526 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2024-12-31 0002017526 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0002017526 us-gaap:RetainedEarningsMember 2024-12-31 0002017526 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2025-01-01 2025-12-31 0002017526 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2025-01-01 2025-12-31 0002017526 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-12-31 0002017526 us-gaap:RetainedEarningsMember 2025-01-01 2025-12-31 0002017526 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2025-12-31 0002017526 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2025-12-31 0002017526 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0002017526 us-gaap:RetainedEarningsMember 2025-12-31 0002017526 2026-04-28 2026-04-28 0002017526 pcsc:AggregateTransactionProceedsConditionRedemptionsScenarioSharesReceivedOfNewFreenomeCommonStockInExchangeForPCSCClassBSharesMember pcsc:PerceptiveCapitalSolutionsHoldingMember 2026-04-28 2026-04-28 0002017526 pcsc:AggregateTransactionProceedsConditionRedemptionsScenarioExchangeOfPCSCClassBSharesMember pcsc:PerceptiveCapitalSolutionsHoldingMember 2026-04-28 2026-04-28 0002017526 pcsc:PCSCClassBSharesPurchasedInConnectionWithPCSCsInitialPublicOfferingMember pcsc:PerceptiveCapitalSolutionsHoldingMember 2026-04-28 2026-04-28 0002017526 pcsc:AggregateTransactionProceedsConditionRedemptionsScenarioSharesReceivedOfNewFreenomeCommonStockInExchangeForPCSCClassASharesMember pcsc:PerceptiveCapitalSolutionsHoldingMember 2026-04-28 2026-04-28 0002017526 pcsc:AggregateTransactionProceedsConditionRedemptionsScenarioExchangeOfPCSCClassASharesMember pcsc:PerceptiveCapitalSolutionsHoldingMember 2026-04-28 2026-04-28 0002017526 pcsc:PCSCClassASharesPurchasedInConnectionWithPCSCsInitialPublicOfferingMember pcsc:PerceptiveCapitalSolutionsHoldingMember 2026-04-28 2026-04-28 0002017526 pcsc:AggregateTransactionProceedsConditionRedemptionsScenarioNewFreenomeCommonStockPurchasedByThePerceptivePIPEInvestorMember pcsc:PerceptiveLifeSciencesMasterFundLtdPerceptivePIPEInvestorMember 2026-04-28 2026-04-28 0002017526 pcsc:AggregateTransactionProceedsConditionRedemptionsScenarioNewFreenomeCommonStockUponExchangeOfFreenomeCapitalStockMember pcsc:PerceptiveLifeSciencesMasterFundLtdPerceptivePIPEInvestorMember 2026-04-28 2026-04-28 0002017526 pcsc:NewFreenomeCommonStockMember pcsc:PerceptiveCapitalSolutionsCorpIndependentDirectorsMember 2026-04-28 2026-04-28 0002017526 pcsc:PCSCClassBSharesMember pcsc:PerceptiveCapitalSolutionsCorpIndependentDirectorsMember 2026-04-28 2026-04-28 0002017526 pcsc:AdamStoneMember 2026-04-28 2026-04-28 0002017526 pcsc:MichaelAltmanMember 2026-04-28 2026-04-28 0002017526 pcsc:JosephEdelmanMember 2026-04-28 2026-04-28 0002017526 pcsc:PIPEFinancingMember 2026-04-28 2026-04-28 0002017526 pcsc:PerceptiveCapitalSolutionsHoldingMember 2026-04-28 2026-04-28 0002017526 pcsc:PerceptiveCapitalSolutionsHoldingMember 2026-04-28 2026-04-28 0002017526 pcsc:PerceptiveLifeSciencesMasterFundLtdPerceptivePIPEInvestorMember 2026-04-28 2026-04-28 0002017526 pcsc:PerceptiveCapitalSolutionsCorpIndependentDirectorsMember 2026-04-28 2026-04-28 0002017526 pcsc:ScalarLLCMember 2026-04-28 2026-04-28 0002017526 spac:NoRedemptionMember 2025-12-31 2025-12-31 0002017526 spac:RedemptionAt25PercentOfMaximumMember 2025-12-31 2025-12-31 0002017526 spac:RedemptionAt50PercentOfMaximumMember 2025-12-31 2025-12-31 0002017526 spac:RedemptionAt100PercentOfMaximumMember 2025-12-31 2025-12-31 0002017526 spac:ShareholderRedemptionsMember spac:NoRedemptionMember 2025-12-31 2025-12-31 0002017526 spac:ShareholderRedemptionsMember spac:RedemptionAt25PercentOfMaximumMember 2025-12-31 2025-12-31 0002017526 spac:ShareholderRedemptionsMember spac:RedemptionAt50PercentOfMaximumMember 2025-12-31 2025-12-31 0002017526 spac:ShareholderRedemptionsMember spac:RedemptionAt100PercentOfMaximumMember 2025-12-31 2025-12-31 0002017526 spac:PipeFinancingMember spac:NoRedemptionMember 2025-12-31 2025-12-31 0002017526 spac:PipeFinancingMember spac:RedemptionAt25PercentOfMaximumMember 2025-12-31 2025-12-31 0002017526 spac:PipeFinancingMember spac:RedemptionAt50PercentOfMaximumMember 2025-12-31 2025-12-31 0002017526 spac:PipeFinancingMember spac:RedemptionAt100PercentOfMaximumMember 2025-12-31 2025-12-31 0002017526 pcsc:ReclassificationOfUnredeemedPublicSharesOfPCSCToPermanentEquityMember spac:NoRedemptionMember 2025-12-31 2025-12-31 0002017526 pcsc:ReclassificationOfUnredeemedPublicSharesOfPCSCToPermanentEquityMember spac:RedemptionAt25PercentOfMaximumMember 2025-12-31 2025-12-31 0002017526 pcsc:ReclassificationOfUnredeemedPublicSharesOfPCSCToPermanentEquityMember spac:RedemptionAt50PercentOfMaximumMember 2025-12-31 2025-12-31 0002017526 pcsc:ReclassificationOfUnredeemedPublicSharesOfPCSCToPermanentEquityMember spac:RedemptionAt100PercentOfMaximumMember 2025-12-31 2025-12-31 0002017526 pcsc:PaymentOfTransactionExpensesOfPCSCNetOfAssociatedLiabilitiesMember spac:NoRedemptionMember 2025-12-31 2025-12-31 0002017526 pcsc:PaymentOfTransactionExpensesOfPCSCNetOfAssociatedLiabilitiesMember spac:RedemptionAt25PercentOfMaximumMember 2025-12-31 2025-12-31 0002017526 pcsc:PaymentOfTransactionExpensesOfPCSCNetOfAssociatedLiabilitiesMember spac:RedemptionAt50PercentOfMaximumMember 2025-12-31 2025-12-31 0002017526 pcsc:PaymentOfTransactionExpensesOfPCSCNetOfAssociatedLiabilitiesMember spac:RedemptionAt100PercentOfMaximumMember 2025-12-31 2025-12-31 0002017526 pcsc:JosephEdelmanMember 2026-04-28 2026-04-28 0002017526 pcsc:AdamStoneMember 2026-04-28 2026-04-28 0002017526 pcsc:MichaelAltmanMember 2026-04-28 2026-04-28 0002017526 pcsc:SamCohnMember 2026-04-28 2026-04-28 0002017526 pcsc:MarkCMcKennaMember 2026-04-28 2026-04-28 0002017526 pcsc:KennethSongMember 2026-04-28 2026-04-28 0002017526 pcsc:HarlanWWaksalMember 2026-04-28 2026-04-28 0002017526 spac:SpacOfficersAndDirectorsMember 2026-04-28 2026-04-28 0002017526 pcsc:PerceptiveCapitalSolutionsHoldingMember 2026-04-28 2026-04-28 0002017526 spac:TargetCompanyOfficersAndDirectorsMember 2026-04-28 2026-04-28 0002017526 pcsc:SeekingShareholderApprovalMember 2026-04-28 2026-04-28 0002017526 srt:MinimumMember 2024-06-13 2024-06-13 0002017526 2024-06-13 2024-06-13 0002017526 2024-06-13 0002017526 us-gaap:OverAllotmentOptionMember 2024-06-13 2024-06-13 0002017526 us-gaap:IPOMember 2024-06-13 0002017526 us-gaap:PrivatePlacementMember 2024-06-13 2024-06-13 0002017526 us-gaap:PrivatePlacementMember 2024-06-13 0002017526 us-gaap:IPOMember 2024-06-13 2024-06-13 0002017526 srt:MinimumMember 2025-01-01 2025-12-31 0002017526 srt:MaximumMember 2025-12-31 0002017526 us-gaap:CommonClassAMember 2024-03-22 2024-12-31 0002017526 us-gaap:CommonClassAMember 2025-01-01 2025-12-31 0002017526 us-gaap:InvestorMember us-gaap:CommonClassBMember 2024-03-27 2024-03-27 0002017526 us-gaap:InvestorMember us-gaap:CommonClassBMember 2024-03-27 0002017526 srt:MaximumMember us-gaap:InvestorMember us-gaap:CommonClassBMember 2024-03-27 2024-03-27 0002017526 us-gaap:InvestorMember us-gaap:CommonClassBMember 2025-12-31 0002017526 srt:DirectorMember us-gaap:InvestorMember 2024-04-22 2024-04-22 0002017526 srt:DirectorMember us-gaap:InvestorMember 2024-04-22 0002017526 pcsc:MarkMcKennaMember 2024-04-22 0002017526 pcsc:KennethSongMember 2024-04-22 0002017526 pcsc:HarlanWaksalMember 2024-04-22 0002017526 2024-04-22 0002017526 2024-04-22 2024-04-22 0002017526 srt:MinimumMember us-gaap:InvestorMember us-gaap:CommonClassAMember 2025-01-01 2025-12-31 0002017526 srt:MinimumMember us-gaap:InvestorMember us-gaap:CommonClassAMember 2025-12-31 0002017526 us-gaap:InvestorMember us-gaap:CommonClassAMember 2025-01-01 2025-12-31 0002017526 us-gaap:PrivatePlacementMember 2025-01-01 2025-12-31 0002017526 us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2025-01-01 2025-12-31 0002017526 us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2025-12-31 0002017526 us-gaap:PrivatePlacementMember 2024-03-22 2024-12-31 0002017526 srt:MaximumMember pcsc:PromissoryNoteToCoverExpensesRelatedToInitialPublicOfferingMember us-gaap:InvestorMember 2024-03-27 2024-03-27 0002017526 pcsc:PromissoryNoteToCoverExpensesRelatedToInitialPublicOfferingMember us-gaap:InvestorMember 2025-12-31 0002017526 srt:MaximumMember pcsc:WorkingCapitalLoansMember pcsc:SponsorAffiliateOfSponsorOrCertainCompanyOfficersAndDirectorsMember 2025-01-01 2025-12-31 0002017526 pcsc:WorkingCapitalLoansMember pcsc:SponsorAffiliateOfSponsorOrCertainCompanyOfficersAndDirectorsMember 2025-12-31 0002017526 pcsc:WorkingCapitalLoansMember pcsc:SponsorAffiliateOfSponsorOrCertainCompanyOfficersAndDirectorsMember 2024-12-31 0002017526 pcsc:AdministrativeSupportAgreementMember us-gaap:InvestorMember 2025-01-01 2025-12-31 0002017526 pcsc:AdministrativeSupportAgreementMember us-gaap:InvestorMember 2024-03-22 2024-12-31 0002017526 srt:MaximumMember 2024-06-13 0002017526 us-gaap:OverAllotmentOptionMember 2024-06-13 0002017526 srt:MaximumMember us-gaap:IPOMember 2024-06-13 2024-06-13 0002017526 us-gaap:IPOMember 2025-01-01 2025-12-31 0002017526 pcsc:StarNetMergerSubIAndStarNetMergerSubIILLCMember us-gaap:InvestorMember us-gaap:CommonClassAMember 2025-12-05 2025-12-05 0002017526 pcsc:StarNetMergerSubIAndStarNetMergerSubIILLCMember us-gaap:InvestorMember us-gaap:CommonClassAMember 2025-12-05 0002017526 pcsc:StarNetMergerSubIAndStarNetMergerSubIILLCMember us-gaap:InvestorMember 2025-12-05 0002017526 pcsc:PIPEInvestorsMember us-gaap:PrivatePlacementMember 2025-12-05 2025-12-05 0002017526 pcsc:PIPEInvestorsMember us-gaap:PrivatePlacementMember 2025-12-05 0002017526 us-gaap:CommonClassBMember 2025-01-01 2025-12-31 0002017526 us-gaap:CashMember 2025-12-31 0002017526 us-gaap:USTreasurySecuritiesMember 2025-12-31 0002017526 us-gaap:CashMember 2024-12-31 0002017526 us-gaap:USTreasurySecuritiesMember 2024-12-31 0002017526 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0002017526 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0002017526 pcsc:PerceptiveMember 2025-12-31 0002017526 pcsc:PerceptiveMember 2024-12-31 0002017526 pcsc:PerceptiveMember 2025-01-01 2025-12-31 0002017526 pcsc:PerceptiveMember 2024-03-22 2024-12-31 iso4217:USD shares iso4217:USD shares pure pcsc:Business pcsc:Subsidiary pcsc:Demand pcsc:Vote pcsc:Classes pcsc:Segment S-4 Perceptive Capital Solutions Corp Non-accelerated Filer true true false <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 12pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On December 4, 2025, the board of directors (the “<span style="font-style: italic; font-weight: bold;">PCSC Board</span>”) of Perceptive Capital Solutions Corp, a Cayman Islands exempted company (“<span style="font-style: italic; font-weight: bold;">PCSC</span>,” “<span style="font-style: italic; font-weight: bold;">we</span>,” “<span style="font-style: italic; font-weight: bold;">us</span>” or “<span style="font-style: italic; font-weight: bold;">our</span>”), based on the unanimous recommendation of the special committee of the PCSC Board, unanimously approved the Business Combination Agreement, dated December 5, 2025 (as it may be amended, supplemented, or otherwise modified from time to time, the “<span style="font-style: italic; font-weight: bold;">Business Combination Agreement</span>”), by and among PCSC, StarNet Merger Sub I, Corp., a Delaware corporation and wholly-owned subsidiary of PCSC (“<span style="font-style: italic; font-weight: bold;">Merger Sub I</span>”), StarNet Merger Sub II, LLC, a Delaware limited liability company and wholly-owned subsidiary of PCSC (“<span style="font-style: italic; font-weight: bold;">Merger Sub II</span>”) and Freenome Holdings, Inc., a Delaware corporation (“<span style="font-style: italic; font-weight: bold;">Freenome</span>”), pursuant to which the following will occur: (a) at least one business day prior to the Closing Date (as defined below), PCSC will de-register from the Register of Companies in the Cayman Islands and transfer by way of continuation from the Cayman Islands to Delaware and domesticate as a Delaware corporation in accordance with Section 388 of the General Corporation Law of the State of Delaware and Part 12 of the Companies Act (Revised) of the Cayman Islands (the “<span style="font-style: italic; font-weight: bold;">Domestication</span>”), upon which PCSC will change its name to “Freenome, Inc.” (“<span style="font-style: italic; font-weight: bold;">New Freenome</span>”); (b) Merger Sub I will merge with and into Freenome, with Freenome as the surviving company in the merger (the “<span style="font-style: italic; font-weight: bold;">First Merger</span>”) and, after giving effect to the First Merger (such time being the “<span style="font-style: italic; font-weight: bold;">Effective Time</span>”), Freenome will be a wholly-owned subsidiary of PCSC, (c) as soon as practicable following the Effective Time, but no later than one business day following the Effective Time, Freenome, as the surviving corporation of the First Merger, will merge with and into Merger Sub II (the “<span style="font-style: italic; font-weight: bold;">Second Merger</span>” and together with the First Merger, the “<span style="font-style: italic; font-weight: bold;">Mergers</span>”), with Merger Sub II continuing as the surviving company in the Second Merger, and (d) the other transactions contemplated by the Business Combination Agreement and documents related thereto (such transactions, together with the Domestication and the Mergers, the “<span style="font-style: italic; font-weight: bold;">Business Combination</span>”), all as described in more detail in the accompanying proxy statement/prospectus. The consummation of the Business Combination is referred to as the “<span style="font-style: italic; font-weight: bold;">Closing</span>” and the date of the Closing, the “<span style="font-style: italic; font-weight: bold;">Closing Date</span>.” References herein to New Freenome denote PCSC following the Business Combination. A copy of the Business Combination Agreement is attached to the accompanying proxy statement/prospectus as <span style="font-weight: bold;">Annex A</span>. </div> <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In connection with the execution of the Business Combination Agreement, on December 5, 2025, PCSC entered into subscription agreements (the “<span style="font-style: italic; font-weight: bold;">Subscription Agreements</span>”) with certain qualified institutional buyers, institutional accredited investors, and other accredited investors, including, among others, Perceptive Life Sciences Master Fund, Ltd., a Cayman Islands exempted company (the “<span style="font-style: italic; font-weight: bold;">Perceptive PIPE Investo</span>r”) and an affiliate of Perceptive Capital Solutions Holding, a Cayman Islands exempted company (the “<span style="font-style: italic; font-weight: bold;">Sponsor</span>”), as well as certain existing stockholders of Freenome (the “<span style="font-style: italic; font-weight: bold;">PIPE Investors</span>”). Pursuant to the Subscription Agreements, the PIPE Investors agreed to subscribe for and purchase, and PCSC agreed to issue and sell to the PIPE Investors, on the Closing Date immediately following the Closing, an aggregate of 24,000,000 shares of New Freenome Common Stock (the “<span style="font-style: italic; font-weight: bold;">PIPE Shares</span>”) for a purchase price of $10.00 per share, and aggregate gross proceeds of $240.0 million (the “<span style="font-style: italic; font-weight: bold;">PIPE Financing</span>”). The obligations of each party to consummate the PIPE Financing are conditioned upon, among other things, (i) the New Freenome Common Stock (including the New Freenome Common Stock issuable to the PIPE Investors pursuant to the Subscription Agreements) having been approved for listing on Nasdaq; and (ii) satisfaction of all conditions precedent to the closing of the transactions set forth in the Business Combination Agreement. The obligations of the PIPE Investors to consummate the PIPE Financing are further subject to additional conditions, including, among other things: (i) the Business Combination Agreement shall not have been amended, modified, or supplemented, and no condition waived thereunder, in a manner that would reasonably be expected to materially and adversely affect the economic benefits that a PIPE Investor would reasonably expect to receive under the Subscription Agreement; (ii) the material truth and accuracy of the representations and warranties of PCSC in the Subscription Agreement, subject to customary bringdown standards; (iii) no subscription agreement, or other agreements or understandings (including side letters) entered into in connection with the sale of New Freenome Common Stock under the Subscription Agreements, with any other PIPE Investors shall have been amended, modified, or waived in any manner that benefits such other PIPE Investor unless all PIPE Investors have been offered substantially the same benefits; and (iv) there has not occurred any material adverse effect or parent material adverse effect since the date of the Subscription Agreement that is continuing. <span style="font-weight: bold;">See</span> “<span style="font-style: italic; font-weight: bold;">Business Combination Proposal—Related Agreements—PIPE Financing</span>.<span style="font-style: italic; font-weight: bold;">”</span> </div> <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Compensation to be Received by the Sponsor, the Perceptive PIPE Investor, and PCSC’s Officers and Directors in Connection with the Business Combination and PIPE Financing: <span style="font-weight: normal;">Assuming the Aggregate Transaction Proceeds Condition Redemptions Scenario, the Sponsor will receive (i) 2,066,250 shares of New Freenome Common Stock upon the exchange of 2,066,250 PCSC Class B Shares, which were initially purchased in connection with PCSC’s initial public offering for approximately $0.01 per share and (ii) 286,250 shares of New Freenome Common Stock upon the exchange of 286,250 PCSC Class A Shares, which were initially purchased in a private placement that closed concurrently with PCSC’s initial public offering for $10.00 per share. The Perceptive PIPE Investor will receive (i) 5,500,000 shares of New Freenome Common Stock, which is equal to the Perceptive PIPE Investor’s $55.0 million PIPE Financing commitment divided by $10.00, the price per share of the PIPE Financing, and (ii) an estimated 5,615,003 shares of New Freenome Common Stock upon the exchange of Freenome capital stock, each of which is equal to $56.2 million divided by $10.00 per share, which is the assumed per share price used in the Business Combination pursuant to the Business Combination Agreement. PCSC’s independent directors (Messrs. McKenna, Song and Waksal) will each receive 30,000 shares of New Freenome Common Stock upon the exchange of 30,000 PCSC Class B Shares held by them. The securities to be issued to the Sponsor, the Perceptive PIPE Investor, and PCSC’s officers and directors may result in a material dilution of the equity interests of non-redeeming public shareholders. </span>See “<span style="font-style: italic;">Dilution</span>,” <span style="font-style: italic;">and </span>“<span style="font-style: italic;">Information About PCSC—Executive Compensation and Director Compensation.</span>”<span style="font-weight: normal;"> </span></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Sponsor, the Perceptive PIPE Investor, and PCSC’s officers and directors will also be reimbursed for loans, advances, and out-of-pocket expenses incurred by them related to identifying, negotiating, investigating and completing the Business Combination. No such loans, advances, or out-of-pocket expenses are outstanding as of the date of this proxy statement/prospectus. In addition, PCSC has agreed to pay the Sponsor $15,000 per month for office space, secretarial and administrative services and the Sponsor and PCSC’s officers and directors will be entitled to continued indemnification and the continuation of directors’ and officer’s liability insurance after the Business Combination. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8.5pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">PCSC’s independent directors are not members of the Sponsor and are not affiliates of the Perceptive PIPE Investor. None of the funds in the trust account will be used to compensate PCSC’s officers or directors. Except for administrative services fees and office rental fees paid or to be paid to the Sponsor, no compensation of any kind, including finder’s and consulting fees, have been paid or will be paid to the Sponsor, officers and directors, or any of their respective affiliates, for services rendered prior to or in connection with the completion of the Business Combination. However, these individuals will be reimbursed for any out-of-pocket expenses incurred in connection with activities performed on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations, as discussed above. The reimbursement of expenses and advances to the Sponsor, and PCSC’s officers and directors may result in a material dilution of the equity interests of non-redeeming public shareholders. <span style="font-weight: bold;">See “</span><span style="font-style: italic; font-weight: bold;">Dilution</span><span style="font-weight: bold;">,” and “</span><span style="font-style: italic; font-weight: bold;">Information About PCSC—Executive Compensation and Director Compensation</span><span style="font-weight: bold;">.”</span> </div> 2066250 2066250 0.01 286250 286250 10 5500000 55000000 10 5615003 56200000 10 30000 30000 true true <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On December 4, 2025, the Special Committee received an opinion from Scalar as to the fairness, from a financial point of view, to PCSC and the PCSC Unaffiliated Shareholders of the shares of New Freenome Common Stock to be paid by PCSC in the First Merger pursuant to the Business Combination Agreement, a copy of which is attached hereto as <span style="font-weight: bold;">Annex L</span>. <span style="font-weight: bold;">For more information, see “</span><span style="font-style: italic; font-weight: bold;">Business Combination Proposal—Background and Material Terms of the Business Combination</span><span style="font-weight: bold;">,” “</span><span style="font-style: italic; font-weight: bold;">Business Combination Proposal—Interests of PCSC’s Sponsor, Directors and Officers in the Business Combination</span><span style="font-weight: bold;">” and “</span><span style="font-style: italic; font-weight: bold;">Business Combination Proposal—Opinion of Scalar, LLC</span><span style="font-weight: bold;">.”</span> </div> <table border="0" cellpadding="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Who is the Sponsor? </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A.<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Our Sponsor, Perceptive Capital Solutions Holdings, is a Cayman Islands exempted company, which was formed to invest in PCSC. The Sponsor currently owns 2,066,250 PCSC Class B Shares and 286,250 private placement shares, which are PCSC Class A Shares. Although our Sponsor is permitted to undertake any activities permitted under the Cayman Companies Act and other applicable law, our Sponsor’s business is focused on investing in PCSC. </div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Our Sponsor is an affiliate of Perceptive Advisors, a leading life sciences focused investment firm with over $9.5 billion of regulatory assets under management as of December 31, 2025. Since its launch in 1999, Perceptive Advisors has focused exclusively on the healthcare industry. Our Founders are the founder and management of Perceptive Advisors. Joseph Edelman, our Chairman, founded Perceptive Advisors in 1999. Adam Stone, our Chief Executive Officer, is the Chief Investment Officer of Perceptive Advisors and Michael Altman, our Chief Business Officer, is a Managing Director at Perceptive Advisors. Perceptive Advisors’ investment activity is focused on identifying both private and public companies in the life sciences and medical technology sectors and has investments in 234 companies as of December 31, 2025. The team at Perceptive Advisors consists of trained scientists, physicians and financial analysts who are passionately committed to identifying innovation that can drive critical change to current treatment paradigms. Perceptive Advisors invests across the capital structure and throughout a company’s growth cycle which provides access to a broad universe of management teams and </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">companies seeking flexible capital solutions. Perceptive Advisors is also an active investor in pre-IPO financing rounds known as “crossovers.” Perceptive Advisors has invested in over 144 private companies since 2013 and in 2025 met with over 200 private companies in evaluation of private growth financing rounds, crossovers, and pre-IPO analysis. For a description of our management team’s previous experience with other special purpose acquisition vehicles, see “<span style="font-style: italic;">Information about PCSC—Experience with Special Purpose Acquisition Vehicles.</span>” </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman, who are U.S. citizens. As such, Messrs. Stone and Altman have voting and investment discretion with respect to the securities held of record by the Sponsor and may each be deemed to have shared beneficial ownership of all of the PCSC Shares held directly by the Sponsor. Additionally, as of March 18, 2026, Mr. Edelman has an aggregate indirect ownership interest in the Sponsor of approximately 37%, and may therefore be considered to have a material interest in the Sponsor. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Sponsor is not “controlled” (as defined in 31 CFR 800.208) by a foreign person, such that the Sponsor’s involvement in any business combination would be a “covered transaction” (as defined in 31 CFR 800.213). However, it is possible that non-U.S. persons could be involved in our business combination, which may increase the risk that our business combination becomes subject to regulatory review, including review by the Committee on Foreign Investment in the U.S. (“<span style="font-style: italic; font-weight: bold;">CFIUS</span>”), and that restrictions, limitations or conditions will be imposed by CFIUS. If our business combination with a U.S. business is subject to CFIUS review, the scope of which was expanded by FIRRMA, to include certain non-passive, non-controlling investments in sensitive U.S. businesses and certain acquisitions of real estate even with no underlying U.S. business. FIRRMA, and subsequent implementing regulations that are now in force, also subjects certain categories of investments to mandatory filings. If our potential business combination with a U.S. business falls within CFIUS’s jurisdiction, we may determine that we are required to make a mandatory filing or that we will submit a voluntary notice to CFIUS, or to proceed with a business combination without notifying CFIUS and risk CFIUS intervention, before or after closing a business combination. CFIUS may decide to block or delay our business combination, impose conditions to mitigate national security concerns with respect to such business combination or order us to divest all or a portion of a U.S. business of the combined company without first obtaining CFIUS clearance, which may limit the attractiveness of or prevent us from pursuing certain initial business combination opportunities that we believe would otherwise be beneficial to us and our shareholders. As a result, the pool of potential targets with which we could complete a business combination may be limited and we may be adversely affected in terms of competing with other special purpose acquisition companies which do not have similar foreign ownership issues. A failure to notify CFIUS of a transaction where such notification was required or otherwise warranted based on the national security considerations presented by an investment target may expose our Sponsor and/or the combined company to legal penalties, costs, and/or other adverse reputational and financial effects, thus potentially diminishing the value of the combined company. In addition, CFIUS is actively pursuing transactions that were not notified to it and may ask questions regarding, or impose restrictions or mitigation on, a business combination post-closing. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Moreover, the process of government review, whether by the CFIUS or otherwise, could be lengthy and we have limited time to complete our business combination. If we cannot complete a business combination within 24 months from the closing of our Initial Public Offering because the transaction is still under review or because our business combination is ultimately prohibited by CFIUS or another U.S. government entity, we may be required to liquidate. If we liquidate, shareholders of record may only receive their pro rata portion of funds available in the Trust Account. This will also cause you to lose the investment opportunity in a target company and the chance of realizing future gains on your investment through any price appreciation in the combined company. </div> Our Sponsor, Perceptive Capital Solutions Holdings, is a Cayman Islands exempted company, which was formed to invest in PCSC. Sponsor Perceptive Capital Solutions Holdings The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman, who are U.S. citizens. As such, Messrs. Stone and Altman have voting and investment discretion with respect to the securities held of record by the Sponsor and may each be deemed to have shared beneficial ownership of all of the PCSC Shares held directly by the Sponsor. Adam Stone Michael Altman Additionally, as of March 18, 2026, Mr. Edelman has an aggregate indirect ownership interest in the Sponsor of approximately 37%, and may therefore be considered to have a material interest in the Sponsor. Mr. Edelman indirect ownership interest 0.37 <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">SUMMARY OF THE PROXY STATEMENT/PROSPECTUS </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">This summary highlights selected information from this proxy statement/prospectus and does not contain all of the information that is important to you. To better understand the proposals to be submitted for a vote at the extraordinary general meeting, including the Business Combination, you should read this proxy statement/prospectus, including the Annexes, such as the Business Combination Agreement attached as <span style="font-weight: bold;">Annex A </span>to this proxy statement/prospectus and other documents referred to herein, carefully and in their entirety. The Business Combination Agreement is the legal document that governs the Business Combination and the other transactions that will be undertaken in connection with the Business Combination. The Business Combination Agreement is also described in detail in this proxy statement/prospectus in the section entitled “Business Combination Proposal—The Business Combination Agreement.”<span style="font-style: normal;"> </span></div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Parties to the Business Combination</div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">Perceptive Capital Solutions Corp</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">PCSC is a blank check company incorporated on March 22, 2024 as a Cayman Islands exempted company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">PCSC Class A Shares are currently listed on Nasdaq under the symbol “PCSC.”</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">PCSC’s principal executive offices are located at 51 Astor Place, 10^th Floor, New York, New York 10003, and its phone number is (212) 284-2300.</div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">StarNet Merger Sub I, Corp.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Merger Sub I is a Delaware corporation and wholly-owned subsidiary of PCSC. Merger Sub I was formed solely for the purpose of effecting the Business Combination and has not carried on any activities other than those in connection with the Business Combination. The address and telephone number for Merger Sub I’s principal executive offices are the same as those for PCSC.</div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 0pt; text-align: left;">StarNet Merger Sub II, LLC </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Merger Sub II is a Delaware limited liability company and wholly-owned subsidiary of PCSC. Merger Sub II was formed solely for the purpose of effecting the Business Combination and has not carried on any activities other than those in connection with the Business Combination. The address and telephone number for Merger Sub II’s principal executive offices are the same as those for PCSC.</div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 0pt; text-align: left;">Freenome Holdings, Inc. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Freenome is a development stage, early cancer detection company developing blood-based screening tests leveraging a proprietary artificial intelligence/machine learning multiomics technology platform to transform multi-cancer and ultimately multi-disease detection. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Freenome is developing a range of blood-based cancer screening tests. Its lead product, SimpleScreen CRC (v1), has been submitted to the FDA for premarket approval, with a decision expected in 2026, and an improved version is also in development. A blood-based lung cancer test aimed at high-risk individuals is on track to launch in the second half of 2026 . Freenome also recently initiated a clinical study which will inform its plans and timing with respect to a regulatory submission to the FDA to support clinical validation of an in vitro device. Looking ahead, Freenome’s preliminary strategy is to eventually expand its platform to screen for more than ten types of cancer, with a broader general-population offering planned for the longer term, each subject to regulatory approval. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Freenome currently has no products approved for commercial sale in the United States and has not generated any material revenue to date, and it continues to incur significant R&amp;D and other expenses related to ongoing operations. Freenome’s ability to generate product revenue sufficient to achieve profitability, if ever, will depend on premarket approval of the SimpleScreen CRC (v1) and future development of multi-cancer early detection tests.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Freenome has incurred operating losses in each year since its inception. Freenome’s net losses were $219.3 million and $274.4 million for the years ended December 31, 2025 and 2024, respectively. As of December 31, 2025, Freenome had an accumulated deficit of $1.3 billion.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Freenome’s principal executive offices are located at Genesis Marina, 3300 Marina Blvd, Brisbane, California 94005, and its phone number is (650) 446-6630. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Background and Material Terms of the Business Combination </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">PCSC is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Following the completion of its initial public offering on June 13, 2024, at the direction of the PCSC Board, representatives of PCSC, including Messrs. Stone and Poukalov, and Dr. Hukkelhoven commenced an active, targeted search for potential business combination candidates, leveraging the Sponsor’s network of investment bankers, private equity firms and hedge funds (including Perceptive Advisors and its affiliates), consulting firms, legal and accounting firms, and numerous other business relationships, as well as the prior experience and network of PCSC’s officers and directors. During this targeted search, PCSC reviewed approximately 200 potential business combination targets and conducted varying levels of preliminary due diligence on each, and evaluated and analyzed each as a potential business combination target based on, among other things, publicly available information and other market research available to PCSC and its representatives and their existing knowledge of the potential targets as a result of their network and existing relationships. Between October 2024 and December 2024, PCSC submitted non-binding term sheets to two companies, neither of which progressed to a business combination. Thereafter, PCSC continued to assess other potential business combination targets. Through this process, and based on discussion with members of the PCSC Board, PCSC further refined its focus and determined to concentrate its near-term efforts on a smaller set of potential business combination targets, including Freenome, that PCSC believed were the most compelling opportunities relative to the others reviewed.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On February 19, 2025, Dr. Hukkelhoven, in her capacity as an executive officer of the Perceptive PIPE Investor, reached out to the other members of the Freenome Board, consisting of Deepika Pakianathan, Douglas VanOort, Randal Scott, Peter Kolchinsky, Moritz Hartmann, and Josh Lauer, to inquire whether Freenome would be interested in exploring a potential business combination with PCSC. The Perceptive PIPE Investor, was as of such time, and remains, an existing investor in Freenome, and Dr. Hukkelhoven, an executive officer of the Perceptive PIPE Investor, was as of such time, and remains, a member of the Freenome Board. As the Perceptive PIPE Investor has been an investor in Freenome since 2019, the Perceptive PIPE Investor has continuously monitored Freenome’s business progress and capital needs. Dr. Hukkelhoven has been a representative appointed by the Perceptive PIPE Investor on the Freenome Board since 2020. At the direction of the Freenome Board, Dr. Hukkelhoven informed the Perceptive PIPE Investor that Freenome was interested in exploring a capital raising transaction involving the Perceptive PIPE Investor and Dr. Hukkelhoven proposed the terms of the PIPE Financing to the Perceptive PIPE Investor. For more information, see “<span style="font-style: italic;">Business Combination Proposal — Interests of PCSC’s Sponsor, Directors and Officers in the Business Combination.</span>”</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The key terms of the Business Combination Agreement are the result of extensive negotiations between the representatives of PCSC and Freenome, each in consultation with its advisors, which occurred between mid-May 2025 through early August 2025. During such period, Freenome was also negotiating its exclusive licensing agreement with Exact Sciences Corporation (“<span style="font-style: italic; font-weight: bold;">Exact Sciences</span>”) to advance the commercialization of Freenome’s colorectal (CRC) blood-based screening test, which was ultimately signed and announced on August 6, 2025 (the “<span style="font-style: italic; font-weight: bold;">Exact Sciences Transaction</span>”). The terms of the Exact Sciences Transaction included an upfront payment by Exact Sciences to Freenome of $75 million, as well as potential milestone payments of up to $700 million in connection with specified regulatory developments, royalties on test sales, $20 million in funding for joint R&amp;D expenses leveraging the technology for three years and a convertible note of $50 million at an interest rate of 5% per annum.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On August 6, 2025, PCSC and Freenome executed the Non-Binding Term Sheet, setting out the material terms of the Business Combination, including that Freenome would be valued at approximately $1.05 billion on a post-Business Combination equity value basis, taking into account, among other things, (i) an assumed $300 million in aggregate proceeds from (a) the PIPE Financing (which would include at least $25 million expected to be contributed by Perceptive Advisors or its affiliates and at least $50 million expected to be contributed by RA Capital or its affiliates) and (b) the Trust Account at the closing, and (ii) an agreed pre-Business Combination base equity value for Freenome of $725 million. The Non-Binding Term Sheet further contemplated, among other things, (a) certain adjustments for leakage to the Freenome base equity value, (b) that any proceeds from the Exact Sciences Transaction or any transaction entered into with Roche would not be counted as part of the base equity value of Freenome and that any shares or other equity interests of Freenome issued and outstanding in connection with such transactions would not be taken into account as part of the Freenome shares outstanding as of immediately prior to the closing of the Business Combination </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">for purposes of determining the applicable Exchange Ratio, (c) that in addition to other customary closing conditions, the obligation of Freenome to consummate the Business Combination would be subject to there being Aggregate Transaction Proceeds of at least $250,000,000, (d) a six-month lockup period after consummation of the Business Combination with respect to New Freenome shares to be issued to insider Freenome stockholders, including Perceptive Advisors and RA Capital, in the Business Combination, as well as certain demand and piggyback registration rights for certain stockholders, and (e) an Exclusivity Period binding on both PCSC and Freenome.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Between October 6, 2025 and December 4, 2025, PCSC and Freenome, with the assistance of their respective advisors, exchanged and negotiated drafts of the definitive Business Combination Agreement, the disclosure schedules to the Business Combination Agreement and the other ancillary documents, including the Investor Rights Agreement, the Transaction Support Agreement, the New Freenome certificate of incorporation and bylaws, the Lock-Up Agreement and the Sponsor Letter Agreement.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Concurrently with the execution of the Business Combination Agreement and the related ancillary documents, on December 5, 2025, the PIPE Investors executed and delivered the Subscription Agreements, which provided for binding subscriptions to purchase an aggregate of 24,000,000 shares of New Freenome Common Stock at $10.00 per share.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">As contemplated by the Business Combination Agreement, the structure and timing of the Business Combination and the PIPE Financing are consistent with common practice in initial business combination transactions consummated by special purpose acquisition companies. In addition, the timing for the consummation of the Business Combination provided for in the Business Combination Agreement and the Subscription Agreements, which was effectively as soon as reasonably practicable following the execution of the Business Combination Agreement, was determined and agreed by the parties in light of general business considerations weighing in favor of consummating the transaction promptly and the deadline for PCSC to complete an initial business combination by June 13, 2026 (unless otherwise extended). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">For more information, see “<span style="font-style: italic;">Business Combination Proposal—Background and Material Terms of the Business Combination.”</span> </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">The Business Combination Agreement </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Pursuant to the Business Combination Agreement: (a) at least one business day prior to the Closing Date, PCSC will de-register from the Register of Companies in the Cayman Islands and transfer by way of continuation from the Cayman Islands to Delaware and domesticate as a Delaware corporation in accordance with Section 388 of the General Corporation Law of the State of Delaware and Part 12 of the Companies Act (Revised) of the Cayman Islands, upon which PCSC will change its name to “Freenome, Inc.”; (b) Merger Sub I will merge with and into Freenome, with Freenome as the surviving company in the merger and, after giving effect to the First Merger, Freenome will be a wholly-owned subsidiary of PCSC, (c) as soon as practicable following the Effective Time, but no later than one business day following the Effective Time, Freenome, as the surviving corporation of the First Merger, will merge with and into Merger Sub II, with Merger Sub II continuing as the surviving company in the Second Merger, and (d) the other transactions contemplated by the Business Combination Agreement and documents related thereto, all as described in more detail in the accompanying proxy statement/prospectus. References herein to New Freenome denote PCSC following the Business Combination. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As further described in the accompanying proxy statement/prospectus, </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the Domestication is intended to occur at least one business day prior to the Closing Date. In connection with the Domestication, (1)(a) immediately prior to the Domestication, the holders of each issued and outstanding PCSC Class B Share will elect to convert their PCSC Class B Shares into PCSC Class A Shares, (b) immediately prior to the Domestication, PCSC will effect the redemption of the public shares initially issued in PCSC’s initial public offering that are validly submitted for redemption and not withdrawn, (c) and after effecting the PCSC Shareholder Redemptions, upon the Domestication, each issued and outstanding PCSC Class A Share will convert automatically by operation of law, on a one-for-one basis, into one share of New Freenome Common Stock, and (2) upon the Domestication, the governing documents of PCSC will become the certificate of incorporation and the bylaws as described in this proxy statement/prospectus and attached as <span style="font-weight: bold;">Annex H</span> and <span style="font-weight: bold;">Annex I</span>, and PCSC’s name will change to “Freenome, Inc.”; and </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">at the Effective Time, (i) the Freenome Common Shares issued and outstanding as of immediately prior to the Effective Time (including such shares issued upon the conversion of all shares of Freenome preferred stock into Freenome Common Shares prior to the Effective Time in accordance with the terms of the Business Combination Agreement, but excluding Freenome Common Shares held in treasury or by Freenome </div></td></tr></table><div class="BRDSX_bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">stockholders who have properly demanded appraisal of such Freenome Common Shares in accordance with Section 262 of the DGCL) will be automatically canceled and extinguished and converted into the right to receive a number of shares of New Freenome Common Stock equal to the Exchange Ratio, which is based on an implied Freenome base equity value of $725,000,000 and subject to certain adjustments as set forth in the Business Combination Agreement; (ii) each Freenome Option, whether vested or unvested, will cease to represent the right to purchase Freenome Common Shares and will be canceled in exchange for a Rollover Option under the New Freenome Equity Incentive Plan, in an amount equal to the product (rounded down to the nearest whole number) of (x) the number of Freenome Common Shares subject to such Freenome Option immediately prior to the Effective Time, multiplied by (y) the Exchange Ratio, at an exercise price per share (rounded up to the nearest whole cent) equal to the quotient of (i) the exercise price per share of such Freenome Option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, and generally subject to the same terms and conditions (including applicable vesting, expiration and forfeiture provisions) that applied to the corresponding Freenome Option immediately prior to the Effective Time; and (iii) each Freenome RSU Award, whether vested or unvested, will cease to have any rights in respect of the Freenome Common Shares and will be canceled in exchange for a Rollover RSU Award that settles in a number of shares of New Freenome Common Stock (rounded down to the nearest whole share) in an amount and subject to such terms and conditions, in each case, as to be set forth on an allocation schedule, that will generally be subject to the same terms and conditions (including applicable vesting, expiration and forfeiture provisions) that applied to the corresponding Freenome RSU Award immediately prior to the Effective Time. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">For more information about the Business Combination, please see the section titled “<span style="font-style: italic;">Business Combination Proposal—The Business Combination Agreement</span>.” A copy of the Business Combination Agreement is attached to this proxy statement/prospectus as <span style="font-weight: bold;">Annex A</span>. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Structure Diagrams </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The following diagrams illustrate in simplified terms the current structure of PCSC and Freenome, the Business Combination, and the expected structure of Freenome immediately following the Closing. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Simplified Pre-Combination Structure</div><img alt="" src="ny20061080x8_flowchart01.jpg" style="height: 423px; width: 609px;"/><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">The Domestication</div><img alt="" src="ny20061080x8_flowchart02.jpg" style="height: 402px; width: 578px;"/><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14pt; margin-left: 0pt; text-align: left;">The First Merger</div><img alt="" src="ny20061080x8_flowchart03.jpg" style="height: 403px; width: 578px;"/><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">The Second Merger</div><img alt="" src="ny20061080x8_flowchart04.jpg" style="height: 351px; width: 593px;"/><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Simplified Post-Combination Structure</div><img alt="" src="ny20061080x8_flowchart05.jpg" style="height: 373px; width: 628px;"/><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">+<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;"><span style="font-style: italic;">Includes the Perceptive PIPE Investor.</span> </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;"><span style="font-style: italic;">The Sponsor and PCSC’s independent directors (Messrs. McKenna, Song and Waksal).</span> </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">**<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;"><span style="font-style: italic;">Previously Perceptive Capital Solutions Corp before the Domestication.</span> </div></td></tr></table><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">PIPE Financing </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In connection with entering into the Business Combination Agreement, on December 5, 2025, PCSC entered into Subscription Agreements with the PIPE Investors. Pursuant to the Subscription Agreements, the PIPE Investors agreed to subscribe for and purchase, and PCSC agreed to issue and sell to the PIPE Investors, on the Closing Date immediately following the Closing, an aggregate of 24,000,000 shares of New Freenome Common Stock for a purchase price of $10.00 per share, and aggregate gross proceeds of $240.0 million. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Existing Freenome stockholders (other than the Perceptive PIPE Investor and investors who were existing PCSC shareholders) subscribed for approximately $72.4 million of the PIPE Financing. Existing PCSC shareholders (other than the Perceptive PIPE Investor and investors who were existing Freenome stockholders) subscribed for approximately $15.0 million of the PIPE Financing. PIPE Investors who were both existing shareholders of PCSC and Freenome (other than the Perceptive PIPE Investor) subscribed for approximately $52.6 million of the PIPE Financing. The Perceptive PIPE Investor subscribed for an aggregate of $55 million of the PIPE Financing. Investors who were neither existing Freenome stockholders nor existing PCSC shareholders subscribed for approximately $45.0 million of the PIPE Financing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The obligations of each party to consummate the PIPE Financing are conditioned upon, among other things, (i) the New Freenome Common Stock (including the New Freenome Common Stock issuable to the PIPE Investors pursuant to the Subscription Agreements) having been approved for listing on Nasdaq; and (ii) satisfaction of all conditions precedent to the closing of the transactions set forth in the Business Combination Agreement. The obligations of the PIPE Investors to consummate the PIPE Financing are further subject to additional conditions, including, among other things: (i) the Business Combination Agreement shall not have been amended, modified, or supplemented, and no condition waived thereunder, in a manner that would reasonably be expected to materially and adversely affect the economic benefits that a PIPE Investor would reasonably expect to receive under the Subscription Agreement; (ii) the material truth and accuracy of the representations and warranties of PCSC in the Subscription Agreement, subject to customary bringdown standards; (iii) no subscription agreement, or other agreements or understandings (including side letters) entered into in connection with the sale of New Freenome Common Stock under the Subscription Agreements, with any other PIPE Investors shall have been amended, modified, or waived in any manner that benefits such other PIPE Investor unless all PIPE Investors have been offered substantially the same benefits; and (iv) there has not occurred any material adverse effect or parent material adverse effect since the date of the Subscription Agreement that is continuing. See “<span style="font-style: italic;">Business Combination Proposal—Related Agreements—PIPE Financing.</span>” </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Lock-Up Agreement </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In connection with the Closing, the Sponsor and certain former Freenome stockholders will enter into the Lock-Up Agreement with PCSC. Pursuant to the Lock-Up Agreement, the Sponsor and certain Freenome stockholders will agree not to transfer (except for certain permitted transfers) any shares of New Freenome Common Stock held by such holder after the Domestication until six (6) months after the Closing Date. See “<span style="font-style: italic;">Business Combination Proposal—Related Agreements—Lock-up Agreements.</span>” </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Sources and Uses of Proceeds </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The following tables summarize the anticipated sources and uses of funds in the Business Combination, in various redemption scenarios. Such tables are for illustrative purposes only. Where actual amounts are not known or knowable, the figures below represent good faith estimates of such amounts. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Sources and Uses of Proceeds (No Redemptions Scenario) (in millions) </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The following table summarizes the sources and uses of funds for the Business Combination assuming no redemptions by PCSC shareholders.</div><table cellpadding="0" class="BRDSX_fintab" style="width: 474pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 48pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 180pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sources</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Uses</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td></tr><tr><td style="width: 180pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash in Trust Account⁽¹⁾</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.25pt; text-align: left;">$<span style="padding-left: 5pt;">91.9</span></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash to Balance Sheet</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.25pt; text-align: left;">$387.2</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marketable Securities of Freenome</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.25pt; text-align: left;"><span style="padding-left: 5pt;">138.1</span></div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marketable securities to Balance Sheet</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.25pt; text-align: left;"><span style="padding-left: 5pt;">138.1</span></div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Existing Cash Balances, as of December 31, 2025</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.25pt; text-align: left;"><span style="padding-left: 10pt;">79.4</span></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Estimated Unpaid Transaction Expenses, as of December 31, 2025</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.25pt; text-align: left;"><span style="padding-left: 10pt;">24.1</span></div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash Proceeds from the PIPE Financing</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.25pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">240.0</span></div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 180pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Sources</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.25pt; text-align: left;">$549.4</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Uses</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.25pt; text-align: left;">$549.4</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 180pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 180pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Sources and Uses of Proceeds (25% Redemptions Scenario) (in millions)</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The following table summarizes the sources and uses of funds for the Business Combination assuming 25% redemptions by PCSC shareholders.</div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 42pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 180pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sources</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Uses</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td></tr><tr><td style="width: 180pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash in Trust Account⁽¹⁾</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;"><span style="padding-left: 5pt;">91.9</span></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash to Balance Sheet</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;">364.2</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marketable Securities of Freenome</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;">138.1</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marketable securities to Balance Sheet</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;">138.1</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Existing Cash Balances, as of December 31, 2025</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;"><span style="padding-left: 5pt;">79.4</span></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Redemption of PCSC Class A Shares held by public shareholders⁽²⁾</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;"><span style="padding-left: 5pt;">23.0</span></div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash Proceeds from the PIPE Financing</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">240.0</span></div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Estimated Unpaid Transaction Expenses, as of December 31, 2025</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;"><span style="padding-left: 5pt;">24.1</span></div></td></tr><tr><td style="width: 180pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Sources</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;">549.4</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Uses</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;">549.4</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 180pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 180pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 42pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Sources and Uses of Proceeds (50% Redemptions Scenario) (in millions)</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The following table summarizes the sources and uses of funds for the Business Combination assuming 50% redemptions by PCSC shareholders.</div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 42pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 180pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sources</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Uses</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td></tr><tr><td style="width: 180pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash in Trust Account⁽¹⁾</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;"><span style="padding-left: 5pt;">91.9</span></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash to Balance Sheet</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;">341.3</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marketable Securities of Freenome</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;">138.1</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marketable securities to Balance Sheet</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;">138.1</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Existing Cash Balances, as of December 31, 2025</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;"><span style="padding-left: 5pt;">79.4</span></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Redemption of PCSC Class A Shares held by public shareholders⁽²⁾</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;"><span style="padding-left: 5pt;">45.9</span></div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash Proceeds from the PIPE Financing</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">240.0</span></div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Estimated Unpaid Transaction Expenses, as of December 31, 2025</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;"><span style="padding-left: 5pt;">24.1</span></div></td></tr><tr><td style="width: 180pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Sources</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;">549.4</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Uses</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;">549.4</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 180pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 180pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 42pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Sources and Uses of Proceeds (Aggregate Transaction Proceeds Condition Redemptions Scenario) <br/></div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in millions)</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The following table summarizes the sources and uses of funds for the Business Combination assuming the Aggregate Transaction Proceeds Condition Redemptions Scenario.</div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 42pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 180pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sources</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Uses</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td></tr><tr><td style="width: 180pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash in Trust Account⁽¹⁾</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;"><span style="padding-left: 5pt;">91.9</span></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash to Balance Sheet</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;">317.2</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marketable Securities of Freenome</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;">138.1</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marketable securities to Balance Sheet</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;">138.1</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Existing Cash Balances, as of December 31, 2025</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;"><span style="padding-left: 5pt;">79.4</span></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Redemption of PCSC Class A Shares held by public shareholders⁽²⁾</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;"><span style="padding-left: 5pt;">70.0</span></div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash Proceeds from the PIPE Financing</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">240.0</span></div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Estimated Unpaid Transaction Expenses, as of December 31, 2025</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;"><span style="padding-left: 5pt;">24.1</span></div></td></tr><tr><td style="width: 180pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Sources</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;">549.4</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Uses</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;">549.4</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 180pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 180pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 42pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Reflects the amount in the trust account as of December 31, 2025. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Assumes a redemption price of $10.65 per share, based on the amount in the trust account as of December 31, 2025. </div></td></tr></table><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Conditions to Closing of the Business Combination </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Under the Business Combination Agreement, the obligations of the parties to consummate the Business Combination are subject to the satisfaction or waiver of certain closing conditions of the respective parties, including, without limitation, the Aggregate Transaction Proceeds equaling no less than $250.0 million. As of the date of this proxy statement/prospectus, the Aggregate Transaction Proceeds Condition has not been satisfied. The parties intend to satisfy the Aggregate Transaction Proceeds Condition through the PIPE Financing and through amounts released to us from the trust account. In the event the Aggregate Transaction Proceeds Condition is not satisfied as a result of redemptions of public shares which reduce the amount available to be released to us from the trust account, Freenome may, in its sole discretion, waive the Aggregate Transaction Proceeds Condition. If Freenome waives the Aggregate Transaction </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Proceeds Condition, PCSC intends to file a Current Report on Form 8-K within four business days of such event, however such condition may be waived at any time prior to the Closing, including after the deadline for submitting redemption requests or the extraordinary general meeting, and, given such timing, you may not be notified before the deadline for submitting redemption requests or the extraordinary general meeting. For more information, see “<span style="font-style: italic;">Business Combination Proposal—The Business Combination Agreement—Conditions to Closing of the Business Combination.</span>” </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Termination </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Business Combination Agreement may be terminated under certain customary and limited circumstances at any time prior to the Closing, including, among others, the following: (i) by either PCSC or Freenome if the transactions contemplated by the Business Combination Agreement are not consummated on or prior to September 5, 2026; (ii) by either PCSC or Freenome if the requisite approvals by the PCSC shareholders of the Condition Precedent Proposals are not obtained at the extraordinary general meeting (including any adjournment thereof); (iii) by PCSC, if Freenome has not delivered, or caused to be delivered to PCSC, the Freenome Stockholder Written Consent or the Transaction Support Agreements as and when required under the Business Combination Agreement; (iv) by PCSC or Freenome, if Freenome or PCSC, as applicable, has breached any of its respective representations, warranties, agreements or covenants under the Business Combination Agreement, and such breach or failure would render certain conditions precedent to the Closing incapable of being satisfied, and such breach or failure is not cured by the time allotted in the Business Combination Agreement; and (v) by the mutual written consent of PCSC and Freenome. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">If the Business Combination Agreement is validly terminated, none of the parties to the Business Combination Agreement will have any liability or any further obligation under the Business Combination Agreement other than in the case of a willful breach of any covenant or agreement under the Business Combination Agreement or fraud. For more information, see “<span style="font-style: italic;">Business Combination Proposal—The Business Combination Agreement—Termination</span>.” </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Related Agreements </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In connection with the Business Combination, certain other related agreements have been, or will be entered into on or prior to the closing of the Business Combination, including the Transaction Support Agreements, the Sponsor Letter Agreement, and the Investor Rights Agreement. See <span style="font-style: italic;">“—Related Agreements</span>” for more information. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Ownership of New Freenome </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The following tables illustrate estimated ownership levels in New Freenome, immediately following the consummation of the Business Combination, based on varying levels of redemptions by public shareholders. In the following tables, the No Redemptions Scenario, the 25% Redemptions Scenario, the 50% Redemptions Scenario and the Aggregate Transaction Proceeds Condition Redemptions Scenario each assume that the $250.0 million Aggregate Transaction Proceeds Condition is satisfied through a combination of the $240.0 million PIPE Financing and retained funds in the trust account. In the event the Aggregate Transaction Proceeds Condition is not satisfied as a result of redemptions of public shares which reduce the amount available to be released to us from the trust account, Freenome may, in its sole discretion, waive the Aggregate Transaction Proceeds Condition. If Freenome waives the Aggregate Transaction Proceeds Condition, PCSC intends to file a Current Report on Form 8-K within four business days of such event, however such condition may be waived at any time prior to the Closing, including after the deadline for submitting redemption requests or the extraordinary general meeting, and, given such timing, you may not be notified before the deadline for submitting redemption requests or the extraordinary general meeting. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The following table excludes the dilutive effect of Rollover Options, Rollover RSU Awards, the Exact Sciences Note (as defined in section “<span style="font-style: italic;">Description of New Freenome Securities—Outstanding Exact Sciences Convertible Note</span>”), and shares of New Freenome Common Stock that will initially be available for issuance under the New Freenome Equity Incentive Plan and the New Freenome Employee Stock Purchase Plan. </div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 108pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 5.11pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 5.11pt;"><div style="font-size: 1pt;"> </div></td><td colspan="22" style="height: 6pt; width: 349.76pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 108pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 5.11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.11pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td colspan="22" style="width: 349.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Pro Forma Combined </div></td></tr><tr class="BRDSX_header"><td style="width: 108pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 5.11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.11pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="width: 79.64pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">No Redemptions <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Scenario</div></td><td style="width: 5.1pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="width: 79.62pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">25% Redemptions <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Scenario</div></td><td style="width: 5.1pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="width: 79.95pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">50% Redemptions <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Scenario</div></td><td style="width: 5.1pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="width: 79.95pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Aggregate <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Transaction<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Proceeds <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Condition <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Redemptions <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Scenario </div></td></tr><tr class="BRDSX_header"><td style="width: 108pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 5.11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.11pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.67pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td style="width: 5.11pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.11pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">%</div></td><td style="width: 5.1pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.67pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td style="width: 5.1pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">%</div></td><td style="width: 5.1pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td style="width: 5.1pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">%</div></td><td style="width: 5.1pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td style="width: 5.1pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">% </div></td></tr><tr><td style="width: 108pt; padding-top: 1.04pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">PCSC public <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 9pt; text-align: left;">shareholders⁽¹⁾</div></td><td style="width: 5.11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.67pt; padding-top: 1.04pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.67pt;">8,625,000</span></div></td><td style="width: 5.11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 1.04pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 9pt;">7.66%</span></div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.67pt; padding-top: 1.04pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 8.67pt;">6,468,750</span></div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 1.04pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 9pt;">5.85%</span></div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.04pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 9pt;">4,312,500</span></div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 1.04pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 9pt;">3.98%</span></div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.04pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 9pt;">2,056,878</span></div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 1.04pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 9pt;">1.94%</span></div></td></tr><tr><td style="width: 108pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 9pt; text-indent: -9pt; text-align: left;">Sponsor and the Perceptive PIPE Investor⁽²⁾</div></td><td style="width: 5.11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.67pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4.17pt;">13,554,087</span></div></td><td style="width: 5.11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">12.03%</span></div></td><td style="width: 5.1pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.67pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.17pt;">13,554,087</span></div></td><td style="width: 5.1pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">12.26%</span></div></td><td style="width: 5.1pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">13,554,087</span></div></td><td style="width: 5.1pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">12.51%</span></div></td><td style="width: 5.1pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">13,554,087</span></div></td><td style="width: 5.1pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">12.77%</span></div></td></tr><tr><td style="width: 108pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 9pt; text-indent: -9pt; text-align: left;">PCSC independent directors⁽³⁾</div></td><td style="width: 5.11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.67pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 19.92pt;">90,000</span></div></td><td style="width: 5.11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 9pt;">0.08%</span></div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.67pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 19.92pt;">90,000</span></div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 9pt;">0.08%</span></div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 20.25pt;">90,000</span></div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 9pt;">0.08%</span></div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 20.25pt;">90,000</span></div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 9pt;">0.08%</span></div></td></tr><tr><td style="width: 108pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 9pt; text-indent: -9pt; text-align: left;">Freenome stockholders (excluding the Perceptive PIPE Investor and Roche)⁽⁴⁾</div></td><td style="width: 5.11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.67pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4.17pt;">52,699,707</span></div></td><td style="width: 5.11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">46.77%</span></div></td><td style="width: 5.1pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.67pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.17pt;">52,699,707</span></div></td><td style="width: 5.1pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">47.69%</span></div></td><td style="width: 5.1pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">52,699,707</span></div></td><td style="width: 5.1pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">48.64%</span></div></td><td style="width: 5.1pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">52,699,707</span></div></td><td style="width: 5.1pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">49.67%</span></div></td></tr><tr><td style="width: 108pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 9pt; text-indent: -9pt; text-align: left;">PIPE Investors (excluding the Perceptive PIPE Investor)⁽⁵⁾</div></td><td style="width: 5.11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.67pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4.17pt;">18,500,000</span></div></td><td style="width: 5.11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">16.42%</span></div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.67pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.17pt;">18,500,000</span></div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">16.74%</span></div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">18,500,000</span></div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">17.07%</span></div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">18,500,000</span></div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">17.44%</span></div></td></tr><tr><td style="width: 108pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Roche⁽⁶⁾</div></td><td style="width: 5.11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.67pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4.17pt;">19,198,197</span></div></td><td style="width: 5.11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">17.04%</span></div></td><td style="width: 5.1pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.67pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.17pt;">19,198,197</span></div></td><td style="width: 5.1pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">17.37%</span></div></td><td style="width: 5.1pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">19,198,197</span></div></td><td style="width: 5.1pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">17.72%</span></div></td><td style="width: 5.1pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">19,198,197</span></div></td><td style="width: 5.1pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">18.09%</span></div></td></tr><tr><td style="width: 108pt; padding-top: 0.17pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; margin-left: 9pt; text-indent: -9pt; text-align: left;">Pro forma total shares of the New Freenome Common Stock outstanding at <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; margin-left: 9pt; text-align: left;">Closing</div></td><td style="width: 5.11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.67pt; padding-top: 0.17pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">112,666,991</div></td><td style="width: 5.11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">100.00%</div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.67pt; padding-top: 0.17pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">110,510,741</div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">100.00%</div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">108,354,491</div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">100.00%</div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">106,098,869</div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">100.00%</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3pt; width: 108pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 5.11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 5.11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 44.67pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 5.11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 5.11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 24.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 44.67pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 24.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 45pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 24.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 45pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 5.1pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 24.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Less than 1%. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Amount comprises the unredeemed public shares in a variety of redemptions scenarios. This amount reflects the assumed redemption of 0 shares under the No Redemptions Scenario, 2,156,250 shares redeemed under the 25% Redemptions Scenario, 4,312,500 shares redeemed under the 50% Redemptions Scenario, and 6,568,122 shares redeemed under the Aggregate Transaction Proceeds Condition Redemptions Scenario. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Amount includes 2,066,250 PCSC Class B Shares held by the Sponsor, 286,250 private placement shares, which are PCSC Class A Shares, held by Sponsor, 5,500,000 shares purchased by the Perceptive PIPE Investor as part of the PIPE Financing, and 5,611,587 shares of New Freenome Common Stock to be issued as merger consideration. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Amount includes 30,000 PCSC Class B Shares held by each of PCSC’s independent directors (Messrs. McKenna, Song and Waksal). </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(4)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Amount includes 71,089,352 shares of New Freenome Common Stock issued to Freenome stockholders <span style="font-style: italic;">less</span> 5,611,587 and 12,778,058 shares that will be held by the Perceptive PIPE Investor and Roche, respectively, which are presented in the rows labeled “Sponsor and the Perceptive PIPE Investor” and “Roche.” The amounts in the table do not include the potentially dilutive shares that could be issued, specifically 8,252,587 Rollover Options issued to holders of Freenome Options (whether vested or unvested immediately prior to the Effective Time), 4,291,830 Rollover RSU Awards issued to holders of Freenome RSU Awards (whether vested or unvested immediately prior to the Effective Time) and 3,441,094 shares which would be issued upon Exact Sciences’ optional election to convert the Exact Sciences Note (assuming accrued interest through May 31, 2026). </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(5)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Amount includes the 18,500,000 shares of New Freenome Common Stock to be issued to the PIPE Investors, <span style="font-style: italic;">less</span> the 5,500,000 shares to be purchased by the Perceptive PIPE Investor as part of the PIPE Financing (which are presented in the row labeled “Sponsor and the Perceptive PIPE Investor”).</div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(6)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Includes 12,778,058 shares of New Freenome Common Stock to be issued as merger consideration and 6,420,139 shares of Freenome Common Stock issued upon conversion of the Roche Convertible Note. The Roche Convertible Note (including the principal amount and accrued interest) will automatically convert into shares of New Freenome Common Stock at a conversion price of $12.00 in connection with the Closing. This amount assumes accrued interest through May 31, 2026. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The following table shows possible sources of dilution and the extent of such dilution that non-redeeming public shareholders could experience in connection with the closing of the Business Combination. The table excludes shares of New Freenome Common Stock that will initially be available for issuance under the New Freenome Equity Incentive Plan and the New Freenome Employee Stock Purchase Plan, as such shares are not expected to be outstanding on the Closing Date. </div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 108pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td colspan="22" style="height: 6pt; width: 349.84pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 108pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td colspan="22" style="width: 349.84pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Pro Forma Combined, Including Dilutive Instruments </div></td></tr><tr class="BRDSX_header"><td style="width: 108pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="width: 79.87pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">No Redemptions <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Scenario</div></td><td style="width: 5.06pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="width: 79.87pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">25% Redemptions <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Scenario</div></td><td style="width: 5.06pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="width: 79.87pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">50% Redemptions <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Scenario</div></td><td style="width: 5.06pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="width: 79.87pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Aggregate<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Transaction <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Proceeds <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Condition <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Redemptions <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Scenario </div></td></tr><tr class="BRDSX_header"><td style="width: 108pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td style="width: 5.06pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">%</div></td><td style="width: 5.06pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td style="width: 5.06pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">%</div></td><td style="width: 5.06pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td style="width: 5.06pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">%</div></td><td style="width: 5.06pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td style="width: 5.06pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">% </div></td></tr><tr><td style="width: 108pt; padding-top: 1.04pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">PCSC public <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 9pt; text-align: left;">shareholders⁽¹⁾</div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.04pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 9pt;">8,625,000</span></div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 1.04pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 9pt;">6.71%</span></div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.04pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 9pt;">6,468,750</span></div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 1.04pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 9pt;">5.12%</span></div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.04pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 9pt;">4,312,500</span></div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 1.04pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 9pt;">3.47%</span></div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.04pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 9pt;">2,056,878</span></div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 1.04pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 9pt;">1.69%</span></div></td></tr><tr><td style="width: 108pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 9pt; text-indent: -9pt; text-align: left;">Sponsor and the Perceptive PIPE Investor⁽²⁾</div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">13,554,087</span></div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">10.54%</span></div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">13,554,087</span></div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">10.72%</span></div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">13,554,087</span></div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">10.91%</span></div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">13,554,087</span></div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4.83pt;">11.11</span><span style="padding-left: 0.33pt;">%</span></div></td></tr><tr><td style="width: 108pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 9pt; text-indent: -9pt; text-align: left;">PCSC independent directors⁽³⁾</div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 20.25pt;">90,000</span></div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 9pt;">0.07%</span></div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 20.25pt;">90,000</span></div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 9pt;">0.07%</span></div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 20.25pt;">90,000</span></div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 9pt;">0.07%</span></div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 20.25pt;">90,000</span></div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 9pt;">0.07%</span></div></td></tr><tr><td style="width: 108pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 9pt; text-indent: -9pt; text-align: left;">Freenome Stockholders (excluding the Perceptive PIPE Investors and Roche)⁽⁴⁾</div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">52,699,707</span></div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">41.00%</span></div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">52,699,707</span></div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">41.70%</span></div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">52,699,707</span></div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">42.42%</span></div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">52,699,707</span></div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">43.20%</span></div></td></tr><tr><td style="width: 108pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 9pt; text-indent: -9pt; text-align: left;">PIPE Investors (excluding the Perceptive PIPE Investor)⁽⁵⁾</div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">18,500,000</span></div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">14.39%</span></div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">18,500,000</span></div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">14.64%</span></div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">18,500,000</span></div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">14.89%</span></div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">18,500,000</span></div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">15.17%</span></div></td></tr><tr><td style="width: 108pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Rollover Options⁽⁶⁾</div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 9pt;">8,252,587</span></div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 9pt;">6.42%</span></div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 9pt;">8,252,587</span></div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 9pt;">6.53%</span></div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 9pt;">8,252,587</span></div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 9pt;">6.64%</span></div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 9pt;">8,252,587</span></div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 9pt;">6.77%</span></div></td></tr><tr><td style="width: 108pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Rollover RSU Awards⁽⁷⁾</div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 9pt;">4,291,830</span></div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 9pt;">3.34%</span></div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 9pt;">4,291,830</span></div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 9pt;">3.40%</span></div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 9pt;">4,291,830</span></div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 9pt;">3.45%</span></div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 9pt;">4,291,830</span></div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 9pt;">3.52%</span></div></td></tr><tr><td style="width: 108pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Roche⁽⁸⁾</div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">19,198,197</span></div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">14.94%</span></div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">19,198,197</span></div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">15.19%</span></div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">19,198,197</span></div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">15.45%</span></div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">19,198,197</span></div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4.5pt;">15.74%</span></div></td></tr><tr><td style="width: 108pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exact Sciences⁽⁹⁾</div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 9pt;">3,333,333</span></div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 9pt;">2.59%</span></div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 9pt;">3,333,333</span></div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 9pt;">2.64%</span></div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 9pt;">3,333,333</span></div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 9pt;">2.68%</span></div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 9pt;">3,333,333</span></div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 9pt;">2.73%</span></div></td></tr><tr><td style="width: 108pt; padding-top: 0.17pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; margin-left: 9pt; text-indent: -9pt; text-align: left;">Pro forma total shares of the New Freenome Common Stock outstanding at <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; margin-left: 9pt; text-align: left;">Closing</div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">128,544,741</div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">100.00%</div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">126,388,491</div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">100.00%</div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">124,232,241</div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">100.00%</div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.17pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">121,976,619</div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.75pt; padding-top: 0.17pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">100.00%</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3pt; width: 108pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 45pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 24.75pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 45pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 24.75pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 45pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 24.75pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 45pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 5.06pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 3pt; width: 24.75pt;"><div style="font-size: 1pt;"> </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Less than 1%. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Amount comprises the unredeemed public shares in a variety of redemptions scenarios. This amount reflects the assumed redemption of 0 shares under the No Redemptions Scenario, 2,156,250 shares redeemed under the 25% Redemptions Scenario, 4,312,500 shares redeemed under the 50% Redemptions Scenario, and 6,568,122 shares redeemed under the Aggregate Transaction Proceeds Condition Redemptions Scenario. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Amount includes 2,066,250 PCSC Class B Shares held by the Sponsor, 286,250 PCSC Class A Shares held by Sponsor, 5,500,000 shares purchased by the Perceptive PIPE Investor as part of the PIPE Financing, and 5,611,587 shares of New Freenome Common Stock to be issued as merger consideration. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Amount includes 30,000 PCSC Class B Shares held by each of PCSC’s independent directors (Messrs. McKenna, Song and Waksal). </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(4)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Amount includes 71,089,352 shares of New Freenome Common Stock issued to Freenome stockholders <span style="font-style: italic;">less</span> 5,611,587 and 12,778,058 shares that will be held by the Perceptive PIPE Investor and Roche, respectively, which are presented in the rows labeled “Sponsor and the Perceptive PIPE Investor” And “Roche.” </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(5)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Amount includes the 18,500,000 shares of New Freenome Common Stock to be issued to the PIPE Investors, <span style="font-style: italic;">less</span> the 5,500,000 shares to be purchased by the Perceptive PIPE Investor as part of the PIPE Financing (which are presented in the row labeled “Sponsor and the Perceptive PIPE Investor”). </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(6)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Amount comprises the potentially dilutive shares that could be issued pursuant to 8,252,587 Rollover Options issued to holders of Freenome Options (whether vested or unvested immediately prior to the Effective Time) in accordance with the terms of the Business Combination Agreement. Does not include shares the Initial Equity Awards and Anti-Dilution Equity Awards. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(7)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Amount comprises the potentially dilutive shares that could be issued pursuant to 4,291,830 Rollover RSU Awards issued to holders of Freenome RSU Awards (whether vested or unvested immediately prior to the Effective Time) in accordance with the terms of the Business Combination Agreement. Does not include shares the Initial Equity Awards and Anti-Dilution Equity Awards. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(8)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Includes 12,778,058 shares of New Freenome Common Stock to be issued as Mergers Consideration and 6,420,139 shares of Freenome Common Stock issued upon conversion of the Roche Convertible Note. The Roche Convertible Note (including the principal amount and accrued interest) will automatically convert into shares of New Freenome Common Stock at a conversion price of $12.00 in connection with the Closing. This amount assumes accrued interest through May 31, 2026.</div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(9)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Includes 3,333,333 shares of New Freenome Common Stock which would be issued upon Exact Sciences’ optional election to convert the Exact Sciences Note. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Share ownership presented in the two tables above is only presented for illustrative purposes and does not necessarily reflect what New Freenome’s share ownership will be after the Closing. PCSC and New Freenome cannot predict how many of the public shareholders will exercise their right to have their public shares redeemed for cash. As a result, the redemption amount and the number of public shares redeemed in connection with the Business Combination may differ from the amounts presented above, and therefore the ownership percentages of public shareholders may also differ if the actual redemptions are different from these assumptions. The public shareholders that do not elect to redeem their public shares will experience immediate dilution as a result of the Business Combination. The public shareholders currently own approximately 77.9% of the issued and outstanding PCSC Shares. As noted in the above table, even if no public shareholders redeem their public shares in the Business Combination, the public shareholders’ ownership will decrease from approximately 77.9% of the PCSC Shares prior to the Business Combination to owning approximately 7.66% of the total outstanding New Freenome Common Stock at the Closing. As redemptions increase, the overall percentage ownership held by the Sponsor, the Perceptive PIPE Investor, PCSC’s independent directors (Messrs. McKenna, Song and Waksal), Freenome Stockholders and the PIPE Investors will increase as compared to the overall percentage ownership and voting percentage held by public shareholders, thereby increasing dilution to public shareholders. For more information about the consideration to be received in the Business Combination, these scenarios, and the underlying assumptions, see “<span style="font-style: italic;">Unaudited Pro Forma Combined Financial Information.</span>” See also “<span style="font-style: italic;">Risk Factors—The public shareholders will experience immediate dilution as a consequence of the issuance of New Freenome Common Stock as consideration in the Business Combination and due to future issuances of equity awards to Freenome employees, directors, or consultants. Having a minority share position may reduce the influence that our current shareholders have on the management of New Freenome.</span>” </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Interests of PCSC’s Directors and Executive Officers, Sponsor and Others in the Business Combination </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In considering the recommendation of the PCSC Board in favor of approval of the Business Combination Proposal, the Domestication Proposal, the Governing Documents Proposal, each of the Advisory Governing Documents Proposals, the Nasdaq Proposal, the Equity Incentive Plan Proposal, the Employee Stock Purchase Plan Proposal and the Adjournment Proposal, PCSC shareholders should keep in mind that the Sponsor, the Perceptive PIPE Investor, and PCSC’s officers and directors have interests in the Business Combination that are different from or in addition to (and which may conflict with) the interests of unaffiliated PCSC shareholders. Further, PCSC’s officers and directors have additional fiduciary or contractual obligations to other entities pursuant to which such officer or director is or will be required to present a business combination opportunity to such entity, which are set forth in more detail in the section titled “<span style="font-style: italic;">Information About PCSC—Conflicts of Interest</span>.” We believe there were no such opportunities that were not presented as a result of the existing fiduciary or contractual obligations of our officers and directors to other entities. The PCSC Board was aware of and considered these interests, among other matters, in evaluating and negotiating the Business Combination and Business Combination Agreement and in recommending to our shareholders that they vote in favor of the proposals to be presented at the extraordinary general meeting, including the Business Combination Proposal. PCSC shareholders should take these interests into account in deciding whether to approve the proposals presented at the extraordinary general meeting, including the Business Combination Proposal. See “<span style="font-style: italic;">Business Combination Proposal—Interests of PCSC’s Directors and Executive Officers, Sponsor and Others in the Business Combination.</span>” </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Compensation to be Received by the Sponsor, the Perceptive PIPE Investor, and PCSC’s Officers and Directors in Connection with the Business Combination and PIPE Financing </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Set forth below is a summary of the amount of compensation and securities received or to be received by the Sponsor, the Perceptive PIPE Investor, and PCSC’s officers and directors in connection with the Business Combination and PIPE Financing. </div><table cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 120pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 144pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 120pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Securities to be Received</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 144pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Other Compensation </div></td></tr><tr><td style="width: 120pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Sponsor</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Assuming the Aggregate Transaction Proceeds Condition Redemptions Scenario: (i) 2,066,250 shares of New Freenome Common Stock upon the exchange of 2,066,250 PCSC Class B Shares in the Domestication, which were initially purchased prior to PCSC’s initial public</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 144pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Reimbursement for Working Capital Loans to PCSC. To date, PCSC has no outstanding borrowings under Working Capital Loans.<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$15,000 per month through the Closing for office space, secretarial </div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 120pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 144pt;"><div style="font-size: 1pt;"> </div></td></tr></table><table cellpadding="0" class="BRDSX_txttab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 120pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 144pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 120pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Securities to be Received</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 144pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Other Compensation </div></td></tr><tr><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">offering for approximately $0.01 per share and (ii) 286,250 shares of New Freenome Common Stock upon the exchange of 286,250 PCSC Class A Shares in the Domestication, which were initially purchased in a private placement that closed concurrently with PCSC’s initial public offering at a price of $10.00 per share.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">and administrative services. As of December 31, 2025, PCSC incurred $180,000 in fees for these services, of which such amount is included in accrued expenses in PCSC’s balance sheet as of December 31, 2025.<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Continued indemnification and the continuation of directors’ and officer’s liability insurance after the Business Combination. </div></td></tr><tr><td style="width: 120pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 144pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 120pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Perceptive PIPE Investor </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Assuming the Aggregate Transaction Proceeds Condition Redemptions Scenario: (i) 5,500,000 shares of New Freenome Common Stock purchased by the Perceptive PIPE Investor for $10.00 per share in the PIPE Financing, for an aggregate amount of $55.0 million, and (iii) 5,615,003 shares of New Freenome Common Stock upon the exchange of Freenome capital stock in the First Merger, which is determined by reference to the Exchange Ratio.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 144pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Continued indemnification after the Business Combination. </div></td></tr><tr><td style="width: 120pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 144pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 120pt; padding-top: 0.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">PCSC’s independent directors (Messrs. McKenna, Song and Waksal)</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 0.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Each will receive 30,000 shares of New Freenome Common Stock upon the exchange of 30,000 PCSC Class B Shares held by them in the Domestication, which shares were issued to them as consideration for services to PCSC.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 144pt; padding-top: 0.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Reimbursement for Working Capital Loans to PCSC. To date, PCSC has no outstanding borrowings under Working Capital Loans.<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">  <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Reimbursement for out-of-pocket expenses incurred related to identifying, negotiating, investigating and completing the Business Combination; no such amounts are outstanding as of the date of this proxy statement/prospectus.<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Continued indemnification and the continuation of directors’ and officer’s liability insurance after the Business Combination.</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 120pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 144pt;"><div style="font-size: 1pt;"> </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The securities to be issued to the Sponsor, the Perceptive PIPE Investor, and PCSC’s officers and directors may result in a material dilution of the equity interests of non-redeeming public shareholders. PCSC’s independent directors are not members of the Sponsor and are not affiliates of the Perceptive PIPE Investor. None of the funds in the trust account will be used to compensate our officers or directors. Except for administrative services fees and office rental fees paid or to be paid to the Sponsor, no compensation of any kind, including finder’s and consulting fees, have been paid or will be paid to the Sponsor, the Perceptive PIPE Investor, officers and directors, or any of their respective affiliates, for services rendered prior to or in connection with the completion of the Business Combination. However, as detailed above, these individuals will be reimbursed for any out-of-pocket expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations, as discussed above. The reimbursement of expenses and advances to the Sponsor, the Perceptive PIPE Investor, and PCSC’s officers and directors may result in a material dilution of the equity interests of non-redeeming public shareholders. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">The Special Committee’s and the PCSC Board’s Reasons for the Approval of the Business Combination </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Before unanimously determining that the terms and conditions of the Business Combination Agreement, each ancillary agreement, and the Business Combination were fair, advisable, and in the best interests of PCSC and its shareholders as a whole, the Special Committee and the PCSC Board considered a wide variety of factors in connection with their evaluation of the Business Combination. In light of the complexity of the factors considered, the Special Committee and the PCSC Board, as a whole, did not consider it practicable to, and did not attempt to, quantify or otherwise assign relative weights to the specific factors they took into account in reaching their respective decisions. Rather, the Special Committee and the PCSC Board based their evaluation, negotiation and recommendation of the Business Combination on the totality of information available and the factors presented to and considered by them. In addition, individual members of the Special Committee and the PCSC Board may have given different weights to different factors. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The PCSC Board and the Special Committee reached its unanimous decision in light of a variety of factors, including but not limited to Freenome’s novel technology for early cancer detection, accompanied with positive data, Freenome’s critical and valuable commercial partnerships, Freenome’s market opportunity, Freenome’s experienced leadership team, and the size of the PIPE Financing committed. The Special Committee also reviewed the financial analysis and opinion of Scalar rendered to the Special Committee to the effect that, as of December 4, 2025 and subject to the procedures followed, assumptions made, matters considered, qualifications and limitations on the review undertaken, and other matters considered by Scalar in connection with the opinion, the consideration to be delivered to the Freenome Stockholders in the First Merger pursuant to the Business Combination was fair, from a financial point of view, to the PCSC Unaffiliated Shareholders. The Special Committee and the PCSC Board also considered a variety of factors and risks, potentially weighing negatively against pursuing the Business Combination, including, but not limited to macroeconomic risks that may cause Freenome’s future financial performance to not meet the Special Committee’s and the PCSC Board’s present expectations, the risk of regulatory changes that may adversely affect Freenome’s projected financial results and the other business benefits anticipated to result from the Business Combination, the redemption risk, the risk that PCSC shareholders may fail to provide the votes necessary to effect the Business Combination, the risks and costs to PCSC if the Business Combination is not completed, including the fact that PCSC may be forced to liquidate if PCSC being unable to effect a business combination by June 13, 2026 (unless otherwise extended), the risk that Closing may not occur due to failure to satisfy Closing conditions to the Business Combination, and the absence of possible structural protections for minority shareholders. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">For more information about the Special Committee’s and PCSC Board’s reasons for the approval of the Business Combination, see “<span style="font-style: italic;">Business Combination Proposal — The Special Committee’s and the PCSC Board’s Reasons for the Approval of the Business Combination.</span>” </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Opinion of Scalar, LLC </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On December 4, 2025, Scalar rendered its oral opinion to the Special Committee, subsequently confirmed in writing, as to the fairness, from a financial point of view, as of such date, to (1) the PCSC Class A Shareholders (other than (i) Freenome, (ii) Sponsor, (iii) the Key Supporting Company Stockholders, (iv) PCSC Class A Shareholders who elect to redeem their shares prior to or in connection with the Transaction, and (v) the PIPE Investors, (collectively, along with their respective affiliates, the “<span style="font-style: italic; font-weight: bold;">Excluded Parties</span>”)) of the consideration to be delivered to the Freenome Stockholders in the Transaction, without giving effect to any impact of the Transaction on any particular PCSC Class A Shareholder other than in its capacity as a PCSC Class A Shareholder, and (2) PCSC. The full text of Scalar’s written opinion, dated December 4, 2025, which sets forth the procedures followed, assumptions made, matters considered, qualifications and limitations on the review undertaken, and other matters considered by Scalar in connection with the opinion are fully described in the subsection “<span style="font-style: italic;">Business Combination Proposal— Opinion of Scalar, LLC</span>”. A copy of Scalar’s opinion is attached hereto as <span style="font-weight: bold;">Annex L</span>. The summary of Scalar’s opinion in this proxy statement/prospectus is qualified in its entirety by reference to the full text of Scalar’s written opinion. Scalar’s opinion was provided for the information and assistance of the Special Committee and does not constitute a recommendation as to how any shareholder of PCSC should vote or act (including with respect to any redemption rights) with respect to the Transaction or any other matter. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">The Extraordinary General Meeting of PCSC </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The following is a summary of the process and procedures for registering for and attending the extraordinary general meeting, and voting and redeeming your PCSC Shares in connection with the extraordinary general meeting. For more information, see the section entitled “<span style="font-style: italic;">Extraordinary General Meeting of PCSC</span>.” </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Date, Time and Place </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The extraordinary general meeting will be held at [•] a.m., Eastern Time, on [•], 2026, at the offices of Cooley LLP located at 55 Hudson Yards, New York, New York 10001, and via a virtual meeting at [•]. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Shareholders may attend the extraordinary general meeting in person. If you wish to attend the extraordinary general meeting in person at the offices of Cooley LLP located at 55 Hudson Yards, New York, New York 10001, you must reserve your attendance at least two business days in advance of the extraordinary general meeting by contacting PCSC’s secretary at [•] by 10:30 a.m., Eastern Time, on [•], 2026. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Proposals to be voted on at the Extraordinary General Meeting </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">At the extraordinary general meeting, PCSC’s shareholders are being asked to consider and vote upon: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Business Combination Proposal; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Domestication Proposal; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Governing Documents Proposal; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Advisory Governing Documents Proposals; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Nasdaq Proposal; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Equity Incentive Plan Proposal; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Employee Stock Purchase Plan Proposal; and </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Adjournment Proposal (if presented). </div></td></tr></table><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Abstentions and Broker Non-Votes; Voting Your Shares; Record Date </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">With respect to each proposal in this proxy statement/prospectus, you may vote “FOR,” “AGAINST” or “ABSTAIN.” </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Proxies that are marked “abstain” and proxies relating to “street name” shares that are returned to PCSC but marked by brokers as “not voted” will be treated as PCSC Shares present for purposes of determining the presence of a quorum on all matters. Abstentions and broker non-votes, while considered present for the purposes of establishing a quorum, will not count as votes cast at the extraordinary general meeting, and otherwise will have no effect on a particular proposal. If a shareholder does not give the broker voting instructions, under applicable self-regulatory organization rules, its broker may not vote its shares on “non-routine” proposals, such as the Business Combination Proposal or any of the other Condition Precedent Proposals. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Each PCSC Share that you own in your name entitles you to one vote. Your proxy card shows the number of PCSC Shares that you own. If your shares are held in “street name” or are in a margin or similar account, you should contact your broker to ensure that votes related to the shares you beneficially own are properly counted. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">PCSC shareholders will be entitled to vote or direct votes to be cast at the extraordinary general meeting if they owned PCSC Shares at the close of business on [•], 2026, which is the record date for the extraordinary general meeting. As of the close of business on the record date, there were 11,067,500 PCSC Shares issued and outstanding, of which 8,911,250 were PCSC Class A Shares and 2,156,250 were PCSC Class B Shares. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Pursuant to the Sponsor Letter Agreement, the Sponsor and each of PCSC’s independent directors (Messrs. McKenna, Song and Waksal) have agreed to, among other things, vote all of their PCSC Shares in favor of the proposals being presented at the extraordinary general meeting. No consideration has been or will be paid by PCSC or Freenome to the Sponsor and each of PCSC’s independent directors in connection with the entry into the Sponsor Letter Agreement. As of the date of the accompanying proxy statement/prospectus, the initial shareholders collectively own 2,442,500 PCSC Shares, or approximately 22.1% of the issued and outstanding ordinary shares as follows: (i) the Sponsor owns 2,066,250 PCSC Class B Shares and 286,250 private placement shares, which are PCSC Class A Shares; and (ii) the PCSC independent directors each own 30,000 PCSC Class B Shares, for an aggregate of 90,000 PCSC Class B Shares. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Quorum and Required Vote for Proposals for the Extraordinary General Meeting </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">A quorum of PCSC shareholders is necessary to hold a valid meeting. A quorum will be present at the extraordinary general meeting if one or more shareholders who together hold not less than one-third of the issued and outstanding PCSC Shares entitled to vote at the extraordinary general meeting are represented in person or by proxy (or if a corporation or other non-natural person by duly authorized representative or proxy) at the extraordinary general meeting. As of the record date, 3,689,167 PCSC Shares would be required to achieve a quorum. As of the record date, the initial shareholders owned of record an aggregate of 2,442,500 PCSC Shares, representing approximately 22.1% of the issued and outstanding PCSC Shares. Therefore, an additional 1,246,667 public shares are required to establish a quorum. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following votes are required to approve each Proposal: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-weight: bold;">Business Combination Proposal</span>: The approval of the Business Combination Proposal requires an ordinary resolution under Cayman Islands law, being the affirmative vote of at least a majority of the votes cast by the holders of the issued and outstanding PCSC Shares present in person or represented by proxy at the extraordinary general meeting and entitled to vote on such matter. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-weight: bold;">Domestication Proposal</span>: The approval of the Domestication Proposal requires a special resolution of the holders of PCSC Class B Shares, being the affirmative vote of at least a two-thirds (2/3) majority of the votes cast by the holders of issued and outstanding PCSC Class B Shares who, being present in person or represented by proxy and entitled to vote at the extraordinary general meeting, vote at the extraordinary general meeting. The holders of the PCSC Class A Shares will have no right to vote on the Domestication Proposal, in accordance with Article 34.2 of the Existing Governing Documents. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-weight: bold;">Governing Documents Proposal</span>: The approval of the Governing Documents Proposal requires a special resolution of the holders of PCSC Class B Shares, being the affirmative vote of at least a two-thirds (2/3) majority of the votes cast by the holders of the issued and outstanding PCSC Class B Shares who, being present in person or represented by proxy and entitled to vote at the extraordinary general meeting, at the extraordinary general meeting. The holders of the PCSC Class A Shares will have no right to vote on the Governing Documents Proposal, in accordance with Article 34.2 of the Existing Governing Documents. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-weight: bold;">Advisory Governing Documents Proposals</span>: The approval of each Advisory Governing Documents Proposals requires an ordinary resolution, on a non-binding and advisory basis only, being the affirmative vote of at least a majority of the votes cast by the holders of the issued and outstanding PCSC Shares present in person or represented by proxy at the extraordinary general meeting and entitled to vote on such matter. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-weight: bold;">Nasdaq Proposal</span>: The approval of the Nasdaq Proposal requires an ordinary resolution, being the affirmative vote of at least a majority of the votes cast by the holders of the issued and outstanding PCSC Shares present in person or represented by proxy at the extraordinary general meeting and entitled to vote on such matter. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-weight: bold;">Equity Incentive Plan Proposal</span>: The approval of the Equity Incentive Plan Proposal requires an ordinary resolution, being the affirmative vote of at least a majority of the votes cast by the holders of the issued and outstanding PCSC Shares present in person or represented by proxy at the extraordinary general meeting and entitled to vote on such matter. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-weight: bold;">Employee Stock Purchase Plan Proposal</span>: The approval of the Employee Stock Purchase Plan Proposal requires an ordinary resolution, being the affirmative vote of at least a majority of the votes cast by the holders of the issued and outstanding PCSC Shares present in person or represented by proxy at the extraordinary general meeting and entitled to vote on such matter. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-weight: bold;">Adjournment Proposal</span>: The approval of the Adjournment Proposal requires an ordinary resolution under Cayman Islands law, being the affirmative vote of at least a majority of the votes cast by the holders of the issued and outstanding PCSC Shares present in person or represented by proxy at the extraordinary general meeting and entitled to vote on such matter. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Each of the Business Combination Proposal, the Domestication Proposal, the Governing Documents Proposal, the Nasdaq Proposal, the Equity Incentive Plan Proposal and the Employee Stock Purchase Plan Proposal is conditioned on the approval and adoption of each of the other Condition Precedent Proposals. Consummation of the Business Combination is not conditioned upon the approval of the Advisory Governing Documents Proposals or the Adjournment Proposal. Neither the Advisory Governing Documents Proposals nor the Adjournment Proposal is conditioned upon the approval of any other proposal. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Redemption Rights </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Pursuant to the Existing Governing Documents, a public shareholder may request that PCSC redeem its public shares for cash contemporaneously with the vote to approve the Business Combination and prior to the Domestication. If the Business Combination is approved, PCSC will pay to the holders any public shares that have been validly tendered or delivered for redemption a pro rata portion of the aggregate amount then on deposit in the trust account, calculated as of two business days prior to the consummation of the Business Combination and including interest earned on the funds held in the Trust Account not previously released to PCSC for permitted withdrawals. Pursuant to the Business Combination Agreement, the Domestication shall occur at least one business day prior to the Closing Date. As a holder of public shares, you will be entitled to receive cash for any public shares to be redeemed only if you: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">hold public shares; and </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">prior to 5:00 p.m., Eastern Time, on [•], 2026 (two business days prior to the initially scheduled vote at the extraordinary general meeting), (a) submit a written request to the PCSC transfer agent in which you (i) request that PCSC redeem all or a portion of your public shares for cash, and (ii) identify yourself as the beneficial holder of the public shares and provide your legal name, phone number and address; and (b) deliver your public shares to the PCSC transfer agent physically or electronically through DTC. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">For illustrative purposes, based on funds in the trust account of approximately $91,918,776.09 on January 6, 2026, the estimated per share redemption price is expected to be approximately $10.66. A public shareholder who has properly tendered or delivered his, her or its public shares for redemption will be entitled to receive his, her or its pro rata portion of the aggregate amount then on deposit in the trust account in cash for such shares only if the Business Combination is completed. If the Business Combination is not completed, the redemptions will be canceled and the tendered shares will be returned to the relevant public shareholders as appropriate. If a public shareholder exercises its redemption rights in full, then it will be electing to exchange its public shares for cash and will no longer own any shares. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Public shareholders who seek to redeem their public shares must demand redemption no later than 5:00 p.m., Eastern Time, on [•], 2026 (two business days prior to the initially scheduled vote at the extraordinary general meeting) by (a) submitting a written request to the PCSC transfer agent that PCSC redeem such holder’s public shares for cash, (b) affirmatively certifying in such request to the PCSC transfer agent for redemption if such holder is acting in concert or as a “group” (as defined in Section 13d-3 of the Exchange Act) with any other shareholder with respect to PCSC Shares and (c) tendering or delivering their PCSC Shares, either physically or electronically through the DWAC system, at the holder’s option, to the PCSC transfer agent prior to the extraordinary general meeting. If you hold the shares in street name, you will have to coordinate with your broker to have your shares certificated or delivered electronically. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Notwithstanding the foregoing, a public shareholder, together with any affiliate of his, her, its or any other person with whom he, she or it is acting in concert or as a “group” (as defined in Section 13(d)(3) of the Exchange Act) will be restricted from seeking redemption rights with respect to more than 15% of the public shares. Accordingly, any shares held by a public shareholder or “group” in excess of such 15% cap will not be redeemed by PCSC. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">See the section entitled “<span style="font-style: italic;">Extraordinary General Meeting of PCSC—Redemption Rights</span>” for a detailed description of the procedures to be followed if you wish to redeem your public shares for cash. See also “<span style="font-style: italic;">Questions and Answers about the Business Combination—Do I have redemption rights and is there a limit on the number of shares I may redeem?—How do I exercise my redemption rights?</span>” for additional information on the exercise of redemption rights. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">As set forth in more detail elsewhere in this proxy statement/prospectus, the public shareholders currently own approximately 77.9% of the issued and outstanding PCSC Shares prior to the Business Combination. Accordingly, public shareholders, as a group, will experience immediate dilution as a consequence of the Business Combination. As redemptions increase, the overall percentage ownership held by the Sponsor, the Perceptive PIPE Investor, Messrs. McKenna, Song and Waksal, Freenome Stockholders and the PIPE Investors will increase as compared to the overall percentage ownership and voting percentage held by public shareholders, thereby increasing dilution to public shareholders. For more information on the percentage of the issued and outstanding shares of New Freenome Common Stock immediately following the Closing that are expected to be held by securityholders, in various redemptions scenarios, see “<span style="font-style: italic;">Dilution</span>.” </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Appraisal Rights and Dissenters’ Rights </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">PCSC’s shareholders do not have appraisal rights in connection with the Business Combination or the Domestication under the DGCL. PCSC’s shareholders do not have dissenters’ rights in connection with the Business Combination or the Domestication under Cayman Islands law. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Proxy Solicitation Costs; Revoking Your Proxy; Changing Your Vote </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">PCSC is soliciting proxies on behalf of the PCSC Board. This solicitation is being made by mail but also may be made by telephone or in person. PCSC and its directors, officers and employees may also solicit proxies in person, by telephone or by other electronic means. PCSC will bear the cost of the solicitation. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">PCSC has engaged Morrow as proxy solicitor to assist in the solicitation of proxies. PCSC has agreed to pay Morrow a fee of $25,000, plus disbursements, and will reimburse Morrow for its reasonable out-of-pocket expenses and indemnify Morrow and its affiliates against certain claims, liabilities, losses, damages and expenses. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">If a shareholder grants a proxy, it may still vote its shares if it revokes its proxy before the extraordinary general meeting. A shareholder also may change its vote by submitting a later-dated proxy as described in the section entitled “<span style="font-style: italic;">Extraordinary General Meeting of PCSC—Revoking Your Proxy; Changing Your Vote</span>.” </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Regulatory Matters </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Under the HSR Act and the rules that have been promulgated thereunder by the Federal Trade Commission (“<span style="font-style: italic; font-weight: bold;">FTC</span>”), certain transactions may not be consummated unless information has been furnished to the Antitrust Division and the FTC and certain waiting period requirements have been satisfied. The Business Combination is subject to these requirements and may not be completed until the expiration of a 30-day waiting period following the filing of the required Notification and Report Forms with the Antitrust Division and the FTC or until early termination is granted. If the FTC or the Antitrust Division issues a second request within the initial 30-day waiting period, the waiting period with respect to the Business Combination will be extended for an additional period of 30 calendar days, which will begin on the date on which the filing parties each certify compliance with the second request. Complying with a second request can take a significant period of time. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Each of PCSC and Freenome filed a Notification and Report Form with the FTC and the Antitrust Division in connection with the Business Combination on December 29, 2025. The initial 30-day waiting period will expire at 11:59 p.m., Eastern time, on January 28, 2026. The regulatory approvals to which completion of the Business Combination are subject are described in more detail in the section of this proxy statement/prospectus entitled “<span style="font-style: italic;">Business Combination Proposal—Business Combination Agreement—Regulatory Matters</span>.” </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Listing of Securities </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">PCSC has applied to list the New Freenome Common Stock on Nasdaq under the symbol “FRNM” upon the closing of the Business Combination. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">It is a condition to Freenome’s and PCSC’s obligations to consummate the Business Combination that the New Freenome Common Stock to be issued in connection with the Business Combination Agreement, including the shares of New Freenome Common Stock in the Business Combination and the PIPE Shares, is approved for listing on Nasdaq, subject only to official notice of issuance. Additionally, it is a condition to the obligations of the parties to the Subscription Agreements to consummate the PIPE Financing that the New Freenome Common Stock, including the PIPE Shares, has been approved for listing on Nasdaq, subject only to official notice of issuance. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Each U.S. stock exchange requires issuers applying for initial listing on such exchange to comply with certain initial listing criteria. New Freenome intends to apply for listing on the Nasdaq Capital Market. In order to qualify for initial listing on the Nasdaq Capital Market, pursuant to Nasdaq Rule IM-5505, New Freenome expects to be required to have at least 1 million unrestricted publicly held shares, a market value of unrestricted publicly held shares of at least $5 million and 300 unrestricted round lot stockholders. Irrespective of redemption levels in connection with the Business Combination, PCSC and Freenome expect that New Freenome will comply with applicable initial listing rules of Nasdaq by issuing at Closing a sufficient number of shares of unrestricted New Freenome Common Stock to existing Freenome stockholders that will not be directors, officers and/or 10% or larger stockholders of New Freenome. See the sections entitled “<span style="font-style: italic;">Adjournment Proposal</span>” and “<span style="font-style: italic;">Risk Factors—Nasdaq may delist PCSC’s Class A Shares from its exchange prior to the Closing or Nasdaq may not list New Freenome’s securities on its exchange, which could limit investors’ ability to make transactions in PCSC's Class A Shares or in New Freenome’s securities and subject PCSC or New Freenome, as applicable, to additional trading restrictions</span>” for additional information. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">If Freenome and PCSC, on the one hand, and/or the PIPE Investors, on the other hand, waive such condition, PCSC intends to file a Current Report on Form 8-K within four business days of such event, however you should know that given such timing you may not be notified before the deadline for submitting redemption requests or the extraordinary </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">general meeting. It is important for you to consider that, at the time of the deadline for submitting redemption requests or the extraordinary general meeting, New Freenome may not have received from Nasdaq either confirmation of the listing of the New Freenome Common Stock or confirmation that approval will be obtained prior to the consummation of the Business Combination, and you will not be notified prior to the deadline for submitting redemption requests or the extraordinary general meeting if New Freenome has not yet received such approval or confirmation. As a result, you may be asked to vote to approve the Business Combination and the other proposals included in this proxy statement/prospectus without knowing whether the New Freenome Common Stock will be listed on Nasdaq or another securities exchange and, further, it is possible that such listing may never be achieved and the Business Combination could still be consummated if such condition is waived. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Recommendation of the PCSC Board </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Special Committee, with the advice and assistance of representatives of Scalar, and its other advisors, evaluated the terms of the Business Combination Agreement and the transactions contemplated thereby. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On December 4, 2025, after careful consideration, the Special Committee unanimously (i) determined that the terms and conditions of the Business Combination Agreement, each ancillary agreement, and the Business Combination were fair, advisable, and in the best interests of PCSC and its shareholders as a whole (ii) recommended that the PCSC Board approve the Business Combination Agreement, each ancillary agreement, the Business Combination and the other agreements and transactions contemplated thereby and (iii) subject to the terms and conditions of the Business Combination Agreement, recommended that the PCSC shareholders approve the Business Combination Agreement, the Business Combination and the other transactions contemplated by the Business Combination Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On the same day, after careful consideration and based in part on the unanimous recommendation of the Special Committee, the PCSC Board unanimously determined that the Business Combination is fair, advisable, and in the best interests of PCSC and its shareholders as a whole, and approved and adopted the Business Combination Agreement, each ancillary agreement, the Business Combination and the other agreements and transactions contemplated thereby. The Business Combination was not structured to require the approval of at least a majority of PCSC’s unaffiliated shareholders because such a vote is not required under Cayman Islands law. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The PCSC Board believes that the Business Combination Proposal and the other proposals to be presented at the extraordinary general meeting are fair, advisable, and in the best interests of PCSC and its shareholders as a whole and unanimously recommends that its shareholders vote “FOR” the Business Combination Proposal, “FOR” the Domestication Proposal (in the case of the holders of PCSC Class B Shares), “FOR” the Governing Documents Proposal (in the case of the holders of PCSC Class B Shares), “FOR” the Advisory Governing Documents Proposal, “FOR” the Nasdaq Proposal, “FOR” the Equity Incentive Plan Proposal, “FOR” the Employee Stock Purchase Plan Proposal and “FOR” the Adjournment Proposal, in each case, if presented to the extraordinary general meeting. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">For a more complete description of the Special Committee’s and the PCSC Board’s reasons for the approval of the Business Combination and the unanimous recommendation of the Special Committee and the PCSC Board, see the subsection entitled “<span style="font-style: italic;">Business Combination Proposal—The Special Committee’s and the PCSC Board’s Reasons for the Approval of the Business Combination</span>.” </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The existence of financial and personal interests of one or more of PCSC’s directors may result in a conflict of interest on the part of such director(s) between what he or they may believe is in the best interests of PCSC and its shareholders, as a whole, and what he or they may believe is best for himself or themselves in determining to recommend that shareholders vote for the proposals. In addition, PCSC’s officers have interests in the Business Combination that may conflict with your interests as a shareholder. See the section entitled “<span style="font-style: italic;">Business Combination Proposal—Interests of PCSC’s Directors and Officers, Sponsor and Others in the Business Combination</span>” for a further discussion of these considerations. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">U.S. Federal Income Tax Considerations </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">For a discussion summarizing material U.S. federal income tax considerations of the Domestication, the Mergers, the exercise of redemption rights and the ownership and disposition by Non-U.S. Holders (as defined below) of New Freenome Common Stock received in the Business Combination, please see “<span style="font-style: italic;">Material U.S. Federal Income Tax Considerations</span>.” </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Anticipated Accounting Treatment of the Business Combination </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Business Combination is expected to be accounted for as a reverse recapitalization in accordance with U.S. GAAP, whereby PCSC is treated as the acquired company and Freenome is treated as the accounting acquirer. Accordingly, for accounting purposes, the Business Combination will be treated as the equivalent of Freenome issuing stock for the net assets of PCSC, accompanied by a recapitalization. The net assets of PCSC will be stated at fair value, which approximates their historical cost, with no goodwill or other intangible assets recorded. Subsequently, results of operations presented for the periods prior to the Business Combination will be for those of Freenome. For more information, see “<span style="font-style: italic;">Unaudited Pro Forma Condensed Combined Financial Information—Anticipated Accounting Treatment of the Business Combination.</span>” </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Emerging Growth Company and Smaller Reporting Company </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">PCSC is, and New Freenome will be, an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act (the “<span style="font-style: italic; font-weight: bold;">JOBS Act</span>”). As such, New Freenome will be eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies” including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. If some investors find New Freenome’s securities less attractive as a result, there may be a less active trading market for New Freenome’s securities and the prices of New Freenome’s securities may be more volatile. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In addition, Section 107 of the JOBS Act also provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. PCSC has not elected, and New Freenome is not expected to elect, to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, New Freenome, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of New Freenome’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">New Freenome will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of PCSC’s initial public offering, (b) in which New Freenome has total annual gross revenue of at least $1.235 billion or (c) in which New Freenome is deemed to be a “large accelerated filer” under the rules of the SEC, which means, among other things, (1) the market value of its common stock that is held by non-affiliates exceeds $700.0 million as of the prior June 30th and (2) the date on which New Freenome has issued more than $1.0 billion in non-convertible debt during the prior three-year period. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Additionally, PCSC is a “smaller reporting company” as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. New Freenome expects to remain a “smaller reporting company” as defined in the Exchange Act. New Freenome may continue to be a smaller reporting company even after it is no longer an emerging growth company. New Freenome may take advantage of certain of the scaled disclosures available to smaller reporting companies until for so long as either (i) its voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of New Freenome’s second fiscal quarter or (ii) New Freenome’s annual revenues are less than $100.0 million during the most recently completed fiscal year and its voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of New Freenome’s second fiscal quarter. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Risk Factors Summary </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In evaluating the proposals to be presented at the extraordinary general meeting, shareholders should carefully read this proxy statement/prospectus and especially consider the factors discussed in the section of this proxy statement/prospectus entitled “<span style="font-style: italic;">Risk Factors</span>” beginning on page <a href="#tRF">25</a>. In particular, such risks include, but are not limited to, the following: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 8pt; margin-left: 20pt; text-align: left;">Risks Related to Freenome’s Business and to New Freenome’s Business Following the Business Combination<span style="font-style: normal;"> </span></div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">We may need to raise additional capital to fund our existing operations, develop our platform, commercialize our product or new product candidates or expand our operations. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Raising additional capital may cause dilution to our stockholders, restrict our operations and could cause the price of our common stock to decline.</div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Our approach to the development of multiple blood-based screening tests though the use of our technology platform is unproven, which makes it difficult to predict the time, cost of development and likelihood of successfully developing and launching additional tests. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">If we are unable to support demand for SimpleScreen CRC, or future products, if approved, including ensuring that we have adequate capacity to meet increased demand, or we are unable to successfully manage our anticipated growth, our business could suffer. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">We may experience challenges attracting and retaining qualified personnel due to competitive labor markets and we may be unable to manage our future growth effectively, all of which could make it difficult to execute our business strategy. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">If we lose the services of our founder, our Chief Executive Officer, or other members of our senior management team, we may not be able to execute our business strategy.</div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Cybersecurity incidents such as security breaches, loss of data and other disruptions in relation to our information technology systems, as well as those of our third-party service providers, could compromise sensitive information related to our business, prevent us from accessing it and expose us to substantial liability, which could adversely affect our business and reputation.</div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">We, our collaborators and our service providers are subject to a variety of privacy and data security laws, regulations and contractual obligations, which may require us to incur substantial compliance costs, and any failure or perceived failure by us to comply with them could expose us to significant fines and other penalties and otherwise harm our business and operations. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">If our existing facility becomes damaged or inoperable or we are required to vacate our existing facility, our ability pursue our research and development efforts may be jeopardized. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">We rely on commercial courier delivery services to transport samples to our laboratory facility in a timely and cost-efficient manner and if these delivery services are disrupted, our business will be harmed. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We face intense competition from other companies and may not be able to compete successfully. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The use of Artificial Intelligence presents new risks and challenges to our business. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Failure of, or defects in, our machine learning algorithms, artificial intelligence, and cloud-based computing infrastructure, including interruptions of service through third-party service providers, or increased regulation in the machine learning or artificial intelligence space, could impair our ability to process our data, develop products, or provide test results, and harm our business and results of operations. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The sizes of the markets for our products, if approved, have not been established with precision, and may be smaller than we estimate. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">We rely on a limited number of suppliers or, in some cases, sole suppliers, for some of our products and materials and may not be able to find replacements or promptly transition to alternative suppliers. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Changes in funding for, or disruptions caused by global health concerns impacting, the FDA and other government agencies or notified bodies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new medical device products from being developed, authorized or commercialized in a timely manner, which could negatively impact our business. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies may not be predictive of future study results. In addition, regulatory authorities may require more extensive clinical evidence than we anticipate, and the standards for clinical data adequacy can evolve over time. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">If the third parties on which we rely for the conduct of our clinical trials and results do not perform our clinical trial activities in accordance with good clinical practices and related regulatory requirements, we may be unable to obtain regulatory clearance or approval for our product candidates or commercialize our products. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Delays in receipt of, or failure to obtain, required FDA clearances or approvals or approvals required in other jurisdictions for our products in development, or improvements to or expanded indications for our current offerings, could materially delay or prevent us from commercializing or otherwise adversely impact future product commercialization. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Our products, if cleared or approved, may in the future be subject to product recalls. A recall of our products, either voluntarily or at the direction of the FDA or another governmental authority, or the discovery of serious safety issues with our products, could have a significant adverse impact on us. In addition, recalls—whether required or voluntary—can trigger increased regulatory scrutiny of our quality systems, manufacturing processes, and post-market surveillance activities.</div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Traditional fee-for-service Medicare generally does not cover screening tests absent a statutory benefit, and if our future tests are treated as screening tests, our ability to obtain Medicare coverage and reimbursement may be limited, delayed, or require legislative or guideline changes. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">If we are unable to obtain and maintain intellectual property protection for our technology, or if the scope of the intellectual property protection we obtain is not sufficiently broad, our competitors may develop and commercialize technology and tests similar or identical to ours, and our ability to successfully commercialize our products may be impaired. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">We cannot ensure that patent rights relating to inventions described and claimed in our pending patent applications will issue or that future patents based on our patent applications will not be challenged and rendered invalid and/or unenforceable. </div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">Risks Related to the Business Combination and PCSC<span style="font-style: normal;"> </span></div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Our Sponsor and our initial shareholders have entered into letter agreements with us to vote in favor of the Business Combination, regardless of how our public shareholders vote. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Since the initial shareholders, including PCSC’s directors and officers, have interests that are different, or in addition to (and which may conflict with), the interests of our shareholders, a conflict of interest may have existed in determining whether the Business Combination with Freenome is appropriate as our initial business combination. Such interests include that Sponsor, as well as our officers and directors, will lose their entire investment in us if our business combination is not completed. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The process of taking a company public by means of a business combination with a special purpose acquisition company is different from taking a company public through an underwritten offering and may create risks for our unaffiliated investors. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The exercise of PCSC’s directors’ and officers’ discretion in agreeing to changes or waivers in the terms of the Business Combination may result in a conflict of interest when determining whether such changes to the terms of the Business Combination or waivers of conditions are appropriate and in PCSC’s shareholders’ best interest. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">If the conditions to the Business Combination Agreement are not met, the Business Combination may not occur. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Because PCSC is incorporated under the laws of the Cayman Islands, in the event the Business Combination is not completed, you may face difficulties in protecting your interests, and your ability to protect your rights through the U.S. federal courts may be limited. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">PCSC shareholders will experience immediate dilution as a consequence of the issuance of New Freenome Common Stock as consideration in the Business Combination. Having a minority share position may reduce the influence that PCSC’s current shareholders have on the management of New Freenome. </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Market Price, Ticker Symbol and Dividends </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">PCSC </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">PCSC Class A Shares are currently listed on Nasdaq under the symbol “PCSC.” As of January 6, 2026, a recent practicable date prior to the date of this proxy statement/prospectus, there were 2 holders of record of PCSC Class A Shares and 4 holders of record of PCSC Class B Shares. The actual number of shareholders is greater than this number of record holders and includes shareholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">PCSC has not paid any cash dividends on the PCSC Shares to date and do not intend to pay cash dividends prior to the completion of the Business Combination. The payment of any cash dividends subsequent to the Business Combination will be within the discretion of the New Freenome Board. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The closing price of the PCSC Class A Shares on December 4, 2025 the last full trading day before the public announcement of the Business Combination, public shares closed at $10.70 per share. On January 6, 2026, a recent practicable date prior to the date of this proxy statement/prospectus, PCSC Class A Shares closed at $13.58 per share. Holders of PCSC Class A Shares should obtain current market quotations for the securities. The market price of PCSC Class A Shares could vary at any time prior to the Closing. Market price information regarding the PCSC Class B Shares is not provided here because there is no established public trading market for the PCSC Class B Shares. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Freenome </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Historical market price information regarding Freenome is not provided because there is no public market for its securities. </div> <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Background and Material Terms of the Business Combination </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">PCSC is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Following the completion of its initial public offering on June 13, 2024, at the direction of the PCSC Board, representatives of PCSC, including Messrs. Stone and Poukalov, and Dr. Hukkelhoven commenced an active, targeted search for potential business combination candidates, leveraging the Sponsor’s network of investment bankers, private equity firms and hedge funds (including Perceptive Advisors and its affiliates), consulting firms, legal and accounting firms, and numerous other business relationships, as well as the prior experience and network of PCSC’s officers and directors. During this targeted search, PCSC reviewed approximately 200 potential business combination targets and conducted varying levels of preliminary due diligence on each, and evaluated and analyzed each as a potential business combination target based on, among other things, publicly available information and other market research available to PCSC and its representatives and their existing knowledge of the potential targets as a result of their network and existing relationships. Between October 2024 and December 2024, PCSC submitted non-binding term sheets to two companies, neither of which progressed to a business combination. Thereafter, PCSC continued to assess other potential business combination targets. Through this process, and based on discussion with members of the PCSC Board, PCSC further refined its focus and determined to concentrate its near-term efforts on a smaller set of potential business combination targets, including Freenome, that PCSC believed were the most compelling opportunities relative to the others reviewed.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On February 19, 2025, Dr. Hukkelhoven, in her capacity as an executive officer of the Perceptive PIPE Investor, reached out to the other members of the Freenome Board, consisting of Deepika Pakianathan, Douglas VanOort, Randal Scott, Peter Kolchinsky, Moritz Hartmann, and Josh Lauer, to inquire whether Freenome would be interested in exploring a potential business combination with PCSC. The Perceptive PIPE Investor, was as of such time, and remains, an existing investor in Freenome, and Dr. Hukkelhoven, an executive officer of the Perceptive PIPE Investor, was as of such time, and remains, a member of the Freenome Board. As the Perceptive PIPE Investor has been an investor in Freenome since 2019, the Perceptive PIPE Investor has continuously monitored Freenome’s business progress and capital needs. Dr. Hukkelhoven has been a representative appointed by the Perceptive PIPE Investor on the Freenome Board since 2020. At the direction of the Freenome Board, Dr. Hukkelhoven informed the Perceptive PIPE Investor that Freenome was interested in exploring a capital raising transaction involving the Perceptive PIPE Investor and Dr. Hukkelhoven proposed the terms of the PIPE Financing to the Perceptive PIPE Investor. For more information, see “<span style="font-style: italic;">Business Combination Proposal — Interests of PCSC’s Sponsor, Directors and Officers in the Business Combination.</span>”</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The key terms of the Business Combination Agreement are the result of extensive negotiations between the representatives of PCSC and Freenome, each in consultation with its advisors, which occurred between mid-May 2025 through early August 2025. During such period, Freenome was also negotiating its exclusive licensing agreement with Exact Sciences Corporation (“<span style="font-style: italic; font-weight: bold;">Exact Sciences</span>”) to advance the commercialization of Freenome’s colorectal (CRC) blood-based screening test, which was ultimately signed and announced on August 6, 2025 (the “<span style="font-style: italic; font-weight: bold;">Exact Sciences Transaction</span>”). The terms of the Exact Sciences Transaction included an upfront payment by Exact Sciences to Freenome of $75 million, as well as potential milestone payments of up to $700 million in connection with specified regulatory developments, royalties on test sales, $20 million in funding for joint R&amp;D expenses leveraging the technology for three years and a convertible note of $50 million at an interest rate of 5% per annum.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On August 6, 2025, PCSC and Freenome executed the Non-Binding Term Sheet, setting out the material terms of the Business Combination, including that Freenome would be valued at approximately $1.05 billion on a post-Business Combination equity value basis, taking into account, among other things, (i) an assumed $300 million in aggregate proceeds from (a) the PIPE Financing (which would include at least $25 million expected to be contributed by Perceptive Advisors or its affiliates and at least $50 million expected to be contributed by RA Capital or its affiliates) and (b) the Trust Account at the closing, and (ii) an agreed pre-Business Combination base equity value for Freenome of $725 million. The Non-Binding Term Sheet further contemplated, among other things, (a) certain adjustments for leakage to the Freenome base equity value, (b) that any proceeds from the Exact Sciences Transaction or any transaction entered into with Roche would not be counted as part of the base equity value of Freenome and that any shares or other equity interests of Freenome issued and outstanding in connection with such transactions would not be taken into account as part of the Freenome shares outstanding as of immediately prior to the closing of the Business Combination </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">for purposes of determining the applicable Exchange Ratio, (c) that in addition to other customary closing conditions, the obligation of Freenome to consummate the Business Combination would be subject to there being Aggregate Transaction Proceeds of at least $250,000,000, (d) a six-month lockup period after consummation of the Business Combination with respect to New Freenome shares to be issued to insider Freenome stockholders, including Perceptive Advisors and RA Capital, in the Business Combination, as well as certain demand and piggyback registration rights for certain stockholders, and (e) an Exclusivity Period binding on both PCSC and Freenome.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Between October 6, 2025 and December 4, 2025, PCSC and Freenome, with the assistance of their respective advisors, exchanged and negotiated drafts of the definitive Business Combination Agreement, the disclosure schedules to the Business Combination Agreement and the other ancillary documents, including the Investor Rights Agreement, the Transaction Support Agreement, the New Freenome certificate of incorporation and bylaws, the Lock-Up Agreement and the Sponsor Letter Agreement.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Concurrently with the execution of the Business Combination Agreement and the related ancillary documents, on December 5, 2025, the PIPE Investors executed and delivered the Subscription Agreements, which provided for binding subscriptions to purchase an aggregate of 24,000,000 shares of New Freenome Common Stock at $10.00 per share.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">As contemplated by the Business Combination Agreement, the structure and timing of the Business Combination and the PIPE Financing are consistent with common practice in initial business combination transactions consummated by special purpose acquisition companies. In addition, the timing for the consummation of the Business Combination provided for in the Business Combination Agreement and the Subscription Agreements, which was effectively as soon as reasonably practicable following the execution of the Business Combination Agreement, was determined and agreed by the parties in light of general business considerations weighing in favor of consummating the transaction promptly and the deadline for PCSC to complete an initial business combination by June 13, 2026 (unless otherwise extended). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">For more information, see “<span style="font-style: italic;">Business Combination Proposal—Background and Material Terms of the Business Combination.”</span> </div> <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Background and Material Terms of the Business Combination </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">PCSC is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Following the completion of its initial public offering on June 13, 2024, at the direction of the PCSC Board, representatives of PCSC, including Messrs. Stone and Poukalov, and Dr. Hukkelhoven commenced an active, targeted search for potential business combination candidates, leveraging the Sponsor’s network of investment bankers, private equity firms and hedge funds (including Perceptive Advisors and its affiliates), consulting firms, legal and accounting firms, and numerous other business relationships, as well as the prior experience and network of PCSC’s officers and directors. During this targeted search, PCSC reviewed approximately 200 potential business combination targets and conducted varying levels of preliminary due diligence on each, and evaluated and analyzed each as a potential business combination target based on, among other things, publicly available information and other market research available to PCSC and its representatives and their existing knowledge of the potential targets as a result of their network and existing relationships. Between October 2024 and December 2024, PCSC submitted non-binding term sheets to two companies, neither of which progressed to a business combination. Thereafter, PCSC continued to assess other potential business combination targets. Through this process, and based on discussion with members of the PCSC Board, PCSC further refined its focus and determined to concentrate its near-term efforts on a smaller set of potential business combination targets, including Freenome, that PCSC believed were the most compelling opportunities relative to the others reviewed.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On February 19, 2025, Dr. Hukkelhoven, in her capacity as an executive officer of the Perceptive PIPE Investor, reached out to the other members of the Freenome Board, consisting of Deepika Pakianathan, Douglas VanOort, Randal Scott, Peter Kolchinsky, Moritz Hartmann, and Josh Lauer, to inquire whether Freenome would be interested in exploring a potential business combination with PCSC. The Perceptive PIPE Investor, was as of such time, and remains, an existing investor in Freenome, and Dr. Hukkelhoven, an executive officer of the Perceptive PIPE Investor, was as of such time, and remains, a member of the Freenome Board. As the Perceptive PIPE Investor has been an investor in Freenome since 2019, the Perceptive PIPE Investor has continuously monitored Freenome’s business progress and capital needs. Dr. Hukkelhoven has been a representative appointed by the Perceptive PIPE Investor on the Freenome Board since 2020. At the direction of the Freenome Board, Dr. Hukkelhoven informed the Perceptive PIPE Investor that Freenome was interested in exploring a capital raising transaction involving the Perceptive PIPE Investor and Dr. Hukkelhoven proposed the terms of the PIPE Financing to the Perceptive PIPE Investor. For more information, see “<span style="font-style: italic;">Business Combination Proposal — Interests of PCSC’s Sponsor, Directors and Officers in the Business Combination.</span>”</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The key terms of the Business Combination Agreement are the result of extensive negotiations between the representatives of PCSC and Freenome, each in consultation with its advisors, which occurred between mid-May 2025 through early August 2025. During such period, Freenome was also negotiating its exclusive licensing agreement with Exact Sciences Corporation (“<span style="font-style: italic; font-weight: bold;">Exact Sciences</span>”) to advance the commercialization of Freenome’s colorectal (CRC) blood-based screening test, which was ultimately signed and announced on August 6, 2025 (the “<span style="font-style: italic; font-weight: bold;">Exact Sciences Transaction</span>”). The terms of the Exact Sciences Transaction included an upfront payment by Exact Sciences to Freenome of $75 million, as well as potential milestone payments of up to $700 million in connection with specified regulatory developments, royalties on test sales, $20 million in funding for joint R&amp;D expenses leveraging the technology for three years and a convertible note of $50 million at an interest rate of 5% per annum.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On August 6, 2025, PCSC and Freenome executed the Non-Binding Term Sheet, setting out the material terms of the Business Combination, including that Freenome would be valued at approximately $1.05 billion on a post-Business Combination equity value basis, taking into account, among other things, (i) an assumed $300 million in aggregate proceeds from (a) the PIPE Financing (which would include at least $25 million expected to be contributed by Perceptive Advisors or its affiliates and at least $50 million expected to be contributed by RA Capital or its affiliates) and (b) the Trust Account at the closing, and (ii) an agreed pre-Business Combination base equity value for Freenome of $725 million. The Non-Binding Term Sheet further contemplated, among other things, (a) certain adjustments for leakage to the Freenome base equity value, (b) that any proceeds from the Exact Sciences Transaction or any transaction entered into with Roche would not be counted as part of the base equity value of Freenome and that any shares or other equity interests of Freenome issued and outstanding in connection with such transactions would not be taken into account as part of the Freenome shares outstanding as of immediately prior to the closing of the Business Combination </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">for purposes of determining the applicable Exchange Ratio, (c) that in addition to other customary closing conditions, the obligation of Freenome to consummate the Business Combination would be subject to there being Aggregate Transaction Proceeds of at least $250,000,000, (d) a six-month lockup period after consummation of the Business Combination with respect to New Freenome shares to be issued to insider Freenome stockholders, including Perceptive Advisors and RA Capital, in the Business Combination, as well as certain demand and piggyback registration rights for certain stockholders, and (e) an Exclusivity Period binding on both PCSC and Freenome.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Between October 6, 2025 and December 4, 2025, PCSC and Freenome, with the assistance of their respective advisors, exchanged and negotiated drafts of the definitive Business Combination Agreement, the disclosure schedules to the Business Combination Agreement and the other ancillary documents, including the Investor Rights Agreement, the Transaction Support Agreement, the New Freenome certificate of incorporation and bylaws, the Lock-Up Agreement and the Sponsor Letter Agreement.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Concurrently with the execution of the Business Combination Agreement and the related ancillary documents, on December 5, 2025, the PIPE Investors executed and delivered the Subscription Agreements, which provided for binding subscriptions to purchase an aggregate of 24,000,000 shares of New Freenome Common Stock at $10.00 per share.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">As contemplated by the Business Combination Agreement, the structure and timing of the Business Combination and the PIPE Financing are consistent with common practice in initial business combination transactions consummated by special purpose acquisition companies. In addition, the timing for the consummation of the Business Combination provided for in the Business Combination Agreement and the Subscription Agreements, which was effectively as soon as reasonably practicable following the execution of the Business Combination Agreement, was determined and agreed by the parties in light of general business considerations weighing in favor of consummating the transaction promptly and the deadline for PCSC to complete an initial business combination by June 13, 2026 (unless otherwise extended). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">For more information, see “<span style="font-style: italic;">Business Combination Proposal—Background and Material Terms of the Business Combination.”</span> </div> <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">PIPE Financing </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In connection with entering into the Business Combination Agreement, on December 5, 2025, PCSC entered into Subscription Agreements with the PIPE Investors. Pursuant to the Subscription Agreements, the PIPE Investors agreed to subscribe for and purchase, and PCSC agreed to issue and sell to the PIPE Investors, on the Closing Date immediately following the Closing, an aggregate of 24,000,000 shares of New Freenome Common Stock for a purchase price of $10.00 per share, and aggregate gross proceeds of $240.0 million. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Existing Freenome stockholders (other than the Perceptive PIPE Investor and investors who were existing PCSC shareholders) subscribed for approximately $72.4 million of the PIPE Financing. Existing PCSC shareholders (other than the Perceptive PIPE Investor and investors who were existing Freenome stockholders) subscribed for approximately $15.0 million of the PIPE Financing. PIPE Investors who were both existing shareholders of PCSC and Freenome (other than the Perceptive PIPE Investor) subscribed for approximately $52.6 million of the PIPE Financing. The Perceptive PIPE Investor subscribed for an aggregate of $55 million of the PIPE Financing. Investors who were neither existing Freenome stockholders nor existing PCSC shareholders subscribed for approximately $45.0 million of the PIPE Financing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The obligations of each party to consummate the PIPE Financing are conditioned upon, among other things, (i) the New Freenome Common Stock (including the New Freenome Common Stock issuable to the PIPE Investors pursuant to the Subscription Agreements) having been approved for listing on Nasdaq; and (ii) satisfaction of all conditions precedent to the closing of the transactions set forth in the Business Combination Agreement. The obligations of the PIPE Investors to consummate the PIPE Financing are further subject to additional conditions, including, among other things: (i) the Business Combination Agreement shall not have been amended, modified, or supplemented, and no condition waived thereunder, in a manner that would reasonably be expected to materially and adversely affect the economic benefits that a PIPE Investor would reasonably expect to receive under the Subscription Agreement; (ii) the material truth and accuracy of the representations and warranties of PCSC in the Subscription Agreement, subject to customary bringdown standards; (iii) no subscription agreement, or other agreements or understandings (including side letters) entered into in connection with the sale of New Freenome Common Stock under the Subscription Agreements, with any other PIPE Investors shall have been amended, modified, or waived in any manner that benefits such other PIPE Investor unless all PIPE Investors have been offered substantially the same benefits; and (iv) there has not occurred any material adverse effect or parent material adverse effect since the date of the Subscription Agreement that is continuing. See “<span style="font-style: italic;">Business Combination Proposal—Related Agreements—PIPE Financing.</span>” </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Lock-Up Agreement </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In connection with the Closing, the Sponsor and certain former Freenome stockholders will enter into the Lock-Up Agreement with PCSC. Pursuant to the Lock-Up Agreement, the Sponsor and certain Freenome stockholders will agree not to transfer (except for certain permitted transfers) any shares of New Freenome Common Stock held by such holder after the Domestication until six (6) months after the Closing Date. See “<span style="font-style: italic;">Business Combination Proposal—Related Agreements—Lock-up Agreements.</span>” </div> <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">PIPE Financing </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In connection with entering into the Business Combination Agreement, on December 5, 2025, PCSC entered into Subscription Agreements with the PIPE Investors. Pursuant to the Subscription Agreements, the PIPE Investors agreed to subscribe for and purchase, and PCSC agreed to issue and sell to the PIPE Investors, on the Closing Date immediately following the Closing, an aggregate of 24,000,000 shares of New Freenome Common Stock for a purchase price of $10.00 per share, and aggregate gross proceeds of $240.0 million. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Existing Freenome stockholders (other than the Perceptive PIPE Investor and investors who were existing PCSC shareholders) subscribed for approximately $72.4 million of the PIPE Financing. Existing PCSC shareholders (other than the Perceptive PIPE Investor and investors who were existing Freenome stockholders) subscribed for approximately $15.0 million of the PIPE Financing. PIPE Investors who were both existing shareholders of PCSC and Freenome (other than the Perceptive PIPE Investor) subscribed for approximately $52.6 million of the PIPE Financing. The Perceptive PIPE Investor subscribed for an aggregate of $55 million of the PIPE Financing. Investors who were neither existing Freenome stockholders nor existing PCSC shareholders subscribed for approximately $45.0 million of the PIPE Financing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The obligations of each party to consummate the PIPE Financing are conditioned upon, among other things, (i) the New Freenome Common Stock (including the New Freenome Common Stock issuable to the PIPE Investors pursuant to the Subscription Agreements) having been approved for listing on Nasdaq; and (ii) satisfaction of all conditions precedent to the closing of the transactions set forth in the Business Combination Agreement. The obligations of the PIPE Investors to consummate the PIPE Financing are further subject to additional conditions, including, among other things: (i) the Business Combination Agreement shall not have been amended, modified, or supplemented, and no condition waived thereunder, in a manner that would reasonably be expected to materially and adversely affect the economic benefits that a PIPE Investor would reasonably expect to receive under the Subscription Agreement; (ii) the material truth and accuracy of the representations and warranties of PCSC in the Subscription Agreement, subject to customary bringdown standards; (iii) no subscription agreement, or other agreements or understandings (including side letters) entered into in connection with the sale of New Freenome Common Stock under the Subscription Agreements, with any other PIPE Investors shall have been amended, modified, or waived in any manner that benefits such other PIPE Investor unless all PIPE Investors have been offered substantially the same benefits; and (iv) there has not occurred any material adverse effect or parent material adverse effect since the date of the Subscription Agreement that is continuing. See “<span style="font-style: italic;">Business Combination Proposal—Related Agreements—PIPE Financing.</span>” </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Lock-Up Agreement </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In connection with the Closing, the Sponsor and certain former Freenome stockholders will enter into the Lock-Up Agreement with PCSC. Pursuant to the Lock-Up Agreement, the Sponsor and certain Freenome stockholders will agree not to transfer (except for certain permitted transfers) any shares of New Freenome Common Stock held by such holder after the Domestication until six (6) months after the Closing Date. See “<span style="font-style: italic;">Business Combination Proposal—Related Agreements—Lock-up Agreements.</span>” </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Sources and Uses of Proceeds </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The following tables summarize the anticipated sources and uses of funds in the Business Combination, in various redemption scenarios. Such tables are for illustrative purposes only. Where actual amounts are not known or knowable, the figures below represent good faith estimates of such amounts. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Sources and Uses of Proceeds (No Redemptions Scenario) (in millions) </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The following table summarizes the sources and uses of funds for the Business Combination assuming no redemptions by PCSC shareholders.</div><table cellpadding="0" class="BRDSX_fintab" style="width: 474pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 48pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 180pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sources</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Uses</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td></tr><tr><td style="width: 180pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash in Trust Account⁽¹⁾</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.25pt; text-align: left;">$<span style="padding-left: 5pt;">91.9</span></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash to Balance Sheet</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.25pt; text-align: left;">$387.2</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marketable Securities of Freenome</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.25pt; text-align: left;"><span style="padding-left: 5pt;">138.1</span></div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marketable securities to Balance Sheet</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.25pt; text-align: left;"><span style="padding-left: 5pt;">138.1</span></div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Existing Cash Balances, as of December 31, 2025</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.25pt; text-align: left;"><span style="padding-left: 10pt;">79.4</span></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Estimated Unpaid Transaction Expenses, as of December 31, 2025</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.25pt; text-align: left;"><span style="padding-left: 10pt;">24.1</span></div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash Proceeds from the PIPE Financing</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.25pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">240.0</span></div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 180pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Sources</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.25pt; text-align: left;">$549.4</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Uses</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.25pt; text-align: left;">$549.4</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 180pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 180pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Sources and Uses of Proceeds (25% Redemptions Scenario) (in millions)</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The following table summarizes the sources and uses of funds for the Business Combination assuming 25% redemptions by PCSC shareholders.</div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 42pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 180pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sources</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Uses</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td></tr><tr><td style="width: 180pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash in Trust Account⁽¹⁾</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;"><span style="padding-left: 5pt;">91.9</span></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash to Balance Sheet</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;">364.2</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marketable Securities of Freenome</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;">138.1</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marketable securities to Balance Sheet</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;">138.1</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Existing Cash Balances, as of December 31, 2025</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;"><span style="padding-left: 5pt;">79.4</span></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Redemption of PCSC Class A Shares held by public shareholders⁽²⁾</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;"><span style="padding-left: 5pt;">23.0</span></div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash Proceeds from the PIPE Financing</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">240.0</span></div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Estimated Unpaid Transaction Expenses, as of December 31, 2025</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;"><span style="padding-left: 5pt;">24.1</span></div></td></tr><tr><td style="width: 180pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Sources</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;">549.4</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Uses</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;">549.4</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 180pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 180pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 42pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Sources and Uses of Proceeds (50% Redemptions Scenario) (in millions)</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The following table summarizes the sources and uses of funds for the Business Combination assuming 50% redemptions by PCSC shareholders.</div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 42pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 180pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sources</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Uses</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td></tr><tr><td style="width: 180pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash in Trust Account⁽¹⁾</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;"><span style="padding-left: 5pt;">91.9</span></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash to Balance Sheet</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;">341.3</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marketable Securities of Freenome</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;">138.1</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marketable securities to Balance Sheet</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;">138.1</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Existing Cash Balances, as of December 31, 2025</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;"><span style="padding-left: 5pt;">79.4</span></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Redemption of PCSC Class A Shares held by public shareholders⁽²⁾</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;"><span style="padding-left: 5pt;">45.9</span></div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash Proceeds from the PIPE Financing</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">240.0</span></div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Estimated Unpaid Transaction Expenses, as of December 31, 2025</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;"><span style="padding-left: 5pt;">24.1</span></div></td></tr><tr><td style="width: 180pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Sources</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;">549.4</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Uses</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;">549.4</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 180pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 180pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 42pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Sources and Uses of Proceeds (Aggregate Transaction Proceeds Condition Redemptions Scenario) <br/></div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in millions)</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The following table summarizes the sources and uses of funds for the Business Combination assuming the Aggregate Transaction Proceeds Condition Redemptions Scenario.</div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 42pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 180pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sources</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Uses</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td></tr><tr><td style="width: 180pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash in Trust Account⁽¹⁾</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;"><span style="padding-left: 5pt;">91.9</span></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash to Balance Sheet</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;">317.2</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marketable Securities of Freenome</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;">138.1</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marketable securities to Balance Sheet</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;">138.1</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Existing Cash Balances, as of December 31, 2025</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;"><span style="padding-left: 5pt;">79.4</span></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Redemption of PCSC Class A Shares held by public shareholders⁽²⁾</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;"><span style="padding-left: 5pt;">70.0</span></div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash Proceeds from the PIPE Financing</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">240.0</span></div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Estimated Unpaid Transaction Expenses, as of December 31, 2025</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;"><span style="padding-left: 5pt;">24.1</span></div></td></tr><tr><td style="width: 180pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Sources</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;">549.4</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Uses</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;">549.4</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 180pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 180pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 42pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Reflects the amount in the trust account as of December 31, 2025. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Assumes a redemption price of $10.65 per share, based on the amount in the trust account as of December 31, 2025. </div></td></tr></table> <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Sources and Uses of Proceeds </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The following tables summarize the anticipated sources and uses of funds in the Business Combination, in various redemption scenarios. Such tables are for illustrative purposes only. Where actual amounts are not known or knowable, the figures below represent good faith estimates of such amounts. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Sources and Uses of Proceeds (No Redemptions Scenario) (in millions) </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The following table summarizes the sources and uses of funds for the Business Combination assuming no redemptions by PCSC shareholders.</div><table cellpadding="0" class="BRDSX_fintab" style="width: 474pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 48pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 180pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sources</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Uses</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td></tr><tr><td style="width: 180pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash in Trust Account⁽¹⁾</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.25pt; text-align: left;">$<span style="padding-left: 5pt;">91.9</span></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash to Balance Sheet</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.25pt; text-align: left;">$387.2</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marketable Securities of Freenome</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.25pt; text-align: left;"><span style="padding-left: 5pt;">138.1</span></div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marketable securities to Balance Sheet</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.25pt; text-align: left;"><span style="padding-left: 5pt;">138.1</span></div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Existing Cash Balances, as of December 31, 2025</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.25pt; text-align: left;"><span style="padding-left: 10pt;">79.4</span></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Estimated Unpaid Transaction Expenses, as of December 31, 2025</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.25pt; text-align: left;"><span style="padding-left: 10pt;">24.1</span></div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash Proceeds from the PIPE Financing</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.25pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">240.0</span></div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 180pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Sources</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.25pt; text-align: left;">$549.4</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Uses</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.25pt; text-align: left;">$549.4</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 180pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 180pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Sources and Uses of Proceeds (25% Redemptions Scenario) (in millions)</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The following table summarizes the sources and uses of funds for the Business Combination assuming 25% redemptions by PCSC shareholders.</div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 42pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 180pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sources</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Uses</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td></tr><tr><td style="width: 180pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash in Trust Account⁽¹⁾</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;"><span style="padding-left: 5pt;">91.9</span></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash to Balance Sheet</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;">364.2</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marketable Securities of Freenome</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;">138.1</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marketable securities to Balance Sheet</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;">138.1</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Existing Cash Balances, as of December 31, 2025</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;"><span style="padding-left: 5pt;">79.4</span></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Redemption of PCSC Class A Shares held by public shareholders⁽²⁾</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;"><span style="padding-left: 5pt;">23.0</span></div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash Proceeds from the PIPE Financing</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">240.0</span></div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Estimated Unpaid Transaction Expenses, as of December 31, 2025</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;"><span style="padding-left: 5pt;">24.1</span></div></td></tr><tr><td style="width: 180pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Sources</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;">549.4</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Uses</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;">549.4</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 180pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 180pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 42pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Sources and Uses of Proceeds (50% Redemptions Scenario) (in millions)</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The following table summarizes the sources and uses of funds for the Business Combination assuming 50% redemptions by PCSC shareholders.</div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 42pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 180pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sources</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Uses</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td></tr><tr><td style="width: 180pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash in Trust Account⁽¹⁾</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;"><span style="padding-left: 5pt;">91.9</span></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash to Balance Sheet</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;">341.3</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marketable Securities of Freenome</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;">138.1</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marketable securities to Balance Sheet</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;">138.1</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Existing Cash Balances, as of December 31, 2025</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;"><span style="padding-left: 5pt;">79.4</span></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Redemption of PCSC Class A Shares held by public shareholders⁽²⁾</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;"><span style="padding-left: 5pt;">45.9</span></div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash Proceeds from the PIPE Financing</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">240.0</span></div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Estimated Unpaid Transaction Expenses, as of December 31, 2025</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;"><span style="padding-left: 5pt;">24.1</span></div></td></tr><tr><td style="width: 180pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Sources</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;">549.4</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Uses</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;">549.4</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 180pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 180pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 42pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Sources and Uses of Proceeds (Aggregate Transaction Proceeds Condition Redemptions Scenario) <br/></div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in millions)</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The following table summarizes the sources and uses of funds for the Business Combination assuming the Aggregate Transaction Proceeds Condition Redemptions Scenario.</div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 42pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 180pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sources</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Uses</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td></tr><tr><td style="width: 180pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash in Trust Account⁽¹⁾</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;"><span style="padding-left: 5pt;">91.9</span></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash to Balance Sheet</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;">317.2</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marketable Securities of Freenome</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;">138.1</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Marketable securities to Balance Sheet</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;">138.1</div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Existing Cash Balances, as of December 31, 2025</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;"><span style="padding-left: 5pt;">79.4</span></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Redemption of PCSC Class A Shares held by public shareholders⁽²⁾</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;"><span style="padding-left: 5pt;">70.0</span></div></td></tr><tr><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash Proceeds from the PIPE Financing</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">240.0</span></div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Estimated Unpaid Transaction Expenses, as of December 31, 2025</div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;"><span style="padding-left: 5pt;">24.1</span></div></td></tr><tr><td style="width: 180pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Sources</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 48pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.75pt; text-align: left;">549.4</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Uses</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 42pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.75pt; text-align: left;">549.4</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 180pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 180pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 42pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Reflects the amount in the trust account as of December 31, 2025. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Assumes a redemption price of $10.65 per share, based on the amount in the trust account as of December 31, 2025. </div></td></tr></table> <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Interests of PCSC’s Directors and Executive Officers, Sponsor and Others in the Business Combination </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In considering the recommendation of the PCSC Board in favor of approval of the Business Combination Proposal, the Domestication Proposal, the Governing Documents Proposal, each of the Advisory Governing Documents Proposals, the Nasdaq Proposal, the Equity Incentive Plan Proposal, the Employee Stock Purchase Plan Proposal and the Adjournment Proposal, PCSC shareholders should keep in mind that the Sponsor, the Perceptive PIPE Investor, and PCSC’s officers and directors have interests in the Business Combination that are different from or in addition to (and which may conflict with) the interests of unaffiliated PCSC shareholders. Further, PCSC’s officers and directors have additional fiduciary or contractual obligations to other entities pursuant to which such officer or director is or will be required to present a business combination opportunity to such entity, which are set forth in more detail in the section titled “<span style="font-style: italic;">Information About PCSC—Conflicts of Interest</span>.” We believe there were no such opportunities that were not presented as a result of the existing fiduciary or contractual obligations of our officers and directors to other entities. The PCSC Board was aware of and considered these interests, among other matters, in evaluating and negotiating the Business Combination and Business Combination Agreement and in recommending to our shareholders that they vote in favor of the proposals to be presented at the extraordinary general meeting, including the Business Combination Proposal. PCSC shareholders should take these interests into account in deciding whether to approve the proposals presented at the extraordinary general meeting, including the Business Combination Proposal. See “<span style="font-style: italic;">Business Combination Proposal—Interests of PCSC’s Directors and Executive Officers, Sponsor and Others in the Business Combination.</span>” </div> <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Set forth below is a summary of the amount of compensation and securities received or to be received by the Sponsor, the Perceptive PIPE Investor, and PCSC’s officers and directors in connection with the Business Combination and PIPE Financing. </div><table cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 120pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 144pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 120pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Securities to be Received</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 144pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Other Compensation </div></td></tr><tr><td style="width: 120pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Sponsor</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Assuming the Aggregate Transaction Proceeds Condition Redemptions Scenario: (i) 2,066,250 shares of New Freenome Common Stock upon the exchange of 2,066,250 PCSC Class B Shares in the Domestication, which were initially purchased prior to PCSC’s initial public</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 144pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Reimbursement for Working Capital Loans to PCSC. To date, PCSC has no outstanding borrowings under Working Capital Loans.<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$15,000 per month through the Closing for office space, secretarial </div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 120pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 144pt;"><div style="font-size: 1pt;"> </div></td></tr></table><table cellpadding="0" class="BRDSX_txttab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 120pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 144pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 120pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Securities to be Received</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 144pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Other Compensation </div></td></tr><tr><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">offering for approximately $0.01 per share and (ii) 286,250 shares of New Freenome Common Stock upon the exchange of 286,250 PCSC Class A Shares in the Domestication, which were initially purchased in a private placement that closed concurrently with PCSC’s initial public offering at a price of $10.00 per share.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">and administrative services. As of December 31, 2025, PCSC incurred $180,000 in fees for these services, of which such amount is included in accrued expenses in PCSC’s balance sheet as of December 31, 2025.<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Continued indemnification and the continuation of directors’ and officer’s liability insurance after the Business Combination. </div></td></tr><tr><td style="width: 120pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 144pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 120pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Perceptive PIPE Investor </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Assuming the Aggregate Transaction Proceeds Condition Redemptions Scenario: (i) 5,500,000 shares of New Freenome Common Stock purchased by the Perceptive PIPE Investor for $10.00 per share in the PIPE Financing, for an aggregate amount of $55.0 million, and (iii) 5,615,003 shares of New Freenome Common Stock upon the exchange of Freenome capital stock in the First Merger, which is determined by reference to the Exchange Ratio.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 144pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Continued indemnification after the Business Combination. </div></td></tr><tr><td style="width: 120pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 144pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 120pt; padding-top: 0.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">PCSC’s independent directors (Messrs. McKenna, Song and Waksal)</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 0.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Each will receive 30,000 shares of New Freenome Common Stock upon the exchange of 30,000 PCSC Class B Shares held by them in the Domestication, which shares were issued to them as consideration for services to PCSC.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 144pt; padding-top: 0.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Reimbursement for Working Capital Loans to PCSC. To date, PCSC has no outstanding borrowings under Working Capital Loans.<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">  <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Reimbursement for out-of-pocket expenses incurred related to identifying, negotiating, investigating and completing the Business Combination; no such amounts are outstanding as of the date of this proxy statement/prospectus.<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Continued indemnification and the continuation of directors’ and officer’s liability insurance after the Business Combination.</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 120pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 144pt;"><div style="font-size: 1pt;"> </div></td></tr></table> <table cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 120pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 144pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 120pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Securities to be Received</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 144pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Other Compensation </div></td></tr><tr><td style="width: 120pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Sponsor</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Assuming the Aggregate Transaction Proceeds Condition Redemptions Scenario: (i) 2,066,250 shares of New Freenome Common Stock upon the exchange of 2,066,250 PCSC Class B Shares in the Domestication, which were initially purchased prior to PCSC’s initial public</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 144pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Reimbursement for Working Capital Loans to PCSC. To date, PCSC has no outstanding borrowings under Working Capital Loans.<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$15,000 per month through the Closing for office space, secretarial </div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 120pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 144pt;"><div style="font-size: 1pt;"> </div></td></tr></table>          Securities to be Received  Other Compensation    offering for approximately $0.01 per share and (ii) 286,250 shares of New Freenome Common Stock upon the exchange of 286,250 PCSC Class A Shares in the Domestication, which were initially purchased in a private placement that closed concurrently with PCSC’s initial public offering at a price of $10.00 per share.  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">and administrative services. As of December 31, 2025, PCSC incurred $180,000 in fees for these services, of which such amount is included in accrued expenses in PCSC’s balance sheet as of December 31, 2025.<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> <br/></div>Continued indemnification and the continuation of directors’ and officer’s liability insurance after the Business Combination. <table cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 120pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 144pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 120pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Securities to be Received</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 144pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Other Compensation </div></td></tr><tr><td style="width: 120pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Sponsor</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Assuming the Aggregate Transaction Proceeds Condition Redemptions Scenario: (i) 2,066,250 shares of New Freenome Common Stock upon the exchange of 2,066,250 PCSC Class B Shares in the Domestication, which were initially purchased prior to PCSC’s initial public</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 144pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Reimbursement for Working Capital Loans to PCSC. To date, PCSC has no outstanding borrowings under Working Capital Loans.<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$15,000 per month through the Closing for office space, secretarial </div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 120pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 144pt;"><div style="font-size: 1pt;"> </div></td></tr></table>          Securities to be Received  Other Compensation    offering for approximately $0.01 per share and (ii) 286,250 shares of New Freenome Common Stock upon the exchange of 286,250 PCSC Class A Shares in the Domestication, which were initially purchased in a private placement that closed concurrently with PCSC’s initial public offering at a price of $10.00 per share.  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">and administrative services. As of December 31, 2025, PCSC incurred $180,000 in fees for these services, of which such amount is included in accrued expenses in PCSC’s balance sheet as of December 31, 2025.<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> <br/></div>Continued indemnification and the continuation of directors’ and officer’s liability insurance after the Business Combination. 15000 Perceptive PIPE Investor   Assuming the Aggregate Transaction Proceeds Condition Redemptions Scenario: (i) 5,500,000 shares of New Freenome Common Stock purchased by the Perceptive PIPE Investor for $10.00 per share in the PIPE Financing, for an aggregate amount of $55.0 million, and (iii) 5,615,003 shares of New Freenome Common Stock upon the exchange of Freenome capital stock in the First Merger, which is determined by reference to the Exchange Ratio.  Continued indemnification after the Business Combination. PCSC’s independent directors (Messrs. McKenna, Song and Waksal)  Each will receive 30,000 shares of New Freenome Common Stock upon the exchange of 30,000 PCSC Class B Shares held by them in the Domestication, which shares were issued to them as consideration for services to PCSC.  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Reimbursement for Working Capital Loans to PCSC. To date, PCSC has no outstanding borrowings under Working Capital Loans.<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">  <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Reimbursement for out-of-pocket expenses incurred related to identifying, negotiating, investigating and completing the Business Combination; no such amounts are outstanding as of the date of this proxy statement/prospectus.<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Continued indemnification and the continuation of directors’ and officer’s liability insurance after the Business Combination.</div> <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The securities to be issued to the Sponsor, the Perceptive PIPE Investor, and PCSC’s officers and directors may result in a material dilution of the equity interests of non-redeeming public shareholders. PCSC’s independent directors are not members of the Sponsor and are not affiliates of the Perceptive PIPE Investor. None of the funds in the trust account will be used to compensate our officers or directors. Except for administrative services fees and office rental fees paid or to be paid to the Sponsor, no compensation of any kind, including finder’s and consulting fees, have been paid or will be paid to the Sponsor, the Perceptive PIPE Investor, officers and directors, or any of their respective affiliates, for services rendered prior to or in connection with the completion of the Business Combination. However, as detailed above, these individuals will be reimbursed for any out-of-pocket expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations, as discussed above. The reimbursement of expenses and advances to the Sponsor, the Perceptive PIPE Investor, and PCSC’s officers and directors may result in a material dilution of the equity interests of non-redeeming public shareholders. </div> Freenome’s novel technology for early cancer detection, accompanied with positive data, Freenome’s critical and valuable commercial partnerships, Freenome’s market opportunity, Freenome’s experienced leadership team the size of the PIPE Financing committed The Special Committee also reviewed the financial analysis and opinion of Scalar rendered to the Special Committee to the effect that, as of December 4, 2025 and subject to the procedures followed, assumptions made, matters considered, qualifications and limitations on the review undertaken, and other matters considered by Scalar in connection with the opinion, the consideration to be delivered to the Freenome Stockholders in the First Merger pursuant to the Business Combination was fair, from a financial point of view, to the PCSC Unaffiliated Shareholders. The Special Committee and the PCSC Board also considered a variety of factors and risks, potentially weighing negatively against pursuing the Business Combination, including, but not limited to macroeconomic risks that may cause Freenome’s future financial performance to not meet the Special Committee’s and the PCSC Board’s present expectations, the risk of regulatory changes that may adversely affect Freenome’s projected financial results and the other business benefits anticipated to result from the Business Combination, the redemption risk, the risk that PCSC shareholders may fail to provide the votes necessary to effect the Business Combination, the risks and costs to PCSC if the Business Combination is not completed, including the fact that PCSC may be forced to liquidate if PCSC being unable to effect a business combination by June 13, 2026 (unless otherwise extended), the risk that Closing may not occur due to failure to satisfy Closing conditions to the Business Combination, and the absence of possible structural protections for minority shareholders. <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Opinion of Scalar, LLC </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On December 4, 2025, Scalar rendered its oral opinion to the Special Committee, subsequently confirmed in writing, as to the fairness, from a financial point of view, as of such date, to (1) the PCSC Class A Shareholders (other than (i) Freenome, (ii) Sponsor, (iii) the Key Supporting Company Stockholders, (iv) PCSC Class A Shareholders who elect to redeem their shares prior to or in connection with the Transaction, and (v) the PIPE Investors, (collectively, along with their respective affiliates, the “<span style="font-style: italic; font-weight: bold;">Excluded Parties</span>”)) of the consideration to be delivered to the Freenome Stockholders in the Transaction, without giving effect to any impact of the Transaction on any particular PCSC Class A Shareholder other than in its capacity as a PCSC Class A Shareholder, and (2) PCSC. The full text of Scalar’s written opinion, dated December 4, 2025, which sets forth the procedures followed, assumptions made, matters considered, qualifications and limitations on the review undertaken, and other matters considered by Scalar in connection with the opinion are fully described in the subsection “<span style="font-style: italic;">Business Combination Proposal— Opinion of Scalar, LLC</span>”. A copy of Scalar’s opinion is attached hereto as <span style="font-weight: bold;">Annex L</span>. The summary of Scalar’s opinion in this proxy statement/prospectus is qualified in its entirety by reference to the full text of Scalar’s written opinion. Scalar’s opinion was provided for the information and assistance of the Special Committee and does not constitute a recommendation as to how any shareholder of PCSC should vote or act (including with respect to any redemption rights) with respect to the Transaction or any other matter. </div> <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Redemption Rights </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Pursuant to the Existing Governing Documents, a public shareholder may request that PCSC redeem its public shares for cash contemporaneously with the vote to approve the Business Combination and prior to the Domestication. If the Business Combination is approved, PCSC will pay to the holders any public shares that have been validly tendered or delivered for redemption a pro rata portion of the aggregate amount then on deposit in the trust account, calculated as of two business days prior to the consummation of the Business Combination and including interest earned on the funds held in the Trust Account not previously released to PCSC for permitted withdrawals. Pursuant to the Business Combination Agreement, the Domestication shall occur at least one business day prior to the Closing Date. As a holder of public shares, you will be entitled to receive cash for any public shares to be redeemed only if you: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">hold public shares; and </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">prior to 5:00 p.m., Eastern Time, on [•], 2026 (two business days prior to the initially scheduled vote at the extraordinary general meeting), (a) submit a written request to the PCSC transfer agent in which you (i) request that PCSC redeem all or a portion of your public shares for cash, and (ii) identify yourself as the beneficial holder of the public shares and provide your legal name, phone number and address; and (b) deliver your public shares to the PCSC transfer agent physically or electronically through DTC. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">For illustrative purposes, based on funds in the trust account of approximately $91,918,776.09 on January 6, 2026, the estimated per share redemption price is expected to be approximately $10.66. A public shareholder who has properly tendered or delivered his, her or its public shares for redemption will be entitled to receive his, her or its pro rata portion of the aggregate amount then on deposit in the trust account in cash for such shares only if the Business Combination is completed. If the Business Combination is not completed, the redemptions will be canceled and the tendered shares will be returned to the relevant public shareholders as appropriate. If a public shareholder exercises its redemption rights in full, then it will be electing to exchange its public shares for cash and will no longer own any shares. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Public shareholders who seek to redeem their public shares must demand redemption no later than 5:00 p.m., Eastern Time, on [•], 2026 (two business days prior to the initially scheduled vote at the extraordinary general meeting) by (a) submitting a written request to the PCSC transfer agent that PCSC redeem such holder’s public shares for cash, (b) affirmatively certifying in such request to the PCSC transfer agent for redemption if such holder is acting in concert or as a “group” (as defined in Section 13d-3 of the Exchange Act) with any other shareholder with respect to PCSC Shares and (c) tendering or delivering their PCSC Shares, either physically or electronically through the DWAC system, at the holder’s option, to the PCSC transfer agent prior to the extraordinary general meeting. If you hold the shares in street name, you will have to coordinate with your broker to have your shares certificated or delivered electronically. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Notwithstanding the foregoing, a public shareholder, together with any affiliate of his, her, its or any other person with whom he, she or it is acting in concert or as a “group” (as defined in Section 13(d)(3) of the Exchange Act) will be restricted from seeking redemption rights with respect to more than 15% of the public shares. Accordingly, any shares held by a public shareholder or “group” in excess of such 15% cap will not be redeemed by PCSC. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">See the section entitled “<span style="font-style: italic;">Extraordinary General Meeting of PCSC—Redemption Rights</span>” for a detailed description of the procedures to be followed if you wish to redeem your public shares for cash. See also “<span style="font-style: italic;">Questions and Answers about the Business Combination—Do I have redemption rights and is there a limit on the number of shares I may redeem?—How do I exercise my redemption rights?</span>” for additional information on the exercise of redemption rights. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">As set forth in more detail elsewhere in this proxy statement/prospectus, the public shareholders currently own approximately 77.9% of the issued and outstanding PCSC Shares prior to the Business Combination. Accordingly, public shareholders, as a group, will experience immediate dilution as a consequence of the Business Combination. As redemptions increase, the overall percentage ownership held by the Sponsor, the Perceptive PIPE Investor, Messrs. McKenna, Song and Waksal, Freenome Stockholders and the PIPE Investors will increase as compared to the overall percentage ownership and voting percentage held by public shareholders, thereby increasing dilution to public shareholders. For more information on the percentage of the issued and outstanding shares of New Freenome Common Stock immediately following the Closing that are expected to be held by securityholders, in various redemptions scenarios, see “<span style="font-style: italic;">Dilution</span>.” </div> <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Redemption Rights </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Pursuant to the Existing Governing Documents, a public shareholder may request that PCSC redeem its public shares for cash contemporaneously with the vote to approve the Business Combination and prior to the Domestication. If the Business Combination is approved, PCSC will pay to the holders any public shares that have been validly tendered or delivered for redemption a pro rata portion of the aggregate amount then on deposit in the trust account, calculated as of two business days prior to the consummation of the Business Combination and including interest earned on the funds held in the Trust Account not previously released to PCSC for permitted withdrawals. Pursuant to the Business Combination Agreement, the Domestication shall occur at least one business day prior to the Closing Date. As a holder of public shares, you will be entitled to receive cash for any public shares to be redeemed only if you: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">hold public shares; and </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">prior to 5:00 p.m., Eastern Time, on [•], 2026 (two business days prior to the initially scheduled vote at the extraordinary general meeting), (a) submit a written request to the PCSC transfer agent in which you (i) request that PCSC redeem all or a portion of your public shares for cash, and (ii) identify yourself as the beneficial holder of the public shares and provide your legal name, phone number and address; and (b) deliver your public shares to the PCSC transfer agent physically or electronically through DTC. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">For illustrative purposes, based on funds in the trust account of approximately $91,918,776.09 on January 6, 2026, the estimated per share redemption price is expected to be approximately $10.66. A public shareholder who has properly tendered or delivered his, her or its public shares for redemption will be entitled to receive his, her or its pro rata portion of the aggregate amount then on deposit in the trust account in cash for such shares only if the Business Combination is completed. If the Business Combination is not completed, the redemptions will be canceled and the tendered shares will be returned to the relevant public shareholders as appropriate. If a public shareholder exercises its redemption rights in full, then it will be electing to exchange its public shares for cash and will no longer own any shares. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Public shareholders who seek to redeem their public shares must demand redemption no later than 5:00 p.m., Eastern Time, on [•], 2026 (two business days prior to the initially scheduled vote at the extraordinary general meeting) by (a) submitting a written request to the PCSC transfer agent that PCSC redeem such holder’s public shares for cash, (b) affirmatively certifying in such request to the PCSC transfer agent for redemption if such holder is acting in concert or as a “group” (as defined in Section 13d-3 of the Exchange Act) with any other shareholder with respect to PCSC Shares and (c) tendering or delivering their PCSC Shares, either physically or electronically through the DWAC system, at the holder’s option, to the PCSC transfer agent prior to the extraordinary general meeting. If you hold the shares in street name, you will have to coordinate with your broker to have your shares certificated or delivered electronically. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Notwithstanding the foregoing, a public shareholder, together with any affiliate of his, her, its or any other person with whom he, she or it is acting in concert or as a “group” (as defined in Section 13(d)(3) of the Exchange Act) will be restricted from seeking redemption rights with respect to more than 15% of the public shares. Accordingly, any shares held by a public shareholder or “group” in excess of such 15% cap will not be redeemed by PCSC. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">See the section entitled “<span style="font-style: italic;">Extraordinary General Meeting of PCSC—Redemption Rights</span>” for a detailed description of the procedures to be followed if you wish to redeem your public shares for cash. See also “<span style="font-style: italic;">Questions and Answers about the Business Combination—Do I have redemption rights and is there a limit on the number of shares I may redeem?—How do I exercise my redemption rights?</span>” for additional information on the exercise of redemption rights. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">As set forth in more detail elsewhere in this proxy statement/prospectus, the public shareholders currently own approximately 77.9% of the issued and outstanding PCSC Shares prior to the Business Combination. Accordingly, public shareholders, as a group, will experience immediate dilution as a consequence of the Business Combination. As redemptions increase, the overall percentage ownership held by the Sponsor, the Perceptive PIPE Investor, Messrs. McKenna, Song and Waksal, Freenome Stockholders and the PIPE Investors will increase as compared to the overall percentage ownership and voting percentage held by public shareholders, thereby increasing dilution to public shareholders. For more information on the percentage of the issued and outstanding shares of New Freenome Common Stock immediately following the Closing that are expected to be held by securityholders, in various redemptions scenarios, see “<span style="font-style: italic;">Dilution</span>.” </div> true <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">As set forth in more detail elsewhere in this proxy statement/prospectus, the public shareholders currently own approximately 77.9% of the issued and outstanding PCSC Shares prior to the Business Combination. Accordingly, public shareholders, as a group, will experience immediate dilution as a consequence of the Business Combination. As redemptions increase, the overall percentage ownership held by the Sponsor, the Perceptive PIPE Investor, Messrs. McKenna, Song and Waksal, Freenome Stockholders and the PIPE Investors will increase as compared to the overall percentage ownership and voting percentage held by public shareholders, thereby increasing dilution to public shareholders. For more information on the percentage of the issued and outstanding shares of New Freenome Common Stock immediately following the Closing that are expected to be held by securityholders, in various redemptions scenarios, see “<span style="font-style: italic;">Dilution</span>.” </div> <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Appraisal Rights and Dissenters’ Rights </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">PCSC’s shareholders do not have appraisal rights in connection with the Business Combination or the Domestication under the DGCL. PCSC’s shareholders do not have dissenters’ rights in connection with the Business Combination or the Domestication under Cayman Islands law. </div> false <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Recommendation of the PCSC Board </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Special Committee, with the advice and assistance of representatives of Scalar, and its other advisors, evaluated the terms of the Business Combination Agreement and the transactions contemplated thereby. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On December 4, 2025, after careful consideration, the Special Committee unanimously (i) determined that the terms and conditions of the Business Combination Agreement, each ancillary agreement, and the Business Combination were fair, advisable, and in the best interests of PCSC and its shareholders as a whole (ii) recommended that the PCSC Board approve the Business Combination Agreement, each ancillary agreement, the Business Combination and the other agreements and transactions contemplated thereby and (iii) subject to the terms and conditions of the Business Combination Agreement, recommended that the PCSC shareholders approve the Business Combination Agreement, the Business Combination and the other transactions contemplated by the Business Combination Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On the same day, after careful consideration and based in part on the unanimous recommendation of the Special Committee, the PCSC Board unanimously determined that the Business Combination is fair, advisable, and in the best interests of PCSC and its shareholders as a whole, and approved and adopted the Business Combination Agreement, each ancillary agreement, the Business Combination and the other agreements and transactions contemplated thereby. The Business Combination was not structured to require the approval of at least a majority of PCSC’s unaffiliated shareholders because such a vote is not required under Cayman Islands law. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The PCSC Board believes that the Business Combination Proposal and the other proposals to be presented at the extraordinary general meeting are fair, advisable, and in the best interests of PCSC and its shareholders as a whole and unanimously recommends that its shareholders vote “FOR” the Business Combination Proposal, “FOR” the Domestication Proposal (in the case of the holders of PCSC Class B Shares), “FOR” the Governing Documents Proposal (in the case of the holders of PCSC Class B Shares), “FOR” the Advisory Governing Documents Proposal, “FOR” the Nasdaq Proposal, “FOR” the Equity Incentive Plan Proposal, “FOR” the Employee Stock Purchase Plan Proposal and “FOR” the Adjournment Proposal, in each case, if presented to the extraordinary general meeting. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">For a more complete description of the Special Committee’s and the PCSC Board’s reasons for the approval of the Business Combination and the unanimous recommendation of the Special Committee and the PCSC Board, see the subsection entitled “<span style="font-style: italic;">Business Combination Proposal—The Special Committee’s and the PCSC Board’s Reasons for the Approval of the Business Combination</span>.” </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The existence of financial and personal interests of one or more of PCSC’s directors may result in a conflict of interest on the part of such director(s) between what he or they may believe is in the best interests of PCSC and its shareholders, as a whole, and what he or they may believe is best for himself or themselves in determining to recommend that shareholders vote for the proposals. In addition, PCSC’s officers have interests in the Business Combination that may conflict with your interests as a shareholder. See the section entitled “<span style="font-style: italic;">Business Combination Proposal—Interests of PCSC’s Directors and Officers, Sponsor and Others in the Business Combination</span>” for a further discussion of these considerations. </div> The Business Combination was not structured to require the approval of at least a majority of PCSC’s unaffiliated shareholders because such a vote is not required under Cayman Islands law. <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">The Business Combination Agreement </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">This subsection of the proxy statement/prospectus describes the material provisions of the Business Combination Agreement, but does not purport to describe all of the terms of the Business Combination Agreement. The following summary is qualified in its entirety by reference to the complete text of the Business Combination Agreement, which is attached as <span style="font-weight: bold;">Annex A</span> to this proxy statement/prospectus. You are urged to read the Business Combination Agreement in its entirety because it is the primary legal document that governs the Business Combination. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Business Combination Agreement contains representations, warranties and covenants that the respective parties made to each other as of the date of the Business Combination Agreement or other specific dates. The assertions embodied in those representations, warranties and covenants were made for purposes of the contract among the respective parties and are subject to important qualifications and limitations agreed to by the parties in connection with negotiating the Business Combination Agreement. The representations, warranties and covenants in the Business Combination Agreement are also modified in part by the underlying disclosure schedules (the “<span style="font-style: italic; font-weight: bold;">disclosure schedules</span>”), which are not filed publicly and which are subject to a contractual standard of materiality different from that generally applicable to shareholders and were used for the purpose of allocating risk among the parties rather than establishing matters as facts. We do not believe that the disclosure schedules contain information that is material to an investment decision. Additionally, the representations and warranties of the parties to the Business Combination Agreement may or may not have been accurate as of any specific date and do not purport to be accurate as of the date of this proxy statement/prospectus. Accordingly, no person should rely on the representations and warranties in the Business Combination Agreement or the summaries thereof in this proxy statement/prospectus as characterizations of the actual state of facts about PCSC, Sponsor, Freenome or any other matter. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On December 5, 2025, PCSC, Merger Sub I, Merger Sub II, and Freenome entered into the Business Combination Agreement, which provides for, among other things, the following transactions: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">at least one business day prior to the Closing Date, PCSC will effect the Domestication by de-registering from the Register of Companies in the Cayman Islands and transfer by way of continuation from the Cayman Islands to Delaware and domesticate as a Delaware corporation in accordance with Section 388 of the DGCL and Part 12 of the Companies Act (Revised) of the Cayman Islands, upon which PCSC will change its name to “Freenome, Inc.”; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the parties to the Business Combination Agreement will effect the First Merger by executing and filing a certificate of merger with the Secretary of State of the State of Delaware, pursuant to which Merger Sub I will merge with and into Freenome, with Freenome as the surviving company in the merger and, after giving effect to the First Merger, Freenome will be a wholly-owned subsidiary of PCSC. In accordance with the terms and subject to the conditions of the Business Combination Agreement, at the Effective Time, (i) the Freenome Common Shares issued and outstanding as of immediately prior to the Effective Time (including such shares issued upon the conversion of all shares of Freenome preferred stock into Freenome Common Shares prior to the Effective Time in accordance with the terms of the Business Combination Agreement, but excluding Freenome Common Shares held in treasury or by Freenome stockholders who have properly demanded appraisal of such Freenome Common Shares in accordance with Section 262 of the DGCL) will be automatically canceled and extinguished and converted into the right to receive a number of shares of New Freenome Common Stock equal to the Exchange Ratio, which is based on an implied Freenome base equity value of $725,000,000 and subject to certain adjustments as set forth in the Business Combination Agreement; (ii) each Freenome Option, being an option to purchase Freenome Common Shares, </div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">whether vested or unvested, will cease to represent the right to purchase Freenome Common Shares and will be canceled in exchange for a Rollover Option, being an option to purchase New Freenome Common Stock under the New Freenome Equity Incentive Plan, in an amount equal to the product (rounded down to the nearest whole number) of (x) the number of Freenome Common Shares subject to such Freenome Option immediately prior to the Effective Time, multiplied by (y) the Exchange Ratio, at an exercise price per share (rounded up to the nearest whole cent) equal to the quotient of (i) the exercise price per share of such Freenome Option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, and generally subject to the same terms and conditions (including applicable vesting, expiration and forfeiture provisions) that applied to the corresponding Freenome Option immediately prior to the Effective Time; and (iii) each Freenome RSU Award, being a restricted stock unit award that is outstanding with respect to Freenome Common Shares, whether vested or unvested, will cease to have any rights in respect of the Freenome Common Shares and will be canceled in exchange for a Rollover RSU Award, being a restricted stock unit award under the New Freenome Equity Incentive Plan that settles in a number of shares of New Freenome Common Stock (rounded down to the nearest whole share) in an amount and subject to such terms and conditions, in each case, as to be set forth on an allocation schedule, that will generally be subject to the same terms and conditions (including applicable vesting, expiration and forfeiture provisions) that applied to the corresponding Freenome RSU Award immediately prior to the Effective Time; and </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">as soon as practicable following the Effective Time, but no later than one business day following the Effective Time, subject to the terms and conditions of the Business Combination Agreement, the parties to the Business Combination Agreement will effect the Second Merger by executing and filing a certificate of merger with the Secretary of State of the State of Delaware, pursuant to which Freenome, as the surviving corporation of the First Merger, will merge with and into Merger Sub II, with Merger Sub II continuing as the surviving company in the Second Merger. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In connection with the foregoing and substantially concurrent with the execution of the Business Combination Agreement, PCSC entered into Subscription Agreements with each of the PIPE Investors, pursuant to which the PIPE Investors have agreed to subscribe for and purchase, and PCSC has agreed to issue and sell to the PIPE Investors, an aggregate of 24,000,000 shares of New Freenome Common Stock at a price of $10.00 per share, for aggregate gross proceeds of $240,000,000, which we refer to as the “PIPE Financing.” Pursuant to the Subscription Agreement, the Perceptive PIPE Investor subscribed for 5,500,000 shares of New Freenome Common Stock at a price of $10.00 per share, for aggregate gross proceeds of $55,000,000. PCSC will grant the PIPE Investors certain registration rights in connection with the PIPE Financing. The PIPE Financing is contingent upon, among other things, the substantially concurrent Closing of the Business Combination. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In connection with the Business Combination, certain related agreements have been, or will be entered into on or prior to the closing of the Business Combination, including the Transaction Support Agreements, the Sponsor Letter Agreement, the Lock-Up Agreement and the Investor Rights Agreement (each as defined in the accompanying proxy statement/prospectus). See <span style="font-style: italic;">“—Related Agreements</span>” for more information. </div> <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">PIPE Financing </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In connection with the execution of the Business Combination Agreement, on December 5, 2025, PCSC entered into Subscription Agreements with the PIPE Investors. Pursuant to the Subscription Agreements, the PIPE Investors agreed to subscribe for and purchase, and PCSC agreed to issue and sell to the PIPE Investors, on the Closing Date immediately following the Closing, an aggregate of 24,000,000 shares of New Freenome Common Stock for a purchase price of $10.00 per share, and aggregate gross proceeds of $240.0 million (the “<span style="font-style: italic; font-weight: bold;">PIPE Financing</span>”). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The obligations of each party to consummate the PIPE Financing are conditioned upon, among other things, (i) the New Freenome Common Stock (including the New Freenome Common Stock issuable to the PIPE Investors pursuant to the Subscription Agreements) having been approved for listing on Nasdaq; (ii) satisfaction of all conditions precedent to the closing of the transactions set forth in the Business Combination Agreement; and (iii) the absence of specified adverse judgements, orders, laws, rules or regulations enjoining or otherwise prohibiting the consummation of the transactions set forth in the Business Combination Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The obligations of PCSC to consummate the PIPE Financing are further subject to additional conditions, including, among other things: (i) material truth and accuracy of the representations and warranties of the PIPE Investors, subject to customary bringdown standards; and (ii) material compliance by the PIPE Investors with their covenants, agreements and conditions under the Subscription Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The obligations of the PIPE Investors to consummate the PIPE Financing are further subject to additional conditions, including, among other things: (i) the Business Combination Agreement shall not have been amended, modified, or supplemented, and no condition waived thereunder, in a manner that would reasonably be expected to materially and adversely affect the economic benefits that a PIPE Investor (in its capacity as such) would reasonably expect to receive under the Subscription Agreement; (ii) the material truth and accuracy of the representations and warranties of PCSC in the Subscription Agreement, subject to customary bringdown standards; (iii) no subscription agreement, or other agreements or understandings (including side letters) entered into in connection with the sale of New Freenome Common Stock under the Subscription Agreements, with any other PIPE Investors shall have been amended, modified, or waived in any manner that benefits such other PIPE Investor unless all PIPE Investors have been offered substantially the same benefits (other than terms particular to the legal or regulatory requirements of such other </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">PIPE Investor or its affiliates or related persons); (iv) all specified consents, waivers or other authorizations and notices, required to be made in connection with the issuance and sale of New Freenome Common Stock under the Subscription Agreements shall have been obtained or made, except where failure to so obtain would not prevent PCSC from consummating the transactions contemplated by the Subscription Agreements; (v) material compliance by PCSC with their covenants, agreements and conditions under the Subscription Agreement; (vi) there has not occurred any material adverse effect or parent material adverse effect since the date of the Subscription Agreement that is continuing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Subscription Agreements provide that New Freenome will grant the investors in the PIPE Financing certain customary registration rights. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The foregoing description of the Subscription Agreements and the PIPE Financing is subject to and qualified in its entirety by reference to the full text of the form of Subscription Agreement, a copy of which is attached as <span style="font-weight: bold;">Annex C </span>to this proxy statement/prospectus. </div> 240000000 <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Sponsor Letter Agreement </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Concurrently with the execution of the Business Combination Agreement, on December 5, 2025, PCSC, the initial shareholders being the Sponsor and PCSC’s independent directors (Messrs. McKenna, Song and Waksal), and Freenome entered into the Sponsor Letter Agreement (the “<span style="font-style: italic; font-weight: bold;">Sponsor Letter Agreement</span>”), pursuant to which the Sponsor and each of PCSC’s independent directors, as a holder of PCSC Shares has agreed to, among other things, (i) vote in favor of the Business Combination Agreement and the transactions contemplated thereby (including the Mergers), (ii) waive any adjustment to the conversion ratio set forth in the governing documents of PCSC or any other anti-dilution or similar protection with respect to the PCSC Class B Shares (whether resulting from the transactions contemplated by the Subscription Agreements or otherwise), (iii) be bound by certain other covenants and agreements related to the Business Combination, (iv) be bound by certain transfer restrictions with respect to his, her or its shares in PCSC prior to the closing of the Business Combination, and (v) be subject to the restrictions contemplated by the Lock-up Agreements in each case, on the terms and subject to the conditions set forth in the Sponsor Letter Agreement. No consideration has been or will be paid to PCSC, Freenome, to the Sponsor or each of PCSC’s independent directors in connection with the entry into the Sponsor Letter Agreement. </div> <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Background to the Business Combination </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">PCSC is a blank check company incorporated on March 22, 2024 as a Cayman Islands exempted company, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On March 27, 2024, prior to the closing of PCSC’s initial public offering, the Sponsor paid $25,000 to cover certain expenses on PCSC’s behalf in exchange for the issuance of 2,156,250 PCSC Class B Shares, or approximately $0.01 per share. In April 2024, the Sponsor transferred 30,000 PCSC Class B Shares to each of the three independent directors of the PCSC Board: Mark C. McKenna, Kenneth Song, M.D. and Harlan W. Waksal, M.D. On June 13, 2024, PCSC consummated its initial public offering of 8,625,000 PCSC Class A Shares, $0.0001 par value per share, at an offering price of $10.00 per share, which included the exercise in full of the underwriter’s option to purchase an additional 1,125,000 PCSC Class A Shares at the initial public offering price of $10.00 per share to cover over-allotments, and a private placement with the Sponsor of 286,250 PCSC Class A Shares at a price of $10.00 per share. The aggregate net proceeds of $86,250,000 from the initial public offering together with certain of the proceeds from the private placement were placed in the Trust Account established for the benefit of PCSC’s public shareholders and the underwriter of the initial public offering, with Continental Stock Transfer &amp; Trust Company acting as trustee. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Following the completion of its initial public offering, at the direction of the PCSC Board, representatives of PCSC, including Messrs. Stone and Poukalov, and Dr. Hukkelhoven commenced an active, targeted search for potential business combination candidates, leveraging the Sponsor’s network of investment bankers, private equity firms and hedge funds (including Perceptive Advisors and its affiliates), consulting firms, legal and accounting firms, and numerous other business relationships, as well as the prior experience and network of PCSC’s officers and directors. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Consistent with the investment focus and acquisition criteria described in PCSC’s initial public offering prospectus, and based on discussion with the PCSC Board, PCSC targeted potential business combination targets in the life sciences and medical technology sectors that its officers and directors believed, based on their experience, could satisfy all (or a portion) of the following key criteria: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">have scientific or other competitive advantages in the markets in which they operate and ability to benefit from access to additional capital as well as PCSC’s industry relationships and expertise; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">are ready to be public companies, with strong management, corporate governance and reporting policies in place; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">will likely be well received by public investors and are expected to have good access to the public capital markets; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">have significant embedded and/or underexploited growth opportunities; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">exhibit unrecognized value or other characteristics that PCSC believes have been misevaluated by the market, based on PCSC’s rigorous analysis and scientific and business due diligence review; and </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">will offer attractive risk-adjusted equity returns for PCSC shareholders.</div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">During this targeted search, representatives of PCSC, including Messrs. Stone, Altman, Poukalov, and Vazquez, and Dr. Hukkelhoven, reviewed approximately 200 potential business combination targets and conducted varying levels of preliminary due diligence on each, and evaluated and analyzed each as a potential business combination target based on, among other things, publicly available information and other market research available to PCSC and its representatives and their existing knowledge of the potential targets as a result of their network and existing relationships. This preliminary diligence, evaluation and analysis with respect to each potential business combination target identified was focused on business, operational and financial matters, including, among other things, product candidate pipelines, other potential product or service offerings, technology, market potential and financial information. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Following this preliminary evaluation, PCSC determined that approximately 20 companies, including Freenome, merited more serious consideration, based on such companies’ scientific approach, development stage, financing needs, management strength and overall alignment with PCSC’s acquisition criteria. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On October 28, 2024, representatives of PCSC, including Messrs. Stone, Altman, Poukalov, and Vazquez, and Dr. Hukkelhoven, submitted a non-binding term sheet to one such company, Party A. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On November 6, 2024, Party A notified PCSC that it intended to continue pursuing a traditional initial public offering rather than a business combination with PCSC in light of prevailing market conditions and its internal strategic priorities. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On December 19, 2024, representatives of PCSC, including Messrs. Stone, Altman, Poukalov, and Vazquez, and Dr. Hukkelhoven, submitted a non-binding term sheet to another such company, Party B. With respect to Party B, PCSC determined following outreach to potential financing sources and other stakeholders that there was limited interest in supporting a business combination with Party B on terms PCSC viewed as appropriate, including taking into account the criteria previously discussed by the PCSC Board. As a result, in February 2025, PCSC discontinued discussions with Party B. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">After concluding its evaluations of Party A and Party B, PCSC continued to assess potential business combination targets. Through this process, and based on discussion with members of the PCSC Board, PCSC further refined its focus and determined to concentrate its near-term efforts on revisiting a smaller set of potential business combination targets, including Freenome, that PCSC believed were the most compelling opportunities relative to the others reviewed. These were targets that PCSC had previously started to evaluate but placed such efforts on hold as PCSC awaited additional data or developments. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In addition to satisfying one or more of PCSC’s key criteria noted above, PCSC believed these targets were most suitable for a potential business combination based on, among other things: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">PCSC’s preliminary assessment of the target’s equity valuation; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the strength, differentiation, and future prospects of the target’s pipeline, platform, or underlying scientific approach; and </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the target’s preparedness for a business combination and readiness to operate as a public company on an expeditious signing and closing timeline. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Each of these targets was a development-stage or commercial-stage life sciences company with product candidates or technologies requiring additional funding for clinical development or commercialization. PCSC contemplated transactions in which consideration to the target’s equityholders would consist primarily (if not exclusively) of shares of PCSC. Representatives of PCSC, including Messrs. Stone, Altman, Poukalov, and Vazquez, and Dr. Hukkelhoven, engaged in varying levels of additional diligence, discussions, and negotiations with these targets, including Freenome, and PCSC management periodically updated the PCSC Board on their progress with respect to screening potential business combination targets. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Perceptive PIPE Investor, an affiliate of PCSC and the Sponsor, was initially introduced to Freenome in 2019 in the context of a potential investment in Freenome. The Perceptive PIPE Investor invested $20 million in Freenome’s Series B financing in July 2019, $40 million in Freenome’s Series C financing in August 2020, $44 million in Freenome’s Series D financing in December 2021 and $20 million in Freenome’s Series F financing in February 2024. Additionally, the Perceptive PIPE Investor was granted a Freenome Board seat in the Series C financing. Dr. Hukkelhoven has occupied such Freenome Board seat since August 14, 2020. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On February 19, 2025, Dr. Hukkelhoven, in her capacity as an executive officer of the Perceptive PIPE Investor, reached out to the other members of the Freenome Board, consisting of Deepika Pakianathan, Douglas VanOort, Randal Scott, Peter Kolchinsky, Moritz Hartmann, and Josh Lauer, to inquire whether Freenome would be interested in exploring a potential business combination with PCSC. The Perceptive PIPE Investor, was as of such time, and remains, an existing investor in Freenome, and Dr. Hukkelhoven, an executive officer of the Perceptive PIPE Investor, was as of such time, and remains, a member of the Freenome Board. As the Perceptive PIPE Investor has been an investor in Freenome since 2019, the Perceptive PIPE Investor has continuously monitored Freenome’s business progress and capital needs. Dr. Hukkelhoven has been a representative appointed by the Perceptive PIPE Investor on the Freenome Board since 2020. At the direction of the Freenome Board, Dr. Hukkelhoven informed the Perceptive PIPE Investor that Freenome was interested in exploring a capital raising transaction involving the Perceptive PIPE Investor and Dr. Hukkelhoven proposed the terms of the PIPE Financing to the Perceptive PIPE Investor. For more information, see “<span style="font-style: italic;">Business Combination Proposal — Interests of PCSC’s Sponsor, Directors and Officers in the Business Combination.</span>” </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In early March 2025, the Freenome Board discussed the outreach from PCSC regarding a potential business combination. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On March 7, 2025, Adam Stone, Chief Executive Officer of PCSC, along with Konstantin Poukalov and Dr. Hukkelhoven, as executive officers of the Perceptive PIPE Investor, met with the Freenome Board (excluding Dr. Hukkelhoven) to discuss the potential business combination opportunity and discussed that PCSC should propose key terms for a potential business combination between the parties to be memorialized in a term sheet. Dr. Hukkelhoven, who has been serving on the Freenome Board in connection with the investment by the Perceptive PIPE Investor in Freenome, reminded the Freenome Board of her affiliation with PCSC and the Sponsor and, after providing an overview of PCSC, recused herself from the remainder of the meeting. The Freenome Board also discussed the de-SPAC process generally. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On May 28, 2025, PCSC circulated an initial draft of the Non-Binding Term Sheet to Freenome. The Freenome Board determined that the Freenome Strategic Transaction Committee would lead the negotiations for Freenome. In August 2023, Freenome’s Board had approved the formation of such Freenome Strategic Transaction Committee in order to explore strategic transactions for Freenome. As of May 2025, the Freenome Strategic Transaction Committee consisted of Deepika Pakianathan, Randal Scott, Doug VanOort and Aaron Elliott. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Over the course of May through early August of 2025, representatives of PCSC, including Adam Stone, Konstantin Poukalov, Dr. Hukkelhoven, Michael Altman, Marcel Rosner, and Carlos Vazquez, and representatives of Freenome, including Aaron Elliott, Riley Ennis, and Thomas Fitzpatrick, and its Freenome Strategic Transaction Committee, consisting of the members identified above, with the assistance of their respective legal counsel at Cooley LLP (“<span style="font-style: italic; font-weight: bold;">Cooley</span>”) and Goodwin Procter LLP (“<span style="font-style: italic; font-weight: bold;">Goodwin</span>”), negotiated certain provisions of the Non-Binding Term Sheet. Such provisions included the pre-money base equity value of Freenome (and related adjustments), totaling $725 million, the minimum Aggregate Transaction Proceeds Amount of $200 million, and the size and terms of the post-closing employee equity pools. Dr. Hukkelhoven conveyed and explained the rationale for PCSC’s valuation of Freenome to Freenome management and the Freenome Board and acted as an intermediary between PCSC and Freenome. In the initial draft of the Non-Binding Term Sheet sent in May 2025, PCSC assigned Freenome a post-money valuation of $1.0 billion, subject to confirmatory due diligence, reflecting the following assumptions: (1) a pre-money </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">base equity value for Freenome of $725.0 million and (2) a minimum Aggregate Transaction Proceeds Amount of $250.0 million. In late July 2025, a revised draft of the Non-Binding Term Sheet from PCSC to Freenome increased the post-money valuation of Freenome to $1.05 billion, reflecting a revised assumption of $300 million in aggregate proceeds raised in the PIPE Financing plus the Trust Account’s balance at Closing. In early August 2025, PCSC sent a further revised draft Non-Binding Term Sheet, clarifying that the $1.05 billion post-money valuation of Freenome was in light of the Perceptive PIPE Investor’s plan to invest approximately $25.0 million in the PIPE Financing. In negotiating the pre-money base equity value of Freenome, the parties discussed whether the proceeds from the Exact Sciences transaction or any transaction entered into with Roche should be included in such value. Although these potential transactions had been under discussion, the parties ultimately agreed that such proceeds would not be included in the pre-money base equity value because the transactions had not been completed at the time the valuation was determined and remained contingent. Accordingly, the economic impact of any such transactions, if consummated, would be reflected in the post-money equity value rather than the pre-money valuation. Consistent with this approach, shares issuable upon conversion of Freenome convertible notes and any equity issued in connection with such transactions were excluded from the definition of fully diluted Freenome shares used in determining the Exchange Ratio so that the effects of such instruments and transactions would be reflected in the post-closing ownership rather than diluting the pre-money equity value. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">During such period, Freenome was also negotiating its exclusive licensing agreement with Exact Sciences to advance the Exact Sciences Transaction, which was ultimately signed and announced on August 6, 2025. The final terms of the Exact Sciences Transaction are described in “<span style="font-style: italic;">Information about Freenome—Key Collaborations</span>.” Additionally, during this period, Freenome began discussions on a collaboration with Roche, as detailed further below. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On August 6, 2025, the PCSC Board met by videoconference, with members of PCSC management, including Messrs. Stone, Altman, Poukalov, and Vazquez, and Dr. Hukkelhoven, and representatives of Cooley present, to discuss the potential business combination with Freenome and the Non-Binding Term Sheet. Among other things, the final terms of the Non-Binding Term Sheet contemplated that Freenome would be valued at approximately $1.05 billion on a post-Business Combination equity value basis, taking into account, among other things, (i) an assumed $300 million in aggregate proceeds from (a) the PIPE Financing (which would include at least $25 million expected to be contributed by Perceptive Advisors or its affiliates and at least $50 million expected to be contributed by RA Capital or its affiliates) and (b) the Trust Account at the closing, and (ii) an agreed pre-Business Combination base equity value for Freenome of $725 million. The Non-Binding Term Sheet further contemplated, among other things, (a) certain adjustments for leakage to the Freenome base equity value, (b) that any proceeds from the Exact Sciences Transaction or any transaction entered into with Roche would not be counted as part of the base equity value of Freenome and that any shares or other equity interests of Freenome issued and outstanding in connection with such transactions would not be taken into account as part of the Freenome shares outstanding as of immediately prior to the closing of the Business Combination for purposes of determining the applicable Exchange Ratio, (c) that in addition to other customary closing conditions, the obligation of Freenome to consummate the Business Combination would be subject to there being Aggregate Transaction Proceeds of at least $250,000,000, (d) a six-month lockup period after consummation of the Business Combination with respect to New Freenome shares to be issued to insider Freenome stockholders, including Perceptive Advisors and RA Capital, in the Business Combination, as well as certain demand and piggyback registration rights for certain stockholders, and (e) the Exclusivity Period binding on both PCSC and Freenome, ending on the later of 5:00 pm Eastern Time on October 5, 2025 and the time at which either party gives written notice to the other party of the termination of exclusivity, provided that PCSC also had the right, in its sole discretion, to elect to earlier terminate the Exclusivity Period by delivering written notice to Freenome at any time on or prior to 11:59 p.m. Eastern Time on September 5, 2025 or by delivering written notice to Freenome at any time if PCSC determines that there has occurred any change or event that has materially and adversely affected, or would reasonably be expected to materially and adversely affect, Freenome. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">During the August 6, 2025 PCSC Board meeting, the PCSC Board noted that (i) the Perceptive PIPE Investor was an affiliate of PCSC and the Sponsor and an existing investor in Freenome, (ii) Dr. Hukkelhoven was an executive officer of the Perceptive PIPE Investor and was a director of Freenome, and (iii) all directors serving on the PCSC Board other than Mr. McKenna, Dr. Song and Dr. Waksal, including Dr. Hukkelhoven, as well as the executive officers of PCSC were also employees and/or service providers of Perceptive Advisors, an affiliate of the Sponsor. As a result, the PCSC Board established the Special Committee, consisting solely of Mr. McKenna, Dr. Song and Dr. Waksal as the independent and disinterested members of the PCSC Board, to (i) consider, review and evaluate the terms and conditions, and determine the advisability, of the potential business combination and any alternatives thereto that the Special Committee deems appropriate, (ii) determine whether the potential business combination or any alternative </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">thereto is fair to, and in the best interests of, PCSC and its shareholders and (iii) with respect to any actions required to be taken by the full PCSC Board with respect to the potential business combination or any alternative thereto, recommend to the PCSC Board what action, if any, should be taken by the PCSC Board. The PCSC Board designated Mr. McKenna, Dr. Song and Dr. Waksal as the members of the Special Committee as each of whom had confirmed to the PCSC Board that they did not have any financial interest in or pre-existing relationship with Freenome. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Following adjournment of the PCSC Board meeting, the Special Committee met, with members of PCSC management and representatives of Cooley present. At this meeting, the Special Committee discussed the Non-Binding Term Sheet, determined that the execution, delivery and performance of the Non-Binding Term Sheet by PCSC and the consummation of the transactions contemplated therein were in the best commercial interests of PCSC, and resolved to recommend to the PCSC Board to approve, execute, deliver and perform the Non-Binding Term Sheet and consummate the transactions contemplated therein. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Following conclusion of the Special Committee meeting, the PCSC Board thereafter reconvened and, after receiving the Special Committee’s recommendation and engaging in further discussion, approved and adopted the Non-Binding Term Sheet. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On August 5, 2025, the Freenome Strategic Transaction Committee met by videoconference, with members of Freenome management and other members of the Freenome Board (excluding Dr. Hukkelhoven and Mr. Kolchinsky) and representatives of Goodwin present, and discussed (i) the Exact Sciences Transaction and (ii) the final terms of the Non-Binding Term Sheet. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On August 6, 2025, the Freenome Board met by videoconference, with members of Freenome management and representatives of Goodwin present. It was noted that pursuant to the final Non-Binding Term Sheet, RA Capital intended to be a significant PIPE Investor in the transaction. It was therefore determined that Mr. Kolchinsky would abstain from any vote related to the Non-Binding Term Sheet and the transactions contemplated thereby. The Freenome Board approved execution of the Non-Binding Term Sheet, with Dr. Hukkelhoven and Mr. Kolchinsky, abstaining from the vote. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Later on August 6, 2025, PCSC and Freenome executed the Non-Binding Term Sheet. As of such date, PCSC had not submitted term sheets or letters of intent with respect to any of the other potential business combination targets that had been under consideration, and PCSC subsequently ceased discussions with each of them. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">PCSC ultimately determined to abandon the pursuit of additional potential business combination opportunities with potential business combination targets other than Freenome because of, among other things: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">PCSC’s directors’ and officers’ belief that Freenome was the most attractive opportunity that met PCSC’s key criteria, including due to its differentiated scientific and technological approach, its advancement toward meaningful near- and medium-term development or commercial milestones and the strength and experience of its management team; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Freenome’s preparedness and willingness to devote appropriate resources to expeditiously negotiate and sign a definitive agreement, consummate a business combination, and transition to becoming a public company; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the more advanced stage of engagement, discussions, and negotiations with Freenome, including substantial progress on key terms and conditions; and </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Freenome’s willingness to enter into a non-binding term sheet, with exclusivity, on terms PCSC’s directors and officers believed were attractive. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On August 20, 2025, the Special Committee held a call with representatives of Ropes &amp; Gray LLP (“<span style="font-style: italic; font-weight: bold;">Ropes &amp; Gray</span>”) regarding the potential engagement of Ropes &amp; Gray by the Special Committee as its U.S. counsel. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On August 28, 2025, PCSC and Freenome finalized the terms of and executed a customary confidentiality agreement to facilitate negotiations and the completion of confirmatory due diligence. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">During August 2025, PCSC contacted Jefferies and Leerink Partners, requesting that (i) Jefferies act as lead financial advisor and lead capital markets advisor to PCSC with respect to the potential business combination, (ii) Leerink Partners act as PCSC’s joint capital markets advisor, and (iii) Jefferies and Leerink Partners act as joint lead placement agents in connection with the PIPE Financing. PCSC, Jefferies and Leerink Partners executed an engagement letter in respect of such services on September 30, 2025. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">During August and September 2025, Freenome connected with a number of potential advisors, including TD Securities (USA) LLC (“TD Cowen”), BTIG, LLC (“BTIG”), and Guggenheim Securities, LLC (“Guggenheim Securities”). It was determined that (i) TD Cowen would act as lead financial advisor to Freenome, (ii) BTIG would act as financial advisor to Freenome and (iii) Guggenheim Securities would act as capital markets advisor to Freenome. Freenome executed engagement letters in respect of such services in November 2025. In connection with these engagements, Freenome agreed to reimburse the financial and capital markets advisors for certain expenses in connection with the Business Combination and to pay an aggregate cash fee of $2.1 million to such advisors, payable upon the closing of the Business Combination. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On September 2, 2025, the Special Committee engaged Ropes &amp; Gray as its U.S. counsel. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On September 8, 2025, Cooley provided to Goodwin and White &amp; Case LLP (“<span style="font-style: italic; font-weight: bold;">W&amp;C</span>”), legal counsel to Jefferies and Leerink Partners, initial drafts of the form of Subscription Agreement for Perceptive Advisors and RA Capital and the form of Subscription Agreement for all other PIPE Investors. From September 8, 2025 to October 28, 2025, Cooley, Goodwin and W&amp;C negotiated the forms of the Subscription Agreement. In parallel to the preparation of the forms of Subscription Agreement, Jefferies and Leerink Partners, as placement agents for PCSC in connection with the PIPE Financing, commenced outreach to potential investors (including existing Freenome investors) to assess interest in participating in the PIPE Financing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On September 29, 2025, Scalar, LLC (“<span style="font-style: italic; font-weight: bold;">Scalar</span>”) was engaged as financial advisor to the Special Committee in connection with the Business Combination. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Throughout September, October and November 2025, the Freenome Strategic Transaction Committee met multiple times to discuss (i) the status of the PIPE Financing and the transaction and (ii) the status of the potential transaction with Roche. In October 2025, the Freenome Board determined to remove Dr. Elliott as a member of the Freenome Strategic Transaction Committee in order to ensure that the Freenome Strategic Transaction Committee would consist solely of disinterested and independent Freenome Board members. As Dr. Elliott is the CEO of Freenome, it was determined he is not independent of Freenome. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On September 30, 2025, the Freenome Strategic Transaction Committee held a meeting. The Freenome Strategic Transaction Committee determined to engage certain of its own advisors as part of its continuing evaluation of the Business Combination. The Freenome Strategic Transaction Committee engaged (i) Richards, Layton &amp; Finger P.A. (“RLF”) as its legal counsel and (ii) H.C. Wainwright &amp; Co., LLC (“HCW”) as its financial advisor in connection with the derivation of an implied valuation analysis of Freenome. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Pursuant to its engagement, HCW agreed to perform certain valuation analyses in order to derive an implied valuation of Freenome and to assist the Freenome Strategic Transaction Committee in assessing whether any developments subsequent to the execution of the non-binding term sheet had affected such valuation. The nature and scope of HCW’s engagement did not require or include the delivery of a fairness opinion. In connection with this engagement, Freenome agreed to pay HCW a fixed cash fee of $475,000, payable upon delivery of its valuation materials, and to reimburse certain expenses and provide customary indemnification. On October 6, 2025, HCW presented certain valuation analyses to the Freenome Strategic Transaction Committee. HCW did not rely on projected or forward-looking financial information provided by Freenome in preparing its analyses. HCW’s analyses included (i) a review of selected publicly traded cancer diagnostics companies, and an examination of enterprise value-to-revenue multiples for such companies, (ii) a review of selected precedent mergers and acquisitions transactions involving cancer diagnostics companies and (iii) an IPO step-up analysis, which considered valuation step-ups observed in recent healthcare initial public offerings relative to prior private financing valuations. These categories of analyses are generally consistent with the types of financial analyses performed by Scalar, LLC (“Scalar”) in connection with Scalar’s fairness opinion, as described in “—Opinion of Scalar, LLC,” although HCW’s work differed in nature and scope and was not performed for the purpose of rendering a fairness opinion. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The materials presented by HCW were provided to the Freenome Strategic Transaction Committee for informational purposes only and did not constitute a recommendation or fairness opinion with respect to the Business Combination. The Freenome Strategic Transaction Committee considered HCW’s analyses as a “market check” in connection with its evaluation of the Business Combination and, based on a review of the respective analyses, did not identify any material inconsistencies between the general valuation ranges implied by HCW’s analyses and the financial analyses underlying Scalar’s fairness opinion, which was provided to the special committee of the board of directors of PCSC. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On October 3, 2025, PCSC and Freenome agreed to extend the Exclusivity Period to November 4, 2025. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On October 6, 2025, Cooley provided to Goodwin an initial draft of the Business Combination Agreement based upon the terms set forth in the Non-Binding Term Sheet. Between October 6, 2025 and December 3, 2025, Goodwin and Cooley exchanged numerous drafts of the Business Combination Agreement and had telephonic discussions and negotiations concerning the terms of the Business Combination Agreement. The matters in the Business Combination Agreement that were discussed and negotiated between the parties and their respective counsel included: (i) the inclusion of a post-closing purchase price adjustment mechanism and related escrow; (ii) the value of the New Freenome common stock to be used in connection with determining the Exchange Ratio (including clarifying that any shares or other equity interests of Freenome issued and outstanding in connection with either the Exact Sciences Transaction or a strategic collaboration agreement with Roche Sequencing Solutions, Inc. to commercialize Freenome’s cancer screening technology (the “<span style="font-style: italic; font-weight: bold;">Roche Transaction</span>”) would not be taken into account as part of the Freenome shares outstanding as of immediately prior to the closing of the Business Combination for purposes of determining the applicable Exchange Ratio); (iii) the treatment of certain unpaid PCSC liabilities in connection with determining the Aggregate Transaction Proceeds; (iv) Freenome’s obligations with respect to the delivery of warrant cancellation agreements and executed Investor Rights Agreements and Transaction Support Agreements by specified Freenome stockholders; (v) the Termination Date; (vi) the composition of the New Freenome board of directors; (vii) PCSC’s obligations relating to obtaining regulatory approval of the Business Combination; and (viii) the size and terms of the New Freenome Incentive Equity Plan and the New Freenome Employee Stock Purchase Plan (including, in each case, agreement to the automatic annual increase in the number of shares of New Freenome Common Stock reserved under each). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Between mid-October 2025 and December 4, 2025, Cooley and Goodwin also exchanged and negotiated on behalf of PCSC and Freenome, respectively, drafts of the disclosure schedules to the Business Combination Agreement and the other ancillary documents, including the Investor Rights Agreement, the Transaction Support Agreement, the New Freenome certificate of incorporation and bylaws, the Lock-Up Agreement and the Sponsor Letter Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On November 4, 2025, PCSC and Freenome agreed to further extend the Exclusivity Period to December 19, 2025. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On November 18, 2025, Freenome announced its entry into the Roche Transaction. The final terms of the Roche Transaction are described in “<span style="font-style: italic;">Information about Freenome—Key Collaborations”</span>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Following the announcement of the Roche Transaction, over the course of mid-November 2025 through December 4, 2025, Cooley, Goodwin and W&amp;C negotiated the terms of the Subscription Agreement with the various PIPE Investors. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On November 26, 2025, Cooley circulated to the PCSC Board written materials summarizing the key terms of the then-current drafts of the Business Combination Agreement and related ancillary documents. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On November 28, 2025, a meeting of the Special Committee was held by videoconference, with representatives of Ropes &amp; Gray LLP in attendance. At the meeting, referring to the summary materials provided by Cooley to the members of the PCSC Board on November 26, 2025, representatives of Ropes &amp; Gray provided an update on the proposed Business Combination, including the key terms of the Business Combination Agreement and related ancillary documents, as well as the directors’ duties as members of the PCSC Board under Cayman Islands law. Also at this meeting, the Special Committee unanimously approved the engagement of Maples and Calder (Cayman) LLP (“<span style="font-style: italic; font-weight: bold;">Maples</span>”) as Cayman Islands counsel to the Special Committee. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On December 1, 2025, a meeting of the Special Committee was held by videoconference, with PCSC management and representatives of Ropes &amp; Gray, Maples, Cooley, Jefferies and Scalar in attendance. At the meeting, PCSC management and representatives of Cooley provided the Special Committee with an update and overview of the potential business combination and the process related thereto, the key terms of the Business Combination Agreement, as well as certain key developments. PCSC management also discussed with the Special Committee the expected timeline and process for a potential signing of the Business Combination Agreement. Also at this meeting, representatives of Jefferies provided an overview of the PIPE transactions process, the PIPE Investors, and the material terms of the PIPE transaction documents, and representatives of Scalar provided the Special Committee with its preliminary analysis of the financial aspects of the business combination, and representatives of Maples presented an overview of the directors’ duties as members of the PCSC Board under Cayman Islands law. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On December 4, 2025, Scalar provided a customary relationship disclosure letter to representatives of PCSC, Cooley and Ropes &amp; Gray which was shared with the Special Committee. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Also on December 4, 2025, a meeting of the Special Committee was held by videoconference, with PCSC management and representatives of Cooley, Ropes &amp; Gray, Maples and Scalar in attendance. At the meeting, PCSC management and representatives of Cooley provided the Special Committee with an update on the potential business combination, the definitive transaction documents, and the process related thereto. Also at the meeting, representatives of Scalar reviewed with the Special Committee Scalar’s financial analysis of the Business Combination and rendered to the Special Committee its oral opinion (subsequently confirmed in writing) that, as of such date and based upon and subject to the procedures followed, assumptions made, qualifications and limitations on the review undertaken, and other matters considered by Scalar in preparing its opinion (attached as Annex L to this proxy statement/prospectus), the Consideration (as defined in such opinion) to be paid by PCSC to the stockholders pursuant to the Business Combination Agreement was fair from a financial point of view to (1) the PCSC Class A Shareholders (other than the Excluded Parties) and (2) PCSC. Based on the factors cited in “<span style="font-style: italic;">Business Combination Proposal—The Special Committee’s and the PCSC Board’s Reasons for the Approval of the Business Combination</span>”, the Special Committee then unanimously (i) determined that the entry into the Business Combination Agreement and the other ancillary documents to which PCSC is a party, and the consummation of the transactions contemplated thereby, including the Mergers, are advisable and fair to, and in the best interest of, PCSC and shareholders of PCSC, (ii) recommended to the PCSC Board that it approve the Business Combination Agreement, such other ancillary documents, and the consummation of the transactions contemplated thereby, including the Mergers, and (iii) subject to the terms and conditions of the Business Combination Agreement, resolved to recommend that the shareholders of PCSC adopt the Business Combination Agreement and approve the Mergers and the other transactions contemplated by the Business Combination Agreement (the “<span style="font-style: italic; font-weight: bold;">Special Committee Recommendation</span>”). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Also on December 4, 2025, a meeting of the PCSC Board was held by videoconference with representatives of Cooley, Ropes &amp; Gray, Ogier, counsel to PCSC with respect to matters of Cayman Islands law since PCSC’s initial public offering, and members of PCSC management in attendance. At the meeting, Cooley and Ogier reviewed the PCSC Board’s fiduciary duties under Cayman law, and then PCSC’s management and representatives of Cooley provided the PCSC Board with an overview of the proposed Business Combination and the key terms of the Business Combination Agreement and related ancillary documents. The PCSC Board was also provided with the Special Committee Recommendation. In addition, members of the PCSC Board reviewed the relationships among certain of the members of the PCSC Board, PCSC officers, the Perceptive PIPE Investor, the Sponsor and Freenome with respect to the proposed Business Combination that were reviewed at the August 6, 2025 meeting of the PCSC Board. Based on the factors cited in “<span style="font-style: italic;">Business Combination Proposal—The Special Committee’s and the PCSC Board’s Reasons for the Approval of the Business Combination</span>” and in light of the fact that the implied fair market value of the vested equity of Freenome to be acquired in the Business Combination was equal to at least 80% of the net assets held in the Trust Account (excluding the deferred underwriting discounts held in trust and taxes payable on the interest earned on the Trust Account) at the time of the execution of a definitive agreement for an initial business combination, the PCSC Board unanimously determined, among other things, (i) that it is in the best interests of PCSC to negotiate, execute and deliver the Business Combination Agreement and the ancillary documents thereto, and to consummate the Business Combination, including, but not limited to, the Domestication, the Mergers and the PIPE Financing, (ii) to authorize and approve the form, terms and provisions of the Business Combination Agreement, the Subscription Agreements and the ancillary documents thereto, and PCSC’s performance thereunder and the transactions contemplated thereby, and (iii) that each of the Business Combination Proposal, the Domestication Proposal, the Governing Documents Proposal, the Advisory Governing Documents Proposal, the Nasdaq Proposal, the Equity Incentive Plan Proposal, the Employee Stock Purchase Plan Proposal and the Adjournment Proposal is in the best interests of PCSC and its shareholders, and to recommend that PCSC’s shareholders adopt and approve at the PCSC Shareholders Meeting each such proposal. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Freenome Strategic Transaction Committee, consisting of Deepika Pakianathan, Randal Scott, and Douglas VanOort met on December 1, December 2, and December 3, 2025, with varying members of Freenome management, including Riley Ennis, Aaron Elliott, and Thomas Fitzpatrick, certain of Freenome’s financial advisors from TD Cowen, Delaware special counsel to the committee from RLF, and Goodwin representatives, to review the final terms of the transaction. On December 3, 2025, the Freenome Strategic Transaction Committee determined to recommend that the Freenome Board approve the transaction, and on December 4, 2025, the Freenome Strategic Transaction Committee unanimously adopted resolutions (i) determining that the entry into the Business Combination Agreement and the other ancillary agreements to which Freenome is a party, and the consummation of the transactions contemplated thereby, are advisable and fair to, and in the best interest of, Freenome and its stockholders; and (ii) recommended to the Freenome Board that it approve the Business Combination Agreement, such other ancillary </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">agreements and the consummation of the transactions contemplated thereby, and that the Freenome Board resolve, subject to the terms and conditions of the Business Combination Agreement, to recommend that the Freenome stockholders adopt the Business Combination Agreement and approve the transactions contemplated thereby. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On December 4, 2025, the Freenome Board held a meeting via teleconference. Following discussions, and upon the recommendation of the Freenome Strategic Transaction Committee, the Freenome Board agreed to adopt and approve resolutions that, among other things, (i) approved the execution, delivery and performance of the Business Combination Agreement and the ancillary agreements; (ii) determined that the Business Combination Agreement, the ancillary agreements, the Business Combination, and other transactions, upon the terms and subject to the conditions set forth therein, are advisable and fair to and in the best interests of Freenome and the Freenome Stockholders; (iii) directed that the adoption of the Business Combination Agreement be submitted to the Freenome Stockholders for consideration and recommended that all of the Freenome Stockholders adopt the Business Combination Agreement; (iv) recommended that the Freenome Stockholders approve the Business Combination and such other transactions and adopt the Business Combination Agreement and the ancillary agreements to which Freenome is a party and (v) approved the filing of a proxy statement in connection therewith. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On December 5, 2025, final versions of the Subscription Agreements were distributed to the prospective PIPE Investors, which reflected the outcome of negotiations between PCSC, Freenome and the prospective PIPE Investors and their respective representatives and advisors. Later that day, the prospective PIPE Investors that had chosen to participate in the PIPE Financing indicated their final subscription amounts, and PCSC and Freenome determined final investment allocations with respect to the PIPE Financing. No material valuations or other information about PCSC, Freenome, New Freenome or the Business Combination were provided to potential PIPE Investors that have not been disclosed publicly. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Also on December 5, 2025, the parties entered into the Business Combination Agreement and the related ancillary documents and the PIPE Investors executed and delivered the Subscription Agreements and applicable Transaction Support Agreements, which provided for binding subscriptions to purchase an aggregate of 24,000,000 shares of New Freenome Common Stock at $10.00 per share. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Later on December 5, 2025, PCSC and Freenome issued a joint press release announcing the execution and delivery of the Business Combination Agreement and Subscription Agreements. </div> <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Background to the Business Combination </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">PCSC is a blank check company incorporated on March 22, 2024 as a Cayman Islands exempted company, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On March 27, 2024, prior to the closing of PCSC’s initial public offering, the Sponsor paid $25,000 to cover certain expenses on PCSC’s behalf in exchange for the issuance of 2,156,250 PCSC Class B Shares, or approximately $0.01 per share. In April 2024, the Sponsor transferred 30,000 PCSC Class B Shares to each of the three independent directors of the PCSC Board: Mark C. McKenna, Kenneth Song, M.D. and Harlan W. Waksal, M.D. On June 13, 2024, PCSC consummated its initial public offering of 8,625,000 PCSC Class A Shares, $0.0001 par value per share, at an offering price of $10.00 per share, which included the exercise in full of the underwriter’s option to purchase an additional 1,125,000 PCSC Class A Shares at the initial public offering price of $10.00 per share to cover over-allotments, and a private placement with the Sponsor of 286,250 PCSC Class A Shares at a price of $10.00 per share. The aggregate net proceeds of $86,250,000 from the initial public offering together with certain of the proceeds from the private placement were placed in the Trust Account established for the benefit of PCSC’s public shareholders and the underwriter of the initial public offering, with Continental Stock Transfer &amp; Trust Company acting as trustee. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Following the completion of its initial public offering, at the direction of the PCSC Board, representatives of PCSC, including Messrs. Stone and Poukalov, and Dr. Hukkelhoven commenced an active, targeted search for potential business combination candidates, leveraging the Sponsor’s network of investment bankers, private equity firms and hedge funds (including Perceptive Advisors and its affiliates), consulting firms, legal and accounting firms, and numerous other business relationships, as well as the prior experience and network of PCSC’s officers and directors. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Consistent with the investment focus and acquisition criteria described in PCSC’s initial public offering prospectus, and based on discussion with the PCSC Board, PCSC targeted potential business combination targets in the life sciences and medical technology sectors that its officers and directors believed, based on their experience, could satisfy all (or a portion) of the following key criteria: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">have scientific or other competitive advantages in the markets in which they operate and ability to benefit from access to additional capital as well as PCSC’s industry relationships and expertise; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">are ready to be public companies, with strong management, corporate governance and reporting policies in place; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">will likely be well received by public investors and are expected to have good access to the public capital markets; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">have significant embedded and/or underexploited growth opportunities; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">exhibit unrecognized value or other characteristics that PCSC believes have been misevaluated by the market, based on PCSC’s rigorous analysis and scientific and business due diligence review; and </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">will offer attractive risk-adjusted equity returns for PCSC shareholders.</div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">During this targeted search, representatives of PCSC, including Messrs. Stone, Altman, Poukalov, and Vazquez, and Dr. Hukkelhoven, reviewed approximately 200 potential business combination targets and conducted varying levels of preliminary due diligence on each, and evaluated and analyzed each as a potential business combination target based on, among other things, publicly available information and other market research available to PCSC and its representatives and their existing knowledge of the potential targets as a result of their network and existing relationships. This preliminary diligence, evaluation and analysis with respect to each potential business combination target identified was focused on business, operational and financial matters, including, among other things, product candidate pipelines, other potential product or service offerings, technology, market potential and financial information. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Following this preliminary evaluation, PCSC determined that approximately 20 companies, including Freenome, merited more serious consideration, based on such companies’ scientific approach, development stage, financing needs, management strength and overall alignment with PCSC’s acquisition criteria. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On October 28, 2024, representatives of PCSC, including Messrs. Stone, Altman, Poukalov, and Vazquez, and Dr. Hukkelhoven, submitted a non-binding term sheet to one such company, Party A. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On November 6, 2024, Party A notified PCSC that it intended to continue pursuing a traditional initial public offering rather than a business combination with PCSC in light of prevailing market conditions and its internal strategic priorities. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On December 19, 2024, representatives of PCSC, including Messrs. Stone, Altman, Poukalov, and Vazquez, and Dr. Hukkelhoven, submitted a non-binding term sheet to another such company, Party B. With respect to Party B, PCSC determined following outreach to potential financing sources and other stakeholders that there was limited interest in supporting a business combination with Party B on terms PCSC viewed as appropriate, including taking into account the criteria previously discussed by the PCSC Board. As a result, in February 2025, PCSC discontinued discussions with Party B. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">After concluding its evaluations of Party A and Party B, PCSC continued to assess potential business combination targets. Through this process, and based on discussion with members of the PCSC Board, PCSC further refined its focus and determined to concentrate its near-term efforts on revisiting a smaller set of potential business combination targets, including Freenome, that PCSC believed were the most compelling opportunities relative to the others reviewed. These were targets that PCSC had previously started to evaluate but placed such efforts on hold as PCSC awaited additional data or developments. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In addition to satisfying one or more of PCSC’s key criteria noted above, PCSC believed these targets were most suitable for a potential business combination based on, among other things: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">PCSC’s preliminary assessment of the target’s equity valuation; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the strength, differentiation, and future prospects of the target’s pipeline, platform, or underlying scientific approach; and </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the target’s preparedness for a business combination and readiness to operate as a public company on an expeditious signing and closing timeline. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Each of these targets was a development-stage or commercial-stage life sciences company with product candidates or technologies requiring additional funding for clinical development or commercialization. PCSC contemplated transactions in which consideration to the target’s equityholders would consist primarily (if not exclusively) of shares of PCSC. Representatives of PCSC, including Messrs. Stone, Altman, Poukalov, and Vazquez, and Dr. Hukkelhoven, engaged in varying levels of additional diligence, discussions, and negotiations with these targets, including Freenome, and PCSC management periodically updated the PCSC Board on their progress with respect to screening potential business combination targets. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Perceptive PIPE Investor, an affiliate of PCSC and the Sponsor, was initially introduced to Freenome in 2019 in the context of a potential investment in Freenome. The Perceptive PIPE Investor invested $20 million in Freenome’s Series B financing in July 2019, $40 million in Freenome’s Series C financing in August 2020, $44 million in Freenome’s Series D financing in December 2021 and $20 million in Freenome’s Series F financing in February 2024. Additionally, the Perceptive PIPE Investor was granted a Freenome Board seat in the Series C financing. Dr. Hukkelhoven has occupied such Freenome Board seat since August 14, 2020. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On February 19, 2025, Dr. Hukkelhoven, in her capacity as an executive officer of the Perceptive PIPE Investor, reached out to the other members of the Freenome Board, consisting of Deepika Pakianathan, Douglas VanOort, Randal Scott, Peter Kolchinsky, Moritz Hartmann, and Josh Lauer, to inquire whether Freenome would be interested in exploring a potential business combination with PCSC. The Perceptive PIPE Investor, was as of such time, and remains, an existing investor in Freenome, and Dr. Hukkelhoven, an executive officer of the Perceptive PIPE Investor, was as of such time, and remains, a member of the Freenome Board. As the Perceptive PIPE Investor has been an investor in Freenome since 2019, the Perceptive PIPE Investor has continuously monitored Freenome’s business progress and capital needs. Dr. Hukkelhoven has been a representative appointed by the Perceptive PIPE Investor on the Freenome Board since 2020. At the direction of the Freenome Board, Dr. Hukkelhoven informed the Perceptive PIPE Investor that Freenome was interested in exploring a capital raising transaction involving the Perceptive PIPE Investor and Dr. Hukkelhoven proposed the terms of the PIPE Financing to the Perceptive PIPE Investor. For more information, see “<span style="font-style: italic;">Business Combination Proposal — Interests of PCSC’s Sponsor, Directors and Officers in the Business Combination.</span>” </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In early March 2025, the Freenome Board discussed the outreach from PCSC regarding a potential business combination. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On March 7, 2025, Adam Stone, Chief Executive Officer of PCSC, along with Konstantin Poukalov and Dr. Hukkelhoven, as executive officers of the Perceptive PIPE Investor, met with the Freenome Board (excluding Dr. Hukkelhoven) to discuss the potential business combination opportunity and discussed that PCSC should propose key terms for a potential business combination between the parties to be memorialized in a term sheet. Dr. Hukkelhoven, who has been serving on the Freenome Board in connection with the investment by the Perceptive PIPE Investor in Freenome, reminded the Freenome Board of her affiliation with PCSC and the Sponsor and, after providing an overview of PCSC, recused herself from the remainder of the meeting. The Freenome Board also discussed the de-SPAC process generally. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On May 28, 2025, PCSC circulated an initial draft of the Non-Binding Term Sheet to Freenome. The Freenome Board determined that the Freenome Strategic Transaction Committee would lead the negotiations for Freenome. In August 2023, Freenome’s Board had approved the formation of such Freenome Strategic Transaction Committee in order to explore strategic transactions for Freenome. As of May 2025, the Freenome Strategic Transaction Committee consisted of Deepika Pakianathan, Randal Scott, Doug VanOort and Aaron Elliott. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Over the course of May through early August of 2025, representatives of PCSC, including Adam Stone, Konstantin Poukalov, Dr. Hukkelhoven, Michael Altman, Marcel Rosner, and Carlos Vazquez, and representatives of Freenome, including Aaron Elliott, Riley Ennis, and Thomas Fitzpatrick, and its Freenome Strategic Transaction Committee, consisting of the members identified above, with the assistance of their respective legal counsel at Cooley LLP (“<span style="font-style: italic; font-weight: bold;">Cooley</span>”) and Goodwin Procter LLP (“<span style="font-style: italic; font-weight: bold;">Goodwin</span>”), negotiated certain provisions of the Non-Binding Term Sheet. Such provisions included the pre-money base equity value of Freenome (and related adjustments), totaling $725 million, the minimum Aggregate Transaction Proceeds Amount of $200 million, and the size and terms of the post-closing employee equity pools. Dr. Hukkelhoven conveyed and explained the rationale for PCSC’s valuation of Freenome to Freenome management and the Freenome Board and acted as an intermediary between PCSC and Freenome. In the initial draft of the Non-Binding Term Sheet sent in May 2025, PCSC assigned Freenome a post-money valuation of $1.0 billion, subject to confirmatory due diligence, reflecting the following assumptions: (1) a pre-money </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">base equity value for Freenome of $725.0 million and (2) a minimum Aggregate Transaction Proceeds Amount of $250.0 million. In late July 2025, a revised draft of the Non-Binding Term Sheet from PCSC to Freenome increased the post-money valuation of Freenome to $1.05 billion, reflecting a revised assumption of $300 million in aggregate proceeds raised in the PIPE Financing plus the Trust Account’s balance at Closing. In early August 2025, PCSC sent a further revised draft Non-Binding Term Sheet, clarifying that the $1.05 billion post-money valuation of Freenome was in light of the Perceptive PIPE Investor’s plan to invest approximately $25.0 million in the PIPE Financing. In negotiating the pre-money base equity value of Freenome, the parties discussed whether the proceeds from the Exact Sciences transaction or any transaction entered into with Roche should be included in such value. Although these potential transactions had been under discussion, the parties ultimately agreed that such proceeds would not be included in the pre-money base equity value because the transactions had not been completed at the time the valuation was determined and remained contingent. Accordingly, the economic impact of any such transactions, if consummated, would be reflected in the post-money equity value rather than the pre-money valuation. Consistent with this approach, shares issuable upon conversion of Freenome convertible notes and any equity issued in connection with such transactions were excluded from the definition of fully diluted Freenome shares used in determining the Exchange Ratio so that the effects of such instruments and transactions would be reflected in the post-closing ownership rather than diluting the pre-money equity value. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">During such period, Freenome was also negotiating its exclusive licensing agreement with Exact Sciences to advance the Exact Sciences Transaction, which was ultimately signed and announced on August 6, 2025. The final terms of the Exact Sciences Transaction are described in “<span style="font-style: italic;">Information about Freenome—Key Collaborations</span>.” Additionally, during this period, Freenome began discussions on a collaboration with Roche, as detailed further below. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On August 6, 2025, the PCSC Board met by videoconference, with members of PCSC management, including Messrs. Stone, Altman, Poukalov, and Vazquez, and Dr. Hukkelhoven, and representatives of Cooley present, to discuss the potential business combination with Freenome and the Non-Binding Term Sheet. Among other things, the final terms of the Non-Binding Term Sheet contemplated that Freenome would be valued at approximately $1.05 billion on a post-Business Combination equity value basis, taking into account, among other things, (i) an assumed $300 million in aggregate proceeds from (a) the PIPE Financing (which would include at least $25 million expected to be contributed by Perceptive Advisors or its affiliates and at least $50 million expected to be contributed by RA Capital or its affiliates) and (b) the Trust Account at the closing, and (ii) an agreed pre-Business Combination base equity value for Freenome of $725 million. The Non-Binding Term Sheet further contemplated, among other things, (a) certain adjustments for leakage to the Freenome base equity value, (b) that any proceeds from the Exact Sciences Transaction or any transaction entered into with Roche would not be counted as part of the base equity value of Freenome and that any shares or other equity interests of Freenome issued and outstanding in connection with such transactions would not be taken into account as part of the Freenome shares outstanding as of immediately prior to the closing of the Business Combination for purposes of determining the applicable Exchange Ratio, (c) that in addition to other customary closing conditions, the obligation of Freenome to consummate the Business Combination would be subject to there being Aggregate Transaction Proceeds of at least $250,000,000, (d) a six-month lockup period after consummation of the Business Combination with respect to New Freenome shares to be issued to insider Freenome stockholders, including Perceptive Advisors and RA Capital, in the Business Combination, as well as certain demand and piggyback registration rights for certain stockholders, and (e) the Exclusivity Period binding on both PCSC and Freenome, ending on the later of 5:00 pm Eastern Time on October 5, 2025 and the time at which either party gives written notice to the other party of the termination of exclusivity, provided that PCSC also had the right, in its sole discretion, to elect to earlier terminate the Exclusivity Period by delivering written notice to Freenome at any time on or prior to 11:59 p.m. Eastern Time on September 5, 2025 or by delivering written notice to Freenome at any time if PCSC determines that there has occurred any change or event that has materially and adversely affected, or would reasonably be expected to materially and adversely affect, Freenome. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">During the August 6, 2025 PCSC Board meeting, the PCSC Board noted that (i) the Perceptive PIPE Investor was an affiliate of PCSC and the Sponsor and an existing investor in Freenome, (ii) Dr. Hukkelhoven was an executive officer of the Perceptive PIPE Investor and was a director of Freenome, and (iii) all directors serving on the PCSC Board other than Mr. McKenna, Dr. Song and Dr. Waksal, including Dr. Hukkelhoven, as well as the executive officers of PCSC were also employees and/or service providers of Perceptive Advisors, an affiliate of the Sponsor. As a result, the PCSC Board established the Special Committee, consisting solely of Mr. McKenna, Dr. Song and Dr. Waksal as the independent and disinterested members of the PCSC Board, to (i) consider, review and evaluate the terms and conditions, and determine the advisability, of the potential business combination and any alternatives thereto that the Special Committee deems appropriate, (ii) determine whether the potential business combination or any alternative </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">thereto is fair to, and in the best interests of, PCSC and its shareholders and (iii) with respect to any actions required to be taken by the full PCSC Board with respect to the potential business combination or any alternative thereto, recommend to the PCSC Board what action, if any, should be taken by the PCSC Board. The PCSC Board designated Mr. McKenna, Dr. Song and Dr. Waksal as the members of the Special Committee as each of whom had confirmed to the PCSC Board that they did not have any financial interest in or pre-existing relationship with Freenome. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Following adjournment of the PCSC Board meeting, the Special Committee met, with members of PCSC management and representatives of Cooley present. At this meeting, the Special Committee discussed the Non-Binding Term Sheet, determined that the execution, delivery and performance of the Non-Binding Term Sheet by PCSC and the consummation of the transactions contemplated therein were in the best commercial interests of PCSC, and resolved to recommend to the PCSC Board to approve, execute, deliver and perform the Non-Binding Term Sheet and consummate the transactions contemplated therein. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Following conclusion of the Special Committee meeting, the PCSC Board thereafter reconvened and, after receiving the Special Committee’s recommendation and engaging in further discussion, approved and adopted the Non-Binding Term Sheet. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On August 5, 2025, the Freenome Strategic Transaction Committee met by videoconference, with members of Freenome management and other members of the Freenome Board (excluding Dr. Hukkelhoven and Mr. Kolchinsky) and representatives of Goodwin present, and discussed (i) the Exact Sciences Transaction and (ii) the final terms of the Non-Binding Term Sheet. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On August 6, 2025, the Freenome Board met by videoconference, with members of Freenome management and representatives of Goodwin present. It was noted that pursuant to the final Non-Binding Term Sheet, RA Capital intended to be a significant PIPE Investor in the transaction. It was therefore determined that Mr. Kolchinsky would abstain from any vote related to the Non-Binding Term Sheet and the transactions contemplated thereby. The Freenome Board approved execution of the Non-Binding Term Sheet, with Dr. Hukkelhoven and Mr. Kolchinsky, abstaining from the vote. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Later on August 6, 2025, PCSC and Freenome executed the Non-Binding Term Sheet. As of such date, PCSC had not submitted term sheets or letters of intent with respect to any of the other potential business combination targets that had been under consideration, and PCSC subsequently ceased discussions with each of them. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">PCSC ultimately determined to abandon the pursuit of additional potential business combination opportunities with potential business combination targets other than Freenome because of, among other things: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">PCSC’s directors’ and officers’ belief that Freenome was the most attractive opportunity that met PCSC’s key criteria, including due to its differentiated scientific and technological approach, its advancement toward meaningful near- and medium-term development or commercial milestones and the strength and experience of its management team; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Freenome’s preparedness and willingness to devote appropriate resources to expeditiously negotiate and sign a definitive agreement, consummate a business combination, and transition to becoming a public company; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the more advanced stage of engagement, discussions, and negotiations with Freenome, including substantial progress on key terms and conditions; and </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Freenome’s willingness to enter into a non-binding term sheet, with exclusivity, on terms PCSC’s directors and officers believed were attractive. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On August 20, 2025, the Special Committee held a call with representatives of Ropes &amp; Gray LLP (“<span style="font-style: italic; font-weight: bold;">Ropes &amp; Gray</span>”) regarding the potential engagement of Ropes &amp; Gray by the Special Committee as its U.S. counsel. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On August 28, 2025, PCSC and Freenome finalized the terms of and executed a customary confidentiality agreement to facilitate negotiations and the completion of confirmatory due diligence. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">During August 2025, PCSC contacted Jefferies and Leerink Partners, requesting that (i) Jefferies act as lead financial advisor and lead capital markets advisor to PCSC with respect to the potential business combination, (ii) Leerink Partners act as PCSC’s joint capital markets advisor, and (iii) Jefferies and Leerink Partners act as joint lead placement agents in connection with the PIPE Financing. PCSC, Jefferies and Leerink Partners executed an engagement letter in respect of such services on September 30, 2025. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">During August and September 2025, Freenome connected with a number of potential advisors, including TD Securities (USA) LLC (“TD Cowen”), BTIG, LLC (“BTIG”), and Guggenheim Securities, LLC (“Guggenheim Securities”). It was determined that (i) TD Cowen would act as lead financial advisor to Freenome, (ii) BTIG would act as financial advisor to Freenome and (iii) Guggenheim Securities would act as capital markets advisor to Freenome. Freenome executed engagement letters in respect of such services in November 2025. In connection with these engagements, Freenome agreed to reimburse the financial and capital markets advisors for certain expenses in connection with the Business Combination and to pay an aggregate cash fee of $2.1 million to such advisors, payable upon the closing of the Business Combination. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On September 2, 2025, the Special Committee engaged Ropes &amp; Gray as its U.S. counsel. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On September 8, 2025, Cooley provided to Goodwin and White &amp; Case LLP (“<span style="font-style: italic; font-weight: bold;">W&amp;C</span>”), legal counsel to Jefferies and Leerink Partners, initial drafts of the form of Subscription Agreement for Perceptive Advisors and RA Capital and the form of Subscription Agreement for all other PIPE Investors. From September 8, 2025 to October 28, 2025, Cooley, Goodwin and W&amp;C negotiated the forms of the Subscription Agreement. In parallel to the preparation of the forms of Subscription Agreement, Jefferies and Leerink Partners, as placement agents for PCSC in connection with the PIPE Financing, commenced outreach to potential investors (including existing Freenome investors) to assess interest in participating in the PIPE Financing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On September 29, 2025, Scalar, LLC (“<span style="font-style: italic; font-weight: bold;">Scalar</span>”) was engaged as financial advisor to the Special Committee in connection with the Business Combination. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Throughout September, October and November 2025, the Freenome Strategic Transaction Committee met multiple times to discuss (i) the status of the PIPE Financing and the transaction and (ii) the status of the potential transaction with Roche. In October 2025, the Freenome Board determined to remove Dr. Elliott as a member of the Freenome Strategic Transaction Committee in order to ensure that the Freenome Strategic Transaction Committee would consist solely of disinterested and independent Freenome Board members. As Dr. Elliott is the CEO of Freenome, it was determined he is not independent of Freenome. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On September 30, 2025, the Freenome Strategic Transaction Committee held a meeting. The Freenome Strategic Transaction Committee determined to engage certain of its own advisors as part of its continuing evaluation of the Business Combination. The Freenome Strategic Transaction Committee engaged (i) Richards, Layton &amp; Finger P.A. (“RLF”) as its legal counsel and (ii) H.C. Wainwright &amp; Co., LLC (“HCW”) as its financial advisor in connection with the derivation of an implied valuation analysis of Freenome. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Pursuant to its engagement, HCW agreed to perform certain valuation analyses in order to derive an implied valuation of Freenome and to assist the Freenome Strategic Transaction Committee in assessing whether any developments subsequent to the execution of the non-binding term sheet had affected such valuation. The nature and scope of HCW’s engagement did not require or include the delivery of a fairness opinion. In connection with this engagement, Freenome agreed to pay HCW a fixed cash fee of $475,000, payable upon delivery of its valuation materials, and to reimburse certain expenses and provide customary indemnification. On October 6, 2025, HCW presented certain valuation analyses to the Freenome Strategic Transaction Committee. HCW did not rely on projected or forward-looking financial information provided by Freenome in preparing its analyses. HCW’s analyses included (i) a review of selected publicly traded cancer diagnostics companies, and an examination of enterprise value-to-revenue multiples for such companies, (ii) a review of selected precedent mergers and acquisitions transactions involving cancer diagnostics companies and (iii) an IPO step-up analysis, which considered valuation step-ups observed in recent healthcare initial public offerings relative to prior private financing valuations. These categories of analyses are generally consistent with the types of financial analyses performed by Scalar, LLC (“Scalar”) in connection with Scalar’s fairness opinion, as described in “—Opinion of Scalar, LLC,” although HCW’s work differed in nature and scope and was not performed for the purpose of rendering a fairness opinion. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The materials presented by HCW were provided to the Freenome Strategic Transaction Committee for informational purposes only and did not constitute a recommendation or fairness opinion with respect to the Business Combination. The Freenome Strategic Transaction Committee considered HCW’s analyses as a “market check” in connection with its evaluation of the Business Combination and, based on a review of the respective analyses, did not identify any material inconsistencies between the general valuation ranges implied by HCW’s analyses and the financial analyses underlying Scalar’s fairness opinion, which was provided to the special committee of the board of directors of PCSC. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On October 3, 2025, PCSC and Freenome agreed to extend the Exclusivity Period to November 4, 2025. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On October 6, 2025, Cooley provided to Goodwin an initial draft of the Business Combination Agreement based upon the terms set forth in the Non-Binding Term Sheet. Between October 6, 2025 and December 3, 2025, Goodwin and Cooley exchanged numerous drafts of the Business Combination Agreement and had telephonic discussions and negotiations concerning the terms of the Business Combination Agreement. The matters in the Business Combination Agreement that were discussed and negotiated between the parties and their respective counsel included: (i) the inclusion of a post-closing purchase price adjustment mechanism and related escrow; (ii) the value of the New Freenome common stock to be used in connection with determining the Exchange Ratio (including clarifying that any shares or other equity interests of Freenome issued and outstanding in connection with either the Exact Sciences Transaction or a strategic collaboration agreement with Roche Sequencing Solutions, Inc. to commercialize Freenome’s cancer screening technology (the “<span style="font-style: italic; font-weight: bold;">Roche Transaction</span>”) would not be taken into account as part of the Freenome shares outstanding as of immediately prior to the closing of the Business Combination for purposes of determining the applicable Exchange Ratio); (iii) the treatment of certain unpaid PCSC liabilities in connection with determining the Aggregate Transaction Proceeds; (iv) Freenome’s obligations with respect to the delivery of warrant cancellation agreements and executed Investor Rights Agreements and Transaction Support Agreements by specified Freenome stockholders; (v) the Termination Date; (vi) the composition of the New Freenome board of directors; (vii) PCSC’s obligations relating to obtaining regulatory approval of the Business Combination; and (viii) the size and terms of the New Freenome Incentive Equity Plan and the New Freenome Employee Stock Purchase Plan (including, in each case, agreement to the automatic annual increase in the number of shares of New Freenome Common Stock reserved under each). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Between mid-October 2025 and December 4, 2025, Cooley and Goodwin also exchanged and negotiated on behalf of PCSC and Freenome, respectively, drafts of the disclosure schedules to the Business Combination Agreement and the other ancillary documents, including the Investor Rights Agreement, the Transaction Support Agreement, the New Freenome certificate of incorporation and bylaws, the Lock-Up Agreement and the Sponsor Letter Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On November 4, 2025, PCSC and Freenome agreed to further extend the Exclusivity Period to December 19, 2025. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On November 18, 2025, Freenome announced its entry into the Roche Transaction. The final terms of the Roche Transaction are described in “<span style="font-style: italic;">Information about Freenome—Key Collaborations”</span>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Following the announcement of the Roche Transaction, over the course of mid-November 2025 through December 4, 2025, Cooley, Goodwin and W&amp;C negotiated the terms of the Subscription Agreement with the various PIPE Investors. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On November 26, 2025, Cooley circulated to the PCSC Board written materials summarizing the key terms of the then-current drafts of the Business Combination Agreement and related ancillary documents. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On November 28, 2025, a meeting of the Special Committee was held by videoconference, with representatives of Ropes &amp; Gray LLP in attendance. At the meeting, referring to the summary materials provided by Cooley to the members of the PCSC Board on November 26, 2025, representatives of Ropes &amp; Gray provided an update on the proposed Business Combination, including the key terms of the Business Combination Agreement and related ancillary documents, as well as the directors’ duties as members of the PCSC Board under Cayman Islands law. Also at this meeting, the Special Committee unanimously approved the engagement of Maples and Calder (Cayman) LLP (“<span style="font-style: italic; font-weight: bold;">Maples</span>”) as Cayman Islands counsel to the Special Committee. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On December 1, 2025, a meeting of the Special Committee was held by videoconference, with PCSC management and representatives of Ropes &amp; Gray, Maples, Cooley, Jefferies and Scalar in attendance. At the meeting, PCSC management and representatives of Cooley provided the Special Committee with an update and overview of the potential business combination and the process related thereto, the key terms of the Business Combination Agreement, as well as certain key developments. PCSC management also discussed with the Special Committee the expected timeline and process for a potential signing of the Business Combination Agreement. Also at this meeting, representatives of Jefferies provided an overview of the PIPE transactions process, the PIPE Investors, and the material terms of the PIPE transaction documents, and representatives of Scalar provided the Special Committee with its preliminary analysis of the financial aspects of the business combination, and representatives of Maples presented an overview of the directors’ duties as members of the PCSC Board under Cayman Islands law. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On December 4, 2025, Scalar provided a customary relationship disclosure letter to representatives of PCSC, Cooley and Ropes &amp; Gray which was shared with the Special Committee. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Also on December 4, 2025, a meeting of the Special Committee was held by videoconference, with PCSC management and representatives of Cooley, Ropes &amp; Gray, Maples and Scalar in attendance. At the meeting, PCSC management and representatives of Cooley provided the Special Committee with an update on the potential business combination, the definitive transaction documents, and the process related thereto. Also at the meeting, representatives of Scalar reviewed with the Special Committee Scalar’s financial analysis of the Business Combination and rendered to the Special Committee its oral opinion (subsequently confirmed in writing) that, as of such date and based upon and subject to the procedures followed, assumptions made, qualifications and limitations on the review undertaken, and other matters considered by Scalar in preparing its opinion (attached as Annex L to this proxy statement/prospectus), the Consideration (as defined in such opinion) to be paid by PCSC to the stockholders pursuant to the Business Combination Agreement was fair from a financial point of view to (1) the PCSC Class A Shareholders (other than the Excluded Parties) and (2) PCSC. Based on the factors cited in “<span style="font-style: italic;">Business Combination Proposal—The Special Committee’s and the PCSC Board’s Reasons for the Approval of the Business Combination</span>”, the Special Committee then unanimously (i) determined that the entry into the Business Combination Agreement and the other ancillary documents to which PCSC is a party, and the consummation of the transactions contemplated thereby, including the Mergers, are advisable and fair to, and in the best interest of, PCSC and shareholders of PCSC, (ii) recommended to the PCSC Board that it approve the Business Combination Agreement, such other ancillary documents, and the consummation of the transactions contemplated thereby, including the Mergers, and (iii) subject to the terms and conditions of the Business Combination Agreement, resolved to recommend that the shareholders of PCSC adopt the Business Combination Agreement and approve the Mergers and the other transactions contemplated by the Business Combination Agreement (the “<span style="font-style: italic; font-weight: bold;">Special Committee Recommendation</span>”). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Also on December 4, 2025, a meeting of the PCSC Board was held by videoconference with representatives of Cooley, Ropes &amp; Gray, Ogier, counsel to PCSC with respect to matters of Cayman Islands law since PCSC’s initial public offering, and members of PCSC management in attendance. At the meeting, Cooley and Ogier reviewed the PCSC Board’s fiduciary duties under Cayman law, and then PCSC’s management and representatives of Cooley provided the PCSC Board with an overview of the proposed Business Combination and the key terms of the Business Combination Agreement and related ancillary documents. The PCSC Board was also provided with the Special Committee Recommendation. In addition, members of the PCSC Board reviewed the relationships among certain of the members of the PCSC Board, PCSC officers, the Perceptive PIPE Investor, the Sponsor and Freenome with respect to the proposed Business Combination that were reviewed at the August 6, 2025 meeting of the PCSC Board. Based on the factors cited in “<span style="font-style: italic;">Business Combination Proposal—The Special Committee’s and the PCSC Board’s Reasons for the Approval of the Business Combination</span>” and in light of the fact that the implied fair market value of the vested equity of Freenome to be acquired in the Business Combination was equal to at least 80% of the net assets held in the Trust Account (excluding the deferred underwriting discounts held in trust and taxes payable on the interest earned on the Trust Account) at the time of the execution of a definitive agreement for an initial business combination, the PCSC Board unanimously determined, among other things, (i) that it is in the best interests of PCSC to negotiate, execute and deliver the Business Combination Agreement and the ancillary documents thereto, and to consummate the Business Combination, including, but not limited to, the Domestication, the Mergers and the PIPE Financing, (ii) to authorize and approve the form, terms and provisions of the Business Combination Agreement, the Subscription Agreements and the ancillary documents thereto, and PCSC’s performance thereunder and the transactions contemplated thereby, and (iii) that each of the Business Combination Proposal, the Domestication Proposal, the Governing Documents Proposal, the Advisory Governing Documents Proposal, the Nasdaq Proposal, the Equity Incentive Plan Proposal, the Employee Stock Purchase Plan Proposal and the Adjournment Proposal is in the best interests of PCSC and its shareholders, and to recommend that PCSC’s shareholders adopt and approve at the PCSC Shareholders Meeting each such proposal. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Freenome Strategic Transaction Committee, consisting of Deepika Pakianathan, Randal Scott, and Douglas VanOort met on December 1, December 2, and December 3, 2025, with varying members of Freenome management, including Riley Ennis, Aaron Elliott, and Thomas Fitzpatrick, certain of Freenome’s financial advisors from TD Cowen, Delaware special counsel to the committee from RLF, and Goodwin representatives, to review the final terms of the transaction. On December 3, 2025, the Freenome Strategic Transaction Committee determined to recommend that the Freenome Board approve the transaction, and on December 4, 2025, the Freenome Strategic Transaction Committee unanimously adopted resolutions (i) determining that the entry into the Business Combination Agreement and the other ancillary agreements to which Freenome is a party, and the consummation of the transactions contemplated thereby, are advisable and fair to, and in the best interest of, Freenome and its stockholders; and (ii) recommended to the Freenome Board that it approve the Business Combination Agreement, such other ancillary </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">agreements and the consummation of the transactions contemplated thereby, and that the Freenome Board resolve, subject to the terms and conditions of the Business Combination Agreement, to recommend that the Freenome stockholders adopt the Business Combination Agreement and approve the transactions contemplated thereby. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On December 4, 2025, the Freenome Board held a meeting via teleconference. Following discussions, and upon the recommendation of the Freenome Strategic Transaction Committee, the Freenome Board agreed to adopt and approve resolutions that, among other things, (i) approved the execution, delivery and performance of the Business Combination Agreement and the ancillary agreements; (ii) determined that the Business Combination Agreement, the ancillary agreements, the Business Combination, and other transactions, upon the terms and subject to the conditions set forth therein, are advisable and fair to and in the best interests of Freenome and the Freenome Stockholders; (iii) directed that the adoption of the Business Combination Agreement be submitted to the Freenome Stockholders for consideration and recommended that all of the Freenome Stockholders adopt the Business Combination Agreement; (iv) recommended that the Freenome Stockholders approve the Business Combination and such other transactions and adopt the Business Combination Agreement and the ancillary agreements to which Freenome is a party and (v) approved the filing of a proxy statement in connection therewith. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On December 5, 2025, final versions of the Subscription Agreements were distributed to the prospective PIPE Investors, which reflected the outcome of negotiations between PCSC, Freenome and the prospective PIPE Investors and their respective representatives and advisors. Later that day, the prospective PIPE Investors that had chosen to participate in the PIPE Financing indicated their final subscription amounts, and PCSC and Freenome determined final investment allocations with respect to the PIPE Financing. No material valuations or other information about PCSC, Freenome, New Freenome or the Business Combination were provided to potential PIPE Investors that have not been disclosed publicly. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Also on December 5, 2025, the parties entered into the Business Combination Agreement and the related ancillary documents and the PIPE Investors executed and delivered the Subscription Agreements and applicable Transaction Support Agreements, which provided for binding subscriptions to purchase an aggregate of 24,000,000 shares of New Freenome Common Stock at $10.00 per share. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Later on December 5, 2025, PCSC and Freenome issued a joint press release announcing the execution and delivery of the Business Combination Agreement and Subscription Agreements. </div> <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Background to the Business Combination </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">PCSC is a blank check company incorporated on March 22, 2024 as a Cayman Islands exempted company, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On March 27, 2024, prior to the closing of PCSC’s initial public offering, the Sponsor paid $25,000 to cover certain expenses on PCSC’s behalf in exchange for the issuance of 2,156,250 PCSC Class B Shares, or approximately $0.01 per share. In April 2024, the Sponsor transferred 30,000 PCSC Class B Shares to each of the three independent directors of the PCSC Board: Mark C. McKenna, Kenneth Song, M.D. and Harlan W. Waksal, M.D. On June 13, 2024, PCSC consummated its initial public offering of 8,625,000 PCSC Class A Shares, $0.0001 par value per share, at an offering price of $10.00 per share, which included the exercise in full of the underwriter’s option to purchase an additional 1,125,000 PCSC Class A Shares at the initial public offering price of $10.00 per share to cover over-allotments, and a private placement with the Sponsor of 286,250 PCSC Class A Shares at a price of $10.00 per share. The aggregate net proceeds of $86,250,000 from the initial public offering together with certain of the proceeds from the private placement were placed in the Trust Account established for the benefit of PCSC’s public shareholders and the underwriter of the initial public offering, with Continental Stock Transfer &amp; Trust Company acting as trustee. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Following the completion of its initial public offering, at the direction of the PCSC Board, representatives of PCSC, including Messrs. Stone and Poukalov, and Dr. Hukkelhoven commenced an active, targeted search for potential business combination candidates, leveraging the Sponsor’s network of investment bankers, private equity firms and hedge funds (including Perceptive Advisors and its affiliates), consulting firms, legal and accounting firms, and numerous other business relationships, as well as the prior experience and network of PCSC’s officers and directors. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Consistent with the investment focus and acquisition criteria described in PCSC’s initial public offering prospectus, and based on discussion with the PCSC Board, PCSC targeted potential business combination targets in the life sciences and medical technology sectors that its officers and directors believed, based on their experience, could satisfy all (or a portion) of the following key criteria: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">have scientific or other competitive advantages in the markets in which they operate and ability to benefit from access to additional capital as well as PCSC’s industry relationships and expertise; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">are ready to be public companies, with strong management, corporate governance and reporting policies in place; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">will likely be well received by public investors and are expected to have good access to the public capital markets; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">have significant embedded and/or underexploited growth opportunities; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">exhibit unrecognized value or other characteristics that PCSC believes have been misevaluated by the market, based on PCSC’s rigorous analysis and scientific and business due diligence review; and </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">will offer attractive risk-adjusted equity returns for PCSC shareholders.</div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">During this targeted search, representatives of PCSC, including Messrs. Stone, Altman, Poukalov, and Vazquez, and Dr. Hukkelhoven, reviewed approximately 200 potential business combination targets and conducted varying levels of preliminary due diligence on each, and evaluated and analyzed each as a potential business combination target based on, among other things, publicly available information and other market research available to PCSC and its representatives and their existing knowledge of the potential targets as a result of their network and existing relationships. This preliminary diligence, evaluation and analysis with respect to each potential business combination target identified was focused on business, operational and financial matters, including, among other things, product candidate pipelines, other potential product or service offerings, technology, market potential and financial information. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Following this preliminary evaluation, PCSC determined that approximately 20 companies, including Freenome, merited more serious consideration, based on such companies’ scientific approach, development stage, financing needs, management strength and overall alignment with PCSC’s acquisition criteria. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On October 28, 2024, representatives of PCSC, including Messrs. Stone, Altman, Poukalov, and Vazquez, and Dr. Hukkelhoven, submitted a non-binding term sheet to one such company, Party A. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On November 6, 2024, Party A notified PCSC that it intended to continue pursuing a traditional initial public offering rather than a business combination with PCSC in light of prevailing market conditions and its internal strategic priorities. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On December 19, 2024, representatives of PCSC, including Messrs. Stone, Altman, Poukalov, and Vazquez, and Dr. Hukkelhoven, submitted a non-binding term sheet to another such company, Party B. With respect to Party B, PCSC determined following outreach to potential financing sources and other stakeholders that there was limited interest in supporting a business combination with Party B on terms PCSC viewed as appropriate, including taking into account the criteria previously discussed by the PCSC Board. As a result, in February 2025, PCSC discontinued discussions with Party B. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">After concluding its evaluations of Party A and Party B, PCSC continued to assess potential business combination targets. Through this process, and based on discussion with members of the PCSC Board, PCSC further refined its focus and determined to concentrate its near-term efforts on revisiting a smaller set of potential business combination targets, including Freenome, that PCSC believed were the most compelling opportunities relative to the others reviewed. These were targets that PCSC had previously started to evaluate but placed such efforts on hold as PCSC awaited additional data or developments. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In addition to satisfying one or more of PCSC’s key criteria noted above, PCSC believed these targets were most suitable for a potential business combination based on, among other things: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">PCSC’s preliminary assessment of the target’s equity valuation; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the strength, differentiation, and future prospects of the target’s pipeline, platform, or underlying scientific approach; and </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the target’s preparedness for a business combination and readiness to operate as a public company on an expeditious signing and closing timeline. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Each of these targets was a development-stage or commercial-stage life sciences company with product candidates or technologies requiring additional funding for clinical development or commercialization. PCSC contemplated transactions in which consideration to the target’s equityholders would consist primarily (if not exclusively) of shares of PCSC. Representatives of PCSC, including Messrs. Stone, Altman, Poukalov, and Vazquez, and Dr. Hukkelhoven, engaged in varying levels of additional diligence, discussions, and negotiations with these targets, including Freenome, and PCSC management periodically updated the PCSC Board on their progress with respect to screening potential business combination targets. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Perceptive PIPE Investor, an affiliate of PCSC and the Sponsor, was initially introduced to Freenome in 2019 in the context of a potential investment in Freenome. The Perceptive PIPE Investor invested $20 million in Freenome’s Series B financing in July 2019, $40 million in Freenome’s Series C financing in August 2020, $44 million in Freenome’s Series D financing in December 2021 and $20 million in Freenome’s Series F financing in February 2024. Additionally, the Perceptive PIPE Investor was granted a Freenome Board seat in the Series C financing. Dr. Hukkelhoven has occupied such Freenome Board seat since August 14, 2020. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On February 19, 2025, Dr. Hukkelhoven, in her capacity as an executive officer of the Perceptive PIPE Investor, reached out to the other members of the Freenome Board, consisting of Deepika Pakianathan, Douglas VanOort, Randal Scott, Peter Kolchinsky, Moritz Hartmann, and Josh Lauer, to inquire whether Freenome would be interested in exploring a potential business combination with PCSC. The Perceptive PIPE Investor, was as of such time, and remains, an existing investor in Freenome, and Dr. Hukkelhoven, an executive officer of the Perceptive PIPE Investor, was as of such time, and remains, a member of the Freenome Board. As the Perceptive PIPE Investor has been an investor in Freenome since 2019, the Perceptive PIPE Investor has continuously monitored Freenome’s business progress and capital needs. Dr. Hukkelhoven has been a representative appointed by the Perceptive PIPE Investor on the Freenome Board since 2020. At the direction of the Freenome Board, Dr. Hukkelhoven informed the Perceptive PIPE Investor that Freenome was interested in exploring a capital raising transaction involving the Perceptive PIPE Investor and Dr. Hukkelhoven proposed the terms of the PIPE Financing to the Perceptive PIPE Investor. For more information, see “<span style="font-style: italic;">Business Combination Proposal — Interests of PCSC’s Sponsor, Directors and Officers in the Business Combination.</span>” </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In early March 2025, the Freenome Board discussed the outreach from PCSC regarding a potential business combination. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On March 7, 2025, Adam Stone, Chief Executive Officer of PCSC, along with Konstantin Poukalov and Dr. Hukkelhoven, as executive officers of the Perceptive PIPE Investor, met with the Freenome Board (excluding Dr. Hukkelhoven) to discuss the potential business combination opportunity and discussed that PCSC should propose key terms for a potential business combination between the parties to be memorialized in a term sheet. Dr. Hukkelhoven, who has been serving on the Freenome Board in connection with the investment by the Perceptive PIPE Investor in Freenome, reminded the Freenome Board of her affiliation with PCSC and the Sponsor and, after providing an overview of PCSC, recused herself from the remainder of the meeting. The Freenome Board also discussed the de-SPAC process generally. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On May 28, 2025, PCSC circulated an initial draft of the Non-Binding Term Sheet to Freenome. The Freenome Board determined that the Freenome Strategic Transaction Committee would lead the negotiations for Freenome. In August 2023, Freenome’s Board had approved the formation of such Freenome Strategic Transaction Committee in order to explore strategic transactions for Freenome. As of May 2025, the Freenome Strategic Transaction Committee consisted of Deepika Pakianathan, Randal Scott, Doug VanOort and Aaron Elliott. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Over the course of May through early August of 2025, representatives of PCSC, including Adam Stone, Konstantin Poukalov, Dr. Hukkelhoven, Michael Altman, Marcel Rosner, and Carlos Vazquez, and representatives of Freenome, including Aaron Elliott, Riley Ennis, and Thomas Fitzpatrick, and its Freenome Strategic Transaction Committee, consisting of the members identified above, with the assistance of their respective legal counsel at Cooley LLP (“<span style="font-style: italic; font-weight: bold;">Cooley</span>”) and Goodwin Procter LLP (“<span style="font-style: italic; font-weight: bold;">Goodwin</span>”), negotiated certain provisions of the Non-Binding Term Sheet. Such provisions included the pre-money base equity value of Freenome (and related adjustments), totaling $725 million, the minimum Aggregate Transaction Proceeds Amount of $200 million, and the size and terms of the post-closing employee equity pools. Dr. Hukkelhoven conveyed and explained the rationale for PCSC’s valuation of Freenome to Freenome management and the Freenome Board and acted as an intermediary between PCSC and Freenome. In the initial draft of the Non-Binding Term Sheet sent in May 2025, PCSC assigned Freenome a post-money valuation of $1.0 billion, subject to confirmatory due diligence, reflecting the following assumptions: (1) a pre-money </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">base equity value for Freenome of $725.0 million and (2) a minimum Aggregate Transaction Proceeds Amount of $250.0 million. In late July 2025, a revised draft of the Non-Binding Term Sheet from PCSC to Freenome increased the post-money valuation of Freenome to $1.05 billion, reflecting a revised assumption of $300 million in aggregate proceeds raised in the PIPE Financing plus the Trust Account’s balance at Closing. In early August 2025, PCSC sent a further revised draft Non-Binding Term Sheet, clarifying that the $1.05 billion post-money valuation of Freenome was in light of the Perceptive PIPE Investor’s plan to invest approximately $25.0 million in the PIPE Financing. In negotiating the pre-money base equity value of Freenome, the parties discussed whether the proceeds from the Exact Sciences transaction or any transaction entered into with Roche should be included in such value. Although these potential transactions had been under discussion, the parties ultimately agreed that such proceeds would not be included in the pre-money base equity value because the transactions had not been completed at the time the valuation was determined and remained contingent. Accordingly, the economic impact of any such transactions, if consummated, would be reflected in the post-money equity value rather than the pre-money valuation. Consistent with this approach, shares issuable upon conversion of Freenome convertible notes and any equity issued in connection with such transactions were excluded from the definition of fully diluted Freenome shares used in determining the Exchange Ratio so that the effects of such instruments and transactions would be reflected in the post-closing ownership rather than diluting the pre-money equity value. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">During such period, Freenome was also negotiating its exclusive licensing agreement with Exact Sciences to advance the Exact Sciences Transaction, which was ultimately signed and announced on August 6, 2025. The final terms of the Exact Sciences Transaction are described in “<span style="font-style: italic;">Information about Freenome—Key Collaborations</span>.” Additionally, during this period, Freenome began discussions on a collaboration with Roche, as detailed further below. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On August 6, 2025, the PCSC Board met by videoconference, with members of PCSC management, including Messrs. Stone, Altman, Poukalov, and Vazquez, and Dr. Hukkelhoven, and representatives of Cooley present, to discuss the potential business combination with Freenome and the Non-Binding Term Sheet. Among other things, the final terms of the Non-Binding Term Sheet contemplated that Freenome would be valued at approximately $1.05 billion on a post-Business Combination equity value basis, taking into account, among other things, (i) an assumed $300 million in aggregate proceeds from (a) the PIPE Financing (which would include at least $25 million expected to be contributed by Perceptive Advisors or its affiliates and at least $50 million expected to be contributed by RA Capital or its affiliates) and (b) the Trust Account at the closing, and (ii) an agreed pre-Business Combination base equity value for Freenome of $725 million. The Non-Binding Term Sheet further contemplated, among other things, (a) certain adjustments for leakage to the Freenome base equity value, (b) that any proceeds from the Exact Sciences Transaction or any transaction entered into with Roche would not be counted as part of the base equity value of Freenome and that any shares or other equity interests of Freenome issued and outstanding in connection with such transactions would not be taken into account as part of the Freenome shares outstanding as of immediately prior to the closing of the Business Combination for purposes of determining the applicable Exchange Ratio, (c) that in addition to other customary closing conditions, the obligation of Freenome to consummate the Business Combination would be subject to there being Aggregate Transaction Proceeds of at least $250,000,000, (d) a six-month lockup period after consummation of the Business Combination with respect to New Freenome shares to be issued to insider Freenome stockholders, including Perceptive Advisors and RA Capital, in the Business Combination, as well as certain demand and piggyback registration rights for certain stockholders, and (e) the Exclusivity Period binding on both PCSC and Freenome, ending on the later of 5:00 pm Eastern Time on October 5, 2025 and the time at which either party gives written notice to the other party of the termination of exclusivity, provided that PCSC also had the right, in its sole discretion, to elect to earlier terminate the Exclusivity Period by delivering written notice to Freenome at any time on or prior to 11:59 p.m. Eastern Time on September 5, 2025 or by delivering written notice to Freenome at any time if PCSC determines that there has occurred any change or event that has materially and adversely affected, or would reasonably be expected to materially and adversely affect, Freenome. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">During the August 6, 2025 PCSC Board meeting, the PCSC Board noted that (i) the Perceptive PIPE Investor was an affiliate of PCSC and the Sponsor and an existing investor in Freenome, (ii) Dr. Hukkelhoven was an executive officer of the Perceptive PIPE Investor and was a director of Freenome, and (iii) all directors serving on the PCSC Board other than Mr. McKenna, Dr. Song and Dr. Waksal, including Dr. Hukkelhoven, as well as the executive officers of PCSC were also employees and/or service providers of Perceptive Advisors, an affiliate of the Sponsor. As a result, the PCSC Board established the Special Committee, consisting solely of Mr. McKenna, Dr. Song and Dr. Waksal as the independent and disinterested members of the PCSC Board, to (i) consider, review and evaluate the terms and conditions, and determine the advisability, of the potential business combination and any alternatives thereto that the Special Committee deems appropriate, (ii) determine whether the potential business combination or any alternative </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">thereto is fair to, and in the best interests of, PCSC and its shareholders and (iii) with respect to any actions required to be taken by the full PCSC Board with respect to the potential business combination or any alternative thereto, recommend to the PCSC Board what action, if any, should be taken by the PCSC Board. The PCSC Board designated Mr. McKenna, Dr. Song and Dr. Waksal as the members of the Special Committee as each of whom had confirmed to the PCSC Board that they did not have any financial interest in or pre-existing relationship with Freenome. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Following adjournment of the PCSC Board meeting, the Special Committee met, with members of PCSC management and representatives of Cooley present. At this meeting, the Special Committee discussed the Non-Binding Term Sheet, determined that the execution, delivery and performance of the Non-Binding Term Sheet by PCSC and the consummation of the transactions contemplated therein were in the best commercial interests of PCSC, and resolved to recommend to the PCSC Board to approve, execute, deliver and perform the Non-Binding Term Sheet and consummate the transactions contemplated therein. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Following conclusion of the Special Committee meeting, the PCSC Board thereafter reconvened and, after receiving the Special Committee’s recommendation and engaging in further discussion, approved and adopted the Non-Binding Term Sheet. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On August 5, 2025, the Freenome Strategic Transaction Committee met by videoconference, with members of Freenome management and other members of the Freenome Board (excluding Dr. Hukkelhoven and Mr. Kolchinsky) and representatives of Goodwin present, and discussed (i) the Exact Sciences Transaction and (ii) the final terms of the Non-Binding Term Sheet. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On August 6, 2025, the Freenome Board met by videoconference, with members of Freenome management and representatives of Goodwin present. It was noted that pursuant to the final Non-Binding Term Sheet, RA Capital intended to be a significant PIPE Investor in the transaction. It was therefore determined that Mr. Kolchinsky would abstain from any vote related to the Non-Binding Term Sheet and the transactions contemplated thereby. The Freenome Board approved execution of the Non-Binding Term Sheet, with Dr. Hukkelhoven and Mr. Kolchinsky, abstaining from the vote. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Later on August 6, 2025, PCSC and Freenome executed the Non-Binding Term Sheet. As of such date, PCSC had not submitted term sheets or letters of intent with respect to any of the other potential business combination targets that had been under consideration, and PCSC subsequently ceased discussions with each of them. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">PCSC ultimately determined to abandon the pursuit of additional potential business combination opportunities with potential business combination targets other than Freenome because of, among other things: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">PCSC’s directors’ and officers’ belief that Freenome was the most attractive opportunity that met PCSC’s key criteria, including due to its differentiated scientific and technological approach, its advancement toward meaningful near- and medium-term development or commercial milestones and the strength and experience of its management team; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Freenome’s preparedness and willingness to devote appropriate resources to expeditiously negotiate and sign a definitive agreement, consummate a business combination, and transition to becoming a public company; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the more advanced stage of engagement, discussions, and negotiations with Freenome, including substantial progress on key terms and conditions; and </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Freenome’s willingness to enter into a non-binding term sheet, with exclusivity, on terms PCSC’s directors and officers believed were attractive. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On August 20, 2025, the Special Committee held a call with representatives of Ropes &amp; Gray LLP (“<span style="font-style: italic; font-weight: bold;">Ropes &amp; Gray</span>”) regarding the potential engagement of Ropes &amp; Gray by the Special Committee as its U.S. counsel. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On August 28, 2025, PCSC and Freenome finalized the terms of and executed a customary confidentiality agreement to facilitate negotiations and the completion of confirmatory due diligence. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">During August 2025, PCSC contacted Jefferies and Leerink Partners, requesting that (i) Jefferies act as lead financial advisor and lead capital markets advisor to PCSC with respect to the potential business combination, (ii) Leerink Partners act as PCSC’s joint capital markets advisor, and (iii) Jefferies and Leerink Partners act as joint lead placement agents in connection with the PIPE Financing. PCSC, Jefferies and Leerink Partners executed an engagement letter in respect of such services on September 30, 2025. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">During August and September 2025, Freenome connected with a number of potential advisors, including TD Securities (USA) LLC (“TD Cowen”), BTIG, LLC (“BTIG”), and Guggenheim Securities, LLC (“Guggenheim Securities”). It was determined that (i) TD Cowen would act as lead financial advisor to Freenome, (ii) BTIG would act as financial advisor to Freenome and (iii) Guggenheim Securities would act as capital markets advisor to Freenome. Freenome executed engagement letters in respect of such services in November 2025. In connection with these engagements, Freenome agreed to reimburse the financial and capital markets advisors for certain expenses in connection with the Business Combination and to pay an aggregate cash fee of $2.1 million to such advisors, payable upon the closing of the Business Combination. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On September 2, 2025, the Special Committee engaged Ropes &amp; Gray as its U.S. counsel. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On September 8, 2025, Cooley provided to Goodwin and White &amp; Case LLP (“<span style="font-style: italic; font-weight: bold;">W&amp;C</span>”), legal counsel to Jefferies and Leerink Partners, initial drafts of the form of Subscription Agreement for Perceptive Advisors and RA Capital and the form of Subscription Agreement for all other PIPE Investors. From September 8, 2025 to October 28, 2025, Cooley, Goodwin and W&amp;C negotiated the forms of the Subscription Agreement. In parallel to the preparation of the forms of Subscription Agreement, Jefferies and Leerink Partners, as placement agents for PCSC in connection with the PIPE Financing, commenced outreach to potential investors (including existing Freenome investors) to assess interest in participating in the PIPE Financing. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On September 29, 2025, Scalar, LLC (“<span style="font-style: italic; font-weight: bold;">Scalar</span>”) was engaged as financial advisor to the Special Committee in connection with the Business Combination. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Throughout September, October and November 2025, the Freenome Strategic Transaction Committee met multiple times to discuss (i) the status of the PIPE Financing and the transaction and (ii) the status of the potential transaction with Roche. In October 2025, the Freenome Board determined to remove Dr. Elliott as a member of the Freenome Strategic Transaction Committee in order to ensure that the Freenome Strategic Transaction Committee would consist solely of disinterested and independent Freenome Board members. As Dr. Elliott is the CEO of Freenome, it was determined he is not independent of Freenome. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On September 30, 2025, the Freenome Strategic Transaction Committee held a meeting. The Freenome Strategic Transaction Committee determined to engage certain of its own advisors as part of its continuing evaluation of the Business Combination. The Freenome Strategic Transaction Committee engaged (i) Richards, Layton &amp; Finger P.A. (“RLF”) as its legal counsel and (ii) H.C. Wainwright &amp; Co., LLC (“HCW”) as its financial advisor in connection with the derivation of an implied valuation analysis of Freenome. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Pursuant to its engagement, HCW agreed to perform certain valuation analyses in order to derive an implied valuation of Freenome and to assist the Freenome Strategic Transaction Committee in assessing whether any developments subsequent to the execution of the non-binding term sheet had affected such valuation. The nature and scope of HCW’s engagement did not require or include the delivery of a fairness opinion. In connection with this engagement, Freenome agreed to pay HCW a fixed cash fee of $475,000, payable upon delivery of its valuation materials, and to reimburse certain expenses and provide customary indemnification. On October 6, 2025, HCW presented certain valuation analyses to the Freenome Strategic Transaction Committee. HCW did not rely on projected or forward-looking financial information provided by Freenome in preparing its analyses. HCW’s analyses included (i) a review of selected publicly traded cancer diagnostics companies, and an examination of enterprise value-to-revenue multiples for such companies, (ii) a review of selected precedent mergers and acquisitions transactions involving cancer diagnostics companies and (iii) an IPO step-up analysis, which considered valuation step-ups observed in recent healthcare initial public offerings relative to prior private financing valuations. These categories of analyses are generally consistent with the types of financial analyses performed by Scalar, LLC (“Scalar”) in connection with Scalar’s fairness opinion, as described in “—Opinion of Scalar, LLC,” although HCW’s work differed in nature and scope and was not performed for the purpose of rendering a fairness opinion. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The materials presented by HCW were provided to the Freenome Strategic Transaction Committee for informational purposes only and did not constitute a recommendation or fairness opinion with respect to the Business Combination. The Freenome Strategic Transaction Committee considered HCW’s analyses as a “market check” in connection with its evaluation of the Business Combination and, based on a review of the respective analyses, did not identify any material inconsistencies between the general valuation ranges implied by HCW’s analyses and the financial analyses underlying Scalar’s fairness opinion, which was provided to the special committee of the board of directors of PCSC. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On October 3, 2025, PCSC and Freenome agreed to extend the Exclusivity Period to November 4, 2025. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On October 6, 2025, Cooley provided to Goodwin an initial draft of the Business Combination Agreement based upon the terms set forth in the Non-Binding Term Sheet. Between October 6, 2025 and December 3, 2025, Goodwin and Cooley exchanged numerous drafts of the Business Combination Agreement and had telephonic discussions and negotiations concerning the terms of the Business Combination Agreement. The matters in the Business Combination Agreement that were discussed and negotiated between the parties and their respective counsel included: (i) the inclusion of a post-closing purchase price adjustment mechanism and related escrow; (ii) the value of the New Freenome common stock to be used in connection with determining the Exchange Ratio (including clarifying that any shares or other equity interests of Freenome issued and outstanding in connection with either the Exact Sciences Transaction or a strategic collaboration agreement with Roche Sequencing Solutions, Inc. to commercialize Freenome’s cancer screening technology (the “<span style="font-style: italic; font-weight: bold;">Roche Transaction</span>”) would not be taken into account as part of the Freenome shares outstanding as of immediately prior to the closing of the Business Combination for purposes of determining the applicable Exchange Ratio); (iii) the treatment of certain unpaid PCSC liabilities in connection with determining the Aggregate Transaction Proceeds; (iv) Freenome’s obligations with respect to the delivery of warrant cancellation agreements and executed Investor Rights Agreements and Transaction Support Agreements by specified Freenome stockholders; (v) the Termination Date; (vi) the composition of the New Freenome board of directors; (vii) PCSC’s obligations relating to obtaining regulatory approval of the Business Combination; and (viii) the size and terms of the New Freenome Incentive Equity Plan and the New Freenome Employee Stock Purchase Plan (including, in each case, agreement to the automatic annual increase in the number of shares of New Freenome Common Stock reserved under each). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Between mid-October 2025 and December 4, 2025, Cooley and Goodwin also exchanged and negotiated on behalf of PCSC and Freenome, respectively, drafts of the disclosure schedules to the Business Combination Agreement and the other ancillary documents, including the Investor Rights Agreement, the Transaction Support Agreement, the New Freenome certificate of incorporation and bylaws, the Lock-Up Agreement and the Sponsor Letter Agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On November 4, 2025, PCSC and Freenome agreed to further extend the Exclusivity Period to December 19, 2025. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On November 18, 2025, Freenome announced its entry into the Roche Transaction. The final terms of the Roche Transaction are described in “<span style="font-style: italic;">Information about Freenome—Key Collaborations”</span>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Following the announcement of the Roche Transaction, over the course of mid-November 2025 through December 4, 2025, Cooley, Goodwin and W&amp;C negotiated the terms of the Subscription Agreement with the various PIPE Investors. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On November 26, 2025, Cooley circulated to the PCSC Board written materials summarizing the key terms of the then-current drafts of the Business Combination Agreement and related ancillary documents. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On November 28, 2025, a meeting of the Special Committee was held by videoconference, with representatives of Ropes &amp; Gray LLP in attendance. At the meeting, referring to the summary materials provided by Cooley to the members of the PCSC Board on November 26, 2025, representatives of Ropes &amp; Gray provided an update on the proposed Business Combination, including the key terms of the Business Combination Agreement and related ancillary documents, as well as the directors’ duties as members of the PCSC Board under Cayman Islands law. Also at this meeting, the Special Committee unanimously approved the engagement of Maples and Calder (Cayman) LLP (“<span style="font-style: italic; font-weight: bold;">Maples</span>”) as Cayman Islands counsel to the Special Committee. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On December 1, 2025, a meeting of the Special Committee was held by videoconference, with PCSC management and representatives of Ropes &amp; Gray, Maples, Cooley, Jefferies and Scalar in attendance. At the meeting, PCSC management and representatives of Cooley provided the Special Committee with an update and overview of the potential business combination and the process related thereto, the key terms of the Business Combination Agreement, as well as certain key developments. PCSC management also discussed with the Special Committee the expected timeline and process for a potential signing of the Business Combination Agreement. Also at this meeting, representatives of Jefferies provided an overview of the PIPE transactions process, the PIPE Investors, and the material terms of the PIPE transaction documents, and representatives of Scalar provided the Special Committee with its preliminary analysis of the financial aspects of the business combination, and representatives of Maples presented an overview of the directors’ duties as members of the PCSC Board under Cayman Islands law. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On December 4, 2025, Scalar provided a customary relationship disclosure letter to representatives of PCSC, Cooley and Ropes &amp; Gray which was shared with the Special Committee. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Also on December 4, 2025, a meeting of the Special Committee was held by videoconference, with PCSC management and representatives of Cooley, Ropes &amp; Gray, Maples and Scalar in attendance. At the meeting, PCSC management and representatives of Cooley provided the Special Committee with an update on the potential business combination, the definitive transaction documents, and the process related thereto. Also at the meeting, representatives of Scalar reviewed with the Special Committee Scalar’s financial analysis of the Business Combination and rendered to the Special Committee its oral opinion (subsequently confirmed in writing) that, as of such date and based upon and subject to the procedures followed, assumptions made, qualifications and limitations on the review undertaken, and other matters considered by Scalar in preparing its opinion (attached as Annex L to this proxy statement/prospectus), the Consideration (as defined in such opinion) to be paid by PCSC to the stockholders pursuant to the Business Combination Agreement was fair from a financial point of view to (1) the PCSC Class A Shareholders (other than the Excluded Parties) and (2) PCSC. Based on the factors cited in “<span style="font-style: italic;">Business Combination Proposal—The Special Committee’s and the PCSC Board’s Reasons for the Approval of the Business Combination</span>”, the Special Committee then unanimously (i) determined that the entry into the Business Combination Agreement and the other ancillary documents to which PCSC is a party, and the consummation of the transactions contemplated thereby, including the Mergers, are advisable and fair to, and in the best interest of, PCSC and shareholders of PCSC, (ii) recommended to the PCSC Board that it approve the Business Combination Agreement, such other ancillary documents, and the consummation of the transactions contemplated thereby, including the Mergers, and (iii) subject to the terms and conditions of the Business Combination Agreement, resolved to recommend that the shareholders of PCSC adopt the Business Combination Agreement and approve the Mergers and the other transactions contemplated by the Business Combination Agreement (the “<span style="font-style: italic; font-weight: bold;">Special Committee Recommendation</span>”). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Also on December 4, 2025, a meeting of the PCSC Board was held by videoconference with representatives of Cooley, Ropes &amp; Gray, Ogier, counsel to PCSC with respect to matters of Cayman Islands law since PCSC’s initial public offering, and members of PCSC management in attendance. At the meeting, Cooley and Ogier reviewed the PCSC Board’s fiduciary duties under Cayman law, and then PCSC’s management and representatives of Cooley provided the PCSC Board with an overview of the proposed Business Combination and the key terms of the Business Combination Agreement and related ancillary documents. The PCSC Board was also provided with the Special Committee Recommendation. In addition, members of the PCSC Board reviewed the relationships among certain of the members of the PCSC Board, PCSC officers, the Perceptive PIPE Investor, the Sponsor and Freenome with respect to the proposed Business Combination that were reviewed at the August 6, 2025 meeting of the PCSC Board. Based on the factors cited in “<span style="font-style: italic;">Business Combination Proposal—The Special Committee’s and the PCSC Board’s Reasons for the Approval of the Business Combination</span>” and in light of the fact that the implied fair market value of the vested equity of Freenome to be acquired in the Business Combination was equal to at least 80% of the net assets held in the Trust Account (excluding the deferred underwriting discounts held in trust and taxes payable on the interest earned on the Trust Account) at the time of the execution of a definitive agreement for an initial business combination, the PCSC Board unanimously determined, among other things, (i) that it is in the best interests of PCSC to negotiate, execute and deliver the Business Combination Agreement and the ancillary documents thereto, and to consummate the Business Combination, including, but not limited to, the Domestication, the Mergers and the PIPE Financing, (ii) to authorize and approve the form, terms and provisions of the Business Combination Agreement, the Subscription Agreements and the ancillary documents thereto, and PCSC’s performance thereunder and the transactions contemplated thereby, and (iii) that each of the Business Combination Proposal, the Domestication Proposal, the Governing Documents Proposal, the Advisory Governing Documents Proposal, the Nasdaq Proposal, the Equity Incentive Plan Proposal, the Employee Stock Purchase Plan Proposal and the Adjournment Proposal is in the best interests of PCSC and its shareholders, and to recommend that PCSC’s shareholders adopt and approve at the PCSC Shareholders Meeting each such proposal. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Freenome Strategic Transaction Committee, consisting of Deepika Pakianathan, Randal Scott, and Douglas VanOort met on December 1, December 2, and December 3, 2025, with varying members of Freenome management, including Riley Ennis, Aaron Elliott, and Thomas Fitzpatrick, certain of Freenome’s financial advisors from TD Cowen, Delaware special counsel to the committee from RLF, and Goodwin representatives, to review the final terms of the transaction. On December 3, 2025, the Freenome Strategic Transaction Committee determined to recommend that the Freenome Board approve the transaction, and on December 4, 2025, the Freenome Strategic Transaction Committee unanimously adopted resolutions (i) determining that the entry into the Business Combination Agreement and the other ancillary agreements to which Freenome is a party, and the consummation of the transactions contemplated thereby, are advisable and fair to, and in the best interest of, Freenome and its stockholders; and (ii) recommended to the Freenome Board that it approve the Business Combination Agreement, such other ancillary </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">agreements and the consummation of the transactions contemplated thereby, and that the Freenome Board resolve, subject to the terms and conditions of the Business Combination Agreement, to recommend that the Freenome stockholders adopt the Business Combination Agreement and approve the transactions contemplated thereby. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On December 4, 2025, the Freenome Board held a meeting via teleconference. Following discussions, and upon the recommendation of the Freenome Strategic Transaction Committee, the Freenome Board agreed to adopt and approve resolutions that, among other things, (i) approved the execution, delivery and performance of the Business Combination Agreement and the ancillary agreements; (ii) determined that the Business Combination Agreement, the ancillary agreements, the Business Combination, and other transactions, upon the terms and subject to the conditions set forth therein, are advisable and fair to and in the best interests of Freenome and the Freenome Stockholders; (iii) directed that the adoption of the Business Combination Agreement be submitted to the Freenome Stockholders for consideration and recommended that all of the Freenome Stockholders adopt the Business Combination Agreement; (iv) recommended that the Freenome Stockholders approve the Business Combination and such other transactions and adopt the Business Combination Agreement and the ancillary agreements to which Freenome is a party and (v) approved the filing of a proxy statement in connection therewith. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On December 5, 2025, final versions of the Subscription Agreements were distributed to the prospective PIPE Investors, which reflected the outcome of negotiations between PCSC, Freenome and the prospective PIPE Investors and their respective representatives and advisors. Later that day, the prospective PIPE Investors that had chosen to participate in the PIPE Financing indicated their final subscription amounts, and PCSC and Freenome determined final investment allocations with respect to the PIPE Financing. No material valuations or other information about PCSC, Freenome, New Freenome or the Business Combination were provided to potential PIPE Investors that have not been disclosed publicly. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Also on December 5, 2025, the parties entered into the Business Combination Agreement and the related ancillary documents and the PIPE Investors executed and delivered the Subscription Agreements and applicable Transaction Support Agreements, which provided for binding subscriptions to purchase an aggregate of 24,000,000 shares of New Freenome Common Stock at $10.00 per share. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Later on December 5, 2025, PCSC and Freenome issued a joint press release announcing the execution and delivery of the Business Combination Agreement and Subscription Agreements. </div> <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Freenome’s Reasons for the Business Combination </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In the course of reaching their decisions to recommend and to approve the Business Combination, respectively, the Freenome Strategic Transaction Committee and Freenome Board held numerous meetings, consulted with Freenome’s management, financial advisors and legal counsel, and considered a wide variety of factors including, among others, the below material factors (which factors are not necessarily presented in any order of relative importance): </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the Business Combination will expand both the access to capital for Freenome and the range of investors potentially available as a public company, compared to the investors Freenome could otherwise gain access to if it continued to operate as a privately-held company; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Freenome’s expected cash resources and need for additional capital to fund the development and commercialization of its product, and the uniqueness of this particular potential Business Combination, as the negotiated transaction will result in the infusion of capital from strategic healthcare investors at the time of Closing; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the potential benefits from increased public market awareness of Freenome and its product and product candidates; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the historical and current information concerning Freenome’s business, including its financial performance and condition, operations, management and research and development programs; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the competitive nature of the industry in which Freenome operates; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Freenome Board’s fiduciary duties to Freenome’s stockholders; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the Freenome Board’s belief that this transaction provides a viable public listing strategy and access to available capital, and addresses the risk of the lack of an available or unfavorable market for an initial public offering at a later date; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the terms and conditions of the Business Combination Agreement; and </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the likelihood that the Business Combination will be consummated on a timely basis. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In light of the number and wide variety of factors considered in connection with its evaluation of the Business Combination, the Freenome Board did not consider it practicable to, and did not attempt to, quantify or otherwise assign relative weights to the specific factors that it considered in reaching its determination and supporting its decision. The Freenome Board viewed its decision as being based on all the information available and the factors presented to and considered by it. In addition, individual directors may have given different weight to different factors. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Freenome Strategic Transaction Committee and Freenome Board also considered a number of uncertainties and risks in its deliberations concerning the Business Combination and the other transactions contemplated by the Business Combination Agreement, including the following: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the possibility that the Business Combination might not be completed in a timely manner or at all, and the potential adverse effect of the public announcement of the Business Combination on the reputation of Freenome and the ability of Freenome to obtain financing in the future in the event the Business Combination is not completed; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the costs involved in connection with completing the Business Combination, the time and effort of Freenome management required to complete the Business Combination, the related disruptions or potential disruptions to Freenome’s business operations and future prospects, including its relationships with its employees, licensors, contract research organizations and partners and others that do business or may do business in the future with Freenome, and related administrative challenges associated with combining the companies; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the additional expenses and obligations to which Freenome’s business will be subject following the Business Combination that Freenome has not previously been subject to, and the operational changes to Freenome’s business, in each case that may result from being a public company; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the fact that the representations and warranties in the Business Combination Agreement do not survive the closing of the merger and the potential risk of liabilities that may arise post-closing; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the risk that the current Public Shareholders of PCSC can redeem their PCSC Class A Shares for cash in connection with the consummation of the Business Combination, thereby reducing the amount of cash available to New Freenome following the consummation of the Business Combination; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the possibility of litigation challenging the Business Combination; and </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">various other risks associated with the combined organization and the merger, including the risks described in the section entitled “<span style="font-style: italic;">Risk Factors</span>” in this prospectus. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The foregoing information is not intended to be exhaustive but summarizes the material factors considered by the Freenome Board in its consideration of the Business Combination Agreement and the transactions contemplated. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Freenome Strategic Transaction Committee also undertook a robust evaluation of the Business Combination, and hired independent legal and financial advisors. Following the recommendation of the Freenome Strategic Transaction Committee, the Freenome Board concluded that the benefits, advantages and opportunities of a potential transaction outweighed the uncertainties and risks described above. After considering these and other factors, the Freenome Board approved the Business Combination Agreement, the Business Combination and the other transactions contemplated by the Business Combination Agreement.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">This explanation of reasons for the Freenome Board’s approval of the Business Combination, and all other information presented in this section, is forward-looking in nature and therefore subject to a number of risks and uncertainties and should be read in light of the factors discussed under the sections entitled “<span style="font-style: italic;">Cautionary Statement Regarding Forward-Looking Statements</span>” and “<span style="font-style: italic;">Risk Factors</span>.” </div> <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Interests of Freenome’s Directors and Officers </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Freenome’s directors and officers have interests in the Business Combination that are different from, or in addition to, those of the Freenome Shareholders generally. These interests include, among other things, the interests listed below:</div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Dr. Hukkelhoven, an executive officer of the Perceptive PIPE Investor, is a director of Freenome. In light of her relationship with both Freenome and the Perceptive PIPE Investor, an affiliate of the Sponsor, and to avoid any potential conflicts of interest, Freenome formed the Freenome Strategic Transaction Committee. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Upon the completion of the Business Combination, the following persons are expected to be appointed Executive Officers of New Freenome: Drs. Elliott and Lin and Messrs. Ennis and Le. For a description of these arrangements see <span style="font-style: italic;">“Management of New Freenome Following the Business Combination—Executive Officers.”</span> </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">In connection with the closing of the Business Combination, Dr. Elliott is expected to receive the Initial Equity Awards and Anti-Dilution Equity Awards. See <span style="font-style: italic;">“Executive Compensation—Employment Arrangements in Place Prior to the Business Combination for Named Executive Officers.”</span> </div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Certain of Freenome’s directors are holders of, and/or are affiliated with entities that are holders of, Freenome equity interests and in such capacity will be entitled to receive the shares of New Freenome Common Stock payable to all holders of such equity interests pursuant to the terms of the Business Combination Agreement. Additionally, certain of Freenome’s directors are affiliated with entities that are PIPE Investors.<span style="font-weight: normal;"> See “</span><span style="font-style: italic;">Certain Relationships and Related Person Transactions—Freenome” and “Beneficial Ownership of Securities</span><span style="font-weight: normal;">.”</span></div> <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">The Special Committee’s and the PCSC Board’s Reasons for the Approval of the Business Combination </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The prospectus for PCSC’s initial public offering identified general criteria and guidelines that PCSC’s management team believed would be important in evaluating prospective target businesses, although in such prospectus PCSC also indicated that it may enter into a business combination with a target business that does not meet these criteria and guidelines. Freenome met a number of the criteria and guidelines that were identified in PCSC’s initial public offering prospectus, and following due diligence conducted by PCSC’s management and its advisors, and detailed discussions with Freenome, PCSC believed Freenome to be an attractive business combination target. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Special Committee and the PCSC Board, in evaluating the business combination with Freenome, (a) considered a wide variety of factors, including but not limited to, the factors discussed below, (b) reviewed the results of due diligence conducted by PCSC’s management team, and (c) consulted with their respective legal counsel, financial and accounting advisors and other advisors, before reaching their respective determinations (i) that the terms and conditions of the Business Combination Agreement and the ancillary documents thereto and the transactions contemplated thereby, including the Business Combination, are advisable and in the best interests of PCSC and its shareholders, as a whole, and (ii) to recommend that PCSC’s shareholders approve the Business Combination Agreement, the consummation of the transactions contemplated thereby and the performance by PCSC of its obligations thereunder. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In light of the complexity of the factors considered in connection with their evaluation of the Business Combination, the Special Committee and the PCSC Board, as a whole, did not consider it practicable to, and did not attempt to, quantify or otherwise assign relative weights to the specific factors taken into account in reaching their respective decisions. Rather, the Special Committee and the PCSC Board based their evaluation, negotiation and recommendation of the Business Combination on the totality of information available and the factors presented to and considered by them. In addition, individual members of the Special Committee and the PCSC Board may have given different weights to different factors. This explanation of the reasons for the Special Committee and the PCSC Board’s approval of the Business Combination, and all other information presented in this section is forward-looking in nature and, therefore, should be read in light of the factors discussed under “<span style="font-style: italic; font-weight: bold;">Cautionary Note Regarding Forward-Looking Statements</span>” and “<span style="font-style: italic; font-weight: bold;">Risk Factors</span>.” </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Before reaching their respective decision, the Special Committee and the PCSC Board, in consultation with their respective legal counsel, financial and accounting advisors and other advisors, reviewed the results of the due diligence conducted by PCSC’s management, which included: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">meetings with Freenome’s management team to understand and analyze Freenome’s business and prospects; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">legal due diligence conducted by Cooley; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">review of Freenome’s historical financial information; and </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">review of the proposed structure of the Business Combination and drafts of definitive documents. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In approving the Business Combination, the Special Committee determined to obtain a fairness opinion from an experienced and qualified independent financial advisor, Scalar. In addition, the officers and directors of PCSC have substantial experience in evaluating the operating and financial merits of companies from a wide range of industries, but particularly the healthcare and life sciences industries, and concluded that their experience and background, together </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">with the experience and sector expertise of PCSC’s advisors and the advisors of the Special Committee, enabled them to make the necessary analyses and determinations regarding the Business Combination. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Special Committee and the PCSC Board considered a variety of factors, including the following positive factors, although not weighted or in any order of significance, in deciding to approve the Business Combination Agreement and transactions contemplated thereby: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Novel Technology for Early Cancer Detection, with Positive Data.</span> Freenome’s commercial, flagship testing product, the SimpleScreen CRC v1, which is designed to deliver high sensitivity at the earliest and most treatable stages of colorectal cancer (CRC), is supported by the largest prospective study of its kind, PREEMPT CRC, which met all primary endpoints (topline readout completed in April 2024) and is designed to meet FDA requirements for a first-line label. Freenome has completed the premarket approval application submission for the SimpleScreen CRC v1 and expects FDA approval in 2026. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Critical and Valuable Commercial Partnerships.</span> The Special Committee and the PCSC Board believe that (i) Freenome’s exclusive U.S. license agreement with Exact Sciences, a leading provider of cancer screening and diagnostic tests, to commercialize SimpleScreen CRC and (ii) Freenome’s exclusive agreement with Roche to expand ongoing technology collaboration and develop and commercialize cancer screening tests outside the U.S., will accelerate market adoption of Freenome’s diagnostic tests and enhance Freenome’s overall screening platform to expedite the development of personalized screening tests for multiple types of cancer indications. For more information, see “<span style="font-style: italic;">Information about Freenome—Key Collaborations—Exact Collaboration and License Agreement</span>.” </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Market Opportunity.</span> The Special Committee and the PCSC Board believe that Freenome’s technology has a significant market opportunity. The Special Committee and the PCSC Board believe that Freenome has promising and differentiated diagnostic blood-based test programs, built off of the components of Freenome’s artificial intelligence and machine learning-based platform. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Experienced Leadership Team.</span> The Special Committee and the PCSC Board believe that Freenome has a proven and experienced team that is positioned to successfully lead New Freenome after the Business Combination and advance its diagnostic tests. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Transaction Proceeds.</span> Depending on the extent of redemptions by PCSC’s public shareholders and on the final amount of transaction expenses incurred in connection with the Business Combination, the Business Combination is expected to provide up to approximately $330 million of gross cash proceeds to New Freenome. This additional cash injection is expected to, among other things, fund New Freenome’s business plan through 2028 in all four redemption scenarios. For more information, see “<span style="font-style: italic; font-weight: bold;">Unaudited Pro Forma Condensed Combined Financial Information</span>.” </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Opinion of the Special Committee’s Financial Advisor. </span>The oral opinion of Scalar (subsequently confirmed in writing) rendered to the Special Committee on December 4, 2025, to the effect that, as of such date and based upon and subject to the Procedures followed, assumptions made, qualifications and limitations on the review undertaken and other matters considered by Scalar in preparing its opinion (attached as <span style="font-weight: bold;">Annex L</span> to this proxy statement/prospectus), the Consideration (as defined in such opinion) to be paid by PCSC to the Freenome Stockholders pursuant to the Business Combination Agreement was fair from a financial point of view to PCSC Class A Shareholders (other than the Excluded Parties) and PCSC, as more fully described below under the caption “<span style="font-style: italic;">Business Combination Proposal—Opinion of Scalar, LLC.</span>” </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">PIPE Equity Commitment.</span> A group of institutional and accredited investors, including certain existing Freenome Stockholders and PCSC Shareholders, have committed $240.0 million in PIPE subscriptions, with those investors who are existing Freenome Stockholders (other than those investors who are existing PCSC Shareholders) subscribing for approximately $72.4 million of the PIPE Financing, those investors who are existing PCSC Shareholders (other than those investors who are existing Freenome Stockholders) subscribing for approximately $15.0 million of the PIPE Financing, those investors who are existing shareholders of both PCSC and Freenome (other than the Perceptive PIPE Investor) subscribing for approximately $52.6 million of the PIPE Financing, the Perceptive PIPE Investor subscribing for an aggregate of $55.0 million of the PIPE Financing, and those investors who are neither existing Freenome Stockholders nor existing PCSC Shareholders subscribing for $45.0 million of the PIPE Financing. This was </div></td></tr></table><div class="BRDSX_bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">viewed by the Special Committee and the PCSC Board as support from investors for the opportunities represented by the Business Combination, and provides for additional capital for the execution by New Freenome of its business plan after the Business Combination is completed. </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Other Alternatives.</span> The Special Committee and the PCSC Board believed, after a review of other business combination opportunities reasonably available to PCSC, that the proposed Business Combination represents the best potential business combination for PCSC based on its evaluation of Freenome and other potential business combination targets.</div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Due Diligence.</span> PCSC’s management team, with the assistance of PCSC’s financial, legal and regulatory advisors, conducted a due diligence review of Freenome including extensive telephonic and in-person meetings with the management team and advisors of Freenome regarding Freenome and its business plan, operations, prospects, evaluation analyses with respect to the Business Combination, review of material contracts, Freenome’s audited and unaudited financial statements and other material matters as well as general financial, technical, legal, intellectual property, regulatory, tax and accounting due diligence. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Financial Condition.</span> The Special Committee and the PCSC Board reviewed factors such as Freenome’s historical financial results, outlook and business and financial plans. In reviewing these factors, the Special Committee and the PCSC Board believe that Freenome is well positioned in its industry for potential strong future growth and therefore is likely to be positively viewed by public investors. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Reasonableness of Consideration.</span> Following a review of the financial data provided to PCSC, the due diligence of Freenome’s business conducted by PCSC’s management, PCSC’s advisors and the Special Committee’s advisors, including the fairness opinion delivered to the Special Committee by Scalar, and the support for the pre-transaction equity value of Freenome of $725 million that was expressed by PIPE Investors that decided to participate in the PIPE Financing, the management of PCSC determined that the aggregate consideration to be paid in the Business Combination was reasonable. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Negotiated Transaction.</span> The Special Committee and the PCSC Board considered the terms and conditions of the Business Combination Agreement and the related agreements and the transactions contemplated thereby, including each party’s representations, warranties and covenants, the conditions to each party’s obligation to consummate the Business Combination and the termination provisions of the Business Combination Agreement, as well as the strong commitment by both PCSC and Freenome to complete the Business Combination. The Special Committee and the PCSC Board also considered the financial and other terms of the Business Combination Agreement and the fact that such terms and conditions were the product of arm’s length negotiations between PCSC and Freenome. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Post-Closing Economic Interest in New Freenome.</span> If the Business Combination is consummated, PCSC’s shareholders (other than the public shareholders that sought redemption of their public shares) would have a meaningful economic interest in New Freenome and, as a result, would have a continuing opportunity to benefit from the success of New Freenome following the consummation of the Business Combination. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Lock-Up.</span> Pursuant to the Lock-up Agreement and subject to customary exceptions set forth therein, the shares of New Freenome Common Stock beneficially owned or owned of record by the Sponsor, the Perceptive PIPE Investor, certain officers and directors of PCSC and New Freenome (including any shares of New Freenome Common Stock issued pursuant to the PIPE Financing or shares of New Freenome Common Stock issued pursuant to the Business Combination Agreement) will be subject to a six-month lock-up period beginning on the Closing Date.</div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Industry and Trends.</span> Freenome’s business approach combines a multiomics platform that analyzes multiple signals in the blood with artificial intelligence and machine learning to tune into cancer’s subtlest clues, even at the earliest stages of the disease. The Special Committee and the PCSC Board consider Freenome’s novel approach towards cancer detection attractive, and, following a review of industry trends and other industry factors (including, among other things, historic and projected market growth), believe it has continued growth potential in future periods. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Advisor Special Purpose Acquisition Company Experience.</span> The fact that PCSC received advice on financial and strategic matters in connection with the Business Combination from advisors that have expertise in a wide </div></td></tr></table><div class="BRDSX_bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">variety of special purpose acquisition company transactions. Certain directors and officers of PCSC have held director and officer positions at multiple special purpose acquisition companies that have successfully completed business combinations in the healthcare industry. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Special Committee and the PCSC Board also identified and considered a variety of factors and risks, potentially weighing negatively against pursuing the Business Combination, including, but not limited to, the following which are not weighted or in any order of significance:</div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Macroeconomic Risks.</span> The risk that the future financial performance of Freenome may not meet the Special Committee’s and the PCSC Board’s expectations due to factors in Freenome’s control or outside of its control. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Regulation.</span> The risk that changes in the regulatory and legislative landscape or new industry developments may adversely affect the financial results and the other business benefits anticipated to result from the Business Combination. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Redemption Risk.</span> The potential that a significant number of public shareholders elect to redeem their shares prior to the consummation of the Business Combination and pursuant to the Existing Governing Documents. However, even in the event that a significant number of public shareholders elect to redeem their shares, this redemption would not be expected to, on its own, prevent the consummation of the Business Combination.</div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Benefits Not Achieved.</span> The risk that the potential benefits of the Business Combination may not be fully achieved or may not be achieved within the expected timeframe.</div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Exclusivity.</span> The fact that the Business Combination Agreement includes an exclusive dealing provision that prohibits PCSC from soliciting or cooperating with other business combination proposals, which restricts PCSC’s ability, so long as the Business Combination Agreement is in effect, to consider other potential business combinations. In addition, under the Business Combination Agreement, unless required by applicable law, the PCSC Board may not modify or withdraw in a manner adverse to Freenome its recommendation to the PCSC shareholders to vote in favor of the Business Combination Proposal and the other proposals set forth in this proxy statement/prospectus. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Shareholder Vote. </span>The risk that PCSC’s shareholders may fail to provide the votes necessary to effect the Business Combination. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Market Volatility.</span> The possibility that the market for PCSC Class A Shares experiences volatility and disruptions, causing deal disruption.</div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Liquidation of PCSC.</span> The risks and costs to PCSC if the Business Combination is not completed, including the risk of diverting management focus and resources from other business combination opportunities, which could result in PCSC being unable to effect a business combination by June 13, 2026, unless otherwise extended, and force PCSC to liquidate. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Closing Conditions. </span>The potential risks and costs associated with the Business Combination failing to be consummated in a timely manner or that Closing might not occur despite the reasonable best efforts of the parties. The completion of the Business Combination is conditioned on the satisfaction of certain Closing conditions that are not within PCSC’s control, including but not limited to approval by PCSC shareholders. See “<span style="font-style: italic;">Business Combination Proposal—Conditions to Closing of the Business Combination</span>” for more information. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Listing Risks.</span> The challenges associated with preparing Freenome, a privately held entity, for the applicable disclosure, controls and listing requirements to which New Freenome will be subject as a publicly traded company on Nasdaq or another stock exchange. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Fees and Expenses. </span>The expected fees and expenses associated with the Business Combination and related transactions, some of which would be payable regardless of whether the Business Combination is ultimately consummated, and the substantial time and effort of management required to complete the Business Combination.</div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Litigation Related to the Business Combination. </span>The possibility of litigation challenging the Business Combination or that an adverse judgment granting permanent injunctive relief could indefinitely enjoin consummation of the Business Combination. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Interests of Certain Persons. </span>The Special Committee was aware that the Perceptive PIPE Investor is an investor in Freenome. The Special Committee was also aware that the Sponsor, the Perceptive PIPE Investor, and PCSC’s officers, and directors may have interests in the Business Combination that are in addition to, and that may be different from, the interests of unaffiliated PCSC shareholders. For instance, the Sponsor will benefit from the completion of a business combination and may be incentivized to complete an acquisition of a less favorable target company or on terms less favorable to shareholders. Such interests are described in more detail under the caption “<span style="font-style: italic;">The Business Combination—Interests of the Sponsor, the Perceptive PIPE Investor, and PCSC’s Directors and Officers in the Business Combination.</span>” The PCSC Board took several steps to mitigate these potential conflicts of interest, including establishing the Special Committee, comprised of three independent directors of PCSC, and requiring Special Committee approval of the Business Combination as a condition precedent to the PCSC Board’s approval of the Business Combination. The Special Committee also engaged Scalar to render an opinion and engaged Ropes &amp; Gray and Maples as separate legal counsel to the Special Committee. Additionally, the Perceptive PIPE Investor’s designee on the Freenome Board recused herself from Freenome Board discussions regarding the Business Combination. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Public Shareholders Will Have a Minority Ownership Interest in New Freenome. </span>The fact that current public shareholders will experience immediate dilution as a consequence of the issuance of New Freenome Common Stock as consideration in the Business Combination and, as a result, such public shareholders will collectively own a minority interest in New Freenome after the Closing. As redemptions increase, the overall percentage ownership and voting percentage held by the Freenome stockholders, the Sponsor, the Perceptive PIPE Investor and the PIPE Investors will increase as compared to the overall percentage ownership and voting percentage held by public shareholders, thereby increasing dilution to public shareholders. Having a minority ownership interest may reduce the influence that current public shareholders have on the management of New Freenome. For more information, see “<span style="font-style: italic;">The Business Combination—Equity Ownership Upon Closing</span>” and “<span style="font-style: italic;">Dilution</span>.”</div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Absence of Possible Structural Protections for Minority Shareholders. </span>The PCSC Board took several steps to mitigate potential conflicts of interest, including requiring Special Committee approval of the Business Combination as a condition precedent to the PCSC Board’s approval of the Business Combination. However, other possible structural protections were not put in place. For example, the Business Combination does not require approval of a majority of unaffiliated security holders, and the Special Committee did not retain an unaffiliated representative to act solely on behalf of unaffiliated security holders for purposes of negotiating the terms of the Business Combination or to prepare a report concerning the approval of the Business Combination. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Other Risks. </span>Various other risks associated with the Business Combination, the business of PCSC and the business of Freenome described under the section entitled “<span style="font-style: italic; font-weight: bold;">Risk Factors</span>.” </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In recommending the Business Combination to PCSC shareholders, the Special Committee considered each of the above factors along with Scalar’s opinion described below under the heading “<span style="font-style: italic;">Opinion of Scalar, LLC</span>.” </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Special Committee and the PCSC Board concluded that the potential benefits that they expected PCSC and its shareholders to achieve as a result of the Business Combination outweighed the potentially negative factors associated with the Business Combination. Accordingly, the Special Committee and the PCSC Board determined that the Business Combination Agreement, the Business Combination and the other transactions contemplated by the Business Combination Agreement and consummated in connection with the Business Combination, are advisable and in the best interests of PCSC and its shareholders, as a whole.</div> <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">The Special Committee’s and the PCSC Board’s Reasons for the Approval of the Business Combination </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The prospectus for PCSC’s initial public offering identified general criteria and guidelines that PCSC’s management team believed would be important in evaluating prospective target businesses, although in such prospectus PCSC also indicated that it may enter into a business combination with a target business that does not meet these criteria and guidelines. Freenome met a number of the criteria and guidelines that were identified in PCSC’s initial public offering prospectus, and following due diligence conducted by PCSC’s management and its advisors, and detailed discussions with Freenome, PCSC believed Freenome to be an attractive business combination target. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Special Committee and the PCSC Board, in evaluating the business combination with Freenome, (a) considered a wide variety of factors, including but not limited to, the factors discussed below, (b) reviewed the results of due diligence conducted by PCSC’s management team, and (c) consulted with their respective legal counsel, financial and accounting advisors and other advisors, before reaching their respective determinations (i) that the terms and conditions of the Business Combination Agreement and the ancillary documents thereto and the transactions contemplated thereby, including the Business Combination, are advisable and in the best interests of PCSC and its shareholders, as a whole, and (ii) to recommend that PCSC’s shareholders approve the Business Combination Agreement, the consummation of the transactions contemplated thereby and the performance by PCSC of its obligations thereunder. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In light of the complexity of the factors considered in connection with their evaluation of the Business Combination, the Special Committee and the PCSC Board, as a whole, did not consider it practicable to, and did not attempt to, quantify or otherwise assign relative weights to the specific factors taken into account in reaching their respective decisions. Rather, the Special Committee and the PCSC Board based their evaluation, negotiation and recommendation of the Business Combination on the totality of information available and the factors presented to and considered by them. In addition, individual members of the Special Committee and the PCSC Board may have given different weights to different factors. This explanation of the reasons for the Special Committee and the PCSC Board’s approval of the Business Combination, and all other information presented in this section is forward-looking in nature and, therefore, should be read in light of the factors discussed under “<span style="font-style: italic; font-weight: bold;">Cautionary Note Regarding Forward-Looking Statements</span>” and “<span style="font-style: italic; font-weight: bold;">Risk Factors</span>.” </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Before reaching their respective decision, the Special Committee and the PCSC Board, in consultation with their respective legal counsel, financial and accounting advisors and other advisors, reviewed the results of the due diligence conducted by PCSC’s management, which included: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">meetings with Freenome’s management team to understand and analyze Freenome’s business and prospects; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">legal due diligence conducted by Cooley; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">review of Freenome’s historical financial information; and </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">review of the proposed structure of the Business Combination and drafts of definitive documents. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In approving the Business Combination, the Special Committee determined to obtain a fairness opinion from an experienced and qualified independent financial advisor, Scalar. In addition, the officers and directors of PCSC have substantial experience in evaluating the operating and financial merits of companies from a wide range of industries, but particularly the healthcare and life sciences industries, and concluded that their experience and background, together </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">with the experience and sector expertise of PCSC’s advisors and the advisors of the Special Committee, enabled them to make the necessary analyses and determinations regarding the Business Combination. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Special Committee and the PCSC Board considered a variety of factors, including the following positive factors, although not weighted or in any order of significance, in deciding to approve the Business Combination Agreement and transactions contemplated thereby: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Novel Technology for Early Cancer Detection, with Positive Data.</span> Freenome’s commercial, flagship testing product, the SimpleScreen CRC v1, which is designed to deliver high sensitivity at the earliest and most treatable stages of colorectal cancer (CRC), is supported by the largest prospective study of its kind, PREEMPT CRC, which met all primary endpoints (topline readout completed in April 2024) and is designed to meet FDA requirements for a first-line label. Freenome has completed the premarket approval application submission for the SimpleScreen CRC v1 and expects FDA approval in 2026. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Critical and Valuable Commercial Partnerships.</span> The Special Committee and the PCSC Board believe that (i) Freenome’s exclusive U.S. license agreement with Exact Sciences, a leading provider of cancer screening and diagnostic tests, to commercialize SimpleScreen CRC and (ii) Freenome’s exclusive agreement with Roche to expand ongoing technology collaboration and develop and commercialize cancer screening tests outside the U.S., will accelerate market adoption of Freenome’s diagnostic tests and enhance Freenome’s overall screening platform to expedite the development of personalized screening tests for multiple types of cancer indications. For more information, see “<span style="font-style: italic;">Information about Freenome—Key Collaborations—Exact Collaboration and License Agreement</span>.” </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Market Opportunity.</span> The Special Committee and the PCSC Board believe that Freenome’s technology has a significant market opportunity. The Special Committee and the PCSC Board believe that Freenome has promising and differentiated diagnostic blood-based test programs, built off of the components of Freenome’s artificial intelligence and machine learning-based platform. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Experienced Leadership Team.</span> The Special Committee and the PCSC Board believe that Freenome has a proven and experienced team that is positioned to successfully lead New Freenome after the Business Combination and advance its diagnostic tests. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Transaction Proceeds.</span> Depending on the extent of redemptions by PCSC’s public shareholders and on the final amount of transaction expenses incurred in connection with the Business Combination, the Business Combination is expected to provide up to approximately $330 million of gross cash proceeds to New Freenome. This additional cash injection is expected to, among other things, fund New Freenome’s business plan through 2028 in all four redemption scenarios. For more information, see “<span style="font-style: italic; font-weight: bold;">Unaudited Pro Forma Condensed Combined Financial Information</span>.” </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Opinion of the Special Committee’s Financial Advisor. </span>The oral opinion of Scalar (subsequently confirmed in writing) rendered to the Special Committee on December 4, 2025, to the effect that, as of such date and based upon and subject to the Procedures followed, assumptions made, qualifications and limitations on the review undertaken and other matters considered by Scalar in preparing its opinion (attached as <span style="font-weight: bold;">Annex L</span> to this proxy statement/prospectus), the Consideration (as defined in such opinion) to be paid by PCSC to the Freenome Stockholders pursuant to the Business Combination Agreement was fair from a financial point of view to PCSC Class A Shareholders (other than the Excluded Parties) and PCSC, as more fully described below under the caption “<span style="font-style: italic;">Business Combination Proposal—Opinion of Scalar, LLC.</span>” </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">PIPE Equity Commitment.</span> A group of institutional and accredited investors, including certain existing Freenome Stockholders and PCSC Shareholders, have committed $240.0 million in PIPE subscriptions, with those investors who are existing Freenome Stockholders (other than those investors who are existing PCSC Shareholders) subscribing for approximately $72.4 million of the PIPE Financing, those investors who are existing PCSC Shareholders (other than those investors who are existing Freenome Stockholders) subscribing for approximately $15.0 million of the PIPE Financing, those investors who are existing shareholders of both PCSC and Freenome (other than the Perceptive PIPE Investor) subscribing for approximately $52.6 million of the PIPE Financing, the Perceptive PIPE Investor subscribing for an aggregate of $55.0 million of the PIPE Financing, and those investors who are neither existing Freenome Stockholders nor existing PCSC Shareholders subscribing for $45.0 million of the PIPE Financing. This was </div></td></tr></table><div class="BRDSX_bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">viewed by the Special Committee and the PCSC Board as support from investors for the opportunities represented by the Business Combination, and provides for additional capital for the execution by New Freenome of its business plan after the Business Combination is completed. </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Other Alternatives.</span> The Special Committee and the PCSC Board believed, after a review of other business combination opportunities reasonably available to PCSC, that the proposed Business Combination represents the best potential business combination for PCSC based on its evaluation of Freenome and other potential business combination targets.</div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Due Diligence.</span> PCSC’s management team, with the assistance of PCSC’s financial, legal and regulatory advisors, conducted a due diligence review of Freenome including extensive telephonic and in-person meetings with the management team and advisors of Freenome regarding Freenome and its business plan, operations, prospects, evaluation analyses with respect to the Business Combination, review of material contracts, Freenome’s audited and unaudited financial statements and other material matters as well as general financial, technical, legal, intellectual property, regulatory, tax and accounting due diligence. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Financial Condition.</span> The Special Committee and the PCSC Board reviewed factors such as Freenome’s historical financial results, outlook and business and financial plans. In reviewing these factors, the Special Committee and the PCSC Board believe that Freenome is well positioned in its industry for potential strong future growth and therefore is likely to be positively viewed by public investors. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Reasonableness of Consideration.</span> Following a review of the financial data provided to PCSC, the due diligence of Freenome’s business conducted by PCSC’s management, PCSC’s advisors and the Special Committee’s advisors, including the fairness opinion delivered to the Special Committee by Scalar, and the support for the pre-transaction equity value of Freenome of $725 million that was expressed by PIPE Investors that decided to participate in the PIPE Financing, the management of PCSC determined that the aggregate consideration to be paid in the Business Combination was reasonable. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Negotiated Transaction.</span> The Special Committee and the PCSC Board considered the terms and conditions of the Business Combination Agreement and the related agreements and the transactions contemplated thereby, including each party’s representations, warranties and covenants, the conditions to each party’s obligation to consummate the Business Combination and the termination provisions of the Business Combination Agreement, as well as the strong commitment by both PCSC and Freenome to complete the Business Combination. The Special Committee and the PCSC Board also considered the financial and other terms of the Business Combination Agreement and the fact that such terms and conditions were the product of arm’s length negotiations between PCSC and Freenome. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Post-Closing Economic Interest in New Freenome.</span> If the Business Combination is consummated, PCSC’s shareholders (other than the public shareholders that sought redemption of their public shares) would have a meaningful economic interest in New Freenome and, as a result, would have a continuing opportunity to benefit from the success of New Freenome following the consummation of the Business Combination. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Lock-Up.</span> Pursuant to the Lock-up Agreement and subject to customary exceptions set forth therein, the shares of New Freenome Common Stock beneficially owned or owned of record by the Sponsor, the Perceptive PIPE Investor, certain officers and directors of PCSC and New Freenome (including any shares of New Freenome Common Stock issued pursuant to the PIPE Financing or shares of New Freenome Common Stock issued pursuant to the Business Combination Agreement) will be subject to a six-month lock-up period beginning on the Closing Date.</div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Industry and Trends.</span> Freenome’s business approach combines a multiomics platform that analyzes multiple signals in the blood with artificial intelligence and machine learning to tune into cancer’s subtlest clues, even at the earliest stages of the disease. The Special Committee and the PCSC Board consider Freenome’s novel approach towards cancer detection attractive, and, following a review of industry trends and other industry factors (including, among other things, historic and projected market growth), believe it has continued growth potential in future periods. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Advisor Special Purpose Acquisition Company Experience.</span> The fact that PCSC received advice on financial and strategic matters in connection with the Business Combination from advisors that have expertise in a wide </div></td></tr></table><div class="BRDSX_bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">variety of special purpose acquisition company transactions. Certain directors and officers of PCSC have held director and officer positions at multiple special purpose acquisition companies that have successfully completed business combinations in the healthcare industry. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Special Committee and the PCSC Board also identified and considered a variety of factors and risks, potentially weighing negatively against pursuing the Business Combination, including, but not limited to, the following which are not weighted or in any order of significance:</div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Macroeconomic Risks.</span> The risk that the future financial performance of Freenome may not meet the Special Committee’s and the PCSC Board’s expectations due to factors in Freenome’s control or outside of its control. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Regulation.</span> The risk that changes in the regulatory and legislative landscape or new industry developments may adversely affect the financial results and the other business benefits anticipated to result from the Business Combination. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Redemption Risk.</span> The potential that a significant number of public shareholders elect to redeem their shares prior to the consummation of the Business Combination and pursuant to the Existing Governing Documents. However, even in the event that a significant number of public shareholders elect to redeem their shares, this redemption would not be expected to, on its own, prevent the consummation of the Business Combination.</div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Benefits Not Achieved.</span> The risk that the potential benefits of the Business Combination may not be fully achieved or may not be achieved within the expected timeframe.</div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Exclusivity.</span> The fact that the Business Combination Agreement includes an exclusive dealing provision that prohibits PCSC from soliciting or cooperating with other business combination proposals, which restricts PCSC’s ability, so long as the Business Combination Agreement is in effect, to consider other potential business combinations. In addition, under the Business Combination Agreement, unless required by applicable law, the PCSC Board may not modify or withdraw in a manner adverse to Freenome its recommendation to the PCSC shareholders to vote in favor of the Business Combination Proposal and the other proposals set forth in this proxy statement/prospectus. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Shareholder Vote. </span>The risk that PCSC’s shareholders may fail to provide the votes necessary to effect the Business Combination. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Market Volatility.</span> The possibility that the market for PCSC Class A Shares experiences volatility and disruptions, causing deal disruption.</div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Liquidation of PCSC.</span> The risks and costs to PCSC if the Business Combination is not completed, including the risk of diverting management focus and resources from other business combination opportunities, which could result in PCSC being unable to effect a business combination by June 13, 2026, unless otherwise extended, and force PCSC to liquidate. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Closing Conditions. </span>The potential risks and costs associated with the Business Combination failing to be consummated in a timely manner or that Closing might not occur despite the reasonable best efforts of the parties. The completion of the Business Combination is conditioned on the satisfaction of certain Closing conditions that are not within PCSC’s control, including but not limited to approval by PCSC shareholders. See “<span style="font-style: italic;">Business Combination Proposal—Conditions to Closing of the Business Combination</span>” for more information. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Listing Risks.</span> The challenges associated with preparing Freenome, a privately held entity, for the applicable disclosure, controls and listing requirements to which New Freenome will be subject as a publicly traded company on Nasdaq or another stock exchange. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Fees and Expenses. </span>The expected fees and expenses associated with the Business Combination and related transactions, some of which would be payable regardless of whether the Business Combination is ultimately consummated, and the substantial time and effort of management required to complete the Business Combination.</div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Litigation Related to the Business Combination. </span>The possibility of litigation challenging the Business Combination or that an adverse judgment granting permanent injunctive relief could indefinitely enjoin consummation of the Business Combination. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Interests of Certain Persons. </span>The Special Committee was aware that the Perceptive PIPE Investor is an investor in Freenome. The Special Committee was also aware that the Sponsor, the Perceptive PIPE Investor, and PCSC’s officers, and directors may have interests in the Business Combination that are in addition to, and that may be different from, the interests of unaffiliated PCSC shareholders. For instance, the Sponsor will benefit from the completion of a business combination and may be incentivized to complete an acquisition of a less favorable target company or on terms less favorable to shareholders. Such interests are described in more detail under the caption “<span style="font-style: italic;">The Business Combination—Interests of the Sponsor, the Perceptive PIPE Investor, and PCSC’s Directors and Officers in the Business Combination.</span>” The PCSC Board took several steps to mitigate these potential conflicts of interest, including establishing the Special Committee, comprised of three independent directors of PCSC, and requiring Special Committee approval of the Business Combination as a condition precedent to the PCSC Board’s approval of the Business Combination. The Special Committee also engaged Scalar to render an opinion and engaged Ropes &amp; Gray and Maples as separate legal counsel to the Special Committee. Additionally, the Perceptive PIPE Investor’s designee on the Freenome Board recused herself from Freenome Board discussions regarding the Business Combination. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Public Shareholders Will Have a Minority Ownership Interest in New Freenome. </span>The fact that current public shareholders will experience immediate dilution as a consequence of the issuance of New Freenome Common Stock as consideration in the Business Combination and, as a result, such public shareholders will collectively own a minority interest in New Freenome after the Closing. As redemptions increase, the overall percentage ownership and voting percentage held by the Freenome stockholders, the Sponsor, the Perceptive PIPE Investor and the PIPE Investors will increase as compared to the overall percentage ownership and voting percentage held by public shareholders, thereby increasing dilution to public shareholders. Having a minority ownership interest may reduce the influence that current public shareholders have on the management of New Freenome. For more information, see “<span style="font-style: italic;">The Business Combination—Equity Ownership Upon Closing</span>” and “<span style="font-style: italic;">Dilution</span>.”</div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Absence of Possible Structural Protections for Minority Shareholders. </span>The PCSC Board took several steps to mitigate potential conflicts of interest, including requiring Special Committee approval of the Business Combination as a condition precedent to the PCSC Board’s approval of the Business Combination. However, other possible structural protections were not put in place. For example, the Business Combination does not require approval of a majority of unaffiliated security holders, and the Special Committee did not retain an unaffiliated representative to act solely on behalf of unaffiliated security holders for purposes of negotiating the terms of the Business Combination or to prepare a report concerning the approval of the Business Combination. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Other Risks. </span>Various other risks associated with the Business Combination, the business of PCSC and the business of Freenome described under the section entitled “<span style="font-style: italic; font-weight: bold;">Risk Factors</span>.” </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In recommending the Business Combination to PCSC shareholders, the Special Committee considered each of the above factors along with Scalar’s opinion described below under the heading “<span style="font-style: italic;">Opinion of Scalar, LLC</span>.” </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Special Committee and the PCSC Board concluded that the potential benefits that they expected PCSC and its shareholders to achieve as a result of the Business Combination outweighed the potentially negative factors associated with the Business Combination. Accordingly, the Special Committee and the PCSC Board determined that the Business Combination Agreement, the Business Combination and the other transactions contemplated by the Business Combination Agreement and consummated in connection with the Business Combination, are advisable and in the best interests of PCSC and its shareholders, as a whole.</div> <table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Novel Technology for Early Cancer Detection, with Positive Data.</span> Freenome’s commercial, flagship testing product, the SimpleScreen CRC v1, which is designed to deliver high sensitivity at the earliest and most treatable stages of colorectal cancer (CRC), is supported by the largest prospective study of its kind, PREEMPT CRC, which met all primary endpoints (topline readout completed in April 2024) and is designed to meet FDA requirements for a first-line label. Freenome has completed the premarket approval application submission for the SimpleScreen CRC v1 and expects FDA approval in 2026. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Critical and Valuable Commercial Partnerships.</span> The Special Committee and the PCSC Board believe that (i) Freenome’s exclusive U.S. license agreement with Exact Sciences, a leading provider of cancer screening and diagnostic tests, to commercialize SimpleScreen CRC and (ii) Freenome’s exclusive agreement with Roche to expand ongoing technology collaboration and develop and commercialize cancer screening tests outside the U.S., will accelerate market adoption of Freenome’s diagnostic tests and enhance Freenome’s overall screening platform to expedite the development of personalized screening tests for multiple types of cancer indications. For more information, see “<span style="font-style: italic;">Information about Freenome—Key Collaborations—Exact Collaboration and License Agreement</span>.” </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Market Opportunity.</span> The Special Committee and the PCSC Board believe that Freenome’s technology has a significant market opportunity. The Special Committee and the PCSC Board believe that Freenome has promising and differentiated diagnostic blood-based test programs, built off of the components of Freenome’s artificial intelligence and machine learning-based platform. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Experienced Leadership Team.</span> The Special Committee and the PCSC Board believe that Freenome has a proven and experienced team that is positioned to successfully lead New Freenome after the Business Combination and advance its diagnostic tests. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Transaction Proceeds.</span> Depending on the extent of redemptions by PCSC’s public shareholders and on the final amount of transaction expenses incurred in connection with the Business Combination, the Business Combination is expected to provide up to approximately $330 million of gross cash proceeds to New Freenome. This additional cash injection is expected to, among other things, fund New Freenome’s business plan through 2028 in all four redemption scenarios. For more information, see “<span style="font-style: italic; font-weight: bold;">Unaudited Pro Forma Condensed Combined Financial Information</span>.” </div></td></tr></table> <table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Opinion of the Special Committee’s Financial Advisor. </span>The oral opinion of Scalar (subsequently confirmed in writing) rendered to the Special Committee on December 4, 2025, to the effect that, as of such date and based upon and subject to the Procedures followed, assumptions made, qualifications and limitations on the review undertaken and other matters considered by Scalar in preparing its opinion (attached as <span style="font-weight: bold;">Annex L</span> to this proxy statement/prospectus), the Consideration (as defined in such opinion) to be paid by PCSC to the Freenome Stockholders pursuant to the Business Combination Agreement was fair from a financial point of view to PCSC Class A Shareholders (other than the Excluded Parties) and PCSC, as more fully described below under the caption “<span style="font-style: italic;">Business Combination Proposal—Opinion of Scalar, LLC.</span>” </div></td></tr></table> <table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">PIPE Equity Commitment.</span> A group of institutional and accredited investors, including certain existing Freenome Stockholders and PCSC Shareholders, have committed $240.0 million in PIPE subscriptions, with those investors who are existing Freenome Stockholders (other than those investors who are existing PCSC Shareholders) subscribing for approximately $72.4 million of the PIPE Financing, those investors who are existing PCSC Shareholders (other than those investors who are existing Freenome Stockholders) subscribing for approximately $15.0 million of the PIPE Financing, those investors who are existing shareholders of both PCSC and Freenome (other than the Perceptive PIPE Investor) subscribing for approximately $52.6 million of the PIPE Financing, the Perceptive PIPE Investor subscribing for an aggregate of $55.0 million of the PIPE Financing, and those investors who are neither existing Freenome Stockholders nor existing PCSC Shareholders subscribing for $45.0 million of the PIPE Financing. This was </div></td></tr></table><div class="BRDSX_bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">viewed by the Special Committee and the PCSC Board as support from investors for the opportunities represented by the Business Combination, and provides for additional capital for the execution by New Freenome of its business plan after the Business Combination is completed. </div> <table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">PIPE Equity Commitment.</span> A group of institutional and accredited investors, including certain existing Freenome Stockholders and PCSC Shareholders, have committed $240.0 million in PIPE subscriptions, with those investors who are existing Freenome Stockholders (other than those investors who are existing PCSC Shareholders) subscribing for approximately $72.4 million of the PIPE Financing, those investors who are existing PCSC Shareholders (other than those investors who are existing Freenome Stockholders) subscribing for approximately $15.0 million of the PIPE Financing, those investors who are existing shareholders of both PCSC and Freenome (other than the Perceptive PIPE Investor) subscribing for approximately $52.6 million of the PIPE Financing, the Perceptive PIPE Investor subscribing for an aggregate of $55.0 million of the PIPE Financing, and those investors who are neither existing Freenome Stockholders nor existing PCSC Shareholders subscribing for $45.0 million of the PIPE Financing. This was </div></td></tr></table><div class="BRDSX_bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">viewed by the Special Committee and the PCSC Board as support from investors for the opportunities represented by the Business Combination, and provides for additional capital for the execution by New Freenome of its business plan after the Business Combination is completed. </div> <table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Due Diligence.</span> PCSC’s management team, with the assistance of PCSC’s financial, legal and regulatory advisors, conducted a due diligence review of Freenome including extensive telephonic and in-person meetings with the management team and advisors of Freenome regarding Freenome and its business plan, operations, prospects, evaluation analyses with respect to the Business Combination, review of material contracts, Freenome’s audited and unaudited financial statements and other material matters as well as general financial, technical, legal, intellectual property, regulatory, tax and accounting due diligence. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Financial Condition.</span> The Special Committee and the PCSC Board reviewed factors such as Freenome’s historical financial results, outlook and business and financial plans. In reviewing these factors, the Special Committee and the PCSC Board believe that Freenome is well positioned in its industry for potential strong future growth and therefore is likely to be positively viewed by public investors. </div></td></tr></table> <table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Reasonableness of Consideration.</span> Following a review of the financial data provided to PCSC, the due diligence of Freenome’s business conducted by PCSC’s management, PCSC’s advisors and the Special Committee’s advisors, including the fairness opinion delivered to the Special Committee by Scalar, and the support for the pre-transaction equity value of Freenome of $725 million that was expressed by PIPE Investors that decided to participate in the PIPE Financing, the management of PCSC determined that the aggregate consideration to be paid in the Business Combination was reasonable. </div></td></tr></table> <table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Public Shareholders Will Have a Minority Ownership Interest in New Freenome. </span>The fact that current public shareholders will experience immediate dilution as a consequence of the issuance of New Freenome Common Stock as consideration in the Business Combination and, as a result, such public shareholders will collectively own a minority interest in New Freenome after the Closing. As redemptions increase, the overall percentage ownership and voting percentage held by the Freenome stockholders, the Sponsor, the Perceptive PIPE Investor and the PIPE Investors will increase as compared to the overall percentage ownership and voting percentage held by public shareholders, thereby increasing dilution to public shareholders. Having a minority ownership interest may reduce the influence that current public shareholders have on the management of New Freenome. For more information, see “<span style="font-style: italic;">The Business Combination—Equity Ownership Upon Closing</span>” and “<span style="font-style: italic;">Dilution</span>.”</div></td></tr></table> false false false <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Benefits and Detriments of the Business Combination and PIPE Financing </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The following describes the potential benefits and detriments to certain groups of stakeholders in connection with the Business Combination and PIPE Financing: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">PCSC: </span>The PCSC Board and the Special Committee determined that the Business Combination presents an attractive business opportunity in light of a variety of factors, including but not limited to Freenome’s novel technology for early cancer detection, critical and valuable commercial partnerships, commercialization strategy, market opportunity, experienced leadership team, and the existence and size of the PIPE Financing. The Special Committee also reviewed the financial analysis and opinion of Scalar to the effect that, as of December 4, 2025 and based upon and subject to the assumptions, limitations, qualifications and other </div></td></tr></table><div class="BRDSX_bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">conditions on the review undertaken, the consideration to be delivered to the Freenome Stockholders in the First Merger pursuant to the Business Combination Agreement was fair from a financial point of view to PCSC and the PCSC Unaffiliated Shareholders. The Special Committee and the PCSC Board also considered the potential detriments of the Business Combination to PCSC, including the regulatory risks, the uncertainty of the potential benefits of the Business Combination being achieved, macroeconomic risks, the absence of possible structural protections for minority shareholders, and the risks and costs to PCSC if the Business Combination is not achieved, including the risk that it may result in PCSC being unable to complete a business combination and force PCSC to liquidate. For more information, see “— <span style="font-style: italic;">The Special Committee’s and the PCSC Board’s Reasons for the Approval of the Business Combination</span>,” and various risks described under the section entitled “<span style="font-style: italic;">Risk Factors.</span>” </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Sponsor and the Perceptive PIPE Investor:</span> The Sponsor and the Perceptive PIPE Investor expect to receive substantial consideration in the Business Combination, including the following shares, calculated assuming the Aggregate Transaction Proceeds Condition Redemptions Scenario: (i) 2,066,250 shares of New Freenome Common Stock upon the exchange of 2,066,250 PCSC Class B Shares in the Domestication, which were initially purchased by the Sponsor prior to PCSC’s initial public offering for approximately $0.01 per share, and which will be voluntarily converted on a one-for-one basis into PCSC Class A Shares immediately prior to the Domestication, which will then automatically convert at the effective time of the Domestication into an equal number of shares of New Freenome Common Stock, valued at $10 per share, which is the assumed per share price used in the Business Combination pursuant to the Business Combination Agreement, (ii) 286,250 shares of New Freenome Common Stock upon the exchange of 286,250 PCSC Class A Shares in the Domestication, which were initially purchased in a private placement that closed concurrently with PCSC’s initial public offering for $10 per share, which will automatically convert at the effective time of the Domestication into an equal number of shares of New Freenome Common Stock valued at $10 per share, which is the assumed per share price used in the Business Combination pursuant to the Business Combination Agreement, (iii) 5,500,000 shares of New Freenome Common Stock, which is equal to the Perceptive PIPE Investor’s $55 million PIPE Financing divided by $10, the price per share of New Freenome Common Stock to be issued pursuant to the PIPE Financing, and (v) an estimated 5,615,003 shares of New Freenome Common Stock upon the exchange of Freenome capital stock in the First Merger held by the Perceptive PIPE Investor, which is determined by reference to the estimated Conversion Ratio using the assumed per share price of $10 in the Business Combination pursuant to the Business Combination Agreement. The Sponsor and its affiliates, including Perceptive Advisors, LLC, are also entitled to continued indemnification by New Freenome following the Closing pursuant to the terms of the Business Combination Agreement. The Sponsor is also entitled to the repayment of any Working Capital Lonas made by the Sponsor (of which there are none as of the date of this proxy statement/prospectus) and the payment of $15,000 per month by PCSC to the Sponsor for office space, secretarial and administrative services pursuant to the Administrative Services and Indemnification Agreement dated June 11, 2024, by and between PCSC and the Sponsor. For more information, see “—<span style="font-style: italic;"> Compensation to be Received by the Sponsor, the Perceptive PIPE Investor, and PCSC’s Officers and Directors in Connection with the Business Combination and PIPE Financing.</span>” The Sponsor will only be able to realize a return on their equity in PCSC (which may be materially higher than the return realized by public shareholders) if PCSC completes a business combination. In addition, the Sponsor faces potential detriments from the Business Combination, including the possibility of litigation challenging the Business Combination or the Sponsor’s role in the Business Combination, and the risk that if the Business Combination is not achieved, PCSC may be unable to consummate a business combination and be forced to liquidate, resulting in the Sponsor’s investment being worthless. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">PCSC Independent Directors: </span>PCSC’s independent directors (Messrs. McKenna, Song and Waksal) each own 30,000 PCSC Class B Shares, which will be exchanged for 30,000 shares of New Freenome Common Stock in the Domestication. Such persons have waived any claim against the trust account for redemption of such PCSC Class B Shares. PCSC’s independent directors are also entitled to the repayment of any out-of-pocket expenses (of which there are none as of the date of this proxy statement/prospectus). Accordingly, in the event that PCSC liquidates, the PCSC independent directors may lose their entire investment. In addition, the PCSC directors face potential detriments from the Business Combination, including the possibility of litigation challenging the Business Combination or such directors’ roles in the Business Combination. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">Freenome: </span>The Freenome Board and the Freenome Strategic Transaction Committee determined that the Business Combination presents an attractive business opportunity in light of certain factors, including that the Business Combination will expand both the access to capital for Freenome and the range of investors potentially available to Freenome as a public company, and taking into account Freenome’s expected cash resources and need for additional capital to fund the development of its diagnostic tests, and the uniqueness of this particular potential Business Combination, as the negotiated transaction will result in the infusion of capital at the time of Closing. The Freenome Strategic Transaction Committee and Freenome Board also considered the potential detriments of the Business Combination to Freenome, including the possibility that the Business Combination might not be completed in a timely manner or at all, the uncertainty of the potential benefits of the Business Combination being achieved, the costs involved in connection with completing the Business Combination, and the time and effort of Freenome management required to complete the Business Combination. For more information, see “— <span style="font-style: italic;">Freenome’s Reasons for the Business Combination</span>” and various risks described under the section entitled “<span style="font-style: italic;">Risk Factors.</span>” </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Unaffiliated PCSC public shareholders: <span style="font-style: normal; font-weight: normal;">The unaffiliated public shareholders have the opportunity to evaluate and consider whether or not to redeem their public shares in connection with the consummation of the Business Combination. Non-redeeming public shareholders will have the opportunity to participate in the potential future growth of Freenome, but may face a number of potential detriments in connection with their continued investment, including the uncertainties and risks identified by the PCSC Board described more fully in “— </span><span style="font-weight: normal;">The Special Committee’s and the PCSC Board’s Reasons for Approval of the Business Combination</span><span style="font-style: normal; font-weight: normal;">,” the various other risks associated with the Business Combination, the business of PCSC and the business of Freenome, as described further under the section entitled “</span><span style="font-weight: normal;">Risk Factors,</span><span style="font-style: normal; font-weight: normal;">” the potential conflicts of interest described under “— </span><span style="font-weight: normal;">Interests of the Sponsor, the Perceptive PIPE Investor, and PCSC’s Directors and Officers in the Business Combination,</span><span style="font-style: normal; font-weight: normal;">” and the potential material dilution they may experience as described more fully in the section entitled “</span><span style="font-weight: normal;">Dilution.</span><span style="font-style: normal; font-weight: normal;">” Redeeming public shareholders have the opportunity to receive their pro rata share of the aggregate amount on deposit in the trust account, less taxes paid and payable, calculated as of two business days prior to the consummation of the Business Combination. However, redeeming public shareholders face the potential of not realizing any future growth in value of Freenome following the Business Combination. </span></div> <table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">PCSC: </span>The PCSC Board and the Special Committee determined that the Business Combination presents an attractive business opportunity in light of a variety of factors, including but not limited to Freenome’s novel technology for early cancer detection, critical and valuable commercial partnerships, commercialization strategy, market opportunity, experienced leadership team, and the existence and size of the PIPE Financing. The Special Committee also reviewed the financial analysis and opinion of Scalar to the effect that, as of December 4, 2025 and based upon and subject to the assumptions, limitations, qualifications and other </div></td></tr></table><div class="BRDSX_bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">conditions on the review undertaken, the consideration to be delivered to the Freenome Stockholders in the First Merger pursuant to the Business Combination Agreement was fair from a financial point of view to PCSC and the PCSC Unaffiliated Shareholders. The Special Committee and the PCSC Board also considered the potential detriments of the Business Combination to PCSC, including the regulatory risks, the uncertainty of the potential benefits of the Business Combination being achieved, macroeconomic risks, the absence of possible structural protections for minority shareholders, and the risks and costs to PCSC if the Business Combination is not achieved, including the risk that it may result in PCSC being unable to complete a business combination and force PCSC to liquidate. For more information, see “— <span style="font-style: italic;">The Special Committee’s and the PCSC Board’s Reasons for the Approval of the Business Combination</span>,” and various risks described under the section entitled “<span style="font-style: italic;">Risk Factors.</span>” </div> <table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">PCSC: </span>The PCSC Board and the Special Committee determined that the Business Combination presents an attractive business opportunity in light of a variety of factors, including but not limited to Freenome’s novel technology for early cancer detection, critical and valuable commercial partnerships, commercialization strategy, market opportunity, experienced leadership team, and the existence and size of the PIPE Financing. The Special Committee also reviewed the financial analysis and opinion of Scalar to the effect that, as of December 4, 2025 and based upon and subject to the assumptions, limitations, qualifications and other </div></td></tr></table><div class="BRDSX_bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">conditions on the review undertaken, the consideration to be delivered to the Freenome Stockholders in the First Merger pursuant to the Business Combination Agreement was fair from a financial point of view to PCSC and the PCSC Unaffiliated Shareholders. The Special Committee and the PCSC Board also considered the potential detriments of the Business Combination to PCSC, including the regulatory risks, the uncertainty of the potential benefits of the Business Combination being achieved, macroeconomic risks, the absence of possible structural protections for minority shareholders, and the risks and costs to PCSC if the Business Combination is not achieved, including the risk that it may result in PCSC being unable to complete a business combination and force PCSC to liquidate. For more information, see “— <span style="font-style: italic;">The Special Committee’s and the PCSC Board’s Reasons for the Approval of the Business Combination</span>,” and various risks described under the section entitled “<span style="font-style: italic;">Risk Factors.</span>” </div> <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Opinion of Scalar, LLC </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On December 4, 2025, at a meeting of the Special Committee, Scalar rendered its oral opinion to the Special Committee, subsequently confirmed in writing, as to the fairness, from a financial point of view, as of such date, to (1) the PCSC Class A Shareholders (for purposes of such opinion and this summary, other than Freenome, the Sponsor, the Key Supporting Company Stockholders, the holders of PCSC Class A Shares who elect to redeem their shares prior to or in connection with the Business Combination, and the PIPE Investors, which we refer to collectively as the Excluded Parties) and (2) PCSC, of the Consideration (as defined in such opinion) to be paid by PCSC to the Freenome stockholders pursuant to the Business Combination Agreement (without giving effect to any impact of the Business Combination on any particular PCSC Class A Shareholder other than in its capacity as a PCSC Class A Shareholder), based upon and subject to the procedures followed, assumptions made, qualifications and limitations on the review undertaken, and other matters considered by Scalar in preparing its opinion. For purposes of Scalar’s opinion and this summary, the “<span style="font-weight: bold;">Consideration</span>” consisted of the total number of shares of New Freenome Common Stock to be issued for the shares of common stock and preferred stock of Freenome (collectively, “<span style="font-weight: bold;">Company Shares</span>”). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The full text of Scalar’s written opinion, dated December 4, 2025, which sets forth the procedures followed, assumptions made, matters considered, qualifications and limitations on the review undertaken, and other matters considered by Scalar in connection with the opinion, is attached to this proxy statement/prospectus as <span style="text-decoration:underline">Annex L</span>. The summary of Scalar’s opinion in this proxy statement/prospectus is qualified in its entirety by reference to the full text of Scalar’s written opinion. Scalar’s opinion was provided for the information and assistance of Special Committee and does not constitute a recommendation as to how any stockholder of PCSC should vote or act (including with respect to any redemption rights) with respect to the Business Combination or any other matter.<span style="font-weight: normal;"> </span></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In arriving at its opinion, Scalar, among other things: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewed a draft of the agreed form, dated November 12, 2025, of the Sponsor Letter Agreement; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewed a draft, dated December 3, 2025, of the Business Combination Agreement; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewed a draft, dated November 3, 2025, of the Investor Subscription Agreements (the drafts described in these first three bullets, the “<span style="font-weight: bold;">Reviewed Transaction Documents</span>”); </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewed certain publicly available business and financial information relating to PCSC and the Company; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewed certain historical financial information and other data relating to the Company that were provided to Scalar by the management of PCSC, approved for our use by PCSC and not publicly available; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewed certain management data relating to the business prospects of the Company that were provided to Scalar by the management of PCSC, approved for Scalar’s use by PCSC and not publicly available; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">conducted discussions with members of the senior management of the Company concerning the business, operations, historical financial results and financial prospects of the Company and its addressable market and the Business Combination; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewed current and historical market prices of the PCSC Class A Shares; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewed certain financial and market data of the Company and compared that data with publicly available data for certain other companies similar to Freenome; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewed certain pro forma effects relating to the Business Combination, including estimated transaction costs and the effects of anticipated financings, approved for Scalar’s use by PCSC; and </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">conducted such other financial studies, analyses and investigations, and considered such other information, as Scalar deemed necessary or appropriate. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In performing its analysis and rendering its opinion, with PCSC’s consent, Scalar relied upon and assumed, without assuming liability or responsibility for independent verification, the accuracy and completeness of information that was publicly available or was furnished, or otherwise made available to Scalar or discussed with or reviewed by Scalar. Scalar further relied upon the assurances of the management of PCSC that the financial information provided had been prepared on a reasonable basis in accordance with industry practice, and that they were not aware of any information or facts that would make any information provided to Scalar inaccurate, incomplete or misleading. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Scalar assumed that the Business Combination will have the tax consequences described in discussions with, and materials furnished to Scalar by, representatives of the Company or PCSC, including that (i) the Domestication qualifies as a “reorganization” within the meaning of Section 368(a)(1)(F) of the Code, (ii) the Mergers, taken together, will be treated as an integrated transaction that qualifies as a “reorganization” within the meaning of Section 368 of the Code, and (iii) the Mergers and the PIPE Financing, taken together, will be treated as an integrated transaction qualifying under Section 351(a) of the Code and Treasury Regulations promulgated thereunder. Scalar is not a legal, accounting, regulatory, or tax expert and its opinion does not address any legal, regulatory, taxation, or accounting matters, as to which Scalar understood that PCSC obtained such advice as it deemed necessary from qualified professionals, and Scalar assumed the accuracy and veracity of all assessments made by such advisors to the Company or PCSC with respect to such matters. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In arriving at its opinion, with PCSC’s consent and without independent verification, Scalar relied upon and assumed that except as would not be in any way meaningful to Scalar’s analysis: (a) the final form of each of the Reviewed Transaction Documents, as executed by the parties thereto, will not differ from the drafts that Scalar reviewed, (b) the representations and warranties of all parties to the Business Combination Agreement, and any related transaction documents, are correct and that such parties will comply with and perform all covenants and agreements required to be complied with or performed by such parties under the Business Combination Agreement and any related transaction documents, (c) the Business Combination will be consummated in accordance with the terms of the Business Combination Agreement and related transaction documents, without any waiver or amendment of any term or condition thereof, and (d) there had been no material change in the assets, financial condition, business or prospects of any party to the Business Combination Agreement since the date of the most recent financial statements and other information made available to Scalar. Additionally, Scalar assumed that all governmental, regulatory or other third-party approvals and consents necessary for the consummation of the Business Combination or otherwise contemplated by the Business Combination Agreement will be obtained without delay, limitation, restriction or condition and otherwise in a way that will not have any adverse effect on the Company or PCSC, or on the expected benefits of the Business Combination, in any way meaningful to Scalar’s analysis. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In addition, Scalar relied upon (without independent verification and without expressing any view, opinion, representation, guaranty or warranty (in each case, express or implied)) the assessments, judgments and estimates of PCSC’s senior management and the Company’s senior management as to, among other things, (a) the potential impact on the Company of market, competitive and other trends in and prospects for, and governmental, regulatory and legislative matters relating to or affecting, the industry in which the Company operates and related industries, (b) the Company’s existing and future products, services, technology and intellectual property and the associated risks thereto (including, without limitation, the probabilities and timing of successful development and marketing thereof; the timing of successful regulatory approvals and clearances; compliance with relevant regulatory requirements; and the potential impact of competition thereon) and (c) PCSC’s and the Company’s existing and future relationships, agreements and arrangements with, and the ability to attract, retain and/or replace, key employees, suppliers and other commercial relationships (in each such case to the extent relevant to the Company, the Business Combination and its contemplated benefits). Scalar assumed that there will not be any developments with respect to any of the foregoing matters that would have an adverse effect on PCSC, the Company or the Business Combination (including the contemplated benefits thereof) or that otherwise would be meaningful in any respect to Scalar’s analyses or opinion. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Given PCSC’s nature as a special purpose acquisition company, for purposes of its opinion and with PCSC’s consent, Scalar assumed a value of $10.61 per PCSC Share in calculating the value of the New Freenome Common Stock to be issued as the Consideration under the Business Combination Agreement, with such $10.61 per share value being based on (a) $91,550,673.98, which was the value of the assets held in PCSC’s Trust Account as of November 30, 2025, divided by (b) 8,625,000, which was the number of outstanding PCSC Class A Shares subject to redemption as of October 31, 2025. In rendering its Opinion, Scalar did not express any view or opinion as to what the value of any PCSC Shares will be when issued pursuant to the Business Combination or the price or range of prices at which any PCSC Class A Shares, PCSC Class B Shares or other securities or financial instruments of or relating to PCSC may trade or otherwise be transferable at any time before or after announcement or consummation of the Business Combination. Additionally, Scalar expressed no opinion with respect to the PCSC Class B Shares and PCSC Preference Shares. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In arriving at its opinion, Scalar did not perform any appraisals or valuations of any specific assets or liabilities (fixed, contingent or other) of the Company or PCSC and Scalar was not furnished or provided with any such appraisals or valuations, nor did Scalar evaluate the solvency of the Company or PCSC under any state or federal law relating to bankruptcy, insolvency or similar matters. The analyses performed by Scalar in connection with its Opinion were going concern analyses, assuming the Business Combination was consummated in accordance with the terms of the Business Combination Agreement. Scalar did not undertake any independent analysis of any pending or threatened litigation, regulatory action, possible unasserted claims or other contingent liabilities, to which the Company or PCSC was a party or may be subject, and at PCSC’s direction and with PCSC’s consent, Scalar’s opinion made no assumption concerning, and therefore did not consider, the possible assertion of claims, outcomes or damages arising out of any such matters. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Scalar’s opinion was necessarily based upon economic, monetary, market, and other conditions as in effect on, the information available to Scalar as of, and the facts and circumstances as they existed on, the date of Scalar’s written opinion and Scalar’s opinion speaks only as of such date; events occurring after that date could materially affect the assumptions used in preparing Scalar’s opinion. Scalar has not undertaken to update, reaffirm, or revise its opinion or otherwise comment upon any events occurring after the date of Scalar’s written opinion, material information provided to Scalar after that date, or any change in facts or circumstances that occurred after that date, and Scalar does not have any obligation to update, revise, or reaffirm its opinion. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Scalar’s opinion did not address PCSC’s underlying business decision to engage in the Business Combination, the relative merits of the Business Combination as compared to other business or investment strategies or transactions that might be available to PCSC, or whether the Consideration to be delivered to Freenome stockholders pursuant to the Business Combination Agreement represents the best price obtainable. In connection with Scalar’s engagement, Scalar was not requested to, and did not, solicit interest from other parties with respect to an acquisition of, or other business combination with, PCSC or any other alternative transaction. Scalar’s opinion addressed only the fairness from a financial point of view, as of the date thereof, to PCSC Class A Shareholders (other than the Excluded Parties) of the Consideration to be paid by PCSC to the Freenome stockholders pursuant to the Business Combination Agreement. Scalar was not asked to, and did not, offer any opinion as to the terms, other than the Consideration to the extent expressly specified therein, of the Business Combination Agreement or any related documents or the form of the Business Combination or any related transaction (including any agreement or transaction between any Excluded Party and the Company or PCSC), including the fairness of the Business Combination to, or any consideration received in connection therewith by, any Excluded Parties, the holders of any class of securities, creditors, or other constituencies </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">of PCSC, the Company, or any of their respective affiliates. Scalar was not asked to, and did not, offer any opinion with respect to any ongoing obligations of the Company, PCSC, or any of their respective affiliates (including any obligations with respect to governance, appraisal rights, preemptive rights, registration rights, voting rights, or otherwise) contained in any Reviewed Transaction Documents, any other agreement related to the Business Combination, or under applicable law, any allocation of the Consideration (or any portion thereof), or the fair market value of the Company, PCSC, PCSC’s ordinary shares, or the Company Shares. In addition, Scalar expressed no opinion as to the fairness of the amount or nature of any compensation to be received by any officers, directors, or employees of any parties to the Business Combination, any Excluded Parties, or any class of such persons, whether relative to the Consideration or otherwise. Scalar’s opinion (i) did not address the individual circumstances of specific holders of PCSC’s securities (including PCSC Class B Shares and PCSC Preference Shares) with respect to rights or aspects which may distinguish such holders or PCSC’s securities (including PCSC Class B Shares and PCSC Preference Shares) held by such holders, (ii) did not address, take into consideration or give effect to any existing or future rights, preferences, restrictions or limitations or other attributes of any such securities (including PCSC Class B Shares and PCSC Preference Shares) or holders (including the Sponsor), (iii) did not address any impact of the Business Combination on any particular PCSC Class A Shareholder other than in its capacity as a PCSC Class A Shareholder, and (iv) did not in any way address proportionate allocation or relative fairness (including, without limitation, the allocation of any consideration among or within any classes or groups of security holders or other constituents of PCSC or any other party). Scalar also did not address, or express a view with respect to, any acquisition of control or effective control of PCSC by any stockholder or group of stockholders of the Company. Scalar’s opinion should not be construed as creating any fiduciary duty of Scalar (or any of its affiliates) to any party. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Scalar’s opinion was provided for the information and assistance of the Special Committee (in its capacity as such) in connection with, and for the purpose of, its evaluation of the Business Combination, and does not constitute a recommendation to any stockholder as to how such stockholder should vote or act (including with respect to any redemption rights) with respect to the Business Combination or any other matter. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Summary of Scalar’s Financial Analysis </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The following is a summary of the material financial analyses delivered by Scalar to the Special Committee in connection with rendering the opinion described above. <span style="font-weight: bold;">The summary set forth below does not purport to be a complete description of the financial analyses performed or factors considered by, and underlying the opinion of, Scalar, nor does the order of the financial analyses described represent the relative importance or weight given to those financial analyses by Scalar. Scalar may have deemed various assumptions more or less probable than other assumptions, so the reference ranges resulting from any particular portion of the analyses summarized below should not be taken to be Scalar’s view of the actual value of the Company. Some of the summaries of the financial analyses set forth below include information presented in tabular format. In order to fully understand the financial analyses, the tables must be read together with the text of each summary, as the tables alone do not constitute a complete description of the financial analyses performed by Scalar. Considering the data in the tables below without considering all financial analyses or factors or the full narrative description of such analyses or factors, including the methodologies and assumptions underlying such analyses or factors, could create a misleading or incomplete view of the processes underlying Scalar’s financial analyses and its opinion.</span> </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In performing its analyses, Scalar made numerous assumptions with respect to industry performance, primarily that the market conditions, the competitive landscape, and the regulatory environment for the Company’s products would remain unchanged, and assumptions related to general business and economic conditions and other matters, many of which are beyond the control of PCSC, the Company, or any other parties to the Business Combination. These analyses do not purport to be appraisals or reflect the prices at which businesses or securities may actually be sold. Accordingly, the assumptions and estimates used in, and the results derived from, the financial analyses are inherently subject to substantial uncertainty. Except as otherwise noted, the following quantitative information, to the extent that it is based on market data, is based on market data as it existed on November 30, 2025, and is not necessarily indicative of current market conditions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Assumed Value of New Freenome Common Stock<span style="font-style: normal;"> </span></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Given PCSC’s nature as a special purpose acquisition company, for purposes of its opinion and with PCSC’s consent, Scalar assumed a value of $10.61 per PCSC Share in calculating the value of the New Freenome Common Stock to be issued as the Consideration under the Business Combination Agreement, with such $10.61 per share value being based on (a) $91,550,673.98, which was the value of the assets held in PCSC’s Trust Account as of November 30, </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">2025, divided by (b) 8,625,000, which was the number of outstanding PCSC Class A Shares subject to redemption as of October 31, 2025. In rendering its opinion, Scalar did not express any view or opinion as to what the value of any PCSC Shares will be when issued pursuant to the Business Combination or the price or range of prices at which any PCSC Class A Shares, PCSC Class B Shares or other securities or financial instruments of or relating to PCSC may trade or otherwise be transferable at any time before or after announcement or consummation of the Business Combination. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">License Agreement Multiples Analysis<span style="font-style: normal;"> </span></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Scalar reviewed certain financial data for selected companies with publicly traded equity securities that had announced license agreements that Scalar deemed relevant for purposes of this analysis based on various factors, including the companies’ product offerings within the biotech industry and their business model. The financial data reviewed included: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Licensor enterprise value as of seven days prior to announcement, or “<span style="font-weight: bold;">Licensor EV Pre-Announcement</span>”; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Licensor enterprise value as of 30 days post-announcement, or “<span style="font-weight: bold;">Licensor EV Post-Announcement</span>”; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The announced nominal value of the potential license payments the licensor could receive pursuant to the license agreement, or “<span style="font-weight: bold;">Potential License Payments</span>”; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The change in enterprise value between the Licensor EV Pre-Announcement and the Licensor EV Post-Announcement, or “<span style="font-weight: bold;">Change in EV</span>”; and </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Change in EV divided by the Potential License Payments, or “<span style="font-weight: bold;">Implied Multiple</span>.” </div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The selected licensors and corresponding financial data included the following: </div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 126pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 35.56pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 66.49pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 69.3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 45pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 45pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 29.33pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 126pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">($ in thousands)<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="font-style: normal; font-weight: bold;">Selected Licensors</span></div></td><td style="width: 4.28pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 35.56pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Date</div></td><td style="width: 4.28pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 66.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Licensor EV <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Pre-Announcement</div></td><td style="width: 4.28pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 69.3pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Licensor EV <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Post-Announcement</div></td><td style="width: 4.28pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Potential <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">License <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Payments</div></td><td style="width: 4.28pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in EV </div></td><td style="width: 4.28pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 29.33pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Implied <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Multiple </div></td></tr><tr><td style="width: 126pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Rani Therapeutics, LLC</div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 35.56pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">10/19/25</div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 66.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.25pt; text-align: left;">$<span style="padding-left: 17.5pt;">25,382</span></div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 69.3pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.84pt; text-align: left;">$<span style="padding-left: 12.13pt;">186,707</span></div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 7.5pt;">185,000</span></div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$<span style="padding-left: 7.5pt;">161,325</span></div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 29.33pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.87x </div></td></tr><tr><td style="width: 126pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Arrowhead Pharmaceuticals, Inc.</div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 35.56pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">09/02/25</div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 66.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.25pt; text-align: left;">$<span style="padding-left: 5pt;">2,628,202</span></div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 69.3pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.84pt; text-align: left;">$<span style="padding-left: 4.63pt;">4,483,618</span></div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$2,200,000</div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$1,855,416</div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 29.33pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.84x </div></td></tr><tr><td style="width: 126pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">IDEAYA Biosciences, Inc.</div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 35.56pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">09/02/25</div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 66.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.25pt; text-align: left;">$<span style="padding-left: 5pt;">1,186,953</span></div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 69.3pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.84pt; text-align: left;">$<span style="padding-left: 4.63pt;">1,392,039</span></div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 7.5pt;">530,000</span></div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$<span style="padding-left: 7.5pt;">205,086</span></div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 29.33pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.39x </div></td></tr><tr><td style="width: 126pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">BioArctic AB (publ)</div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 35.56pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">08/26/25</div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 66.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.25pt; text-align: left;">$<span style="padding-left: 5pt;">2,100,615</span></div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 69.3pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.84pt; text-align: left;">$<span style="padding-left: 4.63pt;">2,523,069</span></div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 7.5pt;">802,000</span></div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$<span style="padding-left: 7.5pt;">422,454</span></div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 29.33pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.53x </div></td></tr><tr><td style="width: 126pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Jazz Pharmaceuticals plc</div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 35.56pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">08/20/25</div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 66.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.25pt; text-align: left;">$10,798,568</div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 69.3pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.84pt; text-align: left;">$11,476,733</div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$1,035,000</div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$<span style="padding-left: 7.5pt;">678,165</span></div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 29.33pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.66x </div></td></tr><tr><td style="width: 126pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Kymera Therapeutics, Inc.</div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 35.56pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">06/25/25</div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 66.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.25pt; text-align: left;">$<span style="padding-left: 5pt;">2,252,135</span></div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 69.3pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.84pt; text-align: left;">$<span style="padding-left: 4.63pt;">2,440,795</span></div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 7.5pt;">750,000</span></div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$<span style="padding-left: 7.5pt;">188,660</span></div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 29.33pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.25x </div></td></tr><tr><td style="width: 126pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Agenus Inc.</div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 35.56pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">06/03/25</div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 66.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.25pt; text-align: left;">$<span style="padding-left: 12.5pt;">133,828</span></div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 69.3pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.84pt; text-align: left;">$<span style="padding-left: 12.13pt;">202,918</span></div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 7.5pt;">141,000</span></div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$<span style="padding-left: 12.5pt;">69,090</span></div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 29.33pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.49x </div></td></tr><tr><td style="width: 126pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Bio-Thera Solutions, Ltd.</div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 35.56pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">02/10/25</div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 66.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.25pt; text-align: left;">$<span style="padding-left: 5pt;">1,098,540</span></div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 69.3pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.84pt; text-align: left;">$<span style="padding-left: 4.63pt;">1,169,853</span></div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 7.5pt;">164,500</span></div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$<span style="padding-left: 12.5pt;">71,312</span></div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 29.33pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.43x </div></td></tr><tr><td style="width: 126pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Valneva SE</div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 35.56pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">12/19/24</div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 66.49pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.25pt; text-align: left;">$<span style="padding-left: 12.5pt;">360,695</span></div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 69.3pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.84pt; text-align: left;">$<span style="padding-left: 12.13pt;">392,508</span></div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 12.5pt;">41,300</span></div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$<span style="padding-left: 12.5pt;">31,813</span></div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 29.33pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.77x</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 126pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 35.56pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 66.49pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 69.3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 45pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 45pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 29.33pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Taking into account the results of the license agreement multiples analysis, Scalar applied a selected multiple range of 0.65x to 0.85x, which is within the range of observed implied multiples. Scalar observed a positive correlation between the Potential License Payments and the Implied Multiples, and Scalar noted that the total Announced Potential Value of Freenome’s license agreements ranked within the top quartile of the observed data. Given the total Announced Potential Value of Freenome’s license agreements and its positioning within the observed dataset, Scalar selected a 0.75x multiple as the midpoint of the range. The selected range of 0.65x and 0.85x is supported by the Implied Multiples from the selected licensors, and aligns with the third quartile and top quartile of the Implied Multiples that Scalar observed. These multiples are applied to the license agreement between Freenome and Exact Sciences with remaining announced potential value of $760 million, and estimated a remaining value between $494 million and $646 million for this license agreement. The $760 million figure is the result of reducing the total announced $885 million potential value for the $50 million convertible note investment received by Freenome and for the $75 million upfront cash payment Freenome received in November 2025 from Exact Sciences pursuant to this license agreement. Scalar, based on its own expertise, applied the selected multiple range of 0.65x and 0.85x to the license agreement between Freenome and Roche with remaining announced potential value of $134 million, and estimated a value between $87 million and $114 million for this license agreement. The $134 million figure is the result of reducing the total announced $209 million potential value for the $75 million convertible note that Freenome has already received from Roche. Scalar summed the aforementioned Exact Sciences license agreement and Roche license agreement values, and concluded a total value of Freenome’s license agreements between $581 million and $760 million and added pro forma net cash of $552 million, which was the sum of (i) the $60.2 million in cash on Freenome’s balance sheet as of June 30, 2025, (ii) an assumed </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">$250 million of proceeds from the PIPE Financing, as directed by PCSC management, (iii) the $75 million proceeds from Roche’s convertible note investment into Freenome, (iv) the $50 million proceeds from Exact Sciences Convertible Note investment into Freenome, (v) the $75 million upfront payment by Exact Sciences to Freenome pursuant to the Exact Sciences license agreement, and (vi) the $91.6 million in cash in the Trust Account as of November 30, 2025, less the $50 million of debt on Freenome’s balance sheet as of June 30, 2025, to the total value of Freenome’s license agreements to calculate implied total equity value. The license agreement multiples analysis indicated implied total equity value reference ranges for Freenome of approximately $1,133,000,000 to $1,312,000,000, as compared to the fully-diluted value of the Consideration (as described and calculated below under “—<span style="font-style: italic;">Pro Forma Consideration Analysis</span>”) of $1,259,657,005<span style="font-style: italic;">.</span> </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Scalar noted that the fully-diluted value of the Consideration was within the above range, which in Scalar’s view supported its assessment of the fairness, from a financial point of view, of the Consideration to (1) the PCSC Class A Shareholders (other than the Excluded Parties) and (2) PCSC. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Cost to Recreate Analysis – All Assets<span style="font-style: normal;"> </span></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Scalar reviewed Freenome’s research and development expenses beginning January 1, 2021 and ending June 30, 2025. Research and development expenses incurred before 2021 were excluded on the basis that earlier development efforts were no longer relevant due to significant advancements in the underlying technology. The analysis included: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Freenome’s research and development expense for annual periods, or “<span style="font-weight: bold;">R&amp;D Expense</span>”; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The estimated required rate of return on R&amp;D Expense, or “<span style="font-weight: bold;">Yearly Return</span>”; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The product of Time Elapsed and Yearly Return, or “<span style="font-weight: bold;">Total Expected Return</span>”; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The product of R&amp;D Expense and Total Expected Return, or “<span style="font-weight: bold;">Entrepreneurial Incentive</span>”; and </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The sum of the R&amp;D Expense and the Entrepreneurial Incentive, or “<span style="font-weight: bold;">Cost to Recreate</span>” </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As an illustrative example, the analysis, with an assumed Yearly Return of 25%, follows: </div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 96pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 51.99pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 27.11pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 24.43pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 31.54pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 55.26pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 37.5pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 96pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Period Ending*</div></td><td style="width: 12.01pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 51.99pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; margin-top: 0pt; text-align: center;">($ in thousands)<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; margin-top: 0pt; text-align: center;"><span style="font-style: normal; font-weight: bold;">R&amp;D </span><br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; margin-top: 0pt; text-align: center;"><span style="font-style: normal; font-weight: bold;">Expense</span></div></td><td style="width: 12.01pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 27.11pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Time <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Elapsed <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(years)</div></td><td style="width: 12.01pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.43pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Yearly <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Return</div></td><td style="width: 12.01pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 31.54pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Expected <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Return</div></td><td style="width: 12.01pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 55.26pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Entrepreneurial <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Incentive</div></td><td style="width: 12.01pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 37.5pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Cost to <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Recreate </div></td></tr><tr><td style="width: 96pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December 31, 2021</div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 51.99pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.26pt; text-align: left;">$147,123 </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 27.11pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.31pt; text-align: left;">3.9 </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.43pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.47pt; text-align: left;">25.0% </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 31.54pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.02pt; text-align: left;">97.9% </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 55.26pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.88pt; text-align: left;">$144,058 </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 37.5pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$291,181 </div></td></tr><tr><td style="width: 96pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December 31, 2022</div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 51.99pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.26pt; text-align: left;">$164,151 </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 27.11pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.31pt; text-align: left;">2.9 </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.43pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.47pt; text-align: left;">25.0% </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 31.54pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.02pt; text-align: left;">72.9% </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 55.26pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.88pt; text-align: left;">$<span style="padding-left: 0.37pt;">119,693</span> </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 37.5pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$283,844 </div></td></tr><tr><td style="width: 96pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December 31, 2023</div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 51.99pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.26pt; text-align: left;">$228,255 </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 27.11pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.31pt; text-align: left;">1.9 </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.43pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.47pt; text-align: left;">25.0% </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 31.54pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.02pt; text-align: left;">47.9% </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 55.26pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.88pt; text-align: left;">$109,372 </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 37.5pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$337,627 </div></td></tr><tr><td style="width: 96pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December 31, 2024</div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 51.99pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.26pt; text-align: left;">$225,749 </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 27.11pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.31pt; text-align: left;">0.9 </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.43pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.47pt; text-align: left;">25.0% </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 31.54pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.02pt; text-align: left;">22.9% </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 55.26pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.88pt; text-align: left;">$<span style="padding-left: 5pt;">51,734</span> </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 37.5pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$277,483 </div></td></tr><tr><td style="width: 96pt; padding-top: 0.51pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">June 30, 2025</div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 51.99pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.26pt; text-align: left;">$<span style="padding-left: 5pt;">94,866</span> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 27.11pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.31pt; text-align: left;">0.4 </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.43pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.47pt; text-align: left;">25.0% </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 31.54pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.02pt; text-align: left;">10.4% </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 55.26pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.88pt; text-align: left;">$<span style="padding-left: 10pt;">9,882</span> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 37.5pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$104,748</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 96pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 51.99pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 27.11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 24.43pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 31.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 55.26pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 37.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">All periods begin January 1 of the respective year </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Obsolescence Adjustment Support<span style="font-style: normal;"> </span></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Scalar reviewed certain financial data for selected transactions that Scalar deemed relevant for purposes of the cost to recreate analysis to support an obsolescence adjustment to account for R&amp;D Expense that is attributable to obsolete parts of Freenome’s product and technology. The analysis includes companies that were acquired in the selected transactions, which Scalar chose based on various factors, such as the acquired companies’ product offerings within the biotech industry and their business model. The financial data reviewed included: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The estimated period over which the applicable asset is expected to contribute a company’s future cash flows before becoming obsolete, or “<span style="font-weight: bold;">Useful Life</span>”; and </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The inverse of the Useful Life, or “<span style="font-weight: bold;">Annual Obsolescence</span>” </div></td></tr></table><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 264pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 58.43pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 37.54pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 72.65pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 264pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Acquired Company</div></td><td style="width: 5.89pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 58.43pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Transaction Year</div></td><td style="width: 5.89pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 37.54pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Useful Life</div></td><td style="width: 5.89pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 72.65pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual Obsolescence </div></td></tr><tr><td style="width: 264pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Curetis N.V.</div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 58.43pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.22pt; text-align: left;">2020</div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 37.54pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.77pt; text-align: left;">10 </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 72.65pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.58pt; text-align: left;">10.0% </div></td></tr><tr><td style="width: 264pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Genomic Health, Inc.</div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 58.43pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.22pt; text-align: left;">2019</div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 37.54pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.77pt; text-align: left;">10 </div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 72.65pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.58pt; text-align: left;">10.0% </div></td></tr><tr><td style="width: 264pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">HD Biosciences Co., Ltd.</div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 58.43pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.22pt; text-align: left;">2017</div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 37.54pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.77pt; text-align: left;">10 </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 72.65pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.58pt; text-align: left;">10.0% </div></td></tr><tr><td style="width: 264pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ipsogen SA</div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 58.43pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.22pt; text-align: left;"><span style="padding-left: 0.37pt;">2011</span></div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 37.54pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.77pt; text-align: left;">10 </div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 72.65pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.58pt; text-align: left;">10.0% </div></td></tr><tr><td style="width: 264pt; padding-top: 0.51pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Boston Biochem, Inc.</div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 58.43pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.22pt; text-align: left;"><span style="padding-left: 0.37pt;">2011</span></div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 37.54pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.77pt; text-align: left;">12 </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 72.65pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.58pt; text-align: left;"><span style="padding-left: 5pt;">8.3%</span> </div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 264pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 58.43pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 37.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 72.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table><table cellpadding="0" class="BRDSX_fintab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 264pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 58.43pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 37.54pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 72.65pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 264pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Acquired Company</div></td><td style="width: 5.89pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 58.43pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Transaction Year</div></td><td style="width: 5.89pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 37.54pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Useful Life</div></td><td style="width: 5.89pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 72.65pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual Obsolescence </div></td></tr><tr><td style="width: 264pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tocris Holdings Ltd.</div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 58.43pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.22pt; text-align: left;"><span style="padding-left: 0.37pt;">2011</span></div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 37.54pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.77pt; text-align: left;">15 </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 72.65pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.58pt; text-align: left;"><span style="padding-left: 5pt;">6.7%</span> </div></td></tr><tr><td style="width: 264pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Astex Therapeutics Ltd.</div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 58.43pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.22pt; text-align: left;"><span style="padding-left: 0.37pt;">2011</span></div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 37.54pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.77pt; text-align: left;"><span style="padding-left: 5pt;">7</span> </div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 72.65pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.58pt; text-align: left;">14.3% </div></td></tr><tr><td style="width: 264pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">SABiosciences Corporation</div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 58.43pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.22pt; text-align: left;">2009</div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 37.54pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.77pt; text-align: left;">10 </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 72.65pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.58pt; text-align: left;">10.0% </div></td></tr><tr><td style="width: 264pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fisher Scientific International Inc.</div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 58.43pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.22pt; text-align: left;">2006</div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 37.54pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.77pt; text-align: left;"><span style="padding-left: 5pt;">9</span> </div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 72.65pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.58pt; text-align: left;"><span style="padding-left: 0.37pt;">11.1%</span> </div></td></tr><tr><td style="width: 264pt; padding-top: 0.51pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Medicis Pharmaceutical Corp.</div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 58.43pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.22pt; text-align: left;">2012</div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 37.54pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.77pt; text-align: left;"><span style="padding-left: 5pt;">5</span> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 72.65pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.58pt; text-align: left;">20.0%</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 264pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 58.43pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 37.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 72.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Based on its review of the acquired companies in the selected transactions, Scalar applied an obsolescence adjustment to the cost to recreate analysis by applying Annual Obsolescence to the cost to recreate analysis. The analysis included: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">100% less the product of Time Elapsed, rounded to the nearest integer, and the Annual Obsolescence, or “<span style="font-weight: bold;">Obsolescence Adjustment</span>”; and </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The product of the Cost to Recreate and Obsolescence Adjustment, or “<span style="font-weight: bold;">Total Cost to Recreate</span>” </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">As an illustrative example, the cost to recreate analysis with an assumed Yearly Return of 25%, with a selected 17.5% Annual Obsolescence applied, follows: </div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 120pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 56.26pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 27.12pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 45.32pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 45.32pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 62.5pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 120pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Period Ending*</div></td><td style="width: 11.15pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 56.26pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; margin-top: 0pt; text-align: center;">($ in thousands)<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; margin-top: 0pt; text-align: center;"><span style="font-style: normal; font-weight: bold;">Cost to Recreate</span></div></td><td style="width: 11.15pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 27.12pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Time <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Elapsed</div></td><td style="width: 11.15pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 45.32pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Obsolescence</div></td><td style="width: 11.15pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 45.32pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Obsolescence <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Adjustment</div></td><td style="width: 11.15pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 62.5pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total Cost <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">to Recreate </div></td></tr><tr><td style="width: 120pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December 31, 2021</div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 56.26pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.38pt; text-align: left;">$291,181 </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 27.12pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.3pt; text-align: left;">3.9 </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45.32pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.91pt; text-align: left;">17.5% </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45.32pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.4pt; text-align: left;"><span style="padding-left: 5pt;">30.0%</span></div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 62.5pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 30pt;">87,354</span> </div></td></tr><tr><td style="width: 120pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December 31, 2022</div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 56.26pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.38pt; text-align: left;">$283,844 </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 27.12pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.3pt; text-align: left;">2.9 </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45.32pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.91pt; text-align: left;">17.5%</div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45.32pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.4pt; text-align: left;"><span style="padding-left: 5pt;">47.5%</span></div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 62.5pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 25pt;">134,826</span> </div></td></tr><tr><td style="width: 120pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December 31, 2023</div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 56.26pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.38pt; text-align: left;">$337,627 </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 27.12pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.3pt; text-align: left;">1.9 </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45.32pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.91pt; text-align: left;">17.5% </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45.32pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.4pt; text-align: left;"><span style="padding-left: 5pt;">65.0%</span></div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 62.5pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 25pt;">219,458</span> </div></td></tr><tr><td style="width: 120pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December 31, 2024</div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 56.26pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.38pt; text-align: left;">$277,483 </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 27.12pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.3pt; text-align: left;">0.9 </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45.32pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.91pt; text-align: left;">17.5%</div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45.32pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.4pt; text-align: left;"><span style="padding-left: 5pt;">82.5%</span></div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 62.5pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 25pt;">228,924</span> </div></td></tr><tr><td style="width: 120pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">June 30, 2025</div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 56.26pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.38pt; text-align: left;">$104,748 </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 27.12pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.3pt; text-align: left;">0.4 </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45.32pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.91pt; text-align: left;">17.5% </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45.32pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.4pt; text-align: left;">100.0%</div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 62.5pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 25pt;">104,748</span> </div></td></tr><tr><td style="width: 120pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Plus: Pro Forma Net Cash</div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 56.26pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 27.12pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45.32pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45.32pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 62.5pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 7.5pt;">551,710,764</span> </div></td></tr><tr><td style="width: 120pt; padding-top: 0.51pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total</div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 56.26pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 27.12pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45.32pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45.32pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 62.5pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$1,327,020,205</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 120pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 56.26pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 27.12pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 45.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 45.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 62.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">All periods begin January 1 of the respective year </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Scalar, based on its own expertise, performed the aforementioned cost to recreate analysis using selected Yearly Returns ranging from 20% to 30%. The selected range was informed by published required rate of return studies, such as the 2025 Pepperdine Private Capital Markets Study that reports required rates of return ranging from 23% to 32% for late-stage companies and the required rates of return studies by Scherlis, et al. and Shalman et al. that suggest a range of 20% to 35% for Bridge/IPO stage companies. The selected range of 20% to 30% falls within the ranges observed in these studies and was selected given the Company’s stage of development. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Scalar selected Annual Obsolescence between 15% and 20%. Using the Yearly Return and Annual Obsolescence inputs, the cost to recreate analysis indicated implied total equity value reference ranges for Freenome of approximately $1,214,000,000 to $1,452,000,000, as compared to the Fully-Diluted Value of the Transaction Consideration (as described and calculated below under “—<span style="font-style: italic;">Pro Forma Consideration Analysis</span>”) of $1,259,657,005<span style="font-style: italic;">.</span> </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Scalar noted that the fully-diluted value of the Consideration was within the above range, which in Scalar’s view supported its assessment of the fairness, from a financial point of view, of the Consideration to (1) the PCSC Class A Shareholders (other than the Excluded Parties) and (2) PCSC. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pro Forma Consideration Analysis<span style="font-style: normal;"> </span></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Utilizing pro forma ownership information provided by PCSC management and the assumptions described above (assuming a value of $10.61 per share of New Freenome Common Stock), Scalar calculated the aggregate implied value of the pro forma shares of New Freenome Common Stock outstanding following the consummation of the Business Combination. These calculations are summarized below: </div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 336pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 45pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 55pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"># of shares</div></td><td style="width: 8pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 55pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value* </div></td></tr><tr><td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">PCSC Class A Shares</div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">8,625,000</span></div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 55pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 5pt;">91,550,674</span> </div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">PCSC Class B Shares</div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">2,156,250</span></div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 55pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">22,887,668</span> </div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">PCSC Class A Private Placement Shares</div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 12.5pt;">286,250</span></div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 55pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 15pt;">3,038,421</span> </div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Shares (“Consideration”)</div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">76,234,625</div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 55pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">809,197,836</span> </div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Roche Investment Shares</div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">6,370,313</span></div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 55pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">67,618,134</span> </div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 45pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 55pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table><table cellpadding="0" class="BRDSX_fintab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 336pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 45pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 55pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"># of shares</div></td><td style="width: 8pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 55pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value* </div></td></tr><tr><td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Perceptive PIPE Investment Shares</div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -4.45pt; text-align: left;"><span style="padding-left: 9.45pt;">2,500,000</span></div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 55pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -7.5pt; text-align: left;"><span style="padding-left: 17.5pt;">26,536,427</span> </div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">RA Capital PIPE Investment Shares</div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -4.45pt; text-align: left;"><span style="padding-left: 9.45pt;">5,000,000</span></div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 55pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -7.5pt; text-align: left;"><span style="padding-left: 17.5pt;">53,072,854</span> </div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Third-Party PIPE Investment Shares</div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -4.45pt; text-align: justify;"><span style="padding-left: 4.45pt;">17,500,000</span></div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 55pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -7.5pt; text-align: left;"><span style="padding-left: 12.5pt;">185,754,991</span> </div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash transaction expenses</div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -4.45pt; text-align: left;"><span style="padding-left: 32.24pt;">N/A</span></div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 55pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -7.5pt; text-align: left;"><span style="padding-left: 17.5pt;">17,625,000</span> </div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fully-Diluted Value of Transaction Consideration</div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -4.45pt; text-align: justify;">118,672,438</div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 55pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -7.5pt; text-align: left;">$1,259,657,005</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 45pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 55pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Value is the product of the # of shares and $10.6145709 </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Scalar noted that the fully-diluted value of the Consideration, as described above, was within the reference ranges calculated in the licensing agreement analysis and the cost to recreate analysis described above, which in Scalar’s view supported its assessment of the fairness, from a financial point of view, of the Consideration to (1) the PCSC Class A Shareholders (other than the Excluded Parties) and (2) PCSC. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Implied Pro Forma Share Value Analysis<span style="font-style: normal;"> </span></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Utilizing the implied total equity value reference ranges for Freenome from the licensing agreement multiples analysis and cost to recreate analysis, the pro forma ownership information provided by PCSC management and the assumptions described above, Scalar calculated the implied pro forma value of a share of New Freenome Common Stock after giving effect to the Business Combination. This analysis took into consideration the impact of the pro forma dilution described above in calculating the fully-diluted value of the Consideration. These calculations are summarized below: </div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 216pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.41pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.41pt;"><div style="font-size: 1pt;"> </div></td><td colspan="7" style="height: 6pt; width: 243.21pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 216pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 4.41pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.41pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td colspan="7" style="width: 243.21pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Implied Pro Forma Value per share of New Freenome Common Stock </div></td></tr><tr class="BRDSX_header"><td style="width: 216pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 4.41pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.41pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 71.98pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Low</div></td><td style="width: 4.41pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.41pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 76.98pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Middle</div></td><td style="width: 4.41pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.41pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 76.61pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">High </div></td></tr><tr><td style="width: 216pt; padding-top: 2.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Average of Pro Forma Value per share of New Freenome Common Stock derived from the licensing agreement multiples analysis and cost to recreate analysis</div></td><td style="width: 4.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 71.98pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.74pt; text-align: left;">$9.89</div></td><td style="width: 4.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 76.98pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.74pt; text-align: left;">$10.73</div></td><td style="width: 4.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 76.61pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.74pt; text-align: left;">$11.65</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 216pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 71.98pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 76.98pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 76.61pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Scalar noted that the assumed value of a share of New Freenome Common Stock of $10.61 was within the reference ranges calculated by the average of the licensing agreement and cost to recreate analyses described above, which in Scalar’s view supported its assessment of the fairness, from a financial point of view, of the Consideration to (1) the PCSC Class A Shareholders (other than the Excluded Parties) and (2) PCSC. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">General<span style="font-style: normal;"> </span></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The preparation of a fairness opinion is a complex process and is not necessarily susceptible to partial analysis or summary description. Selecting portions of the analyses or of the summary set forth above, without considering the analyses as a whole, could create an incomplete view of the processes underlying Scalar’s opinion. In arriving at its fairness determination, Scalar considered the results of all of its analyses and did not attribute any particular weight to any factor or analysis considered by it. Rather, Scalar made its determination as to fairness on the basis of its experience and professional judgment after considering the results of all of its analyses. No company or transaction used in the above analyses as a comparison is directly comparable to PCSC or Freenome or the Business Combination. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Scalar’s financial analyses and opinion were only one of many factors taken into consideration by the Special Committee in its evaluation of the Business Combination. Consequently, the analyses described above should not be viewed as determinative of the views of the Special Committee, the PCSC Board, or management of PCSC with respect to the Consideration or as to whether the Special Committee would have been willing to determine that different consideration was fair to PCSC and its shareholders. The Consideration was determined through arm’s-length negotiations between PCSC and the Company and was approved by the Special Committee and the PCSC Board. Scalar did not advise the PCSC Board during these negotiations, nor did it recommend any specific amount of consideration to PCSC, the Special Committee or the PCSC Board or that any specific amount of consideration constituted the only appropriate consideration for the Business Combination. The foregoing summary does not purport to be a complete description of the analyses performed by Scalar in connection with the fairness opinion and is qualified in its entirety by reference to the written opinion of Scalar attached hereto as <span style="font-weight: bold;">Annex L</span>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Scalar and its affiliates are engaged in transaction advisory, financial reporting, litigation consulting, tax and other financial and non-financial activities and services for various persons and entities. Scalar was engaged by the Special </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Committee to render its opinion to the Special Committee and Scalar received a fee of $225,000 from PCSC for providing its services and rendering its opinion. No portion of these fees was refundable or contingent upon the consummation of the Business Combination or the conclusion reached in Scalar’s opinion. PCSC has also agreed to indemnify Scalar against certain liabilities and reimburse Scalar for certain expenses in connection with Scalar’s services. In the past two years, Scalar and its affiliates have not provided any other advisory services to PCSC or its affiliates for which Scalar and its affiliates received compensation. Since January 1, 2024, Scalar has performed valuation services for affiliates of the Sponsor for which Scalar received approximately $340,000 in aggregate compensation. Scalar and its affiliates may also seek to provide such services to the Company, PCSC, and their respective affiliates in the future and expect to receive fees for the rendering of these services. In the ordinary course of business, certain of Scalar’s employees and affiliates, or entities in which they have invested, may hold or trade, for their own accounts and the accounts of their investors, securities of the Company and PCSC and, accordingly, may at any time hold a long or short position in such securities. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The issuance of Scalar’s opinion was approved by an authorized committee of Scalar. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Special Committee selected Scalar to provide its opinion in connection with the Business Combination based on Scalar’s reputation and experience. Scalar is a valuation firm that has substantial experience in transactions similar to the Business Combination. </div> Scalar, LLC <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On December 4, 2025, at a meeting of the Special Committee, Scalar rendered its oral opinion to the Special Committee, subsequently confirmed in writing, as to the fairness, from a financial point of view, as of such date, to (1) the PCSC Class A Shareholders (for purposes of such opinion and this summary, other than Freenome, the Sponsor, the Key Supporting Company Stockholders, the holders of PCSC Class A Shares who elect to redeem their shares prior to or in connection with the Business Combination, and the PIPE Investors, which we refer to collectively as the Excluded Parties) and (2) PCSC, of the Consideration (as defined in such opinion) to be paid by PCSC to the Freenome stockholders pursuant to the Business Combination Agreement (without giving effect to any impact of the Business Combination on any particular PCSC Class A Shareholder other than in its capacity as a PCSC Class A Shareholder), based upon and subject to the procedures followed, assumptions made, qualifications and limitations on the review undertaken, and other matters considered by Scalar in preparing its opinion. For purposes of Scalar’s opinion and this summary, the “<span style="font-weight: bold;">Consideration</span>” consisted of the total number of shares of New Freenome Common Stock to be issued for the shares of common stock and preferred stock of Freenome (collectively, “<span style="font-weight: bold;">Company Shares</span>”). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The full text of Scalar’s written opinion, dated December 4, 2025, which sets forth the procedures followed, assumptions made, matters considered, qualifications and limitations on the review undertaken, and other matters considered by Scalar in connection with the opinion, is attached to this proxy statement/prospectus as <span style="text-decoration:underline">Annex L</span>. The summary of Scalar’s opinion in this proxy statement/prospectus is qualified in its entirety by reference to the full text of Scalar’s written opinion. Scalar’s opinion was provided for the information and assistance of Special Committee and does not constitute a recommendation as to how any stockholder of PCSC should vote or act (including with respect to any redemption rights) with respect to the Business Combination or any other matter.<span style="font-weight: normal;"> </span></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In arriving at its opinion, Scalar, among other things: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewed a draft of the agreed form, dated November 12, 2025, of the Sponsor Letter Agreement; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewed a draft, dated December 3, 2025, of the Business Combination Agreement; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewed a draft, dated November 3, 2025, of the Investor Subscription Agreements (the drafts described in these first three bullets, the “<span style="font-weight: bold;">Reviewed Transaction Documents</span>”); </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewed certain publicly available business and financial information relating to PCSC and the Company; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewed certain historical financial information and other data relating to the Company that were provided to Scalar by the management of PCSC, approved for our use by PCSC and not publicly available; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewed certain management data relating to the business prospects of the Company that were provided to Scalar by the management of PCSC, approved for Scalar’s use by PCSC and not publicly available; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">conducted discussions with members of the senior management of the Company concerning the business, operations, historical financial results and financial prospects of the Company and its addressable market and the Business Combination; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewed current and historical market prices of the PCSC Class A Shares; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewed certain financial and market data of the Company and compared that data with publicly available data for certain other companies similar to Freenome; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewed certain pro forma effects relating to the Business Combination, including estimated transaction costs and the effects of anticipated financings, approved for Scalar’s use by PCSC; and </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">conducted such other financial studies, analyses and investigations, and considered such other information, as Scalar deemed necessary or appropriate. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In performing its analysis and rendering its opinion, with PCSC’s consent, Scalar relied upon and assumed, without assuming liability or responsibility for independent verification, the accuracy and completeness of information that was publicly available or was furnished, or otherwise made available to Scalar or discussed with or reviewed by Scalar. Scalar further relied upon the assurances of the management of PCSC that the financial information provided had been prepared on a reasonable basis in accordance with industry practice, and that they were not aware of any information or facts that would make any information provided to Scalar inaccurate, incomplete or misleading. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Scalar assumed that the Business Combination will have the tax consequences described in discussions with, and materials furnished to Scalar by, representatives of the Company or PCSC, including that (i) the Domestication qualifies as a “reorganization” within the meaning of Section 368(a)(1)(F) of the Code, (ii) the Mergers, taken together, will be treated as an integrated transaction that qualifies as a “reorganization” within the meaning of Section 368 of the Code, and (iii) the Mergers and the PIPE Financing, taken together, will be treated as an integrated transaction qualifying under Section 351(a) of the Code and Treasury Regulations promulgated thereunder. Scalar is not a legal, accounting, regulatory, or tax expert and its opinion does not address any legal, regulatory, taxation, or accounting matters, as to which Scalar understood that PCSC obtained such advice as it deemed necessary from qualified professionals, and Scalar assumed the accuracy and veracity of all assessments made by such advisors to the Company or PCSC with respect to such matters. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In arriving at its opinion, with PCSC’s consent and without independent verification, Scalar relied upon and assumed that except as would not be in any way meaningful to Scalar’s analysis: (a) the final form of each of the Reviewed Transaction Documents, as executed by the parties thereto, will not differ from the drafts that Scalar reviewed, (b) the representations and warranties of all parties to the Business Combination Agreement, and any related transaction documents, are correct and that such parties will comply with and perform all covenants and agreements required to be complied with or performed by such parties under the Business Combination Agreement and any related transaction documents, (c) the Business Combination will be consummated in accordance with the terms of the Business Combination Agreement and related transaction documents, without any waiver or amendment of any term or condition thereof, and (d) there had been no material change in the assets, financial condition, business or prospects of any party to the Business Combination Agreement since the date of the most recent financial statements and other information made available to Scalar. Additionally, Scalar assumed that all governmental, regulatory or other third-party approvals and consents necessary for the consummation of the Business Combination or otherwise contemplated by the Business Combination Agreement will be obtained without delay, limitation, restriction or condition and otherwise in a way that will not have any adverse effect on the Company or PCSC, or on the expected benefits of the Business Combination, in any way meaningful to Scalar’s analysis. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In addition, Scalar relied upon (without independent verification and without expressing any view, opinion, representation, guaranty or warranty (in each case, express or implied)) the assessments, judgments and estimates of PCSC’s senior management and the Company’s senior management as to, among other things, (a) the potential impact on the Company of market, competitive and other trends in and prospects for, and governmental, regulatory and legislative matters relating to or affecting, the industry in which the Company operates and related industries, (b) the Company’s existing and future products, services, technology and intellectual property and the associated risks thereto (including, without limitation, the probabilities and timing of successful development and marketing thereof; the timing of successful regulatory approvals and clearances; compliance with relevant regulatory requirements; and the potential impact of competition thereon) and (c) PCSC’s and the Company’s existing and future relationships, agreements and arrangements with, and the ability to attract, retain and/or replace, key employees, suppliers and other commercial relationships (in each such case to the extent relevant to the Company, the Business Combination and its contemplated benefits). Scalar assumed that there will not be any developments with respect to any of the foregoing matters that would have an adverse effect on PCSC, the Company or the Business Combination (including the contemplated benefits thereof) or that otherwise would be meaningful in any respect to Scalar’s analyses or opinion. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Given PCSC’s nature as a special purpose acquisition company, for purposes of its opinion and with PCSC’s consent, Scalar assumed a value of $10.61 per PCSC Share in calculating the value of the New Freenome Common Stock to be issued as the Consideration under the Business Combination Agreement, with such $10.61 per share value being based on (a) $91,550,673.98, which was the value of the assets held in PCSC’s Trust Account as of November 30, 2025, divided by (b) 8,625,000, which was the number of outstanding PCSC Class A Shares subject to redemption as of October 31, 2025. In rendering its Opinion, Scalar did not express any view or opinion as to what the value of any PCSC Shares will be when issued pursuant to the Business Combination or the price or range of prices at which any PCSC Class A Shares, PCSC Class B Shares or other securities or financial instruments of or relating to PCSC may trade or otherwise be transferable at any time before or after announcement or consummation of the Business Combination. Additionally, Scalar expressed no opinion with respect to the PCSC Class B Shares and PCSC Preference Shares. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In arriving at its opinion, Scalar did not perform any appraisals or valuations of any specific assets or liabilities (fixed, contingent or other) of the Company or PCSC and Scalar was not furnished or provided with any such appraisals or valuations, nor did Scalar evaluate the solvency of the Company or PCSC under any state or federal law relating to bankruptcy, insolvency or similar matters. The analyses performed by Scalar in connection with its Opinion were going concern analyses, assuming the Business Combination was consummated in accordance with the terms of the Business Combination Agreement. Scalar did not undertake any independent analysis of any pending or threatened litigation, regulatory action, possible unasserted claims or other contingent liabilities, to which the Company or PCSC was a party or may be subject, and at PCSC’s direction and with PCSC’s consent, Scalar’s opinion made no assumption concerning, and therefore did not consider, the possible assertion of claims, outcomes or damages arising out of any such matters. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Scalar’s opinion was necessarily based upon economic, monetary, market, and other conditions as in effect on, the information available to Scalar as of, and the facts and circumstances as they existed on, the date of Scalar’s written opinion and Scalar’s opinion speaks only as of such date; events occurring after that date could materially affect the assumptions used in preparing Scalar’s opinion. Scalar has not undertaken to update, reaffirm, or revise its opinion or otherwise comment upon any events occurring after the date of Scalar’s written opinion, material information provided to Scalar after that date, or any change in facts or circumstances that occurred after that date, and Scalar does not have any obligation to update, revise, or reaffirm its opinion. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Scalar’s opinion did not address PCSC’s underlying business decision to engage in the Business Combination, the relative merits of the Business Combination as compared to other business or investment strategies or transactions that might be available to PCSC, or whether the Consideration to be delivered to Freenome stockholders pursuant to the Business Combination Agreement represents the best price obtainable. In connection with Scalar’s engagement, Scalar was not requested to, and did not, solicit interest from other parties with respect to an acquisition of, or other business combination with, PCSC or any other alternative transaction. Scalar’s opinion addressed only the fairness from a financial point of view, as of the date thereof, to PCSC Class A Shareholders (other than the Excluded Parties) of the Consideration to be paid by PCSC to the Freenome stockholders pursuant to the Business Combination Agreement. Scalar was not asked to, and did not, offer any opinion as to the terms, other than the Consideration to the extent expressly specified therein, of the Business Combination Agreement or any related documents or the form of the Business Combination or any related transaction (including any agreement or transaction between any Excluded Party and the Company or PCSC), including the fairness of the Business Combination to, or any consideration received in connection therewith by, any Excluded Parties, the holders of any class of securities, creditors, or other constituencies </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">of PCSC, the Company, or any of their respective affiliates. Scalar was not asked to, and did not, offer any opinion with respect to any ongoing obligations of the Company, PCSC, or any of their respective affiliates (including any obligations with respect to governance, appraisal rights, preemptive rights, registration rights, voting rights, or otherwise) contained in any Reviewed Transaction Documents, any other agreement related to the Business Combination, or under applicable law, any allocation of the Consideration (or any portion thereof), or the fair market value of the Company, PCSC, PCSC’s ordinary shares, or the Company Shares. In addition, Scalar expressed no opinion as to the fairness of the amount or nature of any compensation to be received by any officers, directors, or employees of any parties to the Business Combination, any Excluded Parties, or any class of such persons, whether relative to the Consideration or otherwise. Scalar’s opinion (i) did not address the individual circumstances of specific holders of PCSC’s securities (including PCSC Class B Shares and PCSC Preference Shares) with respect to rights or aspects which may distinguish such holders or PCSC’s securities (including PCSC Class B Shares and PCSC Preference Shares) held by such holders, (ii) did not address, take into consideration or give effect to any existing or future rights, preferences, restrictions or limitations or other attributes of any such securities (including PCSC Class B Shares and PCSC Preference Shares) or holders (including the Sponsor), (iii) did not address any impact of the Business Combination on any particular PCSC Class A Shareholder other than in its capacity as a PCSC Class A Shareholder, and (iv) did not in any way address proportionate allocation or relative fairness (including, without limitation, the allocation of any consideration among or within any classes or groups of security holders or other constituents of PCSC or any other party). Scalar also did not address, or express a view with respect to, any acquisition of control or effective control of PCSC by any stockholder or group of stockholders of the Company. Scalar’s opinion should not be construed as creating any fiduciary duty of Scalar (or any of its affiliates) to any party. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Scalar’s opinion was provided for the information and assistance of the Special Committee (in its capacity as such) in connection with, and for the purpose of, its evaluation of the Business Combination, and does not constitute a recommendation to any stockholder as to how such stockholder should vote or act (including with respect to any redemption rights) with respect to the Business Combination or any other matter. </div> true false <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In arriving at its opinion, Scalar, among other things: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewed a draft of the agreed form, dated November 12, 2025, of the Sponsor Letter Agreement; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewed a draft, dated December 3, 2025, of the Business Combination Agreement; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewed a draft, dated November 3, 2025, of the Investor Subscription Agreements (the drafts described in these first three bullets, the “<span style="font-weight: bold;">Reviewed Transaction Documents</span>”); </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewed certain publicly available business and financial information relating to PCSC and the Company; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewed certain historical financial information and other data relating to the Company that were provided to Scalar by the management of PCSC, approved for our use by PCSC and not publicly available; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewed certain management data relating to the business prospects of the Company that were provided to Scalar by the management of PCSC, approved for Scalar’s use by PCSC and not publicly available; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">conducted discussions with members of the senior management of the Company concerning the business, operations, historical financial results and financial prospects of the Company and its addressable market and the Business Combination; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewed current and historical market prices of the PCSC Class A Shares; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewed certain financial and market data of the Company and compared that data with publicly available data for certain other companies similar to Freenome; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewed certain pro forma effects relating to the Business Combination, including estimated transaction costs and the effects of anticipated financings, approved for Scalar’s use by PCSC; and </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">conducted such other financial studies, analyses and investigations, and considered such other information, as Scalar deemed necessary or appropriate. </div></td></tr></table> <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In performing its analysis and rendering its opinion, with PCSC’s consent, Scalar relied upon and assumed, without assuming liability or responsibility for independent verification, the accuracy and completeness of information that was publicly available or was furnished, or otherwise made available to Scalar or discussed with or reviewed by Scalar. Scalar further relied upon the assurances of the management of PCSC that the financial information provided had been prepared on a reasonable basis in accordance with industry practice, and that they were not aware of any information or facts that would make any information provided to Scalar inaccurate, incomplete or misleading. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Scalar assumed that the Business Combination will have the tax consequences described in discussions with, and materials furnished to Scalar by, representatives of the Company or PCSC, including that (i) the Domestication qualifies as a “reorganization” within the meaning of Section 368(a)(1)(F) of the Code, (ii) the Mergers, taken together, will be treated as an integrated transaction that qualifies as a “reorganization” within the meaning of Section 368 of the Code, and (iii) the Mergers and the PIPE Financing, taken together, will be treated as an integrated transaction qualifying under Section 351(a) of the Code and Treasury Regulations promulgated thereunder. Scalar is not a legal, accounting, regulatory, or tax expert and its opinion does not address any legal, regulatory, taxation, or accounting matters, as to which Scalar understood that PCSC obtained such advice as it deemed necessary from qualified professionals, and Scalar assumed the accuracy and veracity of all assessments made by such advisors to the Company or PCSC with respect to such matters. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In arriving at its opinion, with PCSC’s consent and without independent verification, Scalar relied upon and assumed that except as would not be in any way meaningful to Scalar’s analysis: (a) the final form of each of the Reviewed Transaction Documents, as executed by the parties thereto, will not differ from the drafts that Scalar reviewed, (b) the representations and warranties of all parties to the Business Combination Agreement, and any related transaction documents, are correct and that such parties will comply with and perform all covenants and agreements required to be complied with or performed by such parties under the Business Combination Agreement and any related transaction documents, (c) the Business Combination will be consummated in accordance with the terms of the Business Combination Agreement and related transaction documents, without any waiver or amendment of any term or condition thereof, and (d) there had been no material change in the assets, financial condition, business or prospects of any party to the Business Combination Agreement since the date of the most recent financial statements and other information made available to Scalar. Additionally, Scalar assumed that all governmental, regulatory or other third-party approvals and consents necessary for the consummation of the Business Combination or otherwise contemplated by the Business Combination Agreement will be obtained without delay, limitation, restriction or condition and otherwise in a way that will not have any adverse effect on the Company or PCSC, or on the expected benefits of the Business Combination, in any way meaningful to Scalar’s analysis. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In addition, Scalar relied upon (without independent verification and without expressing any view, opinion, representation, guaranty or warranty (in each case, express or implied)) the assessments, judgments and estimates of PCSC’s senior management and the Company’s senior management as to, among other things, (a) the potential impact on the Company of market, competitive and other trends in and prospects for, and governmental, regulatory and legislative matters relating to or affecting, the industry in which the Company operates and related industries, (b) the Company’s existing and future products, services, technology and intellectual property and the associated risks thereto (including, without limitation, the probabilities and timing of successful development and marketing thereof; the timing of successful regulatory approvals and clearances; compliance with relevant regulatory requirements; and the potential impact of competition thereon) and (c) PCSC’s and the Company’s existing and future relationships, agreements and arrangements with, and the ability to attract, retain and/or replace, key employees, suppliers and other commercial relationships (in each such case to the extent relevant to the Company, the Business Combination and its contemplated benefits). Scalar assumed that there will not be any developments with respect to any of the foregoing matters that would have an adverse effect on PCSC, the Company or the Business Combination (including the contemplated benefits thereof) or that otherwise would be meaningful in any respect to Scalar’s analyses or opinion. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Given PCSC’s nature as a special purpose acquisition company, for purposes of its opinion and with PCSC’s consent, Scalar assumed a value of $10.61 per PCSC Share in calculating the value of the New Freenome Common Stock to be issued as the Consideration under the Business Combination Agreement, with such $10.61 per share value being based on (a) $91,550,673.98, which was the value of the assets held in PCSC’s Trust Account as of November 30, 2025, divided by (b) 8,625,000, which was the number of outstanding PCSC Class A Shares subject to redemption as of October 31, 2025. In rendering its Opinion, Scalar did not express any view or opinion as to what the value of any PCSC Shares will be when issued pursuant to the Business Combination or the price or range of prices at which any PCSC Class A Shares, PCSC Class B Shares or other securities or financial instruments of or relating to PCSC may trade or otherwise be transferable at any time before or after announcement or consummation of the Business Combination. Additionally, Scalar expressed no opinion with respect to the PCSC Class B Shares and PCSC Preference Shares. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In arriving at its opinion, Scalar did not perform any appraisals or valuations of any specific assets or liabilities (fixed, contingent or other) of the Company or PCSC and Scalar was not furnished or provided with any such appraisals or valuations, nor did Scalar evaluate the solvency of the Company or PCSC under any state or federal law relating to bankruptcy, insolvency or similar matters. The analyses performed by Scalar in connection with its Opinion were going concern analyses, assuming the Business Combination was consummated in accordance with the terms of the Business Combination Agreement. Scalar did not undertake any independent analysis of any pending or threatened litigation, regulatory action, possible unasserted claims or other contingent liabilities, to which the Company or PCSC was a party or may be subject, and at PCSC’s direction and with PCSC’s consent, Scalar’s opinion made no assumption concerning, and therefore did not consider, the possible assertion of claims, outcomes or damages arising out of any such matters. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Scalar’s opinion was necessarily based upon economic, monetary, market, and other conditions as in effect on, the information available to Scalar as of, and the facts and circumstances as they existed on, the date of Scalar’s written opinion and Scalar’s opinion speaks only as of such date; events occurring after that date could materially affect the assumptions used in preparing Scalar’s opinion. Scalar has not undertaken to update, reaffirm, or revise its opinion or otherwise comment upon any events occurring after the date of Scalar’s written opinion, material information provided to Scalar after that date, or any change in facts or circumstances that occurred after that date, and Scalar does not have any obligation to update, revise, or reaffirm its opinion. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Scalar’s opinion did not address PCSC’s underlying business decision to engage in the Business Combination, the relative merits of the Business Combination as compared to other business or investment strategies or transactions that might be available to PCSC, or whether the Consideration to be delivered to Freenome stockholders pursuant to the Business Combination Agreement represents the best price obtainable. In connection with Scalar’s engagement, Scalar was not requested to, and did not, solicit interest from other parties with respect to an acquisition of, or other business combination with, PCSC or any other alternative transaction. Scalar’s opinion addressed only the fairness from a financial point of view, as of the date thereof, to PCSC Class A Shareholders (other than the Excluded Parties) of the Consideration to be paid by PCSC to the Freenome stockholders pursuant to the Business Combination Agreement. Scalar was not asked to, and did not, offer any opinion as to the terms, other than the Consideration to the extent expressly specified therein, of the Business Combination Agreement or any related documents or the form of the Business Combination or any related transaction (including any agreement or transaction between any Excluded Party and the Company or PCSC), including the fairness of the Business Combination to, or any consideration received in connection therewith by, any Excluded Parties, the holders of any class of securities, creditors, or other constituencies </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">of PCSC, the Company, or any of their respective affiliates. Scalar was not asked to, and did not, offer any opinion with respect to any ongoing obligations of the Company, PCSC, or any of their respective affiliates (including any obligations with respect to governance, appraisal rights, preemptive rights, registration rights, voting rights, or otherwise) contained in any Reviewed Transaction Documents, any other agreement related to the Business Combination, or under applicable law, any allocation of the Consideration (or any portion thereof), or the fair market value of the Company, PCSC, PCSC’s ordinary shares, or the Company Shares. In addition, Scalar expressed no opinion as to the fairness of the amount or nature of any compensation to be received by any officers, directors, or employees of any parties to the Business Combination, any Excluded Parties, or any class of such persons, whether relative to the Consideration or otherwise. Scalar’s opinion (i) did not address the individual circumstances of specific holders of PCSC’s securities (including PCSC Class B Shares and PCSC Preference Shares) with respect to rights or aspects which may distinguish such holders or PCSC’s securities (including PCSC Class B Shares and PCSC Preference Shares) held by such holders, (ii) did not address, take into consideration or give effect to any existing or future rights, preferences, restrictions or limitations or other attributes of any such securities (including PCSC Class B Shares and PCSC Preference Shares) or holders (including the Sponsor), (iii) did not address any impact of the Business Combination on any particular PCSC Class A Shareholder other than in its capacity as a PCSC Class A Shareholder, and (iv) did not in any way address proportionate allocation or relative fairness (including, without limitation, the allocation of any consideration among or within any classes or groups of security holders or other constituents of PCSC or any other party). Scalar also did not address, or express a view with respect to, any acquisition of control or effective control of PCSC by any stockholder or group of stockholders of the Company. Scalar’s opinion should not be construed as creating any fiduciary duty of Scalar (or any of its affiliates) to any party. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Scalar’s opinion was provided for the information and assistance of the Special Committee (in its capacity as such) in connection with, and for the purpose of, its evaluation of the Business Combination, and does not constitute a recommendation to any stockholder as to how such stockholder should vote or act (including with respect to any redemption rights) with respect to the Business Combination or any other matter. </div> <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Summary of Scalar’s Financial Analysis </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The following is a summary of the material financial analyses delivered by Scalar to the Special Committee in connection with rendering the opinion described above. <span style="font-weight: bold;">The summary set forth below does not purport to be a complete description of the financial analyses performed or factors considered by, and underlying the opinion of, Scalar, nor does the order of the financial analyses described represent the relative importance or weight given to those financial analyses by Scalar. Scalar may have deemed various assumptions more or less probable than other assumptions, so the reference ranges resulting from any particular portion of the analyses summarized below should not be taken to be Scalar’s view of the actual value of the Company. Some of the summaries of the financial analyses set forth below include information presented in tabular format. In order to fully understand the financial analyses, the tables must be read together with the text of each summary, as the tables alone do not constitute a complete description of the financial analyses performed by Scalar. Considering the data in the tables below without considering all financial analyses or factors or the full narrative description of such analyses or factors, including the methodologies and assumptions underlying such analyses or factors, could create a misleading or incomplete view of the processes underlying Scalar’s financial analyses and its opinion.</span> </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In performing its analyses, Scalar made numerous assumptions with respect to industry performance, primarily that the market conditions, the competitive landscape, and the regulatory environment for the Company’s products would remain unchanged, and assumptions related to general business and economic conditions and other matters, many of which are beyond the control of PCSC, the Company, or any other parties to the Business Combination. These analyses do not purport to be appraisals or reflect the prices at which businesses or securities may actually be sold. Accordingly, the assumptions and estimates used in, and the results derived from, the financial analyses are inherently subject to substantial uncertainty. Except as otherwise noted, the following quantitative information, to the extent that it is based on market data, is based on market data as it existed on November 30, 2025, and is not necessarily indicative of current market conditions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Assumed Value of New Freenome Common Stock<span style="font-style: normal;"> </span></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Given PCSC’s nature as a special purpose acquisition company, for purposes of its opinion and with PCSC’s consent, Scalar assumed a value of $10.61 per PCSC Share in calculating the value of the New Freenome Common Stock to be issued as the Consideration under the Business Combination Agreement, with such $10.61 per share value being based on (a) $91,550,673.98, which was the value of the assets held in PCSC’s Trust Account as of November 30, </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">2025, divided by (b) 8,625,000, which was the number of outstanding PCSC Class A Shares subject to redemption as of October 31, 2025. In rendering its opinion, Scalar did not express any view or opinion as to what the value of any PCSC Shares will be when issued pursuant to the Business Combination or the price or range of prices at which any PCSC Class A Shares, PCSC Class B Shares or other securities or financial instruments of or relating to PCSC may trade or otherwise be transferable at any time before or after announcement or consummation of the Business Combination. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">License Agreement Multiples Analysis<span style="font-style: normal;"> </span></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Scalar reviewed certain financial data for selected companies with publicly traded equity securities that had announced license agreements that Scalar deemed relevant for purposes of this analysis based on various factors, including the companies’ product offerings within the biotech industry and their business model. The financial data reviewed included: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Licensor enterprise value as of seven days prior to announcement, or “<span style="font-weight: bold;">Licensor EV Pre-Announcement</span>”; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Licensor enterprise value as of 30 days post-announcement, or “<span style="font-weight: bold;">Licensor EV Post-Announcement</span>”; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The announced nominal value of the potential license payments the licensor could receive pursuant to the license agreement, or “<span style="font-weight: bold;">Potential License Payments</span>”; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The change in enterprise value between the Licensor EV Pre-Announcement and the Licensor EV Post-Announcement, or “<span style="font-weight: bold;">Change in EV</span>”; and </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Change in EV divided by the Potential License Payments, or “<span style="font-weight: bold;">Implied Multiple</span>.” </div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The selected licensors and corresponding financial data included the following: </div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 126pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 35.56pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 66.49pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 69.3pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 45pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 45pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 29.33pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 126pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">($ in thousands)<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="font-style: normal; font-weight: bold;">Selected Licensors</span></div></td><td style="width: 4.28pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 35.56pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Date</div></td><td style="width: 4.28pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 66.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Licensor EV <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Pre-Announcement</div></td><td style="width: 4.28pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 69.3pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Licensor EV <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Post-Announcement</div></td><td style="width: 4.28pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Potential <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">License <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Payments</div></td><td style="width: 4.28pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in EV </div></td><td style="width: 4.28pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 29.33pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Implied <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Multiple </div></td></tr><tr><td style="width: 126pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Rani Therapeutics, LLC</div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 35.56pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">10/19/25</div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 66.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.25pt; text-align: left;">$<span style="padding-left: 17.5pt;">25,382</span></div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 69.3pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.84pt; text-align: left;">$<span style="padding-left: 12.13pt;">186,707</span></div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 7.5pt;">185,000</span></div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$<span style="padding-left: 7.5pt;">161,325</span></div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 29.33pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.87x </div></td></tr><tr><td style="width: 126pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Arrowhead Pharmaceuticals, Inc.</div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 35.56pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">09/02/25</div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 66.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.25pt; text-align: left;">$<span style="padding-left: 5pt;">2,628,202</span></div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 69.3pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.84pt; text-align: left;">$<span style="padding-left: 4.63pt;">4,483,618</span></div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$2,200,000</div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$1,855,416</div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 29.33pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.84x </div></td></tr><tr><td style="width: 126pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">IDEAYA Biosciences, Inc.</div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 35.56pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">09/02/25</div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 66.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.25pt; text-align: left;">$<span style="padding-left: 5pt;">1,186,953</span></div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 69.3pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.84pt; text-align: left;">$<span style="padding-left: 4.63pt;">1,392,039</span></div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 7.5pt;">530,000</span></div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$<span style="padding-left: 7.5pt;">205,086</span></div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 29.33pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.39x </div></td></tr><tr><td style="width: 126pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">BioArctic AB (publ)</div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 35.56pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">08/26/25</div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 66.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.25pt; text-align: left;">$<span style="padding-left: 5pt;">2,100,615</span></div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 69.3pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.84pt; text-align: left;">$<span style="padding-left: 4.63pt;">2,523,069</span></div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 7.5pt;">802,000</span></div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$<span style="padding-left: 7.5pt;">422,454</span></div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 29.33pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.53x </div></td></tr><tr><td style="width: 126pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Jazz Pharmaceuticals plc</div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 35.56pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">08/20/25</div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 66.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.25pt; text-align: left;">$10,798,568</div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 69.3pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.84pt; text-align: left;">$11,476,733</div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$1,035,000</div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$<span style="padding-left: 7.5pt;">678,165</span></div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 29.33pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.66x </div></td></tr><tr><td style="width: 126pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Kymera Therapeutics, Inc.</div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 35.56pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">06/25/25</div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 66.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.25pt; text-align: left;">$<span style="padding-left: 5pt;">2,252,135</span></div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 69.3pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.84pt; text-align: left;">$<span style="padding-left: 4.63pt;">2,440,795</span></div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 7.5pt;">750,000</span></div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$<span style="padding-left: 7.5pt;">188,660</span></div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 29.33pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.25x </div></td></tr><tr><td style="width: 126pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Agenus Inc.</div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 35.56pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">06/03/25</div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 66.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.25pt; text-align: left;">$<span style="padding-left: 12.5pt;">133,828</span></div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 69.3pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.84pt; text-align: left;">$<span style="padding-left: 12.13pt;">202,918</span></div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 7.5pt;">141,000</span></div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$<span style="padding-left: 12.5pt;">69,090</span></div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 29.33pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.49x </div></td></tr><tr><td style="width: 126pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Bio-Thera Solutions, Ltd.</div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 35.56pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">02/10/25</div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 66.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.25pt; text-align: left;">$<span style="padding-left: 5pt;">1,098,540</span></div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 69.3pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.84pt; text-align: left;">$<span style="padding-left: 4.63pt;">1,169,853</span></div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 7.5pt;">164,500</span></div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$<span style="padding-left: 12.5pt;">71,312</span></div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 29.33pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.43x </div></td></tr><tr><td style="width: 126pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Valneva SE</div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 35.56pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">12/19/24</div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 66.49pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.25pt; text-align: left;">$<span style="padding-left: 12.5pt;">360,695</span></div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 69.3pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.84pt; text-align: left;">$<span style="padding-left: 12.13pt;">392,508</span></div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 12.5pt;">41,300</span></div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$<span style="padding-left: 12.5pt;">31,813</span></div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 29.33pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.77x</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 126pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 35.56pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 66.49pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 69.3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 45pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 45pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.28pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 29.33pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Taking into account the results of the license agreement multiples analysis, Scalar applied a selected multiple range of 0.65x to 0.85x, which is within the range of observed implied multiples. Scalar observed a positive correlation between the Potential License Payments and the Implied Multiples, and Scalar noted that the total Announced Potential Value of Freenome’s license agreements ranked within the top quartile of the observed data. Given the total Announced Potential Value of Freenome’s license agreements and its positioning within the observed dataset, Scalar selected a 0.75x multiple as the midpoint of the range. The selected range of 0.65x and 0.85x is supported by the Implied Multiples from the selected licensors, and aligns with the third quartile and top quartile of the Implied Multiples that Scalar observed. These multiples are applied to the license agreement between Freenome and Exact Sciences with remaining announced potential value of $760 million, and estimated a remaining value between $494 million and $646 million for this license agreement. The $760 million figure is the result of reducing the total announced $885 million potential value for the $50 million convertible note investment received by Freenome and for the $75 million upfront cash payment Freenome received in November 2025 from Exact Sciences pursuant to this license agreement. Scalar, based on its own expertise, applied the selected multiple range of 0.65x and 0.85x to the license agreement between Freenome and Roche with remaining announced potential value of $134 million, and estimated a value between $87 million and $114 million for this license agreement. The $134 million figure is the result of reducing the total announced $209 million potential value for the $75 million convertible note that Freenome has already received from Roche. Scalar summed the aforementioned Exact Sciences license agreement and Roche license agreement values, and concluded a total value of Freenome’s license agreements between $581 million and $760 million and added pro forma net cash of $552 million, which was the sum of (i) the $60.2 million in cash on Freenome’s balance sheet as of June 30, 2025, (ii) an assumed </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">$250 million of proceeds from the PIPE Financing, as directed by PCSC management, (iii) the $75 million proceeds from Roche’s convertible note investment into Freenome, (iv) the $50 million proceeds from Exact Sciences Convertible Note investment into Freenome, (v) the $75 million upfront payment by Exact Sciences to Freenome pursuant to the Exact Sciences license agreement, and (vi) the $91.6 million in cash in the Trust Account as of November 30, 2025, less the $50 million of debt on Freenome’s balance sheet as of June 30, 2025, to the total value of Freenome’s license agreements to calculate implied total equity value. The license agreement multiples analysis indicated implied total equity value reference ranges for Freenome of approximately $1,133,000,000 to $1,312,000,000, as compared to the fully-diluted value of the Consideration (as described and calculated below under “—<span style="font-style: italic;">Pro Forma Consideration Analysis</span>”) of $1,259,657,005<span style="font-style: italic;">.</span> </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Scalar noted that the fully-diluted value of the Consideration was within the above range, which in Scalar’s view supported its assessment of the fairness, from a financial point of view, of the Consideration to (1) the PCSC Class A Shareholders (other than the Excluded Parties) and (2) PCSC. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Cost to Recreate Analysis – All Assets<span style="font-style: normal;"> </span></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Scalar reviewed Freenome’s research and development expenses beginning January 1, 2021 and ending June 30, 2025. Research and development expenses incurred before 2021 were excluded on the basis that earlier development efforts were no longer relevant due to significant advancements in the underlying technology. The analysis included: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Freenome’s research and development expense for annual periods, or “<span style="font-weight: bold;">R&amp;D Expense</span>”; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The estimated required rate of return on R&amp;D Expense, or “<span style="font-weight: bold;">Yearly Return</span>”; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The product of Time Elapsed and Yearly Return, or “<span style="font-weight: bold;">Total Expected Return</span>”; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The product of R&amp;D Expense and Total Expected Return, or “<span style="font-weight: bold;">Entrepreneurial Incentive</span>”; and </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The sum of the R&amp;D Expense and the Entrepreneurial Incentive, or “<span style="font-weight: bold;">Cost to Recreate</span>” </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As an illustrative example, the analysis, with an assumed Yearly Return of 25%, follows: </div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 96pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 51.99pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 27.11pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 24.43pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 31.54pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 55.26pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 37.5pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 96pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Period Ending*</div></td><td style="width: 12.01pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 51.99pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; margin-top: 0pt; text-align: center;">($ in thousands)<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; margin-top: 0pt; text-align: center;"><span style="font-style: normal; font-weight: bold;">R&amp;D </span><br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; margin-top: 0pt; text-align: center;"><span style="font-style: normal; font-weight: bold;">Expense</span></div></td><td style="width: 12.01pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 27.11pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Time <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Elapsed <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(years)</div></td><td style="width: 12.01pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.43pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Yearly <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Return</div></td><td style="width: 12.01pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 31.54pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Expected <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Return</div></td><td style="width: 12.01pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 55.26pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Entrepreneurial <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Incentive</div></td><td style="width: 12.01pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 37.5pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Cost to <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Recreate </div></td></tr><tr><td style="width: 96pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December 31, 2021</div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 51.99pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.26pt; text-align: left;">$147,123 </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 27.11pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.31pt; text-align: left;">3.9 </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.43pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.47pt; text-align: left;">25.0% </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 31.54pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.02pt; text-align: left;">97.9% </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 55.26pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.88pt; text-align: left;">$144,058 </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 37.5pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$291,181 </div></td></tr><tr><td style="width: 96pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December 31, 2022</div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 51.99pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.26pt; text-align: left;">$164,151 </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 27.11pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.31pt; text-align: left;">2.9 </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.43pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.47pt; text-align: left;">25.0% </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 31.54pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.02pt; text-align: left;">72.9% </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 55.26pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.88pt; text-align: left;">$<span style="padding-left: 0.37pt;">119,693</span> </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 37.5pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$283,844 </div></td></tr><tr><td style="width: 96pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December 31, 2023</div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 51.99pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.26pt; text-align: left;">$228,255 </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 27.11pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.31pt; text-align: left;">1.9 </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.43pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.47pt; text-align: left;">25.0% </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 31.54pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.02pt; text-align: left;">47.9% </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 55.26pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.88pt; text-align: left;">$109,372 </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 37.5pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$337,627 </div></td></tr><tr><td style="width: 96pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December 31, 2024</div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 51.99pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.26pt; text-align: left;">$225,749 </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 27.11pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.31pt; text-align: left;">0.9 </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.43pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.47pt; text-align: left;">25.0% </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 31.54pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.02pt; text-align: left;">22.9% </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 55.26pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.88pt; text-align: left;">$<span style="padding-left: 5pt;">51,734</span> </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 37.5pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$277,483 </div></td></tr><tr><td style="width: 96pt; padding-top: 0.51pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">June 30, 2025</div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 51.99pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.26pt; text-align: left;">$<span style="padding-left: 5pt;">94,866</span> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 27.11pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.31pt; text-align: left;">0.4 </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 24.43pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.47pt; text-align: left;">25.0% </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 31.54pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.02pt; text-align: left;">10.4% </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 55.26pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.88pt; text-align: left;">$<span style="padding-left: 10pt;">9,882</span> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 37.5pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$104,748</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 96pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 51.99pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 27.11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 24.43pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 31.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 55.26pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 12.01pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 37.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">All periods begin January 1 of the respective year </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Obsolescence Adjustment Support<span style="font-style: normal;"> </span></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Scalar reviewed certain financial data for selected transactions that Scalar deemed relevant for purposes of the cost to recreate analysis to support an obsolescence adjustment to account for R&amp;D Expense that is attributable to obsolete parts of Freenome’s product and technology. The analysis includes companies that were acquired in the selected transactions, which Scalar chose based on various factors, such as the acquired companies’ product offerings within the biotech industry and their business model. The financial data reviewed included: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The estimated period over which the applicable asset is expected to contribute a company’s future cash flows before becoming obsolete, or “<span style="font-weight: bold;">Useful Life</span>”; and </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The inverse of the Useful Life, or “<span style="font-weight: bold;">Annual Obsolescence</span>” </div></td></tr></table><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 264pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 58.43pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 37.54pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 72.65pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 264pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Acquired Company</div></td><td style="width: 5.89pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 58.43pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Transaction Year</div></td><td style="width: 5.89pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 37.54pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Useful Life</div></td><td style="width: 5.89pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 72.65pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual Obsolescence </div></td></tr><tr><td style="width: 264pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Curetis N.V.</div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 58.43pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.22pt; text-align: left;">2020</div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 37.54pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.77pt; text-align: left;">10 </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 72.65pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.58pt; text-align: left;">10.0% </div></td></tr><tr><td style="width: 264pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Genomic Health, Inc.</div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 58.43pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.22pt; text-align: left;">2019</div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 37.54pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.77pt; text-align: left;">10 </div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 72.65pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.58pt; text-align: left;">10.0% </div></td></tr><tr><td style="width: 264pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">HD Biosciences Co., Ltd.</div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 58.43pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.22pt; text-align: left;">2017</div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 37.54pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.77pt; text-align: left;">10 </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 72.65pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.58pt; text-align: left;">10.0% </div></td></tr><tr><td style="width: 264pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ipsogen SA</div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 58.43pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.22pt; text-align: left;"><span style="padding-left: 0.37pt;">2011</span></div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 37.54pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.77pt; text-align: left;">10 </div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 72.65pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.58pt; text-align: left;">10.0% </div></td></tr><tr><td style="width: 264pt; padding-top: 0.51pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Boston Biochem, Inc.</div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 58.43pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.22pt; text-align: left;"><span style="padding-left: 0.37pt;">2011</span></div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 37.54pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.77pt; text-align: left;">12 </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 72.65pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.58pt; text-align: left;"><span style="padding-left: 5pt;">8.3%</span> </div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 264pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 58.43pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 37.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 72.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table><table cellpadding="0" class="BRDSX_fintab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 264pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 58.43pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 37.54pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 72.65pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 264pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Acquired Company</div></td><td style="width: 5.89pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 58.43pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Transaction Year</div></td><td style="width: 5.89pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 37.54pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Useful Life</div></td><td style="width: 5.89pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 72.65pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual Obsolescence </div></td></tr><tr><td style="width: 264pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tocris Holdings Ltd.</div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 58.43pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.22pt; text-align: left;"><span style="padding-left: 0.37pt;">2011</span></div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 37.54pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.77pt; text-align: left;">15 </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 72.65pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.58pt; text-align: left;"><span style="padding-left: 5pt;">6.7%</span> </div></td></tr><tr><td style="width: 264pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Astex Therapeutics Ltd.</div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 58.43pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.22pt; text-align: left;"><span style="padding-left: 0.37pt;">2011</span></div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 37.54pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.77pt; text-align: left;"><span style="padding-left: 5pt;">7</span> </div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 72.65pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.58pt; text-align: left;">14.3% </div></td></tr><tr><td style="width: 264pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">SABiosciences Corporation</div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 58.43pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.22pt; text-align: left;">2009</div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 37.54pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.77pt; text-align: left;">10 </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 72.65pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.58pt; text-align: left;">10.0% </div></td></tr><tr><td style="width: 264pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fisher Scientific International Inc.</div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 58.43pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.22pt; text-align: left;">2006</div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 37.54pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.77pt; text-align: left;"><span style="padding-left: 5pt;">9</span> </div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 72.65pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.58pt; text-align: left;"><span style="padding-left: 0.37pt;">11.1%</span> </div></td></tr><tr><td style="width: 264pt; padding-top: 0.51pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Medicis Pharmaceutical Corp.</div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 58.43pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.22pt; text-align: left;">2012</div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 37.54pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.77pt; text-align: left;"><span style="padding-left: 5pt;">5</span> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 72.65pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.58pt; text-align: left;">20.0%</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 264pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 58.43pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 37.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 5.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 72.65pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Based on its review of the acquired companies in the selected transactions, Scalar applied an obsolescence adjustment to the cost to recreate analysis by applying Annual Obsolescence to the cost to recreate analysis. The analysis included: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">100% less the product of Time Elapsed, rounded to the nearest integer, and the Annual Obsolescence, or “<span style="font-weight: bold;">Obsolescence Adjustment</span>”; and </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The product of the Cost to Recreate and Obsolescence Adjustment, or “<span style="font-weight: bold;">Total Cost to Recreate</span>” </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">As an illustrative example, the cost to recreate analysis with an assumed Yearly Return of 25%, with a selected 17.5% Annual Obsolescence applied, follows: </div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 120pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 56.26pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 27.12pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 45.32pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 45.32pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 62.5pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 120pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Period Ending*</div></td><td style="width: 11.15pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 56.26pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; margin-top: 0pt; text-align: center;">($ in thousands)<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; margin-top: 0pt; text-align: center;"><span style="font-style: normal; font-weight: bold;">Cost to Recreate</span></div></td><td style="width: 11.15pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 27.12pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Time <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Elapsed</div></td><td style="width: 11.15pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 45.32pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Obsolescence</div></td><td style="width: 11.15pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 45.32pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Obsolescence <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Adjustment</div></td><td style="width: 11.15pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 62.5pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total Cost <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">to Recreate </div></td></tr><tr><td style="width: 120pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December 31, 2021</div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 56.26pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.38pt; text-align: left;">$291,181 </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 27.12pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.3pt; text-align: left;">3.9 </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45.32pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.91pt; text-align: left;">17.5% </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45.32pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.4pt; text-align: left;"><span style="padding-left: 5pt;">30.0%</span></div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 62.5pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 30pt;">87,354</span> </div></td></tr><tr><td style="width: 120pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December 31, 2022</div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 56.26pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.38pt; text-align: left;">$283,844 </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 27.12pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.3pt; text-align: left;">2.9 </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45.32pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.91pt; text-align: left;">17.5%</div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45.32pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.4pt; text-align: left;"><span style="padding-left: 5pt;">47.5%</span></div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 62.5pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 25pt;">134,826</span> </div></td></tr><tr><td style="width: 120pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December 31, 2023</div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 56.26pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.38pt; text-align: left;">$337,627 </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 27.12pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.3pt; text-align: left;">1.9 </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45.32pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.91pt; text-align: left;">17.5% </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45.32pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.4pt; text-align: left;"><span style="padding-left: 5pt;">65.0%</span></div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 62.5pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 25pt;">219,458</span> </div></td></tr><tr><td style="width: 120pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December 31, 2024</div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 56.26pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.38pt; text-align: left;">$277,483 </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 27.12pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.3pt; text-align: left;">0.9 </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45.32pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.91pt; text-align: left;">17.5%</div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45.32pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.4pt; text-align: left;"><span style="padding-left: 5pt;">82.5%</span></div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 62.5pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 25pt;">228,924</span> </div></td></tr><tr><td style="width: 120pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">June 30, 2025</div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 56.26pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.38pt; text-align: left;">$104,748 </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 27.12pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.3pt; text-align: left;">0.4 </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45.32pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.91pt; text-align: left;">17.5% </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45.32pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.4pt; text-align: left;">100.0%</div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 62.5pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 25pt;">104,748</span> </div></td></tr><tr><td style="width: 120pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Plus: Pro Forma Net Cash</div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 56.26pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 27.12pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45.32pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45.32pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 62.5pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 7.5pt;">551,710,764</span> </div></td></tr><tr><td style="width: 120pt; padding-top: 0.51pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total</div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 56.26pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 27.12pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45.32pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45.32pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 62.5pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$1,327,020,205</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 120pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 56.26pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 27.12pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 45.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 45.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 11.15pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 62.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">All periods begin January 1 of the respective year </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Scalar, based on its own expertise, performed the aforementioned cost to recreate analysis using selected Yearly Returns ranging from 20% to 30%. The selected range was informed by published required rate of return studies, such as the 2025 Pepperdine Private Capital Markets Study that reports required rates of return ranging from 23% to 32% for late-stage companies and the required rates of return studies by Scherlis, et al. and Shalman et al. that suggest a range of 20% to 35% for Bridge/IPO stage companies. The selected range of 20% to 30% falls within the ranges observed in these studies and was selected given the Company’s stage of development. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Scalar selected Annual Obsolescence between 15% and 20%. Using the Yearly Return and Annual Obsolescence inputs, the cost to recreate analysis indicated implied total equity value reference ranges for Freenome of approximately $1,214,000,000 to $1,452,000,000, as compared to the Fully-Diluted Value of the Transaction Consideration (as described and calculated below under “—<span style="font-style: italic;">Pro Forma Consideration Analysis</span>”) of $1,259,657,005<span style="font-style: italic;">.</span> </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Scalar noted that the fully-diluted value of the Consideration was within the above range, which in Scalar’s view supported its assessment of the fairness, from a financial point of view, of the Consideration to (1) the PCSC Class A Shareholders (other than the Excluded Parties) and (2) PCSC. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pro Forma Consideration Analysis<span style="font-style: normal;"> </span></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Utilizing pro forma ownership information provided by PCSC management and the assumptions described above (assuming a value of $10.61 per share of New Freenome Common Stock), Scalar calculated the aggregate implied value of the pro forma shares of New Freenome Common Stock outstanding following the consummation of the Business Combination. These calculations are summarized below: </div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 336pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 45pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 55pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"># of shares</div></td><td style="width: 8pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 55pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value* </div></td></tr><tr><td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">PCSC Class A Shares</div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">8,625,000</span></div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 55pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 5pt;">91,550,674</span> </div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">PCSC Class B Shares</div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">2,156,250</span></div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 55pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">22,887,668</span> </div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">PCSC Class A Private Placement Shares</div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 12.5pt;">286,250</span></div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 55pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 15pt;">3,038,421</span> </div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company Shares (“Consideration”)</div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">76,234,625</div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 55pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">809,197,836</span> </div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Roche Investment Shares</div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">6,370,313</span></div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 55pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">67,618,134</span> </div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 45pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 55pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table><table cellpadding="0" class="BRDSX_fintab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 336pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 45pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 55pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"># of shares</div></td><td style="width: 8pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 55pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value* </div></td></tr><tr><td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Perceptive PIPE Investment Shares</div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -4.45pt; text-align: left;"><span style="padding-left: 9.45pt;">2,500,000</span></div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 55pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -7.5pt; text-align: left;"><span style="padding-left: 17.5pt;">26,536,427</span> </div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">RA Capital PIPE Investment Shares</div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -4.45pt; text-align: left;"><span style="padding-left: 9.45pt;">5,000,000</span></div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 55pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -7.5pt; text-align: left;"><span style="padding-left: 17.5pt;">53,072,854</span> </div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Third-Party PIPE Investment Shares</div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -4.45pt; text-align: justify;"><span style="padding-left: 4.45pt;">17,500,000</span></div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 55pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -7.5pt; text-align: left;"><span style="padding-left: 12.5pt;">185,754,991</span> </div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash transaction expenses</div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -4.45pt; text-align: left;"><span style="padding-left: 32.24pt;">N/A</span></div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 55pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -7.5pt; text-align: left;"><span style="padding-left: 17.5pt;">17,625,000</span> </div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fully-Diluted Value of Transaction Consideration</div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -4.45pt; text-align: justify;">118,672,438</div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 55pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -7.5pt; text-align: left;">$1,259,657,005</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 45pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 55pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Value is the product of the # of shares and $10.6145709 </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Scalar noted that the fully-diluted value of the Consideration, as described above, was within the reference ranges calculated in the licensing agreement analysis and the cost to recreate analysis described above, which in Scalar’s view supported its assessment of the fairness, from a financial point of view, of the Consideration to (1) the PCSC Class A Shareholders (other than the Excluded Parties) and (2) PCSC. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Implied Pro Forma Share Value Analysis<span style="font-style: normal;"> </span></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Utilizing the implied total equity value reference ranges for Freenome from the licensing agreement multiples analysis and cost to recreate analysis, the pro forma ownership information provided by PCSC management and the assumptions described above, Scalar calculated the implied pro forma value of a share of New Freenome Common Stock after giving effect to the Business Combination. This analysis took into consideration the impact of the pro forma dilution described above in calculating the fully-diluted value of the Consideration. These calculations are summarized below: </div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 216pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.41pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.41pt;"><div style="font-size: 1pt;"> </div></td><td colspan="7" style="height: 6pt; width: 243.21pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 216pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 4.41pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.41pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td colspan="7" style="width: 243.21pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Implied Pro Forma Value per share of New Freenome Common Stock </div></td></tr><tr class="BRDSX_header"><td style="width: 216pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 4.41pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.41pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 71.98pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Low</div></td><td style="width: 4.41pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.41pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 76.98pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Middle</div></td><td style="width: 4.41pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.41pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 76.61pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">High </div></td></tr><tr><td style="width: 216pt; padding-top: 2.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Average of Pro Forma Value per share of New Freenome Common Stock derived from the licensing agreement multiples analysis and cost to recreate analysis</div></td><td style="width: 4.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 71.98pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.74pt; text-align: left;">$9.89</div></td><td style="width: 4.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 76.98pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.74pt; text-align: left;">$10.73</div></td><td style="width: 4.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 76.61pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.74pt; text-align: left;">$11.65</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 216pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 71.98pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 76.98pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.41pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 76.61pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Scalar noted that the assumed value of a share of New Freenome Common Stock of $10.61 was within the reference ranges calculated by the average of the licensing agreement and cost to recreate analyses described above, which in Scalar’s view supported its assessment of the fairness, from a financial point of view, of the Consideration to (1) the PCSC Class A Shareholders (other than the Excluded Parties) and (2) PCSC. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">General<span style="font-style: normal;"> </span></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The preparation of a fairness opinion is a complex process and is not necessarily susceptible to partial analysis or summary description. Selecting portions of the analyses or of the summary set forth above, without considering the analyses as a whole, could create an incomplete view of the processes underlying Scalar’s opinion. In arriving at its fairness determination, Scalar considered the results of all of its analyses and did not attribute any particular weight to any factor or analysis considered by it. Rather, Scalar made its determination as to fairness on the basis of its experience and professional judgment after considering the results of all of its analyses. No company or transaction used in the above analyses as a comparison is directly comparable to PCSC or Freenome or the Business Combination. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Scalar’s financial analyses and opinion were only one of many factors taken into consideration by the Special Committee in its evaluation of the Business Combination. Consequently, the analyses described above should not be viewed as determinative of the views of the Special Committee, the PCSC Board, or management of PCSC with respect to the Consideration or as to whether the Special Committee would have been willing to determine that different consideration was fair to PCSC and its shareholders. The Consideration was determined through arm’s-length negotiations between PCSC and the Company and was approved by the Special Committee and the PCSC Board. Scalar did not advise the PCSC Board during these negotiations, nor did it recommend any specific amount of consideration to PCSC, the Special Committee or the PCSC Board or that any specific amount of consideration constituted the only appropriate consideration for the Business Combination. The foregoing summary does not purport to be a complete description of the analyses performed by Scalar in connection with the fairness opinion and is qualified in its entirety by reference to the written opinion of Scalar attached hereto as <span style="font-weight: bold;">Annex L</span>. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Scalar and its affiliates are engaged in transaction advisory, financial reporting, litigation consulting, tax and other financial and non-financial activities and services for various persons and entities. Scalar was engaged by the Special </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Committee to render its opinion to the Special Committee and Scalar received a fee of $225,000 from PCSC for providing its services and rendering its opinion. No portion of these fees was refundable or contingent upon the consummation of the Business Combination or the conclusion reached in Scalar’s opinion. PCSC has also agreed to indemnify Scalar against certain liabilities and reimburse Scalar for certain expenses in connection with Scalar’s services. In the past two years, Scalar and its affiliates have not provided any other advisory services to PCSC or its affiliates for which Scalar and its affiliates received compensation. Since January 1, 2024, Scalar has performed valuation services for affiliates of the Sponsor for which Scalar received approximately $340,000 in aggregate compensation. Scalar and its affiliates may also seek to provide such services to the Company, PCSC, and their respective affiliates in the future and expect to receive fees for the rendering of these services. In the ordinary course of business, certain of Scalar’s employees and affiliates, or entities in which they have invested, may hold or trade, for their own accounts and the accounts of their investors, securities of the Company and PCSC and, accordingly, may at any time hold a long or short position in such securities. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The issuance of Scalar’s opinion was approved by an authorized committee of Scalar. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Special Committee selected Scalar to provide its opinion in connection with the Business Combination based on Scalar’s reputation and experience. Scalar is a valuation firm that has substantial experience in transactions similar to the Business Combination. </div> <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Scalar’s financial analyses and opinion were only one of many factors taken into consideration by the Special Committee in its evaluation of the Business Combination. Consequently, the analyses described above should not be viewed as determinative of the views of the Special Committee, the PCSC Board, or management of PCSC with respect to the Consideration or as to whether the Special Committee would have been willing to determine that different consideration was fair to PCSC and its shareholders. The Consideration was determined through arm’s-length negotiations between PCSC and the Company and was approved by the Special Committee and the PCSC Board. Scalar did not advise the PCSC Board during these negotiations, nor did it recommend any specific amount of consideration to PCSC, the Special Committee or the PCSC Board or that any specific amount of consideration constituted the only appropriate consideration for the Business Combination. The foregoing summary does not purport to be a complete description of the analyses performed by Scalar in connection with the fairness opinion and is qualified in its entirety by reference to the written opinion of Scalar attached hereto as <span style="font-weight: bold;">Annex L</span>. </div> Scalar and its affiliates are engaged in transaction advisory, financial reporting, litigation consulting, tax and other financial and non-financial activities and services for various persons and entities. 225000 In the past two years, Scalar and its affiliates have not provided any other advisory services to PCSC or its affiliates for which Scalar and its affiliates received compensation. Since January 1, 2024, Scalar has performed valuation services for affiliates of the Sponsor for which Scalar received approximately $340,000 in aggregate compensation. Scalar and its affiliates may also seek to provide such services to the Company, PCSC, and their respective affiliates in the future and expect to receive fees for the rendering of these services. <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Interests of PCSC’s Directors and Executive Officers, Sponsor and Others in the Business Combination </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In considering the recommendation of the PCSC Board in favor of approval of the Business Combination Proposal, the Domestication Proposal, the Governing Documents Proposal, each of the Advisory Governing Documents Proposals, the Nasdaq Proposal, the Equity Incentive Plan Proposal, the Employee Stock Purchase Plan Proposal and the Adjournment Proposal, PCSC shareholders should keep in mind that the Sponsor, the Perceptive PIPE Investor, and PCSC’s officers and directors have interests in the Business Combination that are different from or in addition to (and which may conflict with) the interests of unaffiliated PCSC shareholders. Further, PCSC’s officers and directors have additional fiduciary or contractual obligations to other entities pursuant to which such officer or director is or will be required to present a business combination opportunity to such entity, which are set forth in more detail in the section titled “<span style="font-style: italic;">Information About PCSC—Conflicts of Interest</span>.” We believe there were no such opportunities that were not presented as a result of the existing fiduciary or contractual obligations of our officers and directors to other entities. The PCSC Board was aware of and considered these interests, among other matters, in evaluating and negotiating the Business Combination and Business Combination Agreement and in recommending to our shareholders that they vote in favor of the proposals to be presented at the extraordinary general meeting, including the Business Combination Proposal. PCSC shareholders should take these interests into account in deciding whether to approve the proposals presented at the extraordinary general meeting, including the Business Combination Proposal. These interests include, among other things: </div><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the fact that the Sponsor invested in PCSC an aggregate of $2,887,500, comprised of the $25,000 purchase price for 2,156,250 PCSC Class B Shares, or approximately $0.01 per share, and the $2,862,500 purchase price for 286,250 private placement shares at a purchase price of $10.00 per share. Subsequent to the initial purchase of the PCSC Class B Shares by the Sponsor, the Sponsor transferred 30,000 PCSC Class B Shares, to each of PCSC’s three independent directors, being Mark C. McKenna, Kenneth Song M.D., and Harlan W. Waksal, M.D. Such shares will have a significantly higher value at the time of the Business Combination or be worthless if the Business Combination is not consummated and PCSC is liquidated. Assuming a trading price of $13.58 per share of New Freenome Common Stock (based upon the closing price of the PCSC Class A Shares on the Nasdaq Capital Market on January 6, 2026), such 2,442,500 shares of New Freenome Common Stock that are expected to be issued to our initial shareholders at Closing would have an implied aggregate market value of $33.12 million (based upon the closing price of the PCSC Class A Shares on January 6, 2026). However, given that such shares of New Freenome Common Stock will be subject to certain restrictions, including those described elsewhere in this proxy statement/prospectus, PCSC believes such shares of New Freenome Common Stock have less value. Even if the trading price of the New Freenome Common Stock were as low as approximately $1.19 per share, the aggregate market value of such shares of New Freenome Common Stock held by the initial shareholders would be approximately equal to the initial investment in PCSC by the initial shareholders. Therefore, the Sponsor and its affiliates could earn a positive rate of return on their investments, even if other PCSC shareholders experience a negative rate of return in New Freenome and PCSC’s directors and officers and the Sponsor may have a conflict of interest in determining whether a particular business is an appropriate business with which to effectuate an initial business combination; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the fact that, as a result of the low purchase price paid for the PCSC Class B Shares, if the Business Combination is completed, the Sponsor and PCSC’s independent directors (Messrs. McKenna, Song and Waksal) are likely to be able to make a substantial profit on their investment in PCSC even at a time when the New Freenome Common Stock has lost significant value. Accordingly, the economic interests of the Sponsor and PCSC’s independent directors diverge from the economic interests of public shareholders because the Sponsor and PCSC’s independent directors will realize a gain on its investment from the completion of any business combination while public shareholders will realize a gain only if the post-closing trading price exceeds $10.00 per share; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the fact that the initial shareholders have agreed not to redeem any PCSC Shares held by them in connection with a shareholder vote to approve a Business Combination; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the fact that the initial shareholders have agreed to vote any PCSC Shares owned by them in favor of the Business Combination Proposal; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the fact that the initial shareholders have agreed to waive their rights to liquidating distributions from the trust account with respect to any PCSC Shares (other than public shares subsequently acquired by them) held by them if the Business Combination is not approved and PCSC fails to complete the Business Combination by June 13, 2026; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the fact that the Business Combination Agreement provides for the continued indemnification of PCSC’s existing directors and officers and requires PCSC to purchase, or cause to be purchased, at or prior to the Effective Time, and New Freenome to maintain in effect for a period of six years after the Effective Time, a “tail” policy providing directors’ and officers’ liability insurance coverage for certain PCSC directors and officers after the Business Combination; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the fact that the Sponsor and PCSC’s officers and directors will lose their entire investment in PCSC and will not be reimbursed for any loans extended, fees due or out-of-pocket expenses incurred on PCSC’s behalf related to identifying, investigating, negotiating and completing an initial business combination if the Business Combination is not consummated by June 13, 2026. As of the date of this proxy statement/prospectus, PCSC does not owe the Sponsor any outstanding sums pursuant to any working capital loans, promissory notes, the existing administrative services and indemnification agreement between PCSC and the Sponsor, or otherwise; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the fact that, in connection with the Closing and immediately prior to the Effective Time, the Sponsor may elect to contribute Working Capital Loans, of up to $3,000,000, to PCSC in exchange for Working Capital Shares, which are convertible at the option of the Sponsor into shares of New Freenome Common Stock, at a conversion price of $10.00 per share; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the fact that if the trust account is liquidated, including in the event PCSC is unable to complete an initial business combination within the required time period, the Sponsor has agreed to indemnify PCSC to ensure that the proceeds in the trust account are not reduced below $10.00 per public share, or such lesser per public share amount as is in the trust account, by the claims of prospective target businesses with which PCSC has entered into an acquisition agreement or claims of any third party for services rendered or products sold to PCSC, but only if such a vendor or target business has not executed a waiver of any and all rights to seek access to the trust account; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the fact that if the Business Combination or another business combination is not consummated by June 13, 2026, PCSC will cease all operations except for the purpose of winding up, redeeming 100% of the outstanding PCSC Class A Shares for cash and, subject to the approval of its remaining shareholders and the PCSC Board, liquidating and dissolving; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the fact that the Investor Rights Agreement was entered into with the initial shareholders, the Perceptive PIPE Investor and certain Freenome stockholders, which, among other things, (a) gives the initial shareholders, the Perceptive PIPE Investor and certain Freenome stockholders certain registration rights, including the right to have the offer and sale of their shares of New Freenome Common Stock registered on a resale registration statement to be filed by New Freenome shortly after the consummation of the Business Combination; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the fact that the Sponsor Letter Agreement was executed with the initial shareholders, pursuant to which the initial shareholders, among other things, waive all adjustments to the conversion ratio set forth in the Existing Governing Documents with respect to the PCSC Class B Shares, and agree to be bound by certain transfer restrictions with respect to PCSC Shares prior to the consummation of the Business Combination, in each case subject to the terms and conditions set forth therein. No consideration has been or will be paid to PCSC, Freenome or the initial shareholders in connection with the entry into the Sponsor Letter Agreement; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the fact that the Perceptive PIPE Investor has entered into a subscription agreement to purchase 5,500,000 shares in the PIPE Financing, subject to the terms and conditions set forth in the Subscription Agreement executed by the Perceptive PIPE Investor. For more information on the assumptions underlying the number of shares described in the foregoing as being issuable on the Closing Date, please see “<span style="font-style: italic;">Risk Factors—Risks Related to the Business Combination and PCSC—PCSC shareholders will experience immediate dilution as a consequence of the issuance of New Freenome Common Stock as consideration in the Business Combination. Having a minority share position may reduce the influence that PCSC’s current shareholders have on the management of New Freenome</span>;” </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the fact that the Perceptive PIPE Investor, which is an affiliate of the Sponsor and certain of PCSC’s directors and officers, has a fully diluted equity ownership stake in Freenome of 7.89% (representing shares of Series B, C, D and F Freenome Preferred Stock), which, assuming a no redemption scenario, will convert into 5,615,003 shares of New Freenome Common Stock, or an approximately 12.04% equity stake in New Freenome in connection with the Business Combination. PCSC estimates that, at the Closing, if unrestricted and freely tradeable, such shares would be valued at approximately $184.1 million, based on the $13.58 closing price of the PCSC Class A Shares on January 6, 2026. However, given that such shares of New Freenome Common Stock will be subject to certain restrictions, including those described elsewhere in this proxy statement/prospectus, PCSC believes such shares have less value. See the assumptions underlying such ownership percentages described in the section entitled “<span style="font-style: italic;">Beneficial Ownership of Securities</span>” and more information to consider under “<span style="font-style: italic;">Risk Factors—Risks Related to the Business Combination and PCSC—PCSC shareholders will experience immediate dilution as a consequence of the issuance of New Freenome Common Stock as consideration in the Business Combination. Having a minority share position may reduce the influence that PCSC’s current shareholders have on the management of New Freenome</span>.” Actual number of shares of New Freenome Common Stock issuable on the Closing Date will be determined pursuant to the terms of the Subscription Agreements and the Business Combination Agreement, as applicable; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the fact that Dr. Hukkelhoven, an executive officer of the Perceptive PIPE Investor, is a director of Freenome; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the fact that Joseph Edelman, Adam Stone, Michael Altman and Sam Cohn are affiliated with the Perceptive PIPE Investor; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the right of the Sponsor and the Perceptive PIPE Investor to hold shares of New Freenome Common Stock following the Business Combination, subject to the terms and conditions of the lock-up restrictions; and </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the fact that PCSC may be entitled to distribute or pay over funds held by PCSC outside the Trust Account to the Sponsor or any of its Affiliates prior to the Closing. </div></td></tr></table> <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Tax Consequences to U.S. Holders of Public Shares That Elect to Exercise Redemption Rights</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">This section is addressed to U.S. Holders of Public Shares that elect to exercise redemption rights to receive cash in exchange for Public Shares in the PCSC Shareholder Redemption. For purposes of this discussion, a “<span style="font-weight: bold;">Converting U.S. Holder</span>” is a U.S. Holder that elects to exercise redemption rights in respect of all or a portion of its Public Shares.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The U.S. federal income tax consequences to a Converting U.S. Holder will depend on whether the redemption of the U.S. Holder’s Public Shares in the PCSC Shareholder Redemption qualifies as a sale of Public Shares under Section 302 of the Code or is treated as a distribution under Section 301 of the Code with respect to the Converting U.S. Holder. If the redemption qualifies as a sale of such U.S. Holder’s Public Shares, such U.S. Holder will generally recognize capital gain or capital loss equal to the difference, if any, between the amount of cash received and such </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">U.S. Holder’s tax basis in Public Shares redeemed. A U.S. Holder’s adjusted tax basis in its Public Shares will generally be equal to the amount such U.S. Holder paid for such Public Shares. This gain or loss should generally be long-term capital gain or loss if the holding period of such Public Shares is more than one year at the time of the redemption. However, it is possible that because of the redemption rights associated with the Public Shares, the holding period of such shares may not be considered to begin until the date of such redemption (and, thus, it is possible that long-term capital gain or loss treatment may not apply). The deductibility of capital losses is subject to limitations. Shareholders who hold different blocks of Public Shares (generally, Public Shares purchased or acquired on different dates or at different prices) are urged to consult their tax advisors to determine how the above rules apply to them.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">A U.S. Holder’s redemption of Public Shares in the PCSC Shareholder Redemption generally will qualify as a sale if such redemption (i) is “substantially disproportionate,” (ii) results in a “complete termination” of such U.S. Holder’s interest in PCSC or (iii) is “not essentially equivalent to a dividend” with respect to the Converting U.S. Holder. For purposes of such tests with respect to a Converting U.S. Holder, that Converting U.S. Holder may be deemed to own not only shares actually owned, but also constructively owned, which in some cases may include shares such Converting U.S. Holder may acquire pursuant to options and shares owned by certain family members, certain estates and trusts of which the Converting U.S. Holder is a beneficiary and certain corporations and partnerships.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Generally, the redemption will be “substantially disproportionate” with respect to the Converting U.S. Holder if (i) the Converting U.S. Holder’s percentage ownership (including constructive ownership) of the outstanding voting shares (including all classes that carry voting rights) of PCSC is reduced immediately after the redemption to less than 80% of the Converting U.S. Holder’s percentage interest (including constructive ownership) in such shares immediately before the redemption; (ii) the Converting U.S. Holder’s percentage ownership (including constructive ownership) of the outstanding PCSC shares (both voting and nonvoting) immediately after the redemption is reduced to less than 80% of such percentage ownership (including constructive ownership) immediately before the redemption; and (iii) the Converting U.S. Holder owns (including constructive ownership), immediately after the redemption, less than 50% of the total combined voting power of all classes of shares of PCSC entitled to vote. There will be a “complete termination” of such Converting U.S. Holder’s interest if either (i) all of the PCSC shares actually and constructively owned by such Converting U.S. Holder are redeemed or (ii) all of the PCSC shares actually owned by such Converting U.S. Holder are redeemed and such Converting U.S. Holder is eligible to waive, and effectively waives in accordance with specific rules, the attribution of the PCSC shares owned by certain family members and such Converting U.S. Holder does not constructively own any other PCSC shares (including as a result of options or convertible securities) and otherwise complies with specific conditions. Whether the redemption will be considered “not essentially equivalent to a dividend” with respect to a Converting U.S. Holder will depend upon the particular circumstances of that Converting U.S. Holder. However, the redemption generally must result in a meaningful reduction in the Converting U.S. Holder’s actual or constructive percentage ownership of PCSC. Whether the redemption will result in a “meaningful reduction” in such Converting U.S. Holder’s proportionate interest will depend on the particular facts and circumstances applicable to it. If the Converting U.S. Holder’s relative interest in PCSC is a small minority interest and the shareholder exercises no control over corporate affairs, taking into account the effect of redemptions by other shareholders, and its percentage ownership (including constructive ownership) is reduced as a result of the redemption, such Converting U.S. Holder may be regarded as having a meaningful reduction in its interest pursuant to a published ruling in which the IRS indicated that even a small reduction in the proportionate interest of a small minority shareholder in a publicly held corporation who exercises no control over corporate affairs may constitute such a “meaningful reduction.” A U.S. Holder is urged to consult with its tax advisors as to the tax consequences to it of any redemption of its Public Shares.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">If none of the tests described above applies, the consideration paid to the Converting U.S. Holder generally will be treated as dividend income for U.S. federal income tax purposes to the extent of PCSC’s current or accumulated earnings and profits. Any distribution in excess of such earnings and profits will reduce the Converting U.S. Holder’s basis in the Public Shares (but not below zero) and any remaining excess will be treated as capital gain realized on the sale or other disposition of the Public Shares. After the application of those rules, any remaining tax basis of the Converting U.S. Holder in the Public Shares redeemed will generally be added to the Converting U.S. Holder’s adjusted tax basis in its remaining Public Shares. U.S. Holders who hold different blocks of Public Shares (generally, shares of PCSC purchased or acquired on different dates or at different prices) are urged to consult their tax advisors to determine how the above rules apply to them.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Because the Domestication will occur after PCSC Shareholder Redemptions, U.S. Holders exercising redemption rights should not be subject to the potential tax consequences of Section 367(b) of the Code as a result of the Domestication (discussed further above).</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">ALL U.S. HOLDERS ARE URGED TO CONSULT THEIR TAX ADVISORS AS TO THE TAX CONSEQUENCES TO THEM OF A REDEMPTION OF ALL OR A PORTION OF THEIR PUBLIC SHARES PURSUANT TO AN EXERCISE OF REDEMPTION RIGHTS.<span style="font-weight: normal;"> </span></div> <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Tax Consequences of the Mergers to U.S. Holders of Freenome Common Stock</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In accordance with the Business Combination Agreement, the parties to the Business Combination Agreement intend that the Mergers, taken together as an integrated transaction (referred to herein as the “Integrated Merger”), qualify as a “reorganization” within the meaning of Section 368(a) of the Code and that each of Freenome, New Freenome, Merger Sub I and Merger Sub II will be a “party to the reorganization” within the meaning of Section 368(b) of the Code, and the Integrated Merger should qualify as a “reorganization” within the meaning of Section 368(a) of the Code. This discussion, to the extent it sets forth legal conclusions with respect to matters of U.S. federal income tax law regarding the material U.S. federal income tax consequences of the Integrated Mergers to holders of Freenome Common Stock, constitutes the opinion of Goodwin Procter LLP, based on, and subject to, customary assumptions, qualifications and limitations, and the assumptions, qualifications and limitations herein and in the opinion included as Exhibit 8.2 hereto.</div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Consequences if the Integrated Merger Qualifies as a Reorganization under Section 368(a) of the Code</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Subject to the foregoing, Freenome and New Freenome intend to report the Integrated Merger as a tax-deferred “reorganization” pursuant to Section 368(a) of the Code. However, neither Freenome nor New Freenome intends to request any ruling or other guidance from the IRS on the U.S. federal income tax treatment of the Integrated Merger. Because of the many fact-specific requirements to qualify as a tax-deferred “reorganization,” no assurance can be given that the Integrated Merger will qualify as a tax-deferred reorganization or that thereunder, or that a court would not sustain such challenge. If the IRS were to successfully challenge the “reorganization” status of the Integrated Merger, the tax consequences would vary significantly from those set forth immediately below; a summary of such tax consequences is provided further below under “<span style="font-style: italic;">Consequences if the Integrated Merger Does Not Qualify as a Reorganization under Section 368(a) of the Code</span>”.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Assuming that the Integrated Merger qualifies as a “reorganization” under the provisions of Section 368(a) of the Code, in general, the following U.S. federal income tax consequences are expected to result to U.S. Holders who exchange shares of Freenome Common Stock for shares of New Freenome Common Stock in the Integrated Merger:</div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">U.S. Holders will not recognize gain or loss on the exchange of shares of Freenome Common Stock solely for shares of New Freenome Common Stock in the Integrated Merger;</div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">U.S. Holders who receive cash in lieu of fractional shares of New Freenome Common Stock in the Integrated Merger generally will be treated as having received such fractional shares in the Integrated Merger and then as having received cash in redemption of such fractional shares. Gain or loss will be recognized based on the difference between the amount of cash received in lieu of the fractional share of New Freenome Common Stock and the portion of the U.S. Holder’s adjusted tax basis in the shares of Freenome Common Stock surrendered which is allocable to the fractional share of New Freenome Common Stock, and adjusted as described above;</div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The aggregate tax basis of the shares of New Freenome Common Stock received by a U.S. Holder in the Integrated Merger generally will be the same as the aggregate tax basis of shares of Freenome Common Stock surrendered in exchange therefor, decreased by the amount of cash received and increased by the amount of gain recognized by the U.S. Holder in the Integrated Merger; and</div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The holding period of New Freenome Common Stock received by a U.S. Holder in the Integrated Merger will include the holding period of the shares of Freenome Common Stock surrendered by the U.S. Holder in the Integrated Merger.</div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">U.S. Holders should consult their tax advisors with respect to the allocation of tax basis between their stock consideration and their non-stock consideration, the amount of gain recognized, and the applicability of any tax reporting requirements to their particular circumstances.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">If the Integrated Merger qualifies as a “reorganization” within the meaning of Section 368(a) of the Code, each significant U.S. Holder receiving shares of New Freenome Common Stock in the Integrated Merger would be required </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">to file a statement with its U.S. federal income tax return containing the information listed in Treasury Regulations Section 1.368-3, including the U.S. Holder’s tax basis in the shares of Freenome Common Stock exchanged therefor and a description of the parties to the reorganization. A significant U.S. Holder includes any U.S. Holder who, immediately before the reorganization, either (i) owned at least 1% (by vote or value) of the outstanding capital stock of Freenome or (ii) owned securities of Freenome that had an adjusted tax basis of $1,000,000 or more. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Consequences if the Integrated Merger Does Not Qualify as a Reorganization under Section 368(a) of the Code</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">A successful IRS challenge to the “reorganization” status of the Integrated Merger would result in U.S. Holders being treated as if they sold their shares of Freenome Common Stock in a fully taxable transaction in the First Merger. In that case, a U.S. Holder would recognize gain or loss equal to the difference between the amount of cash and the fair market value of New Freenome Common Stock received by such U.S. Holder in the First Merger and the U.S. Holder’s adjusted tax basis of the shares of Freenome Common Stock surrendered in the exchange. Such recognized gain or loss will be long-term capital gain or loss if the shares of Freenome Common Stock have been held for more than one year as of the date of the First Merger, and will be short-term capital gain or loss if the shares of Freenome Common Stock have been held for one year or less. The amount and character of gain or loss will be computed separately for each block of shares of Freenome Common Stock that was purchased by the U.S. Holder in the same transaction.</div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Non-U.S. Holders </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.5pt; margin-left: 0pt; text-align: left;">Tax Consequences for Non-U. S. Holders of Owning and Disposing of New Freenome Common Stock</div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Distributions on New Freenome Common Stock. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Distributions of cash or property to a Non-U.S. Holder in respect of New Freenome Common Stock received in the Domestication generally will constitute dividends for U.S. federal income tax purposes to the extent paid from New Freenome’s current or accumulated earnings and profits, as determined under U.S. federal income tax principles. If a distribution exceeds New Freenome’s current and accumulated earnings and profits, the excess will generally be treated first as a tax-free return of capital to the extent of the Non-U.S. Holder’s adjusted tax basis in its New Freenome Common Stock. Any remaining excess will be treated as capital gain and will be treated as described below under “—<span style="font-style: italic;">Gain on Disposition of New Freenome Common Stock</span>.”</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Dividends paid to a Non-U.S. Holder of New Freenome Common Stock generally will be subject to withholding of U.S. federal income tax at a 30% rate unless such Non-U.S. Holder is eligible for a reduced rate of withholding tax under an applicable income tax treaty and provides proper certification of its eligibility for such reduced rate as described below. However, dividends that are effectively connected with the conduct of a trade or business by the Non-U.S. Holder within the United States (and, if required by an applicable income tax treaty, are attributable to a U.S. permanent establishment or fixed base of the Non-U.S. Holder) are not subject to such withholding tax, provided certain certification and disclosure requirements are satisfied (generally by providing an IRS Form W-8ECI). Instead, such dividends are subject to United States federal income tax on a net income basis in the same manner as if the Non-U.S. Holder were a United States person as defined under the Code. Any such effectively connected dividends received by a foreign corporation may be subject to an additional “branch profits tax” at a 30% rate or such lower rate as may be specified by an applicable income tax treaty.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">A Non-U.S. Holder of New Freenome Common Stock who wishes to claim the benefit of an applicable treaty rate and avoid backup withholding, as discussed below, for dividends will be required (a) to complete the applicable IRS Form W-8 and certify under penalty of perjury that such holder is not a United States person as defined under the Code and is eligible for treaty benefits or (b) if such Non-U.S. Holder’s New Freenome Common Stock is held through certain foreign intermediaries, to satisfy the relevant certification requirements of applicable United States Treasury Regulations. Special certification and other requirements apply to certain Non-U.S. Holders that are pass-through entities rather than corporations or individuals.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">A Non-U.S. Holder of New Freenome Common Stock eligible for a reduced rate of U.S. withholding tax pursuant to an income tax treaty may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. Non-U.S. Holders are urged to consult their tax advisors regarding their entitlement to the benefits under any applicable income tax treaty.</div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Gain on Disposition of New Freenome Common Stock. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Subject to the below discussion of backup withholding and the Foreign Account Tax Compliance Act (as defined below), any gain realized by a Non-U.S. Holder on the taxable disposition of New Freenome Common Stock generally will not be subject to U.S. federal income tax unless: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the gain is effectively connected with a trade or business of the Non-U.S. Holder in the United States (and, if required by an applicable income tax treaty, is attributable to a United States permanent establishment or fixed base of the Non-U.S. Holder); </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the Non-U.S. Holder is an individual who is present in the United States for a period or periods aggregating 183 days or more in the taxable year of the disposition, and certain other conditions are met; or </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">New Freenome is or has been a “United States real property holding corporation” for U.S. federal income tax purposes at any time during the shorter of the five-year period ending on the date of disposition or the Non-U.S. Holder’s holding period for such securities disposed of, and either (A) New Freenome Common Stock is not considered to be regularly traded on an established securities market or (B) such Non-U.S. Holder has owned or is deemed to have owned, at any time during the shorter of the five-year period preceding such disposition and such Non-U.S. Holder’s holding period more than 5% of outstanding New Freenome Common Stock. There can be no assurance that New Freenome Common Stock will be treated as regularly traded on an established securities market for this purpose. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">A non-corporate Non-U.S. Holder described in the first bullet point immediately above will be subject to tax on the net gain derived from the sale of New Freenome Common Stock under regular U.S. federal income tax rates. An individual Non-U.S. Holder described in the second bullet point immediately above will be subject to a flat 30% tax on the gain derived from the sale of New Freenome Common Stock, which may be offset by certain United States source capital losses, even though the individual is not considered a resident of the United States, provided that the individual has timely filed U.S. federal income tax returns with respect to such losses. If a Non-U.S. Holder that is a foreign corporation falls under the first bullet point immediately above, it will be subject to tax on its net gain in the same manner as if it were a United States person as defined under the Code and, in addition, may be subject to the “branch profits tax” equal to 30% (or such lower rate as may be specified by an applicable income tax treaty) of its effectively connected earnings and profits, subject to adjustments.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">If the last bullet point immediately above applies to a Non-U.S. Holder, gain recognized by such Non-U.S. Holder on the sale, exchange or other disposition of New Freenome Common Stock generally will be subject to tax at generally applicable U.S. federal income tax rates. In addition, a buyer of such New Freenome Common Stock from a Non-U.S. Holder may be required to withhold U.S. income tax at a rate of 15% of the amount realized upon such disposition. New Freenome generally will be classified as a “U.S. real property holding corporation” if the fair market value of its “United States real property interests” equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests and its other assets used or held for use in a trade or business, as determined for U.S. federal income tax purposes. New Freenome does not expect to be classified as a “U.S. real property holding corporation” following the Business Combination. However, such determination is factual in nature and subject to change, and no assurance can be provided as to whether New Freenome is or will be a U.S. real property holding corporation with respect to a Non-U.S. Holder following the Business Combination or at any future time.</div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Information Reporting and Backup Withholding</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">New Freenome generally must report annually to the IRS and to each Non-U.S. Holder the amount of dividends paid to such holder and the tax withheld with respect to such dividends, regardless of whether withholding was required. Copies of the information returns reporting such dividends and withholding may also be made available to the tax authorities in the country in which the Non-U.S. Holder resides under the provisions of an applicable income tax treaty.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">A Non-U.S. Holder generally will be subject to backup withholding for dividends paid to such holder unless such holder certifies under penalty of perjury that it is a Non-U.S. Holder (and the payor does not have actual knowledge or reason to know that such holder is a United States person as defined under the Code), or such holder otherwise establishes an exemption.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Information reporting and, depending on the circumstances, backup withholding generally will apply to the proceeds of a sale of New Freenome Common Stock within the United States or conducted through certain United </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">States-related financial intermediaries, unless the beneficial owner certifies under penalty of perjury that it is a Non-U.S. Holder (and the payor does not have actual knowledge or reason to know that the beneficial owner is a United States person as defined under the Code), or such owner otherwise establishes an exemption.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against a Non-U.S. Holder’s U.S. federal income tax liability provided the required information is timely furnished to the IRS.</div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Foreign Account Tax Compliance Act</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Sections 1471 through 1474 of the Code and the Treasury Regulations and administrative guidance promulgated there under (commonly referred as the “<span style="font-weight: bold;">Foreign Account Tax Compliance Act</span>” or “<span style="font-weight: bold;">FATCA</span>”) generally impose withholding at a rate of 30% in certain circumstances on dividends in respect of, and (subject to the proposed Treasury Regulations discussed below) gross proceeds from the sale or other disposition of, securities (including New Freenome Common Stock) which are held by or through certain foreign financial institutions (including investment funds), unless any such institution (i) enters into, and complies with, an agreement with the IRS to report, on an annual basis, information with respect to interests in, and accounts maintained by, the institution that are owned by certain U.S. persons and by certain non-U.S. entities that are wholly or partially owned by U.S. persons and to withhold on certain payments or (ii) if required under an inter-governmental agreement between the U.S. and an applicable foreign country, reports such information to its local tax authority, which will exchange such information with the U.S. authorities. An inter-governmental agreement between the U.S. and an applicable foreign country may modify these requirements. Accordingly, the entity through which New Freenome Common Stock are held will affect the determination of whether such withholding is required. Similarly, dividends in respect of, and (subject to the proposed Treasury Regulations discussed below) gross proceeds from the sale or other disposition of, New Freenome Common Stock held by an investor that is a non-financial non-U.S. entity that does not qualify under certain exceptions will generally be subject to with-holding at a rate of 30%, unless such entity either (i) certifies to the applicable with holding agent that such entity does not have any “substantial United States owners” or (ii) provides certain information regarding the entity’s “substantial United States owners,” which will in turn be provided to the U.S. Department of Treasury. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Under the applicable Treasury Regulations and administrative guidance, withholding under FATCA generally applies to payments of dividends in respect of New Freenome Common Stock. While withholding under FATCA generally would also apply to payments of gross proceeds from the sale or other disposition of securities (including New Freenome Common Stock), proposed Treasury Regulations eliminate FATCA withholding on payments of gross proceeds entirely. Tax-payers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued. All holders should consult their tax advisors regarding the possible implications of FATCA on their investment in New Freenome Common Stock. </div> <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Anticipated Accounting Treatment of the Business Combination </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Business Combination is expected to be accounted for as a reverse recapitalization in accordance with U.S. GAAP, whereby PCSC is treated as the acquired company and Freenome is treated as the accounting acquirer. Accordingly, for accounting purposes, the Business Combination will be treated as the equivalent of Freenome issuing stock for the net assets of PCSC, accompanied by a recapitalization. The net assets of PCSC will be stated at fair value, which approximates their historical cost, with no goodwill or other intangible assets recorded. Subsequently, results of operations presented for the periods prior to the Business Combination will be for those of Freenome. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Freenome has been determined to be the accounting acquirer in the Business Combination based on the following predominate factors: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Freenome’s existing shareholders will have the greatest voting interest in the combined entity under the no redemption and maximum redemption scenarios with over 63% of the voting interest in each scenario; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Freenome will have the ability to designate a majority of the initial members of New Freenome’s Board; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Freenome’s senior management will be the senior management of the combined entity; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Freenome is the larger entity based on historical operating activity and has the larger employee base; and </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The post-combined company will assume a Freenome branded name: “Freenome, Inc.” </div></td></tr></table> <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The following table presents the net tangible book value per share at various redemption levels that may occur in connection with the consummation of the Business Combination assuming various sources of material probable dilution, but excluding the effects of the Business Combination transaction itself. This presentation takes into account the PIPE Financing, the reclassification of unredeemed public shares of PCSC to permanent equity, and the payment of PCSC’s estimated transaction costs in connection with the potential Business Combination. In addition to excluding the Business Combination itself, this presentation excludes (i) 8,252,587 shares of New Freenome Common Stock that will be issuable upon the exercise of the Rollover Options, (ii) 4,294,391 shares of New Freenome Common Stock that will be issuable pursuant to the Rollover RSU Awards, (iii) 6,420,139 shares of New Freenome Common Stock that will be issuable upon conversion of the Roche Convertible Note, and (iv) shares of New Freenome Common Stock, that will initially be available for issuance under the New Freenome Equity Incentive Plan and New Freenome Employee Stock Purchase Plan. </div> <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The following table presents the net tangible book value per share at various redemption levels that may occur in connection with the consummation of the Business Combination assuming various sources of material probable dilution, but excluding the effects of the Business Combination transaction itself. This presentation takes into account the PIPE Financing, the reclassification of unredeemed public shares of PCSC to permanent equity, and the payment of PCSC’s estimated transaction costs in connection with the potential Business Combination. In addition to excluding the Business Combination itself, this presentation excludes (i) 8,252,587 shares of New Freenome Common Stock that will be issuable upon the exercise of the Rollover Options, (ii) 4,294,391 shares of New Freenome Common Stock that will be issuable pursuant to the Rollover RSU Awards, (iii) 6,420,139 shares of New Freenome Common Stock that will be issuable upon conversion of the Roche Convertible Note, and (iv) shares of New Freenome Common Stock, that will initially be available for issuance under the New Freenome Equity Incentive Plan and New Freenome Employee Stock Purchase Plan. </div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 120pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="height: 6pt; width: 82.45pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="height: 6pt; width: 82.08pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="height: 6pt; width: 82.45pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="height: 6pt; width: 82.45pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 120pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="width: 82.45pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">No Redemptions <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Scenario⁽¹⁾</div></td><td style="width: 2.32pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="width: 82.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">25% Redemptions <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Scenario⁽²⁾</div></td><td style="width: 2.32pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="width: 82.45pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">50% Redemptions <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Scenario⁽³⁾</div></td><td style="width: 2.32pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="width: 82.45pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Aggregate Transaction <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Proceeds Condition <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Redemptions <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Scenario⁽⁴⁾ </div></td></tr><tr class="BRDSX_header"><td style="width: 120pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares*</div></td><td style="width: 2.32pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 32.81pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Tangible <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Book <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value per <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Share**</div></td><td style="width: 2.32pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.63pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares*</div></td><td style="width: 2.32pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 32.81pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Tangible <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Book <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value per <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Share**</div></td><td style="width: 2.32pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares*</div></td><td style="width: 2.32pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 32.81pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Tangible <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Book <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value per <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Share**</div></td><td style="width: 2.32pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares*</div></td><td style="width: 2.32pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 32.81pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Tangible <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Book <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value per <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Share** </div></td></tr><tr><td style="width: 120pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">PCSC net tangible book value per share as of December 31, 2025</div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 0.37pt;">11,067,500</span></div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 32.81pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.65pt; text-align: left;">($<span style="padding-left: 5pt;">0.43)</span></div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.63pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">11,067,500</div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 32.81pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.65pt; text-align: left;">($<span style="padding-left: 5pt;">0.43)</span></div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 0.37pt;">11,067,500</span></div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 32.81pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.66pt; text-align: left;">($<span style="padding-left: 5pt;">0.43)</span></div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 0.37pt;">11,067,500</span></div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 32.81pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.66pt; text-align: left;">($<span style="padding-left: 5pt;">0.43) </span></div></td></tr><tr><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">PCSC shareholders and PIPE Investors, after the redemption of public shares and payment of estimated transaction costs</div></td><td style="width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">35,067,500</div></td><td style="width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 32.81pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.65pt; text-align: left;">$<span style="padding-left: 5pt;">​9.15</span></div></td><td style="width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.63pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">32,911,250</div></td><td style="width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 32.81pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.65pt; text-align: left;">$<span style="padding-left: 5pt;">9.05</span></div></td><td style="width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">30,755,000</div></td><td style="width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 32.81pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.66pt; text-align: left;">$<span style="padding-left: 5pt;">8.94</span></div></td><td style="width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">28,499,378</div></td><td style="width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 32.81pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.66pt; text-align: left;">$<span style="padding-left: 5pt;">8.80 </span></div></td></tr><tr><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Initial offering price of PCSC Class A Shares</div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 32.81pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.65pt; text-align: left;">$10.00</div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.63pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 32.81pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.65pt; text-align: left;">$10.00</div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 32.81pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.66pt; text-align: left;">$10.00</div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 32.81pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.66pt; text-align: left;">$10.00 </div></td></tr><tr><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Net tangible book value per share giving effect to dilutive securities and other related events, excluding the Business Combination</div></td><td style="width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 32.81pt; padding-top: 1.01pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.65pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">9.15</span></div></td><td style="width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.63pt; padding-top: 1.01pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 32.81pt; padding-top: 1.01pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.65pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">9.05</span></div></td><td style="width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 32.81pt; padding-top: 1.01pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.66pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">8.94</span></div></td><td style="width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 32.81pt; padding-top: 1.01pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.66pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">8.80 </span></div></td></tr><tr><td style="width: 120pt; padding-top: 3.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Dilution to non-redeeming shareholders</div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 32.81pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.65pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">0.85</span></div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.63pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 32.81pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.65pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">0.95</span></div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 32.81pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.66pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">1.06</span></div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 32.81pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.66pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">1.20</span></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 120pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 45pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 32.81pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 44.63pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 32.81pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 45pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 32.81pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 45pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 2.32pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 32.81pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">See table below for a reconciliation of the number of shares. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">**<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">See table below for the calculation of the net tangible book value per share. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The calculation of net tangible book value is as follows (in thousands, except share amounts): </div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 240pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.98pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.98pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 53.54pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.98pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.98pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 44.88pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.98pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.98pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 44.87pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.98pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.98pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 44.87pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 240pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Numerator Adjustments</div></td><td style="width: 4.98pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.98pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 53.54pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">No Redemption <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Scenario⁽¹⁾</div></td><td style="width: 4.98pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.98pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.88pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">25% <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Redemptions <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Scenario⁽²⁾</div></td><td style="width: 4.98pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.98pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.87pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">50% <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Redemptions <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Scenario⁽³⁾</div></td><td style="width: 4.98pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.98pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.87pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Aggregate <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Transaction <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Proceeds <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Condition <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Redemptions <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Scenario⁽⁴⁾ </div></td></tr><tr><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net tangible book value of PCSC as of December 31, 2025</div></td><td style="width: 4.98pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.98pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 53.54pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.02pt; text-align: left;">$<span style="padding-left: 6.67pt;">​(4,797)</span></div></td><td style="width: 4.98pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.98pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.88pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.68pt; text-align: left;">$<span style="padding-left: 6.67pt;">(4,797)</span></div></td><td style="width: 4.98pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.98pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.87pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.68pt; text-align: left;">$<span style="padding-left: 6.67pt;">(4,797)</span></div></td><td style="width: 4.98pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.98pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.87pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.68pt; text-align: left;">$<span style="padding-left: 6.67pt;">(4,797) </span></div></td></tr><tr><td style="width: 240pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Adjustment to reflect the proceeds from PIPE Financing</div></td><td style="width: 4.98pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.98pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 53.54pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.02pt; text-align: left;"><span style="padding-left: 5pt;">240,000</span></div></td><td style="width: 4.98pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.98pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.88pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.68pt; text-align: left;"><span style="padding-left: 5pt;">240,000</span></div></td><td style="width: 4.98pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.98pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.87pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.68pt; text-align: left;"><span style="padding-left: 5pt;">240,000</span></div></td><td style="width: 4.98pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.98pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.87pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.68pt; text-align: left;"><span style="padding-left: 5pt;">240,000</span> </div></td></tr><tr><td style="width: 240pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Adjustment to reflect reclassification of unredeemed public shares of PCSC to permanent equity</div></td><td style="width: 4.98pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.98pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 53.54pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.02pt; text-align: left;"><span style="padding-left: 10pt;">91,872</span></div></td><td style="width: 4.98pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.98pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.88pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.68pt; text-align: left;"><span style="padding-left: 10pt;">68,904</span></div></td><td style="width: 4.98pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.98pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.87pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.68pt; text-align: left;"><span style="padding-left: 10pt;">45,936</span></div></td><td style="width: 4.98pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.98pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.87pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.68pt; text-align: left;"><span style="padding-left: 10pt;">21,909 </span></div></td></tr><tr><td style="width: 240pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Adjustment to reflect payment of transaction expenses of PCSC, net of associated liabilities</div></td><td style="width: 4.98pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.98pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 53.54pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.02pt; text-align: left;"><span style="padding-left: 11.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(6,221</span><span style="padding-bottom: 1.5pt;">)</span></div></td><td style="width: 4.98pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.98pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.88pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.68pt; text-align: left;"><span style="padding-left: 11.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(6,221</span><span style="padding-bottom: 1.5pt;">)</span></div></td><td style="width: 4.98pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.98pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.87pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.68pt; text-align: left;"><span style="padding-left: 11.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(6,221</span><span style="padding-bottom: 1.5pt;">)</span></div></td><td style="width: 4.98pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.98pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.87pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.68pt; text-align: left;"><span style="padding-left: 11.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(6,221</span><span style="padding-bottom: 1.5pt;">) </span></div></td></tr><tr><td style="width: 240pt; padding-top: 1.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Historical net tangible book value of PCSC adjusted for redemptions, proceeds from PIPE Financing, reclassification of unredeemed public shares of PCSC to permanent equity, and payment of transaction costs</div></td><td style="width: 4.98pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.98pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 53.54pt; padding-top: 1.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.02pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$320,854</span></div></td><td style="width: 4.98pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.98pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.88pt; padding-top: 1.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.68pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$297,886</span></div></td><td style="width: 4.98pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.98pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.87pt; padding-top: 1.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.68pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$274,918</span></div></td><td style="width: 4.98pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.98pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 44.87pt; padding-top: 1.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.68pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$250,891</span></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 240pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.98pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.98pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 53.54pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.98pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.98pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 44.88pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.98pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.98pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 44.87pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.98pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.98pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 44.87pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 240pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.93pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.93pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 53.54pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.93pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.93pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 45pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.93pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.93pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 45pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.93pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 4.93pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 45pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 240pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Denominator Adjustments</div></td><td style="width: 4.93pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.93pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 53.54pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">No Redemption <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Scenario⁽¹⁾</div></td><td style="width: 4.93pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.93pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">25% <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Redemptions <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Scenario⁽²⁾</div></td><td style="width: 4.93pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.93pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">50% <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Redemptions <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Scenario⁽³⁾</div></td><td style="width: 4.93pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.93pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Aggregate <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Transaction <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Proceeds <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Condition <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Redemptions <br/></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Scenario⁽⁴⁾ </div></td></tr><tr><td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Shares outstanding held by PCSC shareholders as of December 31, 2025</div></td><td style="width: 4.93pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.93pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 53.54pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.27pt; text-align: left;"><span style="padding-left: 0.37pt;">11,067,500</span></div></td><td style="width: 4.93pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.93pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 0.37pt;">11,067,500</span></div></td><td style="width: 4.93pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.93pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 0.37pt;">11,067,500</span></div></td><td style="width: 4.93pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.93pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 0.37pt;">11,067,500</span> </div></td></tr><tr><td style="width: 240pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Adjustment to reflect assumed redemption of PCSC Class A Shares</div></td><td style="width: 4.93pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.93pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 53.54pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.27pt; text-align: left;"><span style="padding-left: 35pt;">—</span></div></td><td style="width: 4.93pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.93pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 1.67pt;">(2,156,250)</span></div></td><td style="width: 4.93pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.93pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 1.67pt;">(4,312,500)</span></div></td><td style="width: 4.93pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.93pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 1.67pt;">(6,568,122) </span></div></td></tr><tr><td style="width: 240pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Adjustment to reflect shares issuable to PIPE Investors</div></td><td style="width: 4.93pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.93pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 53.54pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.27pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">24,000,000</span></div></td><td style="width: 4.93pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.93pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">24,000,000</span></div></td><td style="width: 4.93pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.93pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">24,000,000</span></div></td><td style="width: 4.93pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.93pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">24,000,000 </span></div></td></tr><tr><td style="width: 240pt; padding-top: 1.26pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">PCSC shareholders and PIPE Investors, after the redemption of PCSC Shares</div></td><td style="width: 4.93pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.93pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 53.54pt; padding-top: 1.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.27pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">35,067,500</span></div></td><td style="width: 4.93pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.93pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 0.37pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">32,911,250</span></div></td><td style="width: 4.93pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.93pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">30,755,000</span></div></td><td style="width: 4.93pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 4.93pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">28,499,378</span></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 240pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.93pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.93pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 53.54pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.93pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.93pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 45pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.93pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.93pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 45pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.93pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 4.93pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 45pt;"><div style="font-size: 1pt;"> </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">This scenario assumes that no public shares are redeemed. This scenario further assumes the closing of the PIPE Financing of $240.0 million, the reclassification of unredeemed public shares of PCSC to permanent equity of $91.9 million and payment of the estimated transaction costs of PCSC of $6.2 million, net of associated liabilities of $5.7 million. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">This scenario assumes that 2,156,250 public shares, or 25% of the Public Shares subject to redemption, are redeemed for an aggregate payment of approximately $22.9 million (based on the estimated per-share redemption price of approximately $10.65 per share) from the trust account based on funds in the trust account as of December 31, 2025. This scenario further assumes the closing of the PIPE Financing of $240.0 million, the reclassification of unredeemed public shares of PCSC to permanent equity of $68.9 million, and payment of the estimated transaction costs of PCSC of $6.2 million net of associated liabilities of $5.7 million. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">This scenario assumes that 4,312,500 public shares, or 50% of the Public Shares subject to redemption, are redeemed for an aggregate payment of approximately $45.9 million (based on the estimated per-share redemption price of approximately $10.65 per share) from the trust account based on funds in the trust account as of December 31, 2025. This scenario further assumes the closing of the PIPE Financing of $240.0 million, the reclassification of unredeemed public shares of PCSC to permanent equity of $45.9 million, and payment of the estimated transaction costs of PCSC of $6.2 million, net of associated liabilities of $5.7 million. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(4)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">This scenario assumes that 6,568,122 public shares, or approximately 76% of the public shares subject to redemption, are redeemed for an aggregate payment of approximately $70.0 million (based on the estimated per-share redemption price of approximately $10.65 per share) from the trust account based on funds in the trust account as of December 31, 2025. This scenario further assumes the closing of the PIPE Financing of $240.0 million, the reclassification of unredeemed public shares of PCSC to permanent equity of $21.9 million and payment of the estimated transaction costs of PCSC of $6.2 million, net of associated liabilities of $5.7 million. Pursuant to the Aggregate Transaction Proceeds Condition, at the Closing, aggregate transaction proceeds be greater than or equal to $250.0 million in cash, including (i) cash from the Trust Account (after reduction for the aggregate amount of payments required to be made in connection with any redemption), plus (ii) the aggregate amount of cash that has been funded pursuant to the PIPE, minus the Unpaid PCSC expenses. Thus, the redemption of 6,568,122 public shares, approximately 76% of the public shares subject to redemption, represents the estimated maximum number of public shares that can be redeemed while still achieving the Aggregate Transaction Proceeds Condition. </div></td></tr></table> 11067500 -0.43 11067500 -0.43 11067500 -0.43 11067500 -0.43 35067500 9.15 32911250 9.05 30755000 8.94 28499378 8.8 10 10 10 10 9.15 9.05 8.94 8.8 0.85 0.95 1.06 1.2 -4797000 -4797000 -4797000 -4797000 240000000 240000000 240000000 240000000 91872000 68904000 45936000 21909000 -6221000 -6221000 -6221000 -6221000 320854000 297886000 274918000 250891000 11067500 11067500 11067500 11067500 0 -2156250 -4312500 -6568122 24000000 24000000 24000000 24000000 35067500 32911250 30755000 28499378 <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Experience with Special Purpose Acquisition Vehicles </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Our management team has previous experience in the execution of public acquisition vehicles. In July 2020, ARYA Sciences Acquisition Corp. consummated its initial business combination with Immatics Biotechnologies GmbH (“<span style="font-style: italic; font-weight: bold;">Immatics</span>”). The ordinary shares of the combined company, Immatics N.V., are traded on Nasdaq under the symbol “IMTX.” Mr. Stone continues to serve on the supervisory board of directors of Immatics N.V. following the consummation of the business combination. The closing price of the ordinary shares of Immatics N.V. on Nasdaq on March 10, 2026 was $10.50. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Additionally, in October 2020, ARYA Sciences Acquisition Corp II consummated its initial business combination with Cerevel Therapeutics. The common stock of the combined company, Cerevel Therapeutics Holdings, Inc. (“<span style="font-style: italic; font-weight: bold;">Cerevel</span>”), is traded on Nasdaq under the symbol “CERE.” On August 1, 2024, Abbvie Inc. and its wholly owned acquisition subsidiaries completed an all-cash tender offer to acquire all outstanding shares of common stock of Cerevel for $45.00 per share. Following the closing of the acquisition, shares of Cerevel’s common stock were delisted from Nasdaq on August 1, 2024. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In June 2021, ARYA Sciences Acquisition Corp III consummated its initial business combination with Nautilus Biotechnology, Inc. (“<span style="font-style: italic; font-weight: bold;">Nautilus</span>”). The common stock of the combined company trades on Nasdaq under the symbol “NAUT.” The closing price of the common stock of Nautilus on Nasdaq on March 10, 2026 was $2.43. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In July 2023, ARYA Sciences Acquisition Corp V announced that it would not consummate an initial business combination within the time period required by its amended and restated memorandum and articles of association, as amended, and was liquidated after the cash held in trust was returned to its shareholders. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In July 2024, ARYA Sciences Acquisition Corp IV consummated its initial business combination with Adagio Medical, Inc. (“<span style="font-style: italic; font-weight: bold;">Adagio</span>”). The common stock of the combined company trades on Nasdaq under the symbol “ADGM.” The closing price of the common stock of Adagio on Nasdaq on March 10, 2026 was $0.96. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Our founders and our directors and officers, Perceptive Advisors, or its affiliates expect in the future to become affiliated with other public special purpose acquisition companies that may have acquisition objectives that are similar to ours. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On June 13, 2024, we consummated an initial public offering of 8,625,000 Class A ordinary shares, $0.0001 par value per share (the “<span style="font-style: italic; font-weight: bold;">PCSC Class A Shares</span>”), at an offering price of $10.00 per share, which includes the exercise in </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">full of the underwriter’s option to purchase an additional 1,125,000 PCSC Class A Shares, at an offering price of $10.00 per share, to cover over-allotments, and a Private Placement with our Sponsor of 286,250 PCSC Class A Shares at a price of $10.00 per share. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Following the closing of our initial public offering and the private placement, an amount equal to $86,250,000 of the net proceeds from its initial public offering and certain of the proceeds from the sale of the private placement were placed in the trust account, located in the U.S. with Continental acting as trustee. The trust account may be invested only in U.S. government treasury bills with a maturity of 185 days or less or in money market funds investing solely in U.S. Treasuries and meeting certain conditions under Rule 2a-7 under the Investment Company Act of 1940, as amended, which invest only in direct U.S. government obligations. At December 31, 2025, assets held in the trust account were comprised of $234 in cash and $91,872,184 in U.S. treasury securities. These funds will remain in the trust account, except for the withdrawal of interest to fund our working capital requirements, subject to an annual limit of $300,000 and/or to pay taxes, if any, until the earliest of (i) the completion of our initial business combination; (ii) the redemption of any public shares properly submitted in connection with the approval by shareholder vote of an amendment to the Existing Governing Documents (A) to modify the substance or timing of our obligation to provide for the redemption of our public shares in connection with an initial business combination or to redeem 100% of our public shares if we have not consummated our initial business combination by June 13, 2026 or (B) with respect to any other provisions relating to rights of our public shares; or (iii) absent an initial business combination by June 13, 2026 (unless such date is extended in accordance with the Existing Governing Documents), our return of the funds held in the trust account to our public shareholders as part of our redemption of the public shares. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">PCSC Class A Shares are currently listed on Nasdaq under the symbol “PCSC.” </div> <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Conflicts of Interest </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under Cayman Islands law, directors and officers owe the following fiduciary duties: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">duty to act in good faith in what the director or officer believes to be in the best interests of the company as a whole; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">duty to exercise powers for the purposes for which those powers were conferred and not for a collateral purpose; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">directors should not improperly fetter the exercise of future discretion; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">duty to exercise authority for the purpose for which it is conferred and a duty to exercise powers fairly as between different sections of shareholders; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">duty not to put themselves in a position in which there is a conflict between their duty to the company and their personal interests; and </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">duty to exercise independent judgement. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In addition to the above, directors also owe a duty of care which is not fiduciary in nature. This duty has been defined as a requirement to act as a reasonably diligent person having both the general knowledge, skill and experience that may reasonably be expected of a person carrying out the same functions as are carried out by that director in relation to the company and the general knowledge skill and experience of that director. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">As set out above, directors have a duty not to put themselves in a position of conflict and this includes a duty not to engage in self-dealing, or to otherwise benefit as a result of their position. However, in some instances what would otherwise be a breach of this duty can be forgiven and/or authorized in advance by the shareholders <span style="font-style: italic;">provided </span>that there is full disclosure by the directors. This can be done by way of permission granted in Existing Governing Documents or alternatively by shareholder approval at shareholder meetings. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Certain of our officers and directors presently have, and any of them in the future may have additional, fiduciary or contractual obligations to other entities, including entities that are affiliates of our sponsor, pursuant to which such officer or director is or will be required to present a business combination opportunity to such entity. Accordingly, if any of our officers or directors becomes aware of a business combination opportunity which is suitable for an entity to which he or she has then-current fiduciary or contractual obligations, he or she will honor his or her fiduciary or contractual obligations to present such business combination opportunity to such entity, subject to their fiduciary duties under Cayman Islands law. Our Existing Governing Documents provide that, to the fullest extent permitted by applicable law: (i) no individual serving as a director or an officer shall have any duty, except and to the extent expressly assumed by contract, to refrain from engaging directly or indirectly in the same or similar business activities or lines of business as us; and (ii) we renounce any interest or expectancy in, or in being offered an opportunity to participate in, any potential transaction or matter which may be a corporate opportunity for any director or officer, on the one hand, and us, on the other. We do not believe, however, that the fiduciary duties or contractual obligations of our officers or directors will materially affect our ability to complete our initial business combination. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Below is a table summarizing the entities to which our officers and directors currently have fiduciary duties, contractual obligations or other material management relationships: </div><table cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 84pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 120pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 96pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 132pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">INDIVIDUAL</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">ENTITY</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">ENTITY’S BUSINESS</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">AFFILIATION </div></td></tr><tr><td style="width: 84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Joseph Edelman</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Perceptive Advisors, LLC</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Hedge Fund</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Executive Officer and Portfolio Manager </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Athira Pharma, Inc.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Biotechnology</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Adam Stone</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Perceptive Advisors, LLC</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Hedge Fund</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Investment Officer </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Solid Biosciences</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Pharmaceuticals</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">LianBio</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Biotechnology</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interim Chief Executive Officer and Director </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Xontogeny</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Biotechnology</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Immatics N.V.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Biotechnology</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Michael Altman</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Perceptive Advisors, LLC</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Hedge Fund</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Managing Director </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vensun Pharmaceuticals, Inc.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Pharmaceuticals</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vitruvius Therapeutics</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Pharmaceuticals</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lyra Therapeutics</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Healthcare</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sam Cohn</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Perceptive Advisors, LLC</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Hedge Fund</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Financial Officer, Credit and Venture Funds </div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 84pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 120pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 96pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 132pt;"><div style="font-size: 1pt;"> </div></td></tr></table><table cellpadding="0" class="BRDSX_txttab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 84pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 120pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 96pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 132pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">INDIVIDUAL</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">ENTITY</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">ENTITY’S BUSINESS</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">AFFILIATION </div></td></tr><tr><td style="width: 84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Mark C. McKenna</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Spyre Therapeutics, Inc.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Biotechnology</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Apogee Therapeutics, Inc.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chair of the board of directors </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">McKenna Capital Partners</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Venture Capital</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Investment Officer and Managing Director </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Arch Venture Partners</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Venture Capital</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Venture Partner </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">New Amsterdam Pharma</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Biopharmaceuticals</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Mirador Therapeutics, Inc.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Biotechnology</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Founder, Chief Executive Officer and Director </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fairmount Funds Management LLC</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Healthcare investment firm</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Senior Advisor </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Apogee Therapeutics, Inc.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Biotechnology</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chairman of the board of directors </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Kenneth Song</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Candid Therapeutics, Inc.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Biotechnology</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">President, Chief Executive Officer and Chairman of the board of directors </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ElevAAte Biotech</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Biotechnology</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Averto Medical Inc.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Medical Devices</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Executive Chairman of the board of directors </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Harlan W. Waksal</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lyra Therapeutics, Inc.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Biotechnology</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Executive Chair and Chairperson </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Roadmap Capital, Inc.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Venture Capital</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Member of Advisory Board </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Waksal Consulting LLC</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Strategic business and clinical development counsel to biotechnology companies</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">President and Sole Proprietor</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 84pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 120pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 96pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 132pt;"><div style="font-size: 1pt;"> </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.25pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Potential investors should also be aware of the following other potential conflicts of interest: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Our officers and directors are not required to, and will not, commit their full time to our affairs, which may result in a conflict of interest in allocating their time between our operations and our search for a business combination and their other businesses. We do not intend to have any full-time employees prior to the completion of our initial business combination. Each of our officers is engaged in several other business endeavors for which he may be entitled to substantial compensation, and our officers are not obligated to contribute any specific number of hours per week to our affairs. Further, our sponsor and our officers and directors may sponsor or form other special purpose acquisition companies similar to ours or may pursue other business or investment ventures during the period in which we are seeking an initial business combination. Any such companies, businesses or investments may present additional conflicts of interest in pursuing an initial business combination. However, we do not believe that any such potential conflicts would materially affect our ability to complete our initial business combination. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Our sponsor subscribed for founder shares and purchased private placement shares in a private placement that closed simultaneously with our initial public offering. In April 2024, our sponsor transferred 30,000 founder shares to each of Mark C. McKenna, Kenneth Song and Harlan W. Waksal. Our sponsor and our management team have entered into the Letter Agreement, pursuant to which they have agreed to waive their redemption rights with respect to their founder shares, private placement shares and PCSC Class A Shares in connection with (i) the completion of our initial business combination and (ii) the approval by the shareholders of an amendment to the Existing Governing Documents (A) that would modify the substance or timing of our obligation to provide holders of our public shares the right to have their shares redeemed or repurchased in connection with our initial business combination or to redeem 100% of our public shares if we do not complete our initial business combination by June 13, 2026 or (B) with respect to any other provision relating to the rights of holders of our public shares. Additionally, our sponsor and each member of our management team have agreed to waive their rights to liquidating distributions from the Trust Account with respect to their founder shares and their private placement shares if we fail to complete our initial business combination by </div></td></tr></table><div class="BRDSX_bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">June 13, 2026. Except as described herein, our sponsor and our management team have agreed not to transfer, assign or sell any of their founder shares until the earliest of (A) one year after the completion of our initial business combination and (B) subsequent to our initial business combination, (x) if the closing price of our PCSC Class A Shares equals or exceeds $12.00 per share (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after our initial business combination, or (y) the date on which we complete a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of our public shareholders having the right to exchange their ordinary shares for cash, securities or other property. With certain limited exceptions, the Private Placement Shares will not be transferable until 30 days following the completion of our initial business combination. Such transfer restrictions applicable to the founder shares and private placement shares will be amended in connection with the Business Combination and pursuant to the Sponsor Letter Agreement and Investor Rights Agreement. As discussed under “<span style="font-style: italic;">Business Combination Proposal—Certain Agreements Related to the Business Combination — Investor Rights Agreement</span>” certain transfer restrictions applicable to the founder shares and private placement shares will be amended in connection with the consummation of the Business Combination. Because each of our officers and director nominees will own ordinary shares directly or indirectly, they may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination. </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Our officers and directors may have a conflict of interest with respect to evaluating a particular business combination if the retention or resignation of any such officers and directors was included by a target business as a condition to any agreement with respect to our initial business combination. The low price that our sponsor, officers and directors (directly or indirectly) paid for the founder shares creates an incentive whereby our officers and directors could potentially make a substantial profit even if we select an acquisition target that subsequently declines in value and is unprofitable for public shareholders. If we do not complete our initial business combination by June 13, 2026, the founder shares may lose most of their value, except to the extent they receive liquidating distributions from assets outside the Trust Account, which could create an incentive for our sponsor, officers and directors to complete a transaction even if we select an acquisition target that subsequently declines in value and is unprofitable for public shareholders. </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">By seeking shareholder approval, we will complete our initial business combination only if a majority of the issued and outstanding PCSC Shares, represented in person or by proxy and entitled to vote thereon, voted at a shareholder meeting are voted in favor of the Business Combination. In such case, our sponsor and directors and officers have agreed to vote their founder shares, private placement shares and public shares in favor of our proposed initial business combination (for more information on voting and permitted purchases of public shares see, “<span style="font-style: italic;">—Effecting Our Business Combination—Permitted Purchases of Our Securities and Other Transactions with Respect to Our Securities.</span>”) </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We cannot assure you that any of the above-mentioned conflicts will be resolved in our favor. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">You should also review the conflicts of interest of the Sponsor and PCSC’s directors and officers disclosed in the section entitled “<span style="font-style: italic;">Business Combination Proposal—Interests of Certain Persons in the Business Combination</span>” in this proxy statement/prospectus. </div> <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Below is a table summarizing the entities to which our officers and directors currently have fiduciary duties, contractual obligations or other material management relationships: </div><table cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 84pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 120pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 96pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 132pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">INDIVIDUAL</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">ENTITY</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">ENTITY’S BUSINESS</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">AFFILIATION </div></td></tr><tr><td style="width: 84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Joseph Edelman</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Perceptive Advisors, LLC</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Hedge Fund</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Executive Officer and Portfolio Manager </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Athira Pharma, Inc.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Biotechnology</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Adam Stone</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Perceptive Advisors, LLC</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Hedge Fund</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Investment Officer </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Solid Biosciences</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Pharmaceuticals</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">LianBio</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Biotechnology</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interim Chief Executive Officer and Director </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Xontogeny</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Biotechnology</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Immatics N.V.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Biotechnology</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Michael Altman</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Perceptive Advisors, LLC</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Hedge Fund</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Managing Director </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vensun Pharmaceuticals, Inc.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Pharmaceuticals</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vitruvius Therapeutics</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Pharmaceuticals</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lyra Therapeutics</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Healthcare</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sam Cohn</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Perceptive Advisors, LLC</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Hedge Fund</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Financial Officer, Credit and Venture Funds </div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 84pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 120pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 96pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 132pt;"><div style="font-size: 1pt;"> </div></td></tr></table><table cellpadding="0" class="BRDSX_txttab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 84pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 120pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 96pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 132pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">INDIVIDUAL</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">ENTITY</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">ENTITY’S BUSINESS</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">AFFILIATION </div></td></tr><tr><td style="width: 84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Mark C. McKenna</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Spyre Therapeutics, Inc.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Biotechnology</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Apogee Therapeutics, Inc.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chair of the board of directors </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">McKenna Capital Partners</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Venture Capital</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Investment Officer and Managing Director </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Arch Venture Partners</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Venture Capital</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Venture Partner </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">New Amsterdam Pharma</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Biopharmaceuticals</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Mirador Therapeutics, Inc.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Biotechnology</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Founder, Chief Executive Officer and Director </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fairmount Funds Management LLC</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Healthcare investment firm</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Senior Advisor </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Apogee Therapeutics, Inc.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Biotechnology</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chairman of the board of directors </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Kenneth Song</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Candid Therapeutics, Inc.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Biotechnology</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">President, Chief Executive Officer and Chairman of the board of directors </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ElevAAte Biotech</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Biotechnology</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Averto Medical Inc.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Medical Devices</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Executive Chairman of the board of directors </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Harlan W. Waksal</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lyra Therapeutics, Inc.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Biotechnology</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Executive Chair and Chairperson </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Roadmap Capital, Inc.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Venture Capital</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Member of Advisory Board </div></td></tr><tr><td style="width: 84pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 120pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Waksal Consulting LLC</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 96pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Strategic business and clinical development counsel to biotechnology companies</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 132pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">President and Sole Proprietor</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 84pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 120pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 96pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 132pt;"><div style="font-size: 1pt;"> </div></td></tr></table> Joseph Edelman  Perceptive Advisors, LLC  Hedge Fund  Chief Executive Officer and Portfolio Manager    Athira Pharma, Inc.  Biotechnology  Director Adam Stone  Perceptive Advisors, LLC  Hedge Fund  Chief Investment Officer    Solid Biosciences  Pharmaceuticals  Director    LianBio  Biotechnology  Interim Chief Executive Officer and Director    Xontogeny  Biotechnology  Director    Immatics N.V.  Biotechnology  Director Michael Altman  Perceptive Advisors, LLC  Hedge Fund  Managing Director    Vensun Pharmaceuticals, Inc.  Pharmaceuticals  Director    Vitruvius Therapeutics  Pharmaceuticals  Director    Lyra Therapeutics  Healthcare  Director Sam Cohn  Perceptive Advisors, LLC  Hedge Fund  Chief Financial Officer, Credit and Venture Funds Mark C. McKenna  Spyre Therapeutics, Inc.  Biotechnology  Director    Apogee Therapeutics, Inc.     Chair of the board of directors    McKenna Capital Partners  Venture Capital  Chief Investment Officer and Managing Director    Arch Venture Partners  Venture Capital  Venture Partner    New Amsterdam Pharma  Biopharmaceuticals  Director    Mirador Therapeutics, Inc.  Biotechnology  Founder, Chief Executive Officer and Director    Fairmount Funds Management LLC  Healthcare investment firm  Senior Advisor    Apogee Therapeutics, Inc.  Biotechnology  Chairman of the board of directors Kenneth Song  Candid Therapeutics, Inc.  Biotechnology  President, Chief Executive Officer and Chairman of the board of directors    ElevAAte Biotech  Biotechnology  Director    Averto Medical Inc.  Medical Devices  Executive Chairman of the board of directors Harlan W. Waksal  Lyra Therapeutics, Inc.  Biotechnology  Executive Chair and Chairperson    Roadmap Capital, Inc.  Venture Capital  Member of Advisory Board    Waksal Consulting LLC  Strategic business and clinical development counsel to biotechnology companies  President and Sole Proprietor <table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Our officers and directors are not required to, and will not, commit their full time to our affairs, which may result in a conflict of interest in allocating their time between our operations and our search for a business combination and their other businesses. We do not intend to have any full-time employees prior to the completion of our initial business combination. Each of our officers is engaged in several other business endeavors for which he may be entitled to substantial compensation, and our officers are not obligated to contribute any specific number of hours per week to our affairs. Further, our sponsor and our officers and directors may sponsor or form other special purpose acquisition companies similar to ours or may pursue other business or investment ventures during the period in which we are seeking an initial business combination. Any such companies, businesses or investments may present additional conflicts of interest in pursuing an initial business combination. However, we do not believe that any such potential conflicts would materially affect our ability to complete our initial business combination. </div></td></tr></table> <table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Our sponsor subscribed for founder shares and purchased private placement shares in a private placement that closed simultaneously with our initial public offering. In April 2024, our sponsor transferred 30,000 founder shares to each of Mark C. McKenna, Kenneth Song and Harlan W. Waksal. Our sponsor and our management team have entered into the Letter Agreement, pursuant to which they have agreed to waive their redemption rights with respect to their founder shares, private placement shares and PCSC Class A Shares in connection with (i) the completion of our initial business combination and (ii) the approval by the shareholders of an amendment to the Existing Governing Documents (A) that would modify the substance or timing of our obligation to provide holders of our public shares the right to have their shares redeemed or repurchased in connection with our initial business combination or to redeem 100% of our public shares if we do not complete our initial business combination by June 13, 2026 or (B) with respect to any other provision relating to the rights of holders of our public shares. Additionally, our sponsor and each member of our management team have agreed to waive their rights to liquidating distributions from the Trust Account with respect to their founder shares and their private placement shares if we fail to complete our initial business combination by </div></td></tr></table><div class="BRDSX_bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">June 13, 2026. Except as described herein, our sponsor and our management team have agreed not to transfer, assign or sell any of their founder shares until the earliest of (A) one year after the completion of our initial business combination and (B) subsequent to our initial business combination, (x) if the closing price of our PCSC Class A Shares equals or exceeds $12.00 per share (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after our initial business combination, or (y) the date on which we complete a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of our public shareholders having the right to exchange their ordinary shares for cash, securities or other property. With certain limited exceptions, the Private Placement Shares will not be transferable until 30 days following the completion of our initial business combination. Such transfer restrictions applicable to the founder shares and private placement shares will be amended in connection with the Business Combination and pursuant to the Sponsor Letter Agreement and Investor Rights Agreement. As discussed under “<span style="font-style: italic;">Business Combination Proposal—Certain Agreements Related to the Business Combination — Investor Rights Agreement</span>” certain transfer restrictions applicable to the founder shares and private placement shares will be amended in connection with the consummation of the Business Combination. Because each of our officers and director nominees will own ordinary shares directly or indirectly, they may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination. </div> <table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Our officers and directors may have a conflict of interest with respect to evaluating a particular business combination if the retention or resignation of any such officers and directors was included by a target business as a condition to any agreement with respect to our initial business combination. The low price that our sponsor, officers and directors (directly or indirectly) paid for the founder shares creates an incentive whereby our officers and directors could potentially make a substantial profit even if we select an acquisition target that subsequently declines in value and is unprofitable for public shareholders. If we do not complete our initial business combination by June 13, 2026, the founder shares may lose most of their value, except to the extent they receive liquidating distributions from assets outside the Trust Account, which could create an incentive for our sponsor, officers and directors to complete a transaction even if we select an acquisition target that subsequently declines in value and is unprofitable for public shareholders. </div></td></tr></table> <table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">•</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">By seeking shareholder approval, we will complete our initial business combination only if a majority of the issued and outstanding PCSC Shares, represented in person or by proxy and entitled to vote thereon, voted at a shareholder meeting are voted in favor of the Business Combination. In such case, our sponsor and directors and officers have agreed to vote their founder shares, private placement shares and public shares in favor of our proposed initial business combination (for more information on voting and permitted purchases of public shares see, “<span style="font-style: italic;">—Effecting Our Business Combination—Permitted Purchases of Our Securities and Other Transactions with Respect to Our Securities.</span>”) </div></td></tr></table> <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Below is a summary chart outlining important similarities and differences in the corporate governance and stockholder/shareholder rights associated with each of PCSC and New Freenome according to applicable law and/or the governing documents of PCSC and New Freenome. You also should review the Proposed Certificate of Incorporation and the Proposed Bylaws of New Freenome attached hereto as <span style="font-weight: bold;">Annex H</span> and <span style="font-weight: bold;">Annex I</span> to this proxy statement/prospectus, as well as the DGCL and corporate laws of the Cayman Islands, including the Cayman Companies Act, to understand how these laws apply to PCSC and New Freenome. </div><table cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 108pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 185pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 151pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 108pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 185pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Cayman Islands</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 151pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Delaware </div></td></tr><tr><td style="width: 108pt; padding-top: 2.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stockholder/Shareholder Approval of Business Combinations</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 185pt; padding-top: 2.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Mergers require a special resolution, and any other authorization as may be specified in the relevant articles of association. Parties holding certain security interests in the constituent companies must also consent.<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">All mergers (other than parent/subsidiary mergers) require shareholder approval—there is no exception for smaller mergers.<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Where a bidder has acquired 90% or more of the shares in a Cayman Islands company, it can compel the acquisition of the shares of the remaining shareholders and thereby become the sole shareholder.<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">A Cayman Islands company may also be acquired through a “scheme of arrangement” sanctioned by (i) in relation to a compromise or arrangement between a company and its creditors or any class of them, a majority in number of such creditors or class of creditors with whom the arrangement is to be made and who must in addition represent 75% in value of such creditors or class of creditors, as the case may be, that are present and voting either in person or by proxy at a meeting summoned for that purpose; and (ii) in relation to a compromise or arrangement between a company and its shareholders or any class of them, shareholders who represent 75% in value of the company’s shareholders or class of shareholders, as the case may be, that are present and voting either in person or by proxy at a meeting summoned for that purpose.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 151pt; padding-top: 2.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Mergers that require a vote of stockholders require approval by the holders of a majority in voting power of all outstanding shares entitled to vote on the matter. Mergers in which (1) the corporation’s certificate of incorporation is not amended, (2) each share of the corporation’s stock outstanding or held in treasury immediately before the effectiveness of the merger is to be an identical outstanding or treasury share of the surviving corporation, and (3) either no shares of common stock of the corporation and no shares, securities or obligations convertible into such stock are to be issued in the merger, or the authorized unissued shares or treasury shares of common stock of the corporation to be issued or delivered plus those initially issuable upon conversion of any other shares, securities or obligations to be issued or delivered under such plan do not exceed 20% of the shares of common stock of the corporation outstanding immediately before the merger. Mergers that contemplate a qualifying holding company reorganization do not require approval of stockholders of the corporation that is the parent prior to the merger. Mergers in which the target is widely traded, the acquirer consummates a qualifying tender offer, and a sufficient number of target stockholders tender do not require approval of target stockholders. Mergers in which a </div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 108pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 185pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 151pt;"><div style="font-size: 1pt;"> </div></td></tr></table><table cellpadding="0" class="BRDSX_txttab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 108pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 185pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 151pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 108pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 185pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Cayman Islands</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 151pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Delaware </div></td></tr><tr><td style="width: 108pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 185pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 151pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">corporation or entity owns 90% or more of the outstanding shares of each class of stock of a corporation that would otherwise be entitled to vote on a merger may be completed without the approval of such corporation’s board of directors or any vote of its stockholders. </div></td></tr><tr><td style="width: 108pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 185pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 151pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 108pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stockholder/Shareholder Votes for Routine Matters</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 185pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Under Cayman Islands law and the Existing Governing Documents, routine corporate matters may be approved by an ordinary resolution (being a resolution passed by a simple majority of the votes cast by or on behalf of the shareholders present in person or represented by proxy at the applicable general meeting and entitled to vote on such matter).</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 151pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unless a different voting standard is set forth in the certificate of incorporation or bylaws, approval of routine corporate matters other than director elections that are put to a stockholder vote require the affirmative vote of the majority of shares present in person or represented by proxy at the meeting and entitled to vote on the subject matter and director elections require a plurality vote of the shares present in person or represented by proxy at the meeting and entitled to vote on the election of directors.</div></td></tr><tr><td style="width: 108pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 185pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 151pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 108pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Appraisal Rights and Dissenters’ Rights</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 185pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Minority shareholders that dissent from a Cayman Islands statutory merger are entitled to be paid the fair market value of their shares, which if necessary may ultimately be determined by the court.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 151pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Appraisal rights permit a stockholder to receive cash generally equal to the fair value of the stockholder’s shares (as determined by agreement of the parties or by a court) in lieu of the consideration such stockholder would otherwise receive in the applicable transaction. Appraisal rights are generally available to the holders of shares of any class or series of stock of a Delaware corporation in a merger, consolidation, conversion or domestication, provided that no appraisal rights are available with respect to shares of any class or series of stock if, at the record date for the meeting held to approve such transaction, such shares of stock, or depositary receipts in respect thereof, are either (i) listed on a national securities exchange or (ii) held of record by more than 2,000 holders of record, unless the stockholders are required to receive anything other than shares of stock of the surviving or resulting corporation (or depositary receipts in respect </div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 108pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 185pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 151pt;"><div style="font-size: 1pt;"> </div></td></tr></table><table cellpadding="0" class="BRDSX_txttab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 108pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 185pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 151pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 108pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 185pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Cayman Islands</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 151pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Delaware </div></td></tr><tr><td style="width: 108pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 185pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 151pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">thereof), or of any other corporation that is listed on a national securities exchange or held by more than 2,000 holders of record, cash in lieu of fractional shares or fractional depositary receipts described above or any combination of the foregoing.</div></td></tr><tr><td style="width: 108pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 185pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 151pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 108pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Inspection of Books and Records</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 185pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shareholders generally do not have any rights to inspect or obtain copies of the register of shareholders or other corporate records of a company.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 151pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Any stockholder, upon written demand stating the purpose thereof, has the right to inspect the corporation’s stock ledger and other books and records for a proper purpose during the usual hours for business, subject to additional terms, requirements and exceptions.</div></td></tr><tr><td style="width: 108pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 185pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 151pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 108pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stockholder/Shareholder Lawsuits</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 185pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">In the Cayman Islands, the decision to institute proceedings on behalf of a company is generally taken by the company’s board of directors. A shareholder may be entitled to bring a derivative action on behalf of the company, but only in certain limited circumstances.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 151pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The DGCL provides that a stockholder may bring a derivative suit by or in the right of the corporation provided that the complaint must aver that the plaintiff was a stockholder at the time of the challenged transaction or that their stock devolved upon them by operation of law. Additional pleading requirements apply under Delaware law.</div></td></tr><tr><td style="width: 108pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 185pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 151pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 108pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fiduciary Duties of Directors</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 185pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">A director owes fiduciary duties to a company, including to exercise loyalty, honesty and good faith to the company as a whole.<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">In addition to fiduciary duties, directors owe a duty of care, diligence and skill.<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Such duties are owed to the company but may be owed directly to creditors or shareholders in certain limited circumstances.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 151pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Directors owe fiduciary duties of care and loyalty to the corporation and its stockholders.</div></td></tr><tr><td style="width: 108pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 185pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 151pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 108pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Indemnification of Directors and Officers</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 185pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">A Cayman Islands company generally may indemnify its directors or officers except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against willful default, willful neglect, civil fraud or the consequences of committing a crime.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 151pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">In actions, suits or proceedings that are not brought by or in right of the corporation, the DGCL permits a corporation to indemnify current and former directors, officers, employees and agents for attorneys’ fees and other expenses, judgments and amounts paid in settlement that the person actually and reasonably incurred in connection with the action, suit or proceeding. The person seeking indemnity may </div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 108pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 185pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 151pt;"><div style="font-size: 1pt;"> </div></td></tr></table><table cellpadding="0" class="BRDSX_txttab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 108pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 185pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 151pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 108pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 185pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Cayman Islands</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 151pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Delaware </div></td></tr><tr><td style="width: 108pt; padding-top: 2.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 185pt; padding-top: 2.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 151pt; padding-top: 2.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">recover under these statutory provisions as long as they acted in good faith and in a manner the person reasonably believed was in or not opposed to the best interests of the corporation, and in the case of a criminal proceeding, that such person had no reasonable cause to believe their conduct was unlawful.<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">In actions, suits or proceedings that are brought by or in right of the corporation, the DGCL permits a corporation to indemnify its directors, officers, employees or agents for expenses that the person actually and reasonably incurred, except that the corporation may not indemnify the person for any claim, issue or matter as to which the person has been adjudged liable to the corporation unless and only to the extent that the court in which the action or suit was brought determines that, despite the adjudication of liability but in view of all the circumstances of the case, the person is fairly and reasonably entitled to indemnity for such expenses.<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The DGCL requires a corporation to indemnify its directors and officers against the expenses they actually and reasonably incur in defending against any action, suit or proceeding for which they may be indemnified if they have been successful on the merits or otherwise in the defense.<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">In addition, the DGCL provides that expenses incurred by an officer, director, employee or agent of a corporation in defending any civil, criminal, administrative or investigative action, suit or proceeding may be paid by the corporation in advance of the final disposition of such action, suit or proceeding. In the case of a current director or officer, the advances may be made only upon the corporation’s receipt of an undertaking by or on behalf of the director or officer to </div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 108pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 185pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 151pt;"><div style="font-size: 1pt;"> </div></td></tr></table>          Cayman Islands  Delaware       <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">repay the amount if it is ultimately determined that the director or officer is not entitled to be indemnified by the corporation as authorized under the DGCL.<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The provisions permitting a corporation to provide rights to indemnification or advancement of expenses may be made mandatory through the certificate of incorporation or bylaws or by agreement.</div>       Limited Liability of Directors  Liability of directors may be limited, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide exculpation for willful default, willful neglect, civil fraud or the consequences of committing a crime.  The DGCL permits the certificate of incorporation of the corporation to contain a provision limiting or eliminating the personal monetary liability of a director or officer to the corporation or its stockholders, except with regard to breaches of duty of loyalty, intentional misconduct, knowing violations of law, unlawful repurchases or dividends for directors, or improper personal benefit, and with respect to an officer in any action by or in the right of the corporation <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Proposed Certificate of Incorporation and Proposed Bylaws differ in certain material respects from the Existing Governing Documents. The following table sets forth a summary of the principal changes proposed to be made between the Existing Governing Documents and the Proposed Certificate of Incorporation and Proposed Bylaws, as applicable, for New Freenome. This summary is qualified by reference to the complete text of the Existing Governing Documents of PCSC, attached as exhibit 3.1 to this registration statement on Form S-4 and the complete text of the Proposed Certificate of Incorporation and Proposed Bylaws, the forms of which are attached to this proxy statement/prospectus as <span style="font-weight: bold;">Annex H</span> and <span style="font-weight: bold;">Annex I</span>. All shareholders are encouraged to read the Proposed Certificate of Incorporation and Proposed Bylaws in their entirety for a more complete description of their terms. </div><table cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 108pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 156pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 108pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Existing Governing Documents</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 156pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Proposed Governing Documents </div></td></tr><tr><td style="width: 108pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Authorized Shares</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The share capital under the Existing Governing Documents is US$50,000 divided into 479,000,000 Class A ordinary shares of par value US$0.0001 per share, 20,000,000 PCSC Class B Shares of par value US$0.0001 per share and 1,000,000 preference shares of par value US$0.0001 per share.<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">See paragraph 8 of the current amended and restated memorandum of association.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 156pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Proposed Governing Documents authorize 1,010,000,000 shares, consisting of 1,000,000,000 shares of New Freenome Common Stock and 10,000,000 shares of undesignated preferred stock, each par value $0.0001 per share.<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">See Article IV of the Proposed Certificate of Incorporation.</div></td></tr><tr><td style="width: 108pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 156pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 108pt; padding-top: 0.51pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Voting</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 0.51pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Existing Governing Documents provide that holders of PCSC Class A Shares and PCSC Class B Shares will vote together as a </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 156pt; padding-top: 0.51pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The holders of New Freenome Common Stock will be entitled to cast one vote per share. Except as </div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 108pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 156pt;"><div style="font-size: 1pt;"> </div></td></tr></table><table cellpadding="0" class="BRDSX_txttab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 108pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 156pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 108pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Existing Governing Documents</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 156pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Proposed Governing Documents </div></td></tr><tr><td style="width: 108pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">single class on all matters submitted to the shareholders for their vote or approval, except as required by applicable law or provided by the Existing Governing Documents, and that shareholders are entitled to one vote per share on all matters submitted to the shareholders for their vote or approval.<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">See Article 15.3 of the Existing Governing Documents. </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 156pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">otherwise required by law, the Proposed Certificate of Incorporation or the Proposed Bylaws, when quorum is present at any meeting of stockholders, any matter before the meeting shall be decided by majority of the votes properly cast for and against such matter and each election of directors shall be determined by a plurality of votes cast.<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">See Article I, Section 6 of the Proposed Bylaws.</div></td></tr><tr><td style="width: 108pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 156pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 108pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Authorize the Company to Make Issuances of Preferred Stock Without Stockholder Consent</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Existing Governing Documents authorize the issuance of 1,000,000 preference shares with such designations, rights and preferences as may be determined from time to time by our board of directors. Accordingly, the PCSC Board is empowered under the Existing Governing Documents, without shareholder approval, to issue preference shares with voting, preferences and other special rights which could adversely affect the voting power or other rights of the holders of ordinary shares.<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">See 3.2 of the Existing Governing Documents.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 156pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Proposed Certificate of Incorporation authorizes the New Freenome Board to create and issue one or more series of preferred stock, with such rights, powers and preferences (and qualifications, limitations and restrictions) as may be determined by the New Freenome Board and as may be permitted by the DGCL.<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">See Article IV, Section B of the Proposed Certificate of Incorporation.</div></td></tr><tr><td style="width: 108pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 156pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 108pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shareholder/Stockholder Written Consent in Lieu of a Meeting</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Existing Governing Documents provide that resolutions may be passed by a vote in person, by proxy at a general meeting, or by unanimous written resolution.<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">See Articles 14.19 and 14.20 of the Existing Governing Documents.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 156pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Proposed Certificate of Incorporation allows stockholders to vote in person or by proxy at a meeting of stockholders but prohibits the ability of stockholders to act by consent in lieu of a meeting (subject to the rights of the holders of one or more outstanding series of preferred stock).<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">See Article V, Section 1 of the Proposed Certificate of Incorporation.</div></td></tr><tr><td style="width: 108pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 156pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 108pt; padding-top: 0.51pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Classified Board</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 0.51pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Existing Governing Documents provide that the PCSC Board will be divided into three classes with only one class of directors being elected in each year and each class serving for a three-year term.<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">See Article 17.4 of the Existing Governing Documents.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 156pt; padding-top: 0.51pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Proposed Certificate of Incorporation provides that, other than any directors elected by a special vote of any series of preferred stock the New Freenome Board will be divided into three classes with only one class of directors being elected in each year and each class serving for a three-year term.<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> <br/></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 108pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 156pt;"><div style="font-size: 1pt;"> </div></td></tr></table><table cellpadding="0" class="BRDSX_txttab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 108pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 156pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 108pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Existing Governing Documents</div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 156pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Proposed Governing Documents </div></td></tr><tr><td style="width: 108pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 156pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">See Article VI, Section 2 of the Proposed Certificate of Incorporation.</div></td></tr><tr><td style="width: 108pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 156pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 108pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Corporate Name</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Existing Governing Documents provide the name of the company is “Perceptive Capital Solutions Corp”<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">See paragraph 1 of the Existing Governing Documents.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 156pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Proposed Certificate of Incorporation will provide that the name of New Freenome will be “Freenome, Inc.”<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">See Article I of the Proposed Certificate of Incorporation.</div></td></tr><tr><td style="width: 108pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 156pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 108pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Perpetual Existence</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Existing Governing Documents provide that if we do not consummate a business combination (as defined in the Existing Governing Documents) by June 13, 2026, PCSC shall cease all operations except for the purposes of winding up and shall redeem the shares issued in PCSC’s initial public offering and liquidate the trust account.<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">See Article 38.8 of the Existing Governing Documents.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 156pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">New Freenome’s existence will be perpetual pursuant to the default rule under the DGCL.</div></td></tr><tr><td style="width: 108pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 156pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 108pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Takeovers by Interested Stockholders</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Existing Governing Documents provide that if we do not consummate a business combination (as defined in the Existing Governing Documents) by June 13, 2026, PCSC shall cease all operations except for the purposes of winding up and shall redeem the shares issued in the IPO and liquidate the trust account.<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">See Article 38.8 of the Existing Governing Documents.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 156pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The DGCL provides for certain restrictions regarding “business combinations” with “interested stockholders” (as such terms are defined in Section 203 of the DGCL) and the Proposed Governing Documents do not opt out of such restrictions.<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">See the description of such restrictions in the subsection titled “— Anti-Takeover Provisions” in the section titled “Description of New Freenome Securities” below.</div></td></tr><tr><td style="width: 108pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 156pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 108pt; padding-top: 0.51pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Provisions Related to Status as Blank Check Company</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 180pt; padding-top: 0.51pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Existing Governing Documents set forth various provisions related to our status as a blank check company prior to the consummation of a business combination.<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">See Article 38 of the Existing Governing Documents.</div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 156pt; padding-top: 0.51pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Proposed Governing Documents do not include such provisions related to our status as a blank check company, which no longer will apply upon the Closing, as we will cease to be a blank check company at such time.</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 108pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 180pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 156pt;"><div style="font-size: 1pt;"> </div></td></tr></table> 865031 1129684 42539 115006 907570 1244690 91872418 88654397 92779988 89899087 2254244 210811 2254244 210811 3450000 3450000 5704244 3660811 8625000 8625000 10.65 10.24 91872418 88354397 0.0001 0.0001 1000000 1000000 0 0 0 0 0 0 0.0001 0.0001 479000000 479000000 286250 286250 286250 286250 8625000 8625000 29 29 0.0001 0.0001 20000000 20000000 2156250 2156250 2156250 2156250 216 216 -4796919 -2116366 -4796674 -2116121 92779988 89899087 281250 281250 2980553 494005 -2980553 -494005 3821319 2366001 -3298 38396 3818021 2404397 837468 1910392 8625000 8625000 6104313 6104313 0.08 0.08 0.23 0.23 2442500 2243636 0.08 0.23 2442500 2320880 0.08 0.23 281250 281250 0 0 0 0 0 0 0 0 0 2156250 216 24784 0 25000 286250 29 0 0 2862471 0 2862500 0 0 15969 0 15969 0 0 2871286 4026758 6898044 0 0 0 1910392 1910392 286250 29 2156250 216 0 -2116366 -2116121 0 0 0 3518021 3518021 0 0 0 837468 837468 286250 29 2156250 216 0 -4796919 -4796674 281250 281250 837468 1910392 0 44577 3821319 2366001 -3298 38396 -72467 115006 2043433 210811 -864653 -353623 0 86250000 600000 0 600000 -86250000 0 84525000 0 2862500 0 862500 0 157056 0 359637 0 87733307 -264653 1129684 1129684 0 865031 1129684 0 25000 0 112479 0 3450000 <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">NOTE 1 — DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Perceptive Capital Solutions Corp (the “Company”) was incorporated as a Cayman Islands exempted company on March 22, 2024. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities (the “Business Combination”). The Company is an emerging growth company and, as such, the Company is subject to all of the risks associated with emerging growth companies. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has two subsidiaries, StarNet Merger Sub I, Corp., a Delaware corporation and a wholly-owned subsidiary of the Company (“Merger Sub I”) and StarNet Merger Sub II, LLC, a Delaware limited liability company (“Merger Sub II”) both incorporated on November 26, 2025. On December 5, 2025, the Company, Merger Sub I, Merger Sub II, and Freenome Holdings, Inc., entered into a business combination agreement (the “Business Combination Agreement”). The Business Combination Agreement sets forth the terms of the proposed business combination by the Company with Freenome (the “Proposed Freenome Business Combination”). The Proposed Freenome Business Combination was unanimously approved by the boards of directors and special committees comprised of independent and disinterested members of the boards of directors of each of the Company and Freenome. The Proposed Freenome Business Combination is expected to close in the first half of 2026, following the receipt of the requisite approvals of the Company shareholders and Freenome stockholders and the fulfillment of other customary closing conditions. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of December 31, 2025, the Company had not commenced any operations. All activity for the period from March 22, 2024 (inception) through December 31, 2025 relates to the Company’s formation, the initial public offering (“Initial Public Offering”), which is described below, and since the Initial Public Offering, the search for a prospective initial Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company generates non-operating income in the form of interest income on investments from the proceeds derived from the Initial Public Offering. The Company has selected December 31 as its fiscal year end. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The registration statement for the Initial Public Offering was declared effective on June 11, 2024. On June 13, 2024, the Company consummated the Initial Public Offering of 8,625,000 Class A ordinary shares, par value $0.0001 per share (the “Public Shares”), which included the full exercise by the underwriter of the Initial Public Offering of its over-allotment option in the amount of 1,125,000 Public Shares, at $10.00 per Public Share, generating gross proceeds of $86,250,000, which is discussed in Note 3. Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 286,250 private placement shares (the “Private Placement Shares”) to Perceptive Capital Solutions Holdings (the “Sponsor”) at a price of $10.00 per Private Placement Share, or $2,862,500 in the aggregate, which is described in Note 4. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Transaction costs amounted to $4,809,616, consisting of $1,725,000 of cash underwriting fee, $3,450,000 of deferred underwriting fee (see Note 5), and $497,116 of other offering costs, offset by a reimbursement from the underwriter of $862,500. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of Private Placement Shares, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the net assets held in the Trust Account (as defined below) (excluding the amount of deferred underwriting commissions and taxes payable on the interest earned on the Trust Account) at the time of the signing of the agreement to enter into the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the “Investment Company Act”). </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Following the closing of the Initial Public Offering, on June 13, 2024, an amount of $86,250,000 ($10.00 per share) from the net proceeds of the sale of the Public Shares and the sale of the Private Placement Shares was placed in the trust account (“Trust Account”), located in the United States, with Continental Stock Transfer &amp; Trust Company acting as </div><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">trustee, including in demand deposit accounts at a bank, or invested only in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations, until the earlier of (i) the completion of a Business Combination and (ii) the distribution of the Trust Account as described below. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company will provide the holders of Public Shares (the “Public Shareholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination, including the Proposed Freenome Business Combination, either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.00 per Public Share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company for Permitted Withdrawals (as defined below)). The per-share amount to be distributed to Public Shareholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriter (as discussed in Note 5). The Public Shares were recorded at redemption value and classified as temporary equity upon the completion of the Initial Public Offering, in accordance with Accounting Standards Codification (“ASC”) Topic 480, “Distinguishing Liabilities from Equity.” </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Upon the public announcement of the initial Business Combination, if the Company elects to conduct redemptions pursuant to the tender offer rules, the Company and the Sponsor will terminate any plan established in accordance with Rule 10b5-1 to purchase the Public Shares in the open market, in order to comply with Rule 14e-5 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In the event the Company conducts redemptions pursuant to the tender offer rules, the offer to redeem will remain open for at least 20 business days, in accordance with Rule 14e-1(a) under the Exchange Act, and the Company will not be permitted to complete the initial Business Combination until the expiration of the tender offer period. In addition, the tender offer will be conditioned on public shareholders not tendering more than the number of public shares the Company is permitted to redeem. If public shareholders tender more shares than the Company has offered to purchase, the Company will withdraw the tender offer and not complete such initial Business Combination. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Notwithstanding the foregoing, if the Company seeks shareholder approval of its Business Combination and does not conduct redemptions in connection with its Business Combination pursuant to the tender offer rules, the Company’s Amended and Restated Memorandum and Articles of Association (the “Amended and Restated Memorandum and Articles of Association”) provide that a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Exchange Act), will be restricted from redeeming its Public Shares with respect to more than an aggregate of 15% of the Public Shares issued in the Initial Public Offering, without the prior consent of the Company. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company’s Sponsor, officers and directors (the “Initial Shareholders”) have agreed not to propose an amendment to the Amended and Restated Memorandum and Articles of Association (a) that would modify the substance or timing of the Company’s obligation to provide Public Shareholders the right to have their shares redeemed or repurchased in connection with a Business Combination or to redeem 100% of the Company’s Public Shares if the Company does not complete its Business Combination within the time period during which the Company is required to consummate a Business Combination pursuant to the Amended and Restated Memorandum and Articles of Association (the “Business Combination Period”) or (b) with respect to any other provision relating to the rights of Public Shareholders, unless the Company provides the Public Shareholders with the opportunity to redeem their Public Shares in conjunction with any such amendment at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously withdrawn or eligible to be withdrawn by the Company to fund the Company’s working capital requirements, subject to an annual limit of $300,000, and/or to pay the Company’s taxes (which shall not be subject to the $300,000 annual limitation described in the foregoing) (“Permitted Withdrawals”), divided by the number of the then-outstanding Public Shares. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If the Company has not completed a Business Combination within the Business Combination Period, the Company will (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company for Permitted Withdrawals (less up to $100,000 of interest to pay dissolution expenses), divided by the number of the then-outstanding Public Shares, which redemption will completely extinguish </div></div></div><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Public Shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining shareholders and its board of directors, liquidate and dissolve, subject in the case of clauses (ii) and (iii) to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Initial Shareholders agreed to waive their liquidation rights with respect to the Founder Shares (as defined below) and Private Placement Shares held by them if the Company fails to complete a Business Combination within the Business Combination Period. However, if the Initial Shareholders acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Business Combination Period. The underwriter has agreed to waive its rights to its deferred underwriting commission (see Note 5) held in the Trust Account in the event the Company does not complete a Business Combination within the Business Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution (including Trust Account assets) will be only $10.00 per share initially held in the Trust Account. In order to protect the amounts held in the Trust Account, the Sponsor agreed to be liable to the Company if and to the extent any claims by a third party (excluding the Company’s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a written letter of intent, confidentially or other similar agreement or business combination agreement, reduce the amount of funds in the Trust Account to below the lesser of (i) $10.00 per Public Share and (ii) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.00 per Public Share due to reductions in the value of the trust assets. This liability will not apply with respect to any claims by a third party who executed a waiver of any right, title, interest or claim of any kind in or to any monies held in the Trust Account or to any claims under the Company’s indemnity of the underwriter against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Sponsor has not made reserves for such indemnification obligations, nor has the Company independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and the Company believes that the Sponsor’s only assets are securities of the Company. Therefore, the Sponsor may not be able to satisfy those obligations. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (excluding the Company’s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Liquidity, Capital Resources and Going Concern </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of December 31, 2025, the Company had operating cash of $865,031 and a working capital deficit of $1,346,674. The Company intends to use the funds held outside the Trust Account primarily to identify and evaluate target businesses, perform business due diligence on prospective target businesses, travel to and from the offices, plants or similar locations of prospective target businesses or their representatives or owners, review corporate documents and material agreements of prospective target businesses, and structure, negotiate and complete a Business Combination. The Company does not believe it has sufficient funds for the working capital needs of the Company until a minimum of one year from the date of issuance of these consolidated financial statements. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In accordance with Amended and Restated Memorandum and Articles of Association, the Company has 24 months from the date of IPO (“Initial Public Offering”), or until June 13, 2026, to consummate the Initial Business Combination. If a Business Combination is not consummated by the end of the Combination Period, currently June 13, 2026, there will be a mandatory liquidation and subsequent dissolution of the Company. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after the Combination Period. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In connection with the Company’s assessment of going concern considerations in accordance with ASC 205-40, “Going Concern,” as of December 31, 2025, the Company may need to raise additional capital through loans or additional investments from its Sponsor, shareholders, officers, directors, or third parties. The Company’s officers, directors and Sponsor may, but are not obligated to, loan the Company funds, from time to time or at any time, in </div></div></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">whatever amount they deem reasonable in their sole discretion, to meet the Company’s working capital needs. Accordingly, the Company may not be able to obtain additional financing. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company’s liquidity condition and mandatory liquidation raise substantial doubt about the Company’s ability to continue as a going concern for a period of time within one year after the date that the accompanying consolidated financial statements are issued. Management plans to address this uncertainty through a Business Combination. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after the Combination Period. The Company intends to complete the initial Business Combination before the end of the Combination Period. However, there can be no assurance that the Company will be able to consummate any Business Combination by the end of the Combination Period. </div> 1 2 8625000 0.0001 1125000 10 86250000 286250 10 2862500 4809616 1725000 3450000 497116 862500 1 0.80 0.50 86250000 10 10 P20D 0.15 1 300000 300000 P10D 100000 10 10 10 865031 1346674 <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">NOTE 2— SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Basis of Presentation </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The accompanying consolidated financial statements are presented in U.S. dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the “SEC”). </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Principles of Consolidation </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Emerging Growth Company </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Use of Estimates </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. </div><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Cash and Cash Equivalents </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company has $865,031 and $1,129,684 in cash and no cash equivalents as of December 31, 2025 and 2024, respectively. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Cash and Investments Held in Trust Account </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">At December 31, 2025 and 2024, substantially all the assets held in the Trust Account amounting to $91,872,418 and $88,654,397, respectively, were invested in U.S. Treasury securities. The Company’s marketable securities are presented at fair value on the balance sheet. Gains and losses resulting from the change in fair value of marketable securities held in the Trust Account are included in interest earned on investments held in Trust Account in the statement of operations. For the year ended December 31, 2025, the Company withdrew an amount of $600,000 from the Trust Account for working capital purposes. For the period from March 22, 2024 (inception) through December 31, 2024, the Company did not withdraw any interest earned on the Trust Account. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Offering Costs </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company complies with the requirements of the ASC 340-10-S99 and SEC Staff Accounting Bulletin Topic 5A, — “Expenses of Offering.” Offering costs consist principally of professional and registration fees that are related to the Initial Public Offering. Financial Accounting Standards Board (“FASB”) ASC 470-20, “Debt with Conversion and Other Options,” addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components. The Company applies this guidance to allocate Initial Public Offering proceeds from the Public Shares using the residual method. At Initial Public Offering, offering costs allocated to the Class A ordinary shares subject to possible redemption were charged to temporary equity and offering costs allocated to the Private Placement Shares were charged to shareholders’ deficit. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Fair Value of Financial Instruments </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The fair value of the Company’s assets and liabilities, which qualify as financial instruments under FASB ASC 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the consolidated balance sheets, primarily due to its short-term nature. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Class A Ordinary Shares Subject to Possible Redemption </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Public Shares contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company’s liquidation, or if there is a shareholder vote or tender offer in connection with the Company’s initial Business Combination. In accordance with ASC 480-10-S99, the Company classifies Public Shares subject to redemption outside of permanent equity as the redemption provisions are not solely within the control of the Company. The Company recognizes changes in redemption value immediately as it occurs and will adjust the carrying value of redeemable shares to equal the redemption value at the end of each reporting period. Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable shares will result in charges against additional paid-in capital (to the extent available) and accumulated deficit. Accordingly, at December 31, 2025 and 2024, Public Shares subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders’ deficit section of the Company’s consolidated balance sheets. For the period ended December 31, 2025, the Company withdrew $600,000 of interest income from the Trust Account to fund working capital as permitted. </div></div></div><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">At December 31, 2025 and 2024, the Public Shares subject to redemption reflected in the consolidated balance sheets are reconciled in the following table: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 396pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 50pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr><tr><td style="width: 396pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Gross proceeds </div></td><td style="width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$86,250,000 </div></td></tr><tr><td style="width: 396pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Less: <br/></div></td><td style="width: 11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 396pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Class A ordinary shares issuance costs </div></td><td style="width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 6.67pt;">(4,793,647) </span></div></td></tr><tr><td style="width: 396pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Plus: <br/></div></td><td style="width: 11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 396pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accretion of carrying value to redemption value </div></td><td style="width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">6,898,044 </span></div></td></tr><tr><td style="width: 396pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Class A ordinary shares subject to possible redemption, December 31, 2024 </div></td><td style="width: 11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">88,354,397 </span></div></td></tr><tr><td style="width: 396pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Plus: <br/></div></td><td style="width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 396pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accretion of carrying value to redemption value </div></td><td style="width: 11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">3,518,021 </span></div></td></tr><tr><td style="width: 396pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Class A ordinary shares subject to possible redemption, December 31, 2025 </div></td><td style="width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$91,872,418</span></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 396pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 50pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Income Taxes </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company follows the asset and liability method of accounting for income taxes under FASB ASC Topic 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company’s management determined that the Cayman Islands is the Company’s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of December 31, 2025 and 2024, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Net Income per Ordinary Share </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” The Company has two classes of shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Certain of its Class A ordinary shares are redeemable and certain of its Class A ordinary shares are non-redeemable. Income and losses are shared pro rata between its Class A redeemable shares and its Class A and Class B non-redeemable shares. This presentation assumes an initial Business Combination as the most likely outcome. The Company does not have any dilutive instruments. Net income per ordinary share is calculated by dividing the net income by the weighted average shares of ordinary shares outstanding for the respective period. Accretion associated with the Class A ordinary shares subject to possible redemption is excluded from earnings per share as the redemption value approximates fair value. </div></div></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The following tables reflect the calculation of basic and diluted net income per ordinary share (in dollars, except per share amounts): </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 233pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="height: 6pt; width: 104.93pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="height: 6pt; width: 104.92pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 233pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="width: 104.93pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the Year Ended <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2025</div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="width: 104.92pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the Period from <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March 22, 2024 (Inception)<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Through December 31, 2024 </div></td></tr><tr class="BRDSX_header"><td style="width: 233pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class A <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Redeemable</div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class A and B<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Non-<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">redeemable</div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class A <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Redeemable</div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class A and B<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Non-<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">redeemable </div></td></tr><tr><td style="width: 233pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Basic net income per ordinary share: <br/></div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 233pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Numerator: <br/></div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 233pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Allocation of net income </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 7.5pt;">652,646</span></div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.17pt; text-align: left;">$<span style="padding-left: 7.5pt;">184,822</span></div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$1,396,946</div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.17pt; text-align: left;">$<span style="padding-left: 7.5pt;">513,446 </span></div></td></tr><tr><td style="width: 233pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Denominator: <br/></div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 233pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Basic weighted average ordinary shares outstanding </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">8,625,000</span></div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.17pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,442,500</span></div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">6,104,313</span></div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.17pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,243,636 </span></div></td></tr><tr><td style="width: 233pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Basic net income per ordinary share </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 22.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">0.08</span></div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.17pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 22.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">0.08</span></div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 22.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">0.23</span></div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.17pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 22.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">0.23</span></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 233pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 45pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 47.35pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 45pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 47.34pt;"><div style="font-size: 1pt;"> </div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"> </div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 233pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="height: 6pt; width: 104.93pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="height: 6pt; width: 104.92pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 233pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="width: 104.93pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the Year Ended <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2025</div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="width: 104.92pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the Period from <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March 22, 2024 (Inception)<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Through December 31, 2024 </div></td></tr><tr class="BRDSX_header"><td style="width: 233pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class A <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Redeemable</div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class A and B <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Non-<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">redeemable</div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class A<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Redeemable</div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class A and B<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Non-<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">redeemable </div></td></tr><tr><td style="width: 233pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Diluted net income per ordinary share: <br/></div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 233pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Numerator: <br/></div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 233pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Allocation of net income </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 7.5pt;">652,646</span></div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.17pt; text-align: left;">$<span style="padding-left: 7.5pt;">184,822</span></div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$1,384,138</div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.17pt; text-align: left;">$<span style="padding-left: 7.5pt;">526,254 </span></div></td></tr><tr><td style="width: 233pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Denominator: <br/></div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 233pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Diluted weighted average ordinary shares outstanding </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">8,625,000</span></div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.17pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,442,500</span></div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">6,104,313</span></div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.17pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,320,880 </span></div></td></tr><tr><td style="width: 233pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Diluted net income per ordinary share </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 22.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">0.08</span></div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.17pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 22.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">0.08</span></div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 22.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">0.23</span></div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.17pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 22.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">0.23</span></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 233pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 45pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 47.35pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 45pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 47.34pt;"><div style="font-size: 1pt;"> </div></td></tr></table><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Concentration of Credit Risk </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Recent Accounting Standards </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In November 2024, the FASB issued Accounting Standards Update (“ASU”) 2024-03, “Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses”, requiring public entities to disclose additional information about specific expense categories in the notes to the consolidated financial statements on an interim and annual basis. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2024-03. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the accompanying consolidated financial statements. </div> <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Basis of Presentation </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The accompanying consolidated financial statements are presented in U.S. dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the “SEC”). </div> <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Principles of Consolidation </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. </div> <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Use of Estimates </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. </div> <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Cash and Cash Equivalents </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company has $865,031 and $1,129,684 in cash and no cash equivalents as of December 31, 2025 and 2024, respectively. </div> 865031 1129684 0 0 <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Cash and Investments Held in Trust Account </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">At December 31, 2025 and 2024, substantially all the assets held in the Trust Account amounting to $91,872,418 and $88,654,397, respectively, were invested in U.S. Treasury securities. The Company’s marketable securities are presented at fair value on the balance sheet. Gains and losses resulting from the change in fair value of marketable securities held in the Trust Account are included in interest earned on investments held in Trust Account in the statement of operations. For the year ended December 31, 2025, the Company withdrew an amount of $600,000 from the Trust Account for working capital purposes. For the period from March 22, 2024 (inception) through December 31, 2024, the Company did not withdraw any interest earned on the Trust Account. </div> 91872418 88654397 600000 0 <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Offering Costs </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company complies with the requirements of the ASC 340-10-S99 and SEC Staff Accounting Bulletin Topic 5A, — “Expenses of Offering.” Offering costs consist principally of professional and registration fees that are related to the Initial Public Offering. Financial Accounting Standards Board (“FASB”) ASC 470-20, “Debt with Conversion and Other Options,” addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components. The Company applies this guidance to allocate Initial Public Offering proceeds from the Public Shares using the residual method. At Initial Public Offering, offering costs allocated to the Class A ordinary shares subject to possible redemption were charged to temporary equity and offering costs allocated to the Private Placement Shares were charged to shareholders’ deficit. </div> <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Fair Value of Financial Instruments </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The fair value of the Company’s assets and liabilities, which qualify as financial instruments under FASB ASC 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the consolidated balance sheets, primarily due to its short-term nature. </div> <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Class A Ordinary Shares Subject to Possible Redemption </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Public Shares contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company’s liquidation, or if there is a shareholder vote or tender offer in connection with the Company’s initial Business Combination. In accordance with ASC 480-10-S99, the Company classifies Public Shares subject to redemption outside of permanent equity as the redemption provisions are not solely within the control of the Company. The Company recognizes changes in redemption value immediately as it occurs and will adjust the carrying value of redeemable shares to equal the redemption value at the end of each reporting period. Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable shares will result in charges against additional paid-in capital (to the extent available) and accumulated deficit. Accordingly, at December 31, 2025 and 2024, Public Shares subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders’ deficit section of the Company’s consolidated balance sheets. For the period ended December 31, 2025, the Company withdrew $600,000 of interest income from the Trust Account to fund working capital as permitted. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">At December 31, 2025 and 2024, the Public Shares subject to redemption reflected in the consolidated balance sheets are reconciled in the following table: </div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 396pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 50pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr><tr><td style="width: 396pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Gross proceeds </div></td><td style="width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$86,250,000 </div></td></tr><tr><td style="width: 396pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Less: <br/></div></td><td style="width: 11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 396pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Class A ordinary shares issuance costs </div></td><td style="width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 6.67pt;">(4,793,647) </span></div></td></tr><tr><td style="width: 396pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Plus: <br/></div></td><td style="width: 11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 396pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accretion of carrying value to redemption value </div></td><td style="width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">6,898,044 </span></div></td></tr><tr><td style="width: 396pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Class A ordinary shares subject to possible redemption, December 31, 2024 </div></td><td style="width: 11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">88,354,397 </span></div></td></tr><tr><td style="width: 396pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Plus: <br/></div></td><td style="width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 396pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accretion of carrying value to redemption value </div></td><td style="width: 11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">3,518,021 </span></div></td></tr><tr><td style="width: 396pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Class A ordinary shares subject to possible redemption, December 31, 2025 </div></td><td style="width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$91,872,418</span></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 396pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 50pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table> 600000 <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">At December 31, 2025 and 2024, the Public Shares subject to redemption reflected in the consolidated balance sheets are reconciled in the following table: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 396pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 50pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr><tr><td style="width: 396pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Gross proceeds </div></td><td style="width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$86,250,000 </div></td></tr><tr><td style="width: 396pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Less: <br/></div></td><td style="width: 11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 396pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Class A ordinary shares issuance costs </div></td><td style="width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 6.67pt;">(4,793,647) </span></div></td></tr><tr><td style="width: 396pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Plus: <br/></div></td><td style="width: 11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 396pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accretion of carrying value to redemption value </div></td><td style="width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">6,898,044 </span></div></td></tr><tr><td style="width: 396pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Class A ordinary shares subject to possible redemption, December 31, 2024 </div></td><td style="width: 11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">88,354,397 </span></div></td></tr><tr><td style="width: 396pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Plus: <br/></div></td><td style="width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 396pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accretion of carrying value to redemption value </div></td><td style="width: 11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 11pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">3,518,021 </span></div></td></tr><tr><td style="width: 396pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Class A ordinary shares subject to possible redemption, December 31, 2025 </div></td><td style="width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$91,872,418</span></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 396pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 11pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 50pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table> 86250000 4793647 6898044 88354397 3518021 91872418 <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Income Taxes </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company follows the asset and liability method of accounting for income taxes under FASB ASC Topic 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company’s management determined that the Cayman Islands is the Company’s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of December 31, 2025 and 2024, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. </div> 0 0 0 0 <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Net Income per Ordinary Share </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” The Company has two classes of shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Certain of its Class A ordinary shares are redeemable and certain of its Class A ordinary shares are non-redeemable. Income and losses are shared pro rata between its Class A redeemable shares and its Class A and Class B non-redeemable shares. This presentation assumes an initial Business Combination as the most likely outcome. The Company does not have any dilutive instruments. Net income per ordinary share is calculated by dividing the net income by the weighted average shares of ordinary shares outstanding for the respective period. Accretion associated with the Class A ordinary shares subject to possible redemption is excluded from earnings per share as the redemption value approximates fair value. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The following tables reflect the calculation of basic and diluted net income per ordinary share (in dollars, except per share amounts): </div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 233pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="height: 6pt; width: 104.93pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="height: 6pt; width: 104.92pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 233pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="width: 104.93pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the Year Ended <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2025</div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="width: 104.92pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the Period from <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March 22, 2024 (Inception)<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Through December 31, 2024 </div></td></tr><tr class="BRDSX_header"><td style="width: 233pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class A <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Redeemable</div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class A and B<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Non-<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">redeemable</div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class A <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Redeemable</div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class A and B<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Non-<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">redeemable </div></td></tr><tr><td style="width: 233pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Basic net income per ordinary share: <br/></div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 233pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Numerator: <br/></div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 233pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Allocation of net income </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 7.5pt;">652,646</span></div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.17pt; text-align: left;">$<span style="padding-left: 7.5pt;">184,822</span></div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$1,396,946</div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.17pt; text-align: left;">$<span style="padding-left: 7.5pt;">513,446 </span></div></td></tr><tr><td style="width: 233pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Denominator: <br/></div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 233pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Basic weighted average ordinary shares outstanding </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">8,625,000</span></div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.17pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,442,500</span></div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">6,104,313</span></div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.17pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,243,636 </span></div></td></tr><tr><td style="width: 233pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Basic net income per ordinary share </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 22.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">0.08</span></div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.17pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 22.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">0.08</span></div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 22.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">0.23</span></div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.17pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 22.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">0.23</span></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 233pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 45pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 47.35pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 45pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 47.34pt;"><div style="font-size: 1pt;"> </div></td></tr></table><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 233pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="height: 6pt; width: 104.93pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="height: 6pt; width: 104.92pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 233pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="width: 104.93pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the Year Ended <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2025</div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="width: 104.92pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the Period from <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March 22, 2024 (Inception)<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Through December 31, 2024 </div></td></tr><tr class="BRDSX_header"><td style="width: 233pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class A <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Redeemable</div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class A and B <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Non-<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">redeemable</div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class A<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Redeemable</div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class A and B<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Non-<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">redeemable </div></td></tr><tr><td style="width: 233pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Diluted net income per ordinary share: <br/></div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 233pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Numerator: <br/></div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 233pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Allocation of net income </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 7.5pt;">652,646</span></div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.17pt; text-align: left;">$<span style="padding-left: 7.5pt;">184,822</span></div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$1,384,138</div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.17pt; text-align: left;">$<span style="padding-left: 7.5pt;">526,254 </span></div></td></tr><tr><td style="width: 233pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Denominator: <br/></div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 233pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Diluted weighted average ordinary shares outstanding </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">8,625,000</span></div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.17pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,442,500</span></div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">6,104,313</span></div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.17pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,320,880 </span></div></td></tr><tr><td style="width: 233pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Diluted net income per ordinary share </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 22.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">0.08</span></div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.17pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 22.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">0.08</span></div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 22.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">0.23</span></div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.17pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 22.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">0.23</span></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 233pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 45pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 47.35pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 45pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 47.34pt;"><div style="font-size: 1pt;"> </div></td></tr></table> <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The following tables reflect the calculation of basic and diluted net income per ordinary share (in dollars, except per share amounts): </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 233pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="height: 6pt; width: 104.93pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="height: 6pt; width: 104.92pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 233pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="width: 104.93pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the Year Ended <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2025</div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="width: 104.92pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the Period from <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March 22, 2024 (Inception)<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Through December 31, 2024 </div></td></tr><tr class="BRDSX_header"><td style="width: 233pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class A <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Redeemable</div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class A and B<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Non-<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">redeemable</div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class A <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Redeemable</div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class A and B<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Non-<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">redeemable </div></td></tr><tr><td style="width: 233pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Basic net income per ordinary share: <br/></div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 233pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Numerator: <br/></div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 233pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Allocation of net income </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 7.5pt;">652,646</span></div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.17pt; text-align: left;">$<span style="padding-left: 7.5pt;">184,822</span></div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$1,396,946</div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.17pt; text-align: left;">$<span style="padding-left: 7.5pt;">513,446 </span></div></td></tr><tr><td style="width: 233pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Denominator: <br/></div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 233pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Basic weighted average ordinary shares outstanding </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">8,625,000</span></div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.17pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,442,500</span></div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">6,104,313</span></div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.17pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,243,636 </span></div></td></tr><tr><td style="width: 233pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Basic net income per ordinary share </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 22.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">0.08</span></div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.17pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 22.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">0.08</span></div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 22.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">0.23</span></div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.17pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 22.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">0.23</span></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 233pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 45pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 47.35pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 45pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 47.34pt;"><div style="font-size: 1pt;"> </div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"> </div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 233pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="height: 6pt; width: 104.93pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="height: 6pt; width: 104.92pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 233pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="width: 104.93pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the Year Ended <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2025</div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td colspan="4" style="width: 104.92pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the Period from <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March 22, 2024 (Inception)<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Through December 31, 2024 </div></td></tr><tr class="BRDSX_header"><td style="width: 233pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class A <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Redeemable</div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class A and B <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Non-<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">redeemable</div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class A<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Redeemable</div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class A and B<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Non-<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">redeemable </div></td></tr><tr><td style="width: 233pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Diluted net income per ordinary share: <br/></div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 233pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Numerator: <br/></div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 233pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Allocation of net income </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 7.5pt;">652,646</span></div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.17pt; text-align: left;">$<span style="padding-left: 7.5pt;">184,822</span></div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$1,384,138</div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.17pt; text-align: left;">$<span style="padding-left: 7.5pt;">526,254 </span></div></td></tr><tr><td style="width: 233pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Denominator: <br/></div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> </div></td></tr><tr><td style="width: 233pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Diluted weighted average ordinary shares outstanding </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">8,625,000</span></div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.17pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,442,500</span></div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">6,104,313</span></div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.17pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,320,880 </span></div></td></tr><tr><td style="width: 233pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Diluted net income per ordinary share </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 22.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">0.08</span></div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.35pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.17pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 22.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">0.08</span></div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 45pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 22.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">0.23</span></div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 47.34pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.17pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 22.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">0.23</span></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 233pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 45pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 47.35pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 45pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.29pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 47.34pt;"><div style="font-size: 1pt;"> </div></td></tr></table> 652646 184822 1396946 513446 8625000 2442500 6104313 2243636 0.08 0.08 0.23 0.23 652646 184822 1384138 526254 8625000 2442500 6104313 2320880 0.08 0.08 0.23 0.23 <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Concentration of Credit Risk </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows. </div> <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Recent Accounting Standards </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In November 2024, the FASB issued Accounting Standards Update (“ASU”) 2024-03, “Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses”, requiring public entities to disclose additional information about specific expense categories in the notes to the consolidated financial statements on an interim and annual basis. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2024-03. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the accompanying consolidated financial statements. </div> <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">NOTE 3. PUBLIC OFFERING </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the Initial Public Offering, the Company sold 8,625,000 Public Shares, which included a full exercise by the underwriter of its over-allotment option in the amount of 1,125,000 Public Shares, at a price of $10.00 per Public Share. </div> 8625000 1125000 10 <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">NOTE 4. RELATED PARTY TRANSACTIONS </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Founder Shares </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On March 27, 2024, the Sponsor paid $25,000 to cover certain of the Company’s expenses in exchange for the issuance of 2,156,250 Class B ordinary shares, par value $0.0001 (the “Founder Shares”). The Sponsor agreed to forfeit up to 281,250 Founder Shares to the extent that the over-allotment option is not exercised in full by the underwriter so that the </div><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Founder Shares would represent 20.0% of the Company’s issued and outstanding ordinary shares (excluding the Private Placement Shares) after the Initial Public Offering. On June 13, 2024, the underwriter exercised its over-allotment option in full as part of the closing of the Initial Public Offering. As such, 281,250 Founder Shares were no longer subject to forfeiture. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On April 22, 2024, the Sponsor assigned 30,000 Founder Shares to each of the Company’s independent directors, Mark McKenna, Kenneth Song, and Harlan Waksal, at a price of $0.01 per share. Each director paid $300 or an aggregate purchase price of $900 in consideration of the assignment of Founder Shares. The sale or allocation of the Founders Shares to the Company’s independent directors is within the scope of FASB ASC Topic 718, “Compensation-Stock Compensation” (“ASC 718”). Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date. The Company assigned Founder Shares to the Company’s director nominees at a price of $900. This set of Founder Shares was granted subject to a performance condition (i.e., the occurrence of a Business Combination). Compensation expense related to this set of Founder Shares is recognized only when the performance condition is probable of occurrence under the applicable accounting literature in this circumstance. Stock-based compensation would be recognized at the consummation of the Proposed Freenome Business Combination, in an amount equal to the number of Founder Shares times the grant date fair value per share (unless subsequently modified) less the amount initially received for the purchase of the Founder Shares. The Company will reflect the transactions in its financial statements when the Proposed Freenome Business Combination is consummated. If the Proposed Freenome Business Combination does not close for any reason, the Company will not recognize compensation expense associated with the Founder Shares. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Initial Shareholders agreed, subject to limited exceptions, not to transfer, assign or sell any of their Founder Shares until the earlier to occur of (A) one year after the completion of the initial Business Combination and (B) subsequent to the initial Business Combination, (x) if the closing price of Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of the Public Shareholders having the right to exchange their ordinary shares for cash, securities or other property. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Private Placement Shares </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 286,250 Private Placement Shares at a price of $10.00 per Private Placement Share, for an aggregate purchase price of $2,862,500. A portion of the proceeds from the Private Placement Shares was added to the proceeds from the Initial Public Offering and held in the Trust Account. Such Private Placement Shares are identical to the Class A ordinary shares sold in the Initial Public Offering. If the Company does not consummate an initial Business Combination within 24 months from the closing of the Initial Public Offering, any proceeds from the sale of the Private Placement Shares held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law). Holders of the Private Placement Shares have entered into an agreement, pursuant to which they have agreed to waive their redemption rights with respect to their Founder Shares, Private Placement Shares and Public Shares in connection with (i) the completion of the initial Business Combination and (ii) the implementation by the directors of, following a shareholder vote to approve, an amendment to the Amended and Restated Memorandum and Articles of Association (A) that would modify the substance or timing of the obligation to provide holders of the Class A ordinary shares the right to have their shares redeemed or repurchased in connection with the initial Business Combination or to redeem 100% of the Public Shares if the Company does not complete the initial Business Combination within 24 months from the closing of the Initial Public Offering or (B) with respect to any other provision relating to the rights of holders of the Class A ordinary shares. The Private Placement Shares will not be transferable or salable until 30 days after the completion of the initial Business Combination. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Related Party Loans </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On March 27, 2024, the Sponsor agreed to loan the Company an aggregate of up to $300,000 to cover expenses related to the Initial Public Offering pursuant to a promissory note (the “Note”). This loan is non-interest bearing and payable on the earlier of December 31, 2024 or the completion of the Initial Public Offering. Upon the completion of the Initial Public Offering, on June 13, 2024, the Company fully repaid this promissory note and it is no longer available. As of December 31, 2025, the Company had no borrowings under the promissory note. </div></div></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a Business Combination, the Company may repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans may be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of the proceeds held outside the Trust Account or funds from Permitted Withdrawals to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $3.0 million of such Working Capital Loans may be convertible into shares of the post-Business Combination entity at a price of $10.00 per share. As of December 31, 2025 and 2024, the Company had no outstanding borrowings under the Working Capital Loans. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Administrative Services and Indemnification Agreement </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company entered into an agreement, commencing on June 11, 2024, through the earlier of the Company’s consummation of a Business Combination and its liquidation, (i) to pay the Sponsor a total of $15,000 per month for office space, secretarial and administrative services and (ii) to indemnify the Sponsor and its affiliates, including Perceptive Advisors, LLC, from any liability arising with respect to their activities in connection with the Company’s affairs, as described in more details in the Administrative Services and Indemnification Agreement. For the year ended December 31, 2025, the Company incurred and paid $180,000 in fees for these services, respectively. For the period from March 22, 2024 (inception) through December 31, 2024, the Company incurred and paid $99,500 in fees for these services. </div> 25000 2156250 0.0001 281250 0.20 281250 30000 0.01 300 300 300 900 900 0 P1Y 12 P20D P30D P30D P150D 286250 10 2862500 P24M 1 P30D 300000 0 3000000 10 0 0 15000 180000 99500 <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">NOTE 5. COMMITMENTS AND CONTINGENCIES </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Registration Rights </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Initial Shareholders, as the holders of the Founder Shares and Private Placement Shares, including from time to time the Private Placement Shares that may be issued upon conversion of Working Capital Loans and any Class A ordinary shares issuable upon conversion of Founder Shares, will be entitled to registration rights pursuant to the registration and shareholder rights agreement, dated as of June 13, 2024, by and among the Company, the Sponsor and the Initial Shareholders party thereto. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain “piggyback” registration rights with respect to registration statements filed subsequent to the completion of the initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Underwriting Agreement </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company granted the underwriter a 45-day option to purchase up to 1,125,000 additional Public Shares to cover over-allotments, if any, at the Initial Public Offering price less the underwriting discounts and commissions. On June 13, 2024, simultaneously with the closing of the Initial Public Offering, the underwriter elected to fully exercise the over-allotment option to purchase the additional 1,125,000 Public Shares at a price of $10.00 per Public Share. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The underwriter was entitled to a cash underwriting discount of $0.20 per Public Share, or $1,725,000 in the aggregate, paid upon the closing of the Initial Public Offering. The underwriter agreed to reimburse the Company at the closing of the Initial Public Offering for all reasonable out-of-pocket expenses and fees (including for the avoidance of doubt, a portion of the upfront underwriting commissions payable in connection with the closing of the Initial Public Offering) incurred by the Company in connection with the Initial Public Offering in an amount not to exceed 1.0% of the gross proceeds of the Initial Public Offering. On June 13, 2024, as part of the closing of the Initial Public Offering, the Company received reimbursement from the underwriter of $862,500. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition, the underwriter is entitled to a deferred fee of $0.40 per Public Share, or $3,450,000 in the aggregate. The deferred fee will become payable to the underwriter from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. </div><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Risks and Uncertainties </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">United States and global markets are experiencing volatility and disruption following the geopolitical tensions and conflicts. Although the length and impact of the ongoing geopolitical conflicts are highly unpredictable, they could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions and increased cyberattacks against U.S. companies. Additionally, any resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Further, there have recently been significant changes to international trade policies and tariffs affecting imports and exports. Any significant increases in tariffs on goods or materials or other changes in trade policy could negatively affect the Company’s search for a target and/or the Company’s ability to complete an initial Business Combination. Recently, the United States has implemented a range of new tariffs and increases to existing tariffs. In response to the tariffs announced by the United States, other countries have imposed, are considering imposing, and may in the future impose new or increased tariffs on certain exports from the United States. There is currently significant uncertainty about the future relationship between the United States and other countries with respect to trade policies, taxes, government regulations and tariffs, and the Company cannot predict whether, and to what extent, current tariffs will continue or trade policies will change in the future. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Tariffs, or the threat of tariffs or increased tariffs, could have a significant negative impact on certain businesses (either due to domestic businesses’ reliance on imported goods or dependence on access to foreign markets, or foreign businesses’ reliance on sales into the United States). In addition, retaliatory tariffs could have a significant negative impact on foreign businesses that rely on imports from the United States, and domestic businesses that rely on exporting goods internationally. These tariffs and threats of tariffs and other potential trade policy changes could negatively affect the attractiveness of certain initial Business Combination targets, negatively impact the Company’s ability to raise capital in connection with an initial Business Combination or lead to material adverse effects on a post-Business combination company. Among other things, historical financial performance of companies affected by trade policies and/or tariffs may not provide useful guidance as to the future performance of such companies, because future financial performance of those companies may be materially affected by new U.S. tariffs or foreign retaliatory tariffs, or other changes to trade policies. The business prospects of a particular target for a Business Combination could change even after the Company enters into a business combination agreement, as a result of tariffs or the threat of tariffs that may have a material impact on that target’s business, and it may be costly or impractical for the Company to terminate that business combination agreement. In addition, investors may be hesitant or unwilling to invest in businesses due to the impact of the tariffs and foreign retaliatory tariffs on the global macroeconomic conditions and the public trading markets. These factors could affect the Company’s selection of a Business Combination target. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Any of the above mentioned factors, or any other negative impact on the global economy, capital markets or other geopolitical conditions resulting from the such factors, could adversely affect the Company’s search for an initial Business Combination and any target business with which the Company may ultimately consummate an initial Business Combination. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Business Combination Agreement </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On December 5, 2025, the Company, Merger Sub I, Merger Sub II, and Freenome Holdings, Inc., a Delaware corporation (“Freenome”), entered into a Business Combination Agreement (as it may be amended, supplemented or otherwise modified from time to time, the “Business Combination Agreement”). The Business Combination Agreement and the transactions contemplated thereby (the “Proposed Freenome Business Combination”) were unanimously approved by the boards of directors and special committees comprised of independent and disinterested members of the boards of directors of each of the Company and Freenome. The Proposed Freenome Business Combination is expected to close in the first half of 2026, following the receipt of the requisite approvals of the Company shareholders and Freenome stockholders and the fulfillment of other customary closing conditions. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Subject to the terms and conditions of the Business Combination Agreement, we will de-register from the Register of Companies in the Cayman Islands and transfer by way of continuation from the Cayman Islands to Delaware and domesticate as a Delaware corporation (the “Domestication”) and change our name to Freenome, Inc. (“New Freenome”). Immediately prior to the Domestication, the holders of each issued and outstanding Class B ordinary share will elect to convert their Class B ordinary shares into Class A ordinary shares and immediately prior to the Domestication, the Company will effect the redemption of the Public Shares that are validly submitted for redemption and not withdrawn. In connection with the Domestication, each issued and outstanding Class A ordinary share will be converted into one share of common stock, par value $0.0001 per share, of New Freenome (the </div></div></div><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">“New Freenome Common Stock”). Following the Domestication, Merger Sub I will merge with and into Freenome, with Freenome as the surviving company in the merger and, after giving effect to such merger, as a wholly-owned subsidiary of New Freenome (the “First Merger”). At the time the First Merger becomes effective (the “Effective Time”), (i) each share of Freenome common stock (collectively, “Freenome Common Shares”) issued and outstanding as of immediately prior to the Effective Time (including such shares issued upon the conversion of all shares of Freenome preferred stock into Freenome Common Shares prior to the Effective Time in accordance with the terms of the Business Combination Agreement, but excluding Freenome Common Shares held in treasury or by Freenome stockholders who have properly demanded appraisal of such Freenome Common Shares in accordance with Section 262 of the DGCL) will be automatically canceled and extinguished and converted into the right to receive a number of shares of New Freenome Common Stock based on an exchange ratio, which is based on an implied Freenome base equity value of $725,000,000 and subject to certain adjustments as set forth in the Business Combination Agreement (the “Exchange Ratio”); (ii) each option to purchase Freenome Common Shares (each, a “Freenome Option”), whether vested or unvested, will cease to represent the right to purchase Freenome Common Shares and will be canceled in exchange for options to purchase New Freenome Common Stock under the equity incentive plan to be adopted by PCSC in advance of the Closing (the “New Freenome Equity Incentive Plan”), in an amount equal to the product (rounded down to the nearest whole number) of (x) the number of Freenome Common Shares subject to such Freenome Option immediately prior to the Effective Time, multiplied by (y) the Exchange Ratio, at an exercise price per share (rounded up to the nearest whole cent) equal to the quotient of (i) the exercise price per share of such Freenome Option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, and generally subject to the same terms and conditions (including applicable vesting, expiration and forfeiture provisions) that applied to the corresponding Freenome Option immediately prior to the Effective Time; and (iii) each restricted stock unit award that is outstanding with respect to Freenome Common Shares (each, a “Freenome RSU Award”), whether vested or unvested, will cease to have any rights in respect of the Freenome Common Shares and will be canceled in exchange for a restricted stock unit award under the New Freenome Equity Incentive Plan that settles in a number of shares of New Freenome Common Stock (rounded down to the nearest whole share) in an amount and subject to such terms and conditions, in each case, as to be set forth on an allocation schedule, that will generally be subject to the same terms and conditions (including applicable vesting, expiration and forfeiture provisions) that applied to the corresponding Freenome RSU Award immediately prior to the Effective Time. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As part of the same overall transaction as the First Merger, subject to the terms and conditions of the Business Combination Agreement, Freenome, as the surviving corporation of the First Merger, will merge with and into Merger Sub II with Merger Sub II continuing as the surviving company in the merger (the “Second Merger” and together with the First Merger, the “Mergers”). </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Sponsor Letter Agreement </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Concurrently with the execution of the Business Combination Agreement, the Company, the Sponsor, certain insiders of the Company (“PCSC Insiders”) and Freenome entered into the Sponsor Letter Agreement (the “Sponsor Letter Agreement”), pursuant to which the Sponsor and each PCSC Insider, as a holder of Class B ordinary shares has agreed to, among other things, (i) vote in favor of the Business Combination Agreement and the Proposed Freenome Business Combination, (ii) waive any adjustment to the conversion ratio set forth in the governing documents of the Company or any other anti-dilution or similar protection with respect to the Class B ordinary shares (whether resulting from the transactions contemplated by the Subscription Agreements (as defined below) or otherwise), (iii) be bound by certain other covenants and agreements related to the Proposed Freenome Business Combination, (iv) be bound by certain transfer restrictions with respect to his, her or its shares in the Company prior to the Closing, and (v) be subject to the restrictions contemplated by the Lock-Up Agreements (as defined below) in each case, on the terms and subject to the conditions set forth in the Sponsor Letter Agreement. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">PIPE Financing (Private Placement) </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Concurrently with the execution of the Business Combination Agreement, on December 5, 2025, the Company entered into subscription agreements (the “Subscription Agreements”) with certain qualified institutional buyers, institutional accredited investors, and other accredited investors, including, among others, Perceptive Life Sciences Master Fund Ltd, a fund managed by Perceptive Advisors, an affiliate of the Sponsor, as well as certain existing stockholders of Freenome (collectively, the “PIPE Investors”). Pursuant to the Subscription Agreements, the PIPE Investors agreed to subscribe for and purchase, and the Company agreed to issue and sell to the PIPE Investors, on the date the Closing occurs (the “Closing Date”), an aggregate of 24,000,000 shares of New Freenome Common Stock for a purchase price of $10.00 per share, for aggregate gross proceeds of $240,000,000 (the “PIPE Financing”). </div></div></div><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The obligations of each party to consummate the PIPE Financing are conditioned upon, among other things, (i) the New Freenome Common Stock (including the New Freenome Common Stock issuable to the PIPE Investors pursuant to the Subscription Agreements) having been approved for listing on Nasdaq; (ii) satisfaction of all conditions precedent to the Closing ; and (iii) the absence of specified adverse judgements, orders, laws, rules or regulations enjoining or otherwise prohibiting the consummation of the Proposed Freenome Business Combination. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The obligations of the PIPE Investors to consummate the PIPE Financing are further subject to additional conditions, including, among other things: (i) the Business Combination Agreement shall not have been amended, modified, or supplemented, and no condition waived thereunder, in a manner that would reasonably be expected to materially and adversely affect the economic benefits that a PIPE Investor (in its capacity as such) would reasonably expect to receive under the Subscription Agreements; (ii) the material truth and accuracy of the representations and warranties of the Company in the Subscription Agreements, subject to customary bringdown standards; (iii) no subscription agreement, or other agreements or understandings (including side letters) entered into in connection with the sale of New Freenome Common Stock under the Subscription Agreements, with any other PIPE Investors shall have been amended, modified, or waived in any manner that benefits such other PIPE Investor unless all PIPE Investors have been offered substantially the same benefits (other than terms particular to the legal or regulatory requirements of such other PIPE Investor or its affiliates or related persons); (iv) all specified consents, waivers or other authorizations and notices, required to be made in connection with the issuance and sale of New Freenome Common Stock under the Subscription Agreements shall have been obtained or made, except where failure to so obtain would not prevent the Company from consummating the transactions contemplated by the Subscription Agreements; (v) material compliance by the Company with its covenants, agreements and conditions under the Subscription Agreements; (vi) there has not occurred any Material Adverse Effect or Parent Material Adverse Effect (each as defined in the Business Combination Agreement) since the date of the Subscription Agreements that is continuing. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;">The Subscription Agreements provide that the Company will grant the Investors certain customary registration rights. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Subscription Agreement represents a freestanding equity-linked contract that obligates the Company to issue a fixed number of shares for a fixed amount of cash upon satisfaction of the closing conditions. The contract does not include any embedded features requiring separate accounting under ASC 815-10 and does not meet the criteria for liability classification under ASC 480-10, as it does not require redemption, cash settlement, or issuance of a variable number of shares. The contract is indexed to the Company’s own stock and requires physical delivery of common shares. The Company has sufficient authorized and unissued common shares to settle the contract, and all settlement alternatives are within the Company’s control. Accordingly, the Subscription Agreement qualifies for equity classification under ASC 815-40. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company will recognize the proceeds from the Subscription Agreement and record the related equity issuance upon the closing of the Business Combination, when the Company receives the cash consideration and issues the Subscribed Shares. </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Freenome Transaction Support Agreements and Stockholder Written Consents </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Promptly after the signing of the Business Combination Agreement, certain stockholders of Freenome (collectively, the “Freenome Supporting Stockholders”) entered into a Transaction Support Agreement (collectively, the “Transaction Support Agreements”) with the Company, pursuant to which the Freenome Supporting Stockholders have agreed to, among other things, (a) (i) in favor of the approval and adoption of the Business Combination Agreement and the Proposed Freenome Business Combination, and (ii) against and withhold consent to any alternative acquisition proposal or other matter, action or proposal intended or that would reasonably be expected to result in a breach of any of Freenome’s covenants or obligations under the Business Combination Agreement, result in any breach to the conditions to Closing thereunder and otherwise impede or prevent the consummation of the Proposed Freenome Business Combination, (c) not, directly or indirectly, initiate, encourage or otherwise facilitate an alternative acquisition proposal, and (d) refrain from transferring any covered securities </div><div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Investor Rights Agreement </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In connection with the Closing, New Freenome, the Sponsor, and certain stockholders of Freenome will enter into an investor rights agreement (the “Investor Rights Agreement”). Pursuant to the Investor Rights Agreement, among other things, New Freenome will agree that, within 30 calendar days following the Closing Date, New Freenome will file with the SEC a registration statement registering the resale of certain shares of New Freenome Common Stock held by or issuable to the parties thereto (the “Resale Registration Statement”), and New Freenome will use its commercially </div></div></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">reasonable efforts to have the Resale Registration Statement declared effective as soon as reasonably practicable after the filing thereof. Such holders will be entitled to customary piggyback registration rights and demand registration rights, including underwritten demands. The Investor Rights Agreement amends and restates the Registration Rights Agreement. </div> 3 P45D 1125000 1125000 10 0.2 1725000 0.01 862500 0.4 3450000 1 0.0001 725000000 24000000 10 240000000 P30D <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">NOTE 6. SHAREHOLDERS’ DEFICIT </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Preference Shares<span style="font-style: normal; font-weight: normal;"> — The Company is authorized to issue 1,000,000 preference shares with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of December 31, 2025 and 2024, there were no preference shares issued or outstanding. </span></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Class A Ordinary Shares<span style="font-style: normal; font-weight: normal;"> — The Company is authorized to issue 479,000,000 Class A ordinary shares with a par value of $0.0001 per share. As of December 31, 2025 and 2024, there were 286,250 Class A ordinary shares issued and outstanding, excluding 8,625,000 Class A ordinary shares subject to possible redemption. </span></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Class B Ordinary Shares<span style="font-style: normal; font-weight: normal;"> — The Company is authorized to issue 20,000,000 Class B ordinary shares with a par value of $0.0001 per share. As of December 31, 2025 and 2024, there were 2,156,250 Class B ordinary shares issued and outstanding. </span></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Ordinary shareholders of record are entitled to one vote for each share held on all matters to be voted on by shareholders. Holders of Class A ordinary shares and holders of Class B ordinary shares will vote together as a single class on all matters submitted to a vote of the shareholders except as required by law. Unless otherwise specified in the Amended and Restated Memorandum and Articles of Association, or as required by applicable provisions of the Companies Act (As Revised) of the Cayman Islands or applicable stock exchange rules, the affirmative vote of a majority of the ordinary shares that are represented in person or by proxy and are voted is required to approve any such matter voted on by the shareholders. Approval of certain actions will require a special resolution under Cayman Islands law, being the affirmative vote of at least two-thirds of the votes cast by such shareholders as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at the applicable general meeting of the Company, and pursuant to the Amended and Restated Memorandum and Articles of Association; such actions include amending the Amended and Restated Memorandum and Articles of Association and approving a statutory merger or consolidation with another company. The board of directors is divided into three classes, each of which will generally serve for terms of three years with only one class of directors being elected in each year. There is no cumulative voting with respect to the election of directors, with the result that the holders of more than 50% of the shares entitled to vote and voted for the election of directors can elect all of the directors. The shareholders are entitled to receive ratable dividends when, as and if declared by the board of directors out of funds legally available therefor. Prior to the initial Business Combination, only holders of the Founder Shares will have the right to vote on the appointment of directors. Holders of the Public Shares are not entitled to vote on the election of directors during such time. Further, prior to the closing of the Business Combination, only holders of the Class B ordinary shares will be entitled to vote on transferring the Company by way of continuation in a jurisdiction outside the Cayman Islands (including any special resolution required to amend the constitutional documents of the Company or to adopt new constitutional documents of the Company, in each case, as a result of the Company approving a transfer by way of continuation in a jurisdiction outside the Cayman Islands) and, as a result, the Initial Shareholders will be able to approve any such proposal without the vote of any other shareholder. The provisions of the Amended and Restated Memorandum and Articles of Association governing the appointment of directors prior to the Business Combination and the Company’s continuation in a jurisdiction outside the Cayman Islands prior to the initial Business Combination may only be amended by a special resolution passed by holders representing at least two-thirds of the Company’s outstanding Class B ordinary shares. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Subject to adjustment for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like, and subject to further adjustment as provided herein, the Founder Shares, which are designated as Class B ordinary shares, will be convertible at the option of the holder on a one-for-one basis or will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the initial Business Combination at a ratio such that the number of Class A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate, on an as-converted basis, 20% of the sum of (i) the total number of ordinary shares issued and outstanding (excluding the Private Placement Shares and including any Class A ordinary share issued pursuant to the underwriter’s over-allotment option and including any Class A ordinary shares that may have been issued on a <span style="-sec-ix-hidden: hidden-fact-2"><span style="-sec-ix-hidden: hidden-fact-3">one-for-one</span></span> basis upon conversion of the Class B ordinary shares at the option of the holder thereof prior to the initial Business Combination pursuant to the Amended and Restated Memorandum and Articles of Association) upon consummation of the Initial Public Offering, plus (ii) the sum of the total number of Class A ordinary shares issued or deemed issued or issuable </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial Business Combination, excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, deemed issued, or to be issued, to any seller in the Business Combination and any private placement-equivalent shares issued to the Sponsor, members of the management team or any of their affiliates upon conversion of Working Capital Loans made to the Company. In no event will the Class B ordinary shares convert into Class A ordinary shares at a rate of less than one to one. </div> 1000000 0 0 0 0 479000000 0.0001 286250 286250 286250 286250 8625000 20000000 0.0001 2156250 2156250 2156250 2156250 1 3 P3Y 1 0.50 0.20 <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">NOTE 7. FAIR VALUE MEASUREMENTS </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Level 1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Level 2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Level 3: Unobservable inputs based on assessment of the assumptions that market participants would use in pricing the asset or liability. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">At December 31, 2025, assets held in the Trust Account were comprised of $234 in cash and $91,872,184 in U.S. Treasury securities. During the year ended December 31, 2025, the Company withdrew $600,000 of interest income from the Trust Account to fund working capital as permitted. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">At December 31, 2024, assets held in the Trust Account were comprised of $430 in cash and $88,653,967 in U.S. Treasury securities. During the period from March 22, 2024 (inception) through December 31, 2024, the Company did not withdraw any interest income from the Trust Account. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following tables present information about the Company’s assets that are measured at fair value on a recurring basis at December 31, 2025 and 2024 and indicate the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value. The gross holding gains and fair value of held-to-maturity securities at December 31, 2025 and 2024 are as follows: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 84pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 168pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 18.66pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 50pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 32.5pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 50pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 168pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Held to Maturity</div></td><td style="width: 6.48pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 18.66pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level</div></td><td style="width: 6.48pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amortized <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Cost</div></td><td style="width: 6.48pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 32.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gross <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Holding <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gain</div></td><td style="width: 6.48pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair Value </div></td></tr><tr><td style="width: 84pt; padding-top: 2.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December 31, 2025 </div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 168pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">U.S. Treasury Securities (matured February 19, 2026) </div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 18.66pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">1</span></div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$91,837,137</span></div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 32.5pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$35,047</span></div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$91,872,184</span></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 84pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 168pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 18.66pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 50pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 32.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 50pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"> </div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 84pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 168pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 18.66pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 50pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 32.5pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 50pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 168pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Held to Maturity</div></td><td style="width: 6.48pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 18.66pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level</div></td><td style="width: 6.48pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amortized <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Cost</div></td><td style="width: 6.48pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 32.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gross <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Holding <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gain</div></td><td style="width: 6.48pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair Value </div></td></tr><tr><td style="width: 84pt; padding-top: 2.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December 31, 2024 </div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 168pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">U.S. Treasury Securities (matured April 3, 2025) </div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 18.66pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">1</span></div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$88,615,571</span></div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 32.5pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$38,396</span></div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$88,653,967</span></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 84pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 168pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 18.66pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 50pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 32.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 50pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table> 234 91872184 600000 430 88653967 0 <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following tables present information about the Company’s assets that are measured at fair value on a recurring basis at December 31, 2025 and 2024 and indicate the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value. The gross holding gains and fair value of held-to-maturity securities at December 31, 2025 and 2024 are as follows: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 84pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 168pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 18.66pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 50pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 32.5pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 50pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 168pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Held to Maturity</div></td><td style="width: 6.48pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 18.66pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level</div></td><td style="width: 6.48pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amortized <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Cost</div></td><td style="width: 6.48pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 32.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gross <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Holding <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gain</div></td><td style="width: 6.48pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair Value </div></td></tr><tr><td style="width: 84pt; padding-top: 2.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December 31, 2025 </div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 168pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">U.S. Treasury Securities (matured February 19, 2026) </div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 18.66pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">1</span></div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$91,837,137</span></div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 32.5pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$35,047</span></div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$91,872,184</span></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 84pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 168pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 18.66pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 50pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 32.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 50pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"> </div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 84pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 168pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 18.66pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 50pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 32.5pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 50pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 6.48pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 168pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Held to Maturity</div></td><td style="width: 6.48pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 18.66pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level</div></td><td style="width: 6.48pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amortized <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Cost</div></td><td style="width: 6.48pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 32.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gross <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Holding <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Gain</div></td><td style="width: 6.48pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair Value </div></td></tr><tr><td style="width: 84pt; padding-top: 2.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December 31, 2024 </div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 168pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">U.S. Treasury Securities (matured April 3, 2025) </div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 18.66pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">1</span></div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$88,615,571</span></div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 32.5pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$38,396</span></div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$88,653,967</span></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 84pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 168pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 18.66pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 50pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 32.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 6.48pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 50pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td></tr></table> 91837137 35047 91872184 88615571 38396 88653967 <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">NOTE 8. SEGMENT INFORMATION </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">ASC Topic 280, “Segment Reporting,” establishes standards for companies to report in their financial statement information about operating segments, products, services, geographic areas, and major customers. Operating segments are defined as components of an enterprise that engage in business activities from which it may recognize revenues and incur expenses, and for which separate financial information is available that is regularly evaluated by the Company’s chief operating decision maker (“CODM”), or group, in deciding how to allocate resources and assess performance. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company’s CODM has been identified as the Chief Financial Officer, who reviews the assets, operating results, and financial metrics for the Company as a whole to make decisions about allocating resources and assessing financial performance. Accordingly, management has determined that the Company only has one operating segment. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The CODM assesses performance for the single segment and decides how to allocate resources based on net income (loss) that also is reported on the consolidated statements of operations as net income (loss). The measure of segment assets is reported on the consolidated balance sheets as total assets. When evaluating the Company’s performance and making key decisions regarding resource allocation, the CODM reviews several key metrics included in net income and total assets, which include the following: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 336pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 50pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 50pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As of <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div></td><td style="width: 8pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As of <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31,<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div></td></tr><tr><td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash </div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 12.5pt;">865,031</span></div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 5pt;">1,129,684 </span></div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Investments held in Trust Account </div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$91,872,418</div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$88,654,397</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 336pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 50pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 50pt;"><div style="font-size: 1pt;"> </div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"> </div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 336pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3.95pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3.95pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 46.5pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3.95pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3.95pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 69.7pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 3.95pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3.95pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 46.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the Year<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Ended<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31,<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div></td><td style="width: 3.95pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 3.95pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 69.7pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the Period from<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March 22, 2024<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Inception) Through<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31,<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div></td></tr><tr><td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative expenses </div></td><td style="width: 3.95pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3.95pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 46.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;">$2,980,553</div></td><td style="width: 3.95pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3.95pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 69.7pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.35pt; text-align: left;">$<span style="padding-left: 7.5pt;">494,005 </span></div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest earned on investments held in Trust Account </div></td><td style="width: 3.95pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3.95pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 46.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;">$3,821,319</div></td><td style="width: 3.95pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3.95pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 69.7pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.35pt; text-align: left;">$2,366,001</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 336pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3.95pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3.95pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 46.5pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3.95pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3.95pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 69.7pt;"><div style="font-size: 1pt;"> </div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The CODM reviews interest earned on investments held in Trust Account to measure and monitor shareholder value and determine the most effective strategy of investment with the Trust Account funds while maintaining compliance with the Trust Agreement. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">General and administrative expenses are reviewed and monitored by the CODM to manage and forecast cash to ensure enough capital is available to complete a business combination or similar transaction within the business combination period. The CODM also reviews general and administrative costs to manage, maintain and enforce all contractual agreements to ensure costs are aligned with all agreements and budget. General and administrative expenses, as reported on the consolidated statements of operations, are the significant segment expenses provided to the CODM on a regular basis. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">All other segment items included in net income are reported on the consolidated statements of operations and described within their respective disclosures. The accounting policies used to measure the profit and loss of the segment are the same as those described in the summary of significant accounting policies. </div> 1 1 <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The CODM assesses performance for the single segment and decides how to allocate resources based on net income (loss) that also is reported on the consolidated statements of operations as net income (loss). The measure of segment assets is reported on the consolidated balance sheets as total assets. When evaluating the Company’s performance and making key decisions regarding resource allocation, the CODM reviews several key metrics included in net income and total assets, which include the following: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 336pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 50pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 50pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As of <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div></td><td style="width: 8pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As of <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31,<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div></td></tr><tr><td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash </div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 12.5pt;">865,031</span></div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 5pt;">1,129,684 </span></div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Investments held in Trust Account </div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$91,872,418</div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 50pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$88,654,397</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 336pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 50pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 8pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 50pt;"><div style="font-size: 1pt;"> </div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"> </div><table cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0px;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 336pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3.95pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3.95pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 46.5pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3.95pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 3.95pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 6pt; width: 69.7pt;"><div style="font-size: 1pt;"> </div></td></tr><tr class="BRDSX_header"><td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"> </div></td><td style="width: 3.95pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3.95pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 46.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the Year<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Ended<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31,<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div></td><td style="width: 3.95pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 3.95pt; border-bottom: none;"><div style="font-size: 1pt;"> </div></td><td style="width: 69.7pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the Period from<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March 22, 2024<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Inception) Through<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31,<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div></td></tr><tr><td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative expenses </div></td><td style="width: 3.95pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3.95pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 46.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;">$2,980,553</div></td><td style="width: 3.95pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 3.95pt; background-color: #CCEEFF;"><div style="font-size: 1pt;"> </div></td><td style="width: 69.7pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.35pt; text-align: left;">$<span style="padding-left: 7.5pt;">494,005 </span></div></td></tr><tr><td style="width: 336pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest earned on investments held in Trust Account </div></td><td style="width: 3.95pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3.95pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 46.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.75pt; text-align: left;">$3,821,319</div></td><td style="width: 3.95pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 3.95pt;"><div style="font-size: 1pt;"> </div></td><td style="width: 69.7pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.35pt; text-align: left;">$2,366,001</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 336pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3.95pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3.95pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 46.5pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3.95pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 3.95pt;"><div style="font-size: 1pt;"> </div></td><td style="height: 2.75pt; width: 69.7pt;"><div style="font-size: 1pt;"> </div></td></tr></table> 865031 1129684 91872418 88654397 2980553 494005 3821319 2366001 <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">NOTE 9. SUBSEQUENT EVENTS </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the consolidated financial statements were issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the consolidated financial statements. </div> <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; text-align: center;">OPINION OF SCALAR, LLC</div><img alt="" src="ny20061080x8_logoannexl.jpg" style="height: 40px; width: 165px;"/><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; text-align: right;">December 4, 2025 </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">The Special Committee of the Board of Directors <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Perceptive Capital Solutions Corp <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">c/o Perceptive Advisors LLC <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">51 Astor Place, 10^th Floor <br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">New York, NY 10003 </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">To the Special Committee of the Board of Directors: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As per our engagement letter dated September 29, 2025, the Special Committee of the Board of Directors of Perceptive Capital Solutions Corp (“<span style="font-weight: bold;">PCSC</span>”) retained Scalar, LLC (herein referred to as “<span style="font-weight: bold;">Scalar</span>,” “<span style="font-weight: bold;">we</span>”, “<span style="font-weight: bold;">our</span>”, or “<span style="font-weight: bold;">us</span>”) to provide an opinion (this “<span style="font-weight: bold;">Opinion</span>”) as to the fairness, from a financial point of view, to (1) the holders of PCSC’s Class A ordinary shares, par value $0.0001 per share (such shares, at all times prior to the Effective Time, the “<span style="font-weight: bold;">PCSC Class A Shares</span>”, and such holders, the “<span style="font-weight: bold;">PCSC Class A Shareholders</span>”) (other than (i) Freenome Holdings, Inc. (the “<span style="font-weight: bold;">Company</span>”), (ii) Perceptive Capital Solutions Holdings (the “<span style="font-weight: bold;">Sponsor</span>”), (iii) the Key Supporting Company Shareholders, (iv) holders of PCSC Class A Shares who elect to redeem their shares prior to or in connection with the Transaction, and (v) the PIPE Investors, (collectively, along with their respective affiliates, the “<span style="font-weight: bold;">Excluded Parties</span>”)) of the Consideration (as defined below) to be delivered to the Company Shareholders in the proposed business combination with the Company pursuant to the Business Combination Agreement described below (the “<span style="font-weight: bold;">Transaction</span>”),<span style="font-weight: bold;"> </span>without giving effect to any impact of the Transaction on any particular PCSC Class A Shareholder other than in its capacity as a PCSC Class A Shareholder, and (2) PCSC. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><span style="text-decoration:underline">Overview of the Transaction:</span> </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Business Combination Agreement (the “<span style="font-weight: bold;">Agreement</span>”), to be entered into among PCSC, Starnet Merger Sub I, Inc., a Delaware corporation, and a wholly-owned subsidiary of PCSC (“<span style="font-weight: bold;">Merger Sub I</span>”), Starnet Merger Sub II, LLC, a Delaware limited liability company and a wholly-owned subsidiary of PCSC (“<span style="font-weight: bold;">Merger Sub II</span>”, and together with Merger Sub I, the “<span style="font-weight: bold;">Merger Subs</span>”) and the Company sets forth the terms of the Transaction. Capitalized terms used but not defined in this Opinion have the meanings ascribed thereto in the Agreement. We understand that the Agreement provides, among other things, that: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Immediately prior to the Domestication, PCSC Class A Shares held by the PCSC Class A Shareholders who duly elect to exercise the right of the holders of PCSC Class A Shares to redeem all or a portion of their PCSC Class A Shares as set forth in the Governing Documents of PCSC (the “<span style="font-weight: bold;">PCSC Shareholder Redemption</span>”) will have their PCSC Class A Shares redeemed and canceled and such PCSC Class A Shareholders will cease to have any rights as shareholders of PCSC other than the right to be paid their pro rata share of the Trust Account; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">At least one Business Day prior to the Closing Date, prior to the time at which the Effective Time occurs, PCSC shall transfer by way of continuation from the Cayman Islands to Delaware and domesticate as a Delaware corporation in accordance with the DGCL (the “<span style="font-weight: bold;">Domestication</span>”); </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">On the Closing Date, following the Domestication, at the Effective Time, Merger Sub I will merge with and into the Company, with the Company continuing as the surviving corporation (the “<span style="font-weight: bold;">First Merger</span>”) and, after giving effect to the First Merger, each Company Share will be automatically canceled and extinguished and will be automatically converted, as of the Effective Time, into the right to receive a number of PCSC Shares equal to the Exchange Ratio, in each case, on the terms and subject to the conditions set forth in the Agreement (collectively, the total number of PCSC shares of common stock to be issued for the Company Shares is the “<span style="font-weight: bold;">Consideration</span>”); </div></td></tr></table><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">Valuation | Transaction Advisory<br/></div><table border="0" cellpadding="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">On the Closing Date, as part of the same overall transaction as the First Merger, at the Second Effective Time, the surviving corporation of the First Merger will merge with and into Merger Sub II with Merger Sub II continuing as the surviving corporation (the “<span style="font-weight: bold;">Second Merger</span>” and together with the First Merger, the “<span style="font-weight: bold;">Mergers</span>”); </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Concurrently with the execution of the Agreement, the PIPE Investors are each entering into the Investor Subscription Agreements, pursuant to which, among other things, each PIPE Investor has agreed to subscribe for and purchase on the Closing Date, and PCSC has agreed to issue and sell to the each PIPE Investor on the Closing Date immediately following the Closing, the number of PCSC Shares set forth in the applicable Investor Subscription Agreement in exchange for the purchase price set forth therein (the financing under all PIPE Subscription Agreements, collectively, the “<span style="font-weight: bold;">PIPE Financing</span>”), in each case, on the terms and subject to the conditions set forth in the applicable Investor Subscription Agreement; and </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(f)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Concurrently with the execution of the Agreement, the Sponsor, the Other Class B Holders, PCSC, and the Company are entering into the Sponsor Letter Agreement, pursuant to which, among other things, the Sponsor and each Other Class B Shareholder has agreed to (i) vote in favor of the Agreement and the transactions contemplated by the Agreement (including the Mergers), and (ii) waive any adjustment to the conversion ratio set forth in the Governing Documents of PCSC or any other anti-dilution or similar protection, in each case, with respect to the PCSC Class B Shares, in each case, on the terms and subject to the conditions set forth in the Sponsor Letter Agreement. </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;"><span style="text-decoration:underline">Scalar’s Procedures and Processes:</span> </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">In arriving at our Opinion, among other things, we have: </div><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewed a draft of the agreed form, dated November 12, 2025, of the Sponsor Letter Agreement; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewed a draft, dated December 3, 2025, of the Agreement; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewed a draft, dated November 3, 2025, of the Investor Subscription Agreements (the drafts described in (a) through (c), the “<span style="font-weight: bold;">Reviewed Transaction Documents</span>”); </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewed certain publicly available business and financial information relating to PCSC and the Company; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewed certain historical financial information and other data relating to the Company that were provided to us by the management of PCSC, approved for our use by PCSC and not publicly available; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(f)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewed certain management data relating to the business prospects of the Company that were provided to us by the management of PCSC, approved for our use by PCSC and not publicly available; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(g)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">conducted discussions with members of the senior management of the Company concerning the business, operations, historical financial results and financial prospects of the Company and its addressable market and the Transaction; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(h)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewed current and historical market prices of the PCSC Class A Shares; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewed certain financial and market data of the Company and compared that data with publicly available data for certain other companies similar to the Company; </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(j)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">reviewed certain pro forma effects relating to the Transaction, including estimated transaction costs and the effects of anticipated financings, approved for our use by PCSC; and </div></td></tr></table><table border="0" cellpadding="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0px;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(k)<br/></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">conducted such other financial studies, analyses and investigations, and considered such other information, as we deemed necessary or appropriate. </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;"><span style="text-decoration:underline">Limiting Conditions and Assumptions:</span> </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In performing our analyses and rendering this Opinion, with your consent, we have relied upon and assumed, without assuming liability or responsibility for independent verification, the accuracy and completeness of all information and data that was publicly available or was furnished, or otherwise made available to us or discussed with or reviewed by us. We have further relied upon the assurances of the management of PCSC that the financial information provided has been prepared on a reasonable basis in accordance with industry practice, and that they are not aware of any information, facts or circumstances that would make any information provided to us inaccurate, incomplete or misleading in any </div><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">Valuation | Transaction Advisory<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">respect. We also have been advised by PCSC’s senior management, and we have assumed, that the prospective information, including, but not limited to, projections for the timely receipt of governmental, regulatory and other third-party approvals, represent a reasonable basis upon which to evaluate the future business and financial prospects of the Company.  We have relied upon the assessments of the management of PCSC and the Company as to, among other things, the potential impact on the Company and PCSC of market, competitive, seasonal, macroeconomic, geopolitical and other conditions, trends and developments in and prospects for, and governmental, regulatory and legislative matters relating to or affecting, the industry in which the Company operates and the geographic regions and local communities in which the Company operates. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Without limiting the generality of the foregoing, for the purpose of this Opinion, we have relied upon, with your consent, (a) the assumptions of the management of the Company and PCSC and third-party data sources, as to all accounting, legal, tax and financial reporting matters with respect to the Company and (b) that PCSC has been advised by counsel as to all legal matters with respect to the Transaction, including whether all procedures required by law in connection with the Transaction have been duly, validly and timely taken. We have also assumed that the Transaction will have the tax consequences described in discussions with, and materials furnished to us by, representatives of PCSC and that (i) the Domestication qualifies as a “reorganization” within the meaning of Section 368(a)(1)(F) of the Code, (ii) the Mergers, taken together, will be treated as an integrated transaction that qualifies as a “reorganization” within the meaning of Section 368 of the Code, and (iii) the Mergers and the PIPE Financing, taken together, will be treated as an integrated transaction qualifying under Section 351(a) of the Code and Treasury Regulations promulgated thereunder. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We are not legal, accounting, regulatory or tax experts and this Opinion does not address any legal, regulatory, taxation or accounting matters as to which we understand that you have obtained such advice as you deemed necessary from qualified professionals, and we have assumed the accuracy and veracity of all assessments made by such advisors to the Company or PCSC with respect to such matters. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In arriving at our Opinion, with your consent and without independent verification, we have relied upon the assumption that, except as would not be in any way meaningful to our analysis: (a) the final form of each of the Reviewed Transaction Documents, as executed by the parties thereto, will not differ from the drafts that we have reviewed, (b) the representations and warranties of all parties to the Agreement, and any related Transaction documents, are correct and that such parties will comply with and perform all covenants and agreements required to be complied with or performed by such parties under the Agreement and any related Transaction documents, (c) the Transaction will be consummated in accordance with the terms of the Agreement and related Transaction documents, without any waiver or amendment of any term or condition thereof, and (d) there has been no material change in the assets, financial condition, business or prospects of any party to the Agreement since the date of the most recent financial statements and other information made available to us. Additionally, we have assumed that all governmental, regulatory or other third-party approvals and consents necessary for the consummation of the Transaction or otherwise contemplated by the Agreement will be obtained without delay, limitation, restriction or condition and otherwise in a way that will not have any adverse effect on the Company or PCSC, or on the expected benefits of the Transaction, in any way meaningful to our analysis. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition, we have relied upon (without independent verification and without expressing any view, opinion, representation, guaranty or warranty (in each case, express or implied)) the assessments, judgments and estimates of PCSC’s senior management and the Company’s senior management as to, among other things, (a) the potential impact on the Company of market, competitive and other trends in and prospects for, and governmental, regulatory and legislative matters relating to or affecting, the industry in which the Company operates and related industries, (b) the Company’s existing and future products, services, technology and intellectual property and the associated risks thereto (including, without limitation, the probabilities and timing of successful development and marketing thereof; the timing of successful regulatory approvals and clearances; compliance with relevant regulatory requirements; and the potential impact of competition thereon) and (c) PCSC’s and the Company’s existing and future relationships, agreements and arrangements with, and the ability to attract, retain and/or replace, key employees, suppliers and other commercial relationships (in each such case to the extent relevant to the Company, the Transaction and its contemplated benefits). We have assumed that there will not be any developments with respect to any of the foregoing matters that would have an adverse effect on PCSC, the Company or the Transaction (including the contemplated benefits thereof) or that otherwise would be meaningful in any respect to our analyses or opinion. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Given PCSC’s nature as a special purpose acquisition company, for purposes of our Opinion and with PCSC’s consent, we have assumed a value of $10.61 per PCSC Share in calculating the value of the PCSC Shares to be issued as the Consideration under the Agreement, with such $10.61 per share value being based on (a) $91,550,673.98, which is the </div><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">Valuation | Transaction Advisory<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">value of the assets held in PCSC’s Trust Account as of November 30, 2025, <span style="font-style: italic;">divided</span> by (b) 8,625,000, which is the number of outstanding PCSC Class A Shares subject to redemption as of October 31, 2025. In rendering our Opinion, we do not express any view or opinion as to what the value of any PCSC Shares will be when issued pursuant to the Transaction or the price or range of prices at which any PCSC Class A Shares, PCSC Class B Shares or other securities or financial instruments of or relating to PCSC may trade or otherwise be transferable at any time before or after announcement or consummation of the Transaction. Additionally, we express no opinion with respect to the PCSC Class B Shares and PCSC Preference Shares. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In arriving at our Opinion, we have not performed any appraisals or valuations of any specific assets or liabilities (fixed, contingent or other) of the Company or PCSC and have not been furnished or provided with any such appraisals or valuations, nor have we evaluated the solvency of the Company or PCSC under any state or federal law relating to bankruptcy, insolvency or similar matters. The analyses performed by us in connection with this Opinion were going concern analyses, assuming the Transaction was consummated in accordance with the terms of the Agreement. Without limiting the generality of the foregoing, we have undertaken no independent analysis of any pending or threatened litigation, regulatory action, possible unasserted claims or other contingent liabilities, to which the Company or PCSC is a party or may be subject, and at your direction and with your consent, our Opinion makes no assumption concerning, and therefore does not consider, the possible assertion of claims, outcomes, liabilities or damages arising out of any such matters. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">This Opinion is necessarily based upon financial, economic, monetary, market and other conditions and circumstances as in effect on, the information available to us as of, and the facts and circumstances as they exist on, the date hereof and our Opinion speaks only as of the date hereof; events occurring after the date hereof could materially affect the assumptions used in preparing this Opinion. We have not undertaken to update, reaffirm or revise this Opinion or otherwise comment upon any events occurring after the date hereof, material information provided to us after the date hereof or any change in facts or circumstances occurring after the date hereof and do not have any obligation to update, revise or reaffirm this Opinion. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We have been engaged by the Special Committee of the Board of Directors of PCSC to provide a fairness opinion, and we will receive a fee from PCSC for providing our services and rendering this Opinion. No portion of this fee is refundable or contingent upon the consummation of the Transaction or the conclusion reached in this Opinion. PCSC has also agreed to indemnify us against certain liabilities and reimburse us for certain expenses in connection with our services. In the past two years, we and our affiliates have provided other advisory services, including a fairness opinion, to an affiliate of PCSC for which we and our affiliates received compensation. We and our affiliates may seek to provide services to the Company, PCSC and their respective affiliates in the future and expect to receive fees for the rendering of these services. In the ordinary course of business, certain of our employees<span style="font-weight: bold;"> </span>and affiliates, or entities in which they have invested, may hold or trade, for their own accounts and the accounts of their investors, securities of the Company and PCSC and, accordingly, may at any time hold a long or short position in such securities. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The issuance of this Opinion was approved by an authorized committee of Scalar. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">This Opinion is provided for the information and assistance of the Special Committee of the Board of Directors of PCSC (in its capacity as such) in connection with, and for the purpose of, its evaluation of the Transaction, and does not constitute a recommendation to any stockholder as to how such stockholder should vote or act (including with respect to any redemption rights) with respect to the Transaction or any other matter. This Opinion shall not be disclosed, referred to, published or otherwise used (in whole or in part), nor shall any public references to us or this Opinion be made without Scalar’s prior written approval.Notwithstanding the foregoing, this Opinion in its entirety may be included in any filing with the Securities and Exchange Commission (“<span style="font-weight: bold;">SEC</span>”) made by PCSC in connection with the Transaction, and a summary of Scalar’s work may be included in any filing with the SEC made by PCSC in connection with the Transaction subject to Scalar’s prior written approval (not to be unreasonably withheld, conditioned or delayed). </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our Opinion does not address PCSC’s underlying business decision to engage in the Transaction, the relative merits of the Transaction as compared to other business or investment strategies or transactions that might be available to PCSC or whether the Consideration to be delivered to the Company Shareholders pursuant to the Agreement represents the best price obtainable. In connection with our engagement, we were not requested to, and did not, solicit interest from other parties with respect to an acquisition of, or other business combination with, PCSC or any other alternative transaction. This Opinion addresses only the fairness from a financial point of view, as of the date hereof, to the PCSC Class A Shareholders (other than the Excluded Parties) of the Consideration to be delivered to the Company </div><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">Valuation | Transaction Advisory<br/></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Shareholders pursuant to the Agreement. We have not been asked to, nor do we, offer any opinion as to the terms, other than the Consideration to the extent expressly specified herein, of the Agreement or the Ancillary Documents or the form of the Transaction or any related transaction (including any agreement or transaction between any Excluded Party and the Company or PCSC), including the fairness of the Transaction to, or any consideration received in connection therewith by, any Excluded Parties, the holders of any class of securities, creditors or other constituencies of PCSC, the Company or any of their respective affiliates. We have not been asked to, nor do we, offer any opinion with respect to any ongoing obligations of the Company, PCSC or any of their respective affiliates (including any obligations with respect to governance, appraisal rights, preemptive rights, registration rights, voting rights or otherwise) contained in any Ancillary Documents or any other agreement related to the Transaction or under applicable law, any allocation of the Consideration (or any portion thereof) or the fair market value of the Company, PCSC, any PCSC Shares or the Company Shares. In addition, we express no opinion as to the fairness of the amount or nature of any compensation to be received by any officers, directors or employees of any parties to the Transaction, any Excluded Parties or any class of such persons, whether relative to the Consideration or otherwise. Our Opinion (a) does not address the individual circumstances of specific holders of PCSC securities (including PCSC Class B Shares and PCSC Preference Shares) with respect to rights or aspects which may distinguish such holders or PCSC securities (including PCSC Class B Shares and PCSC Preference Shares) held by such holders, (b) does not address, take into consideration or give effect to any existing or future rights, preferences, restrictions or limitations or other attributes of any such securities (including PCSC Class B Shares and PCSC Preference Shares) or holders (including the Sponsor), (c) does not address any impact of the Transaction on any particular PCSC Class A Shareholder, other than in its capacity as a PCSC Class A Shareholder, and (d) does not in any way address proportionate allocation or relative fairness (including, without limitation, the allocation of any consideration among or within any classes or groups of security holders or other constituents of PCSC or any other party). We also do not address, or express a view with respect to, any acquisition of control or effective control of PCSC by any shareholder or group of shareholders of the Company. This letter should not be construed as creating any fiduciary duty of Scalar (or any of its affiliates) to any other party. To the extent any of the foregoing assumptions or any of the facts on which this Opinion is based prove to be untrue in any material respect, this Opinion cannot and should not be relied upon. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Based upon and subject to the foregoing, including the various assumptions and limitations set forth herein, it is our opinion that, as of the date hereof, the Consideration to be delivered to the Company Shareholders pursuant to the Agreement is fair, from a financial point of view, to (1) the PCSC Class A Shareholders (other than the Excluded Parties); and (2) PCSC.<span style="font-weight: normal;"> </span></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">Sincerely, </div><img alt="" src="ny20061080x8_sigannexl.jpg" style="height: 35px; width: 105px;"/><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">Scalar, LLC </div><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">Valuation | Transaction Advisory<br/></div> 1 1 0002017526 false This number includes up to 281,250 Class B ordinary shares subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriter (Notes 4 and 6). On June 13, 2024, the underwriter exercised its over-allotment option in full as part of the closing of the Initial Public Offering. As such, 281,250 Founder Shares were no longer subject to forfeiture. This number includes up to 281,250 Class B ordinary shares subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriter (Notes 4 and 6). On June 13, 2024, the underwriter exercised its over-allotment option in full as part of the closing of the Initial Public Offering. As such, 281,250 Founder Shares were no longer subject to forfeiture. This number includes up to 281,250 Class B ordinary shares subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriter (Notes 4 and 6). On June 13, 2024, the underwriter exercised its over-allotment option in full as part of the closing of the Initial Public Offering. As such, 281,250 Founder Shares were no longer subject to forfeiture.